JPWO2020219959A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219959A5 JPWO2020219959A5 JP2021563185A JP2021563185A JPWO2020219959A5 JP WO2020219959 A5 JPWO2020219959 A5 JP WO2020219959A5 JP 2021563185 A JP2021563185 A JP 2021563185A JP 2021563185 A JP2021563185 A JP 2021563185A JP WO2020219959 A5 JPWO2020219959 A5 JP WO2020219959A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- cells
- pharmaceutical composition
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Description
é¢é£åºé¡ã®çžäºåç
§ïŒœ
æ¬åºé¡ã¯ã2019幎4æ24æ¥ã«åºé¡ãããç±³åœä»®åºé¡ç¬¬62/838,280å·ã«å¯ŸããŠåªå æš©ã䞻匵ããããã®åªå åºé¡ã®å šå 容ã¯ãæ¬åºé¡ã«åç §ã«ããåã蟌ãŸããã
æ¬åºé¡ã¯ã2019幎4æ24æ¥ã«åºé¡ãããç±³åœä»®åºé¡ç¬¬62/838,280å·ã«å¯ŸããŠåªå æš©ã䞻匵ããããã®åªå åºé¡ã®å šå 容ã¯ãæ¬åºé¡ã«åç §ã«ããåã蟌ãŸããã
é
åãªã¹ã
ãã®åºé¡ã«ã¯ãASCIIãã©ãŒãããã§é»åçã«æåºããããåã³ãã®å šäœãæ¬åºé¡ã«åç §ã«ããåã蟌ãŸããé åãªã¹ãïŒSequence ListingïŒãå«ãŸãããåèšASCIIã³ããŒã¯ã2020幎4æ23æ¥ã«äœæãããM103034_2100WO_0359_4_SL.txtãšåä»ãããããµã€ãºã¯99,264ãã€ã ã§ããã
ãã®åºé¡ã«ã¯ãASCIIãã©ãŒãããã§é»åçã«æåºããããåã³ãã®å šäœãæ¬åºé¡ã«åç §ã«ããåã蟌ãŸããé åãªã¹ãïŒSequence ListingïŒãå«ãŸãããåèšASCIIã³ããŒã¯ã2020幎4æ23æ¥ã«äœæãããM103034_2100WO_0359_4_SL.txtãšåä»ãããããµã€ãºã¯99,264ãã€ã ã§ããã
æè¡åé
æ¬çºæã¯ãæ-CD45æäœåã¯ãã®æäœè¬ç©ã³ã³ãžã¥ã²ãŒãã®åéã«é¢ãããæ¬çºæã¯æŽã«ãæ-CD45æäœåã¯æäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã®æäžã«ããããšããããè¡æ¶²çŸæ£ã代è¬é害ããããåã³èªå·±å ç«çŸæ£ãªã©ã®æ§ã ãªç æ ã«çœ¹æ£ããŠããæ£è ã®æ²»çã«é¢ãããããã§ãåèšæäœåã¯ADCã¯ãé è¡å¹¹çŽ°èåã¯å ç«çŽ°èã®äœããã®è¡šé¢ã«ããCD45ã«å¯ŸããŠçµåããããšãã§ããã
æ¬çºæã¯ãæ-CD45æäœåã¯ãã®æäœè¬ç©ã³ã³ãžã¥ã²ãŒãã®åéã«é¢ãããæ¬çºæã¯æŽã«ãæ-CD45æäœåã¯æäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã®æäžã«ããããšããããè¡æ¶²çŸæ£ã代è¬é害ããããåã³èªå·±å ç«çŸæ£ãªã©ã®æ§ã ãªç æ ã«çœ¹æ£ããŠããæ£è ã®æ²»çã«é¢ãããããã§ãåèšæäœåã¯ADCã¯ãé è¡å¹¹çŽ°èåã¯å ç«çŽ°èã®äœããã®è¡šé¢ã«ããCD45ã«å¯ŸããŠçµåããããšãã§ããã
å»çæè¡ã®é²æ©ã«ãããããããé è¡ã·ã¹ãã ã®ç
æ
ïŒãšããããç¹å®ã®è¡æ¶²çŽ°èã®çŸæ£ã代è¬é害ããããåã³èªå·±å
ç«çç¶ãªã©ïŒãæ²»çããããšãäŸç¶ãšããŠæ±ããããŠãããé è¡å¹¹çŽ°è(HSC)ã¯ã倧ããªæ²»çå¯èœæ§ãæããäžæ¹ã§ã宿䞻ã«ãããŠãHSC移æ€çã確å®ã«ççãããããšãå°é£ã§ããããšã«ãã£ãŠãèšåºã§ã®äœ¿çšã劚ããŠããéçããããç¹ã«ãå
å æ§ã®HSCäžã«ãã现èè¡šé¢æåãã¿ãŒã²ãããšããæäœãå«ãé è¡å¹¹çŽ°èçæ³ã¯ãå€å æ§ã®HSC移æ€çãççããããšã劚ãããæãŸãããªãå
ç«åºæ¿æ©èœåã³ãšãã§ã¯ã¿ãŒæ©èœãèªçºããããšãããã
æ-CD45æäœåã¯ãã®æåçµåéšåãåã³ãã³ãŸãžã¢ãŒãã³éšåæ§é ïŒäŸãã°ãããããã³ãŸãžã¢ãŒãã³(PBD)åã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³(IGN)ïŒãå«ã现èæ¯çŽ ããå«ãæäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ããæ¬åºé¡ã§é瀺ããããCD45+现èãæžå°ãããããã®ADCã®äœ¿çšãæäŸãããã
åŸã£ãŠã1ã€ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯ãæ-CD45æäœåã¯ãã®æåçµåéšå(Ab)ãå«ã¿ããªã³ã«ãŒ(L)ãä»ããŠçŽ°èæ¯çŽ (Cy)ã«ã³ã³ãžã¥ã²ãŒããããæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãããã§ãåèšçŽ°èæ¯çŽ ã¯ããããã³ãŸãžã¢ãŒãã³(PBD)ãå«ãããæäŸããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯PBDäºéäœã§ããããšããããäŸãã°ã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšPBDã¯ãåŒ(I)ã§è¡šãããïŒ
ããã§ãæ³¢ç·ã¯ãADCã®ãªã³ã«ãŒãžã®å
±æçµåã®äœçœ®ã瀺ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒïŒLïŒã¯ã1皮以äžã®ããããããªãªãŽç³ã-(CH2)p-, -(CH2CH2O)q-, -(C=O)(CH2)r-, -(C=O)(CH2CH2O)t-, -(NHCH2CH2)u-, -PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, å㯠Ala-PABãå«ããããã§ãpãqãrãtãåã³uã®åã
ã¯ã1ãã12ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæããããäŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãåŒ(II)ã®æ§é ãæããïŒ
ããã§ãR1 ã¯ãCH3(Ala)åã¯(CH2)3NH(CO)NH2(Cit)ã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãL-Z'ãšããŠäžç·ã«ãªã£ãŠããŠã以äžã®æ§é ãæããïŒ
ã
äŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåè¿°ã®æ§é ã®R1ã¯ãCH3ã§ããããšãããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããŠããã·ãªã³ã§ãããåŒ(IV)ã®æ§é ãæããïŒ
ã
äŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåèšADCã¯ãåŒ(V)ã®æ§é ãå«ãããšãããïŒ
ããã§ãAbã¯ãæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã§ãããåã³Sã¯ãåèšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®ãäžã«ååšããåã¯äžã«å°å
¥ãããç¡«é»ååã§ããã
å¥ã®æ
æ§ã§ã¯ããªã³ã«ãŒ(L)ãä»ããŠçŽ°èæ¯çŽ (Cy)ã«ã³ã³ãžã¥ã²ãŒããããæ-CD45æäœåã¯ãã®æåçµåéšå(Ab)ãå«ããæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãããã§ãåèšçŽ°èæ¯çŽ ã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³(IGN)ãå«ãããæ¬åºé¡ã§æäŸãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ãIGNäºéäœåã¯åœäºéäœã§ããããšããããäŸãã°ãããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ãåŒ(VI)ã§è¡šãããIGNåœäºéäœã§ããããšãããïŒ
ããã§ãæ³¢ç·ã¯ãADCã®ãªã³ã«ãŒãžã®å
±æçµåã®äœçœ®ã瀺ãã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ããžããããããžã¹ã«ãã£ããC1-C12ã¢ã«ãã«ãC=Oãåã¯ãããã®çµã¿åããããå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ã
ãå«ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœåã¯ãã®æåçµåéšåã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããŠãåŒ(VII)ã®æ§é ãæããïŒ
ã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã1ãã10ã®è¬ç©æäœæ¯(drug to antibody ratio (DAR))ãæããããšããããäŸãã°ã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã1ã2ã3ã4ã5ã6ã7ã8ã9åã¯10ã®è¬ç©æäœæ¯ãæããããšããããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã1ãã8ã®DARãæããããšããããäŸãã°ã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã1ã2ã3ã4ã5ã6ã7ãåã¯8ã®DARãæããããšããããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã1ãã4ã®DARãæããããšããããäŸãã°ã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã1ã2ã3åã¯4ã®DARãæããããšããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã1ã®DARãæãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã2ã®DARãæãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã3ã®DARãæãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã4ã®DARãæãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã5ã®DARãæãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã6ã®DARãæãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã7ã®DARãæãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ã8ã®DARãæããã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ããã¡ã©æäœåã¯ãã®æåçµåéšåã§ããããšããããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãããåæäœåã¯ãã®æåçµåéšåã§ããããšããããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãå®å
šããæäœåã¯ãã®æåçµåéšåã§ããããšãããã
äŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãæ-CD45æäœåã¯ãã®æå-çµåéšåã¯ãã¢ãã¯ããŒãã«æäœåã¯ãã®æå-çµåéšåãããªã¯ããŒãã«æäœåã¯ãã®æå-çµåéšåããã€ã¹ãã·ãã£ãã¯æäœåã¯ãã®æå-çµåéšåãäºéå¯å€å
ç«ã°ãããªã³ã»ãã¡ã€ã³(dual-variable immunoglobulin domain)ãåéFvåå(scFv)ããã€ã¢ããã£ãããªã¢ããã£ãããããã£ãæäœ-æ§ã¿ã³ãã¯è³ªã¹ãã£ããã©ã«ããFvãã©ã°ã¡ã³ããFabãã©ã°ã¡ã³ããF(ab')2ååãåã¯ã¿ã³ãã di-scFvãã§ããããšããããåèšæäœã¯ãIgGãIgAãIgMãIgDåã³IgEããªã©ã®äœããã®ã¢ã€ãœã¿ã€ãã§ããããšãããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãIgGã§ãããäŸãã°ãåèšæäœã¯ãããã€ãã®å®æœåœ¢æ
ã§ã¯ãããIgG1ãIgG2ãIgG3ãåã¯IgG4ã¢ã€ãœã¿ã€ãFcãã¡ã€ã³ãå«ãããšãããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æåçµåéšåã¯ãFcãã¡ã€ã³ãå«ããåã³åèšæäœåã¯ãã®æåçµåéšåã¯ãFcãã¡ã€ã³å
ã®ã·ã¹ãã€ã³æ®åºãçµç±ããŠãPBDã«ã³ã³ãžã¥ã²ãŒããããFcãã¡ã€ã³å
ã®ã·ã¹ãã€ã³æ®åºã¯ãçæ¥ã®Fcé
åå
ã«ååšããããšããããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšã·ã¹ãã€ã³æ®åºããFcãã¡ã€ã³å
ã®ã¢ããé
žçœ®æã«ãã£ãŠå°å
¥ããããšããããäŸãã°ãåèšFc ãã¡ã€ã³ã¯ã眮æD265Cåã³ïŒåã¯V205C (EU çªå·ä»ã) ãå«ãããšãããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ãããCD45 ROã«ç¹ç°çã«çµåããããšãã§ãããæ-CD45æäœåã¯ãã®æåçµåéšåãå«ãããšãããã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯ãæ¬åºé¡ã«èšèŒãããADCåã³è¬åŠçã«èš±å®¹å¯èœãªæ
äœåã¯è³Šåœ¢å€ããå«ãå»è¬çµæç©ãæäŸããã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯ãããæ£è
ã«ãããŠãCD45+现èã®éå£ãæžå°ãããæ¹æ³ãããã§ãåèšæ¹æ³ã¯ãæ¬åºé¡ã«èšèŒãããADCåã¯å»è¬çµæç©ã®æå¹éãåèšæ£è
ã«æäžããããšãå«ãããæäŸããã
ãã®æ
æ§ã®1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšCD45+现èã¯ãé è¡å¹¹çŽ°èã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšé è¡å¹¹çŽ°èã¯ãCD45ROãçºçŸããããšãããã
ä»ã®å®æœåœ¢æ
ã§ã¯ãåèšCD45+现èã¯ãå
ç«çŽ°èã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå
ç«çŽ°èã¯ãCD137ãCD2ãåã³ïŒåã¯CD5ããçºçŸããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ¹æ³ã¯ãæŽã«ãé è¡å¹¹çŽ°èãå«ã移æ€çããåèšæ£è
ã«æäžããããšãå«ãã
1ã€ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯ãé è¡å¹¹çŽ°èãå«ã移æ€çããããæ£è
ã«æäžããããšãå«ãæ¹æ³ãããã§ãåèšæ£è
ã¯ãæ¬åºé¡ã«èšèŒãããADCãåã¯å»è¬çµæç©ããåèšæ£è
ããCD45+现èã®éå£ãæžå°ãããã®ã«ååãªéã§ã以åã«æäžãããããšãããããã®æ
æ§ã®1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšCD45+现èã¯ãé è¡å¹¹çŽ°èã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšé è¡å¹¹çŽ°èã¯ãCD45ROãçºçŸããããšãããã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯ãé è¡å¹¹çŽ°èãå«ã移æ€çããããæ£è
ã«æäžããããšãå«ãæ¹æ³ãããã§ãåèšæ£è
ã¯ãæ¬åºé¡ã«èšèŒãããADCãåã¯å»è¬çµæç©ããåèšæ£è
ããå
ç«çŽ°èã®éå£ãæžå°ãããã®ã«ååãªéã§ã以åã«æäžãããããšããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå
ç«çŽ°èã¯ãCD137ãCD2ãåã³ïŒåã¯CD5ããçºçŸããã
äžè¿°ã®æ
æ§ã«é¢ããŠãåèšæ£è
ã¯ãããã€ãã®å®æœåœ¢æ
ã§ã¯ãè¡æ¶²çŸæ£ã代è¬é害ããããèªå·±å
ç«çŸæ£ãåã¯é床è€åå
ç«äžå
šç(SCID)ãæããæ£è
ã§ããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšç§»æ€çã¯ãåçš®ç°ç³»ã§ãããäŸãã°ãåèšç§»æ€çã¯åçš®ç°ç³»ã®é è¡å¹¹çŽ°è移æ€ã§ããããšããããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšç§»æ€çã¯ãèªå·±ã®ç§»æ€çã§ããããšãããã
äŸãã°ãåèšæ£è
ã¯ãè¡æ¶²ããïŒäŸãã°ãçœè¡ç
åã¯ãªã³ãè
«ãªã©ïŒãæããããšããããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšæ£è
ã¯ãèªå·±å
ç«çŸæ£ïŒäŸãã°ãå€çºæ§ç¡¬åçåã¯åŒ·ç®çãªã©ïŒãæããããšãããã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯ãé è¡å¹¹çŽ°è(HSC)移æ€ãå¿
èŠãšããããã®æ£è
ã«ãããŠãCD45+现èã®éå£ãæžå°ãããæ¹æ³ãããã§ãåèšæ¹æ³ã¯ãCD45+现èã®éå£ãæžå°ããããã«ãæå¹éã®æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãåèšããæ£è
ã«æäžããããšãå«ããããã§ãåèšADCã¯ããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããæ-CD45æäœåã¯ãã®æåçµåéšåãå«ããããã§ãåèšçŽ°èæ¯çŽ ã¯ããããã³ãŸãžã¢ãŒãã³(PBD)ãå«ãã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯ãé è¡å¹¹çŽ°è(HSC)移æ€ãåããããã«ãããæ£è
ãã³ã³ãã£ã·ã§ãã³ã°ããæ¹æ³ãããã§ãåèšæ¹æ³ã¯ãæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãåèšããæ£è
ã«æäžããããšãå«ããããã§ãåèšADCã¯ããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããæ-CD45æäœåã¯ãã®æåçµåéšåãå«ããããã§ãåèšçŽ°èæ¯çŽ ã¯ããããã³ãŸãžã¢ãŒãã³(PBD)ãå«ãã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯PBDäºéäœã§ãããäŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåèšPBDã¯ãåŒ(I)ã§è¡šãããïŒ
ããã§ãæ³¢ç·ã¯ãADCã®ãªã³ã«ãŒãžã®å
±æçµåã®äœçœ®ã瀺ãã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ã1皮以äžã®ããããããªãªãŽç³ã-(CH2)p-, -(CH2CH2O)q-, -(C=O)(CH2)r-, -(C=O)(CH2CH2O)t-, -(NHCH2CH2)u-, -PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, å㯠Ala-PABãå«ããããã§ãpãqãrãtãåã³uã®åã
ã¯ã1ãã12ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæããããäŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãåŒ(II)ã®æ§é ãæããïŒ
ããã§ãR1ã¯ãCH3(Ala) åã¯(CH2)3NH(CO)NH2(Cit)ã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãL-Z'ãšããŠäžç·ã«ãªã£ãŠããŠã以äžã®æ§é ãæããïŒ
ã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãäžè¿°ã®æ§é ã«ããR1ã¯ãCH3ã§ããã
å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããŠããã·ãªã³ã§ãããåŒ(IV)ã®æ§é ãæããïŒ
ã
äžè¿°ã®æ
æ§ã®å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ãåŒ(V)ã®æ§é ãæããïŒ
ããã§ãAbã¯ãæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã§ãããåã³Sã¯ãåèšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®ãäžã«ååšããåã¯äžã«å°å
¥ãããç¡«é»ååã§ããã
å¥ã®æ
æ§ã§ã¯ãé è¡å¹¹çŽ°è(HSC)移æ€ãå¿
èŠãšããããæ£è
ã«ãããŠãCD45+现èã®éå£ãæžå°ãããæ¹æ³ãããã§ãåèšæ¹æ³ã¯ãCD45+现èã®éå£ãæžå°ããããã«ãæå¹éã®æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãåèšããæ£è
ã«æäžããããšãå«ããããã§ãåèšADCã¯ããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããæ-CD45æäœåã¯ãã®æåçµåéšåãå«ããããã§ãåèšçŽ°èæ¯çŽ ã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³(IGN)ãå«ãããæ¬åºé¡ã§æäŸãããã
å¥ã®æ
æ§ã§ã¯ãé è¡å¹¹çŽ°è(HSC)移æ€ãåããããã«ãããæ£è
ãã³ã³ãã£ã·ã§ãã³ã°ããæ¹æ³ãããã§ãåèšæ¹æ³ã¯ãæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãåèšããæ£è
ã«æäžããããšãå«ããããã§ãåèšADCã¯ããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããæ-CD45æäœåã¯ãã®æåçµåéšåãå«ããããã§ãåèšçŽ°èæ¯çŽ ã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³(IGN)ãå«ãããæ¬åºé¡ã§æäŸãããã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ãIGNäºéäœåã¯åœäºéäœã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ãåŒ(VI)ã§è¡šãããIGNåœäºéäœã§ããïŒ
ããã§ãæ³¢ç·ã¯ãADCã®ãªã³ã«ãŒãžã®å
±æçµåã®äœçœ®ã瀺ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ããžããããããžã¹ã«ãã£ããC1-C12ã¢ã«ãã«ãC=Oãåã¯ãããã®çµã¿åããããå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ã
ãå«ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœåã¯ãã®æåçµåéšåã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããŠãåŒ(VII)ã®æ§é ãæããïŒ
ã
äžè¿°ã®æ
æ§ã®1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšADCã¯ãäžèšã®éãã1ãã10ãå³ã¡ã1ã2ã3ã4ã5ã6ã7ã8ã9ãåã¯10ã®è¬ç©æäœæ¯(DAR)ãæããããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æåçµåéšåã¯ããã¡ã©æäœãããåæäœãè¥ããã¯ããæäœãåã¯ãããã®æåçµåéšåã§ããããšããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æå-çµåéšåã¯ãã¢ãã¯ããŒãã«æäœåã¯ãã®æå-çµåéšåãããªã¯ããŒãã«æäœåã¯ãã®æå-çµåéšåããã€ã¹ãã·ãã£ãã¯æäœåã¯ãã®æå-çµåéšåãäºéå¯å€å
ç«ã°ãããªã³ã»ãã¡ã€ã³(dual-variable immunoglobulin domain)ãåéFvåå(scFv)ããã€ã¢ããã£ãããªã¢ããã£ãããããã£ãæäœ-æ§ã¿ã³ãã¯è³ªã¹ãã£ããã©ã«ããFvãã©ã°ã¡ã³ããFabãã©ã°ã¡ã³ããF(ab')2ååãåã³ã¿ã³ãã di-scFvããããªã矀ããéžæãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æåçµåéšåã¯ãFcãã¡ã€ã³ãå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æåçµåéšåã¯ãCD45+现èã«ãã£ãŠå
éšã«åã蟌ãŸãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ä»¥äžã®ã¢ã€ãœã¿ã€ãã®ãã¡ã®1çš®ãæããããšãããïŒIgGãIgAãIgMãIgDãåã¯IgEãäŸãã°ãåèšæäœã¯ãããIgG1ãIgG2ãIgG3ãåã¯IgG4ã¢ã€ãœã¿ã€ãã®Fcãã¡ã€ã³ãæããããšããããåèšæäœåã¯ãã®æåçµåéšåããFcãã¡ã€ã³ãå«ãããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æåçµåéšåã¯ãFcãã¡ã€ã³å
ã®ã·ã¹ãã€ã³æ®åºãçµç±ããŠãPBDã«ã³ã³ãžã¥ã²ãŒãããããšããããåèšã·ã¹ãã€ã³æ®åºã¯ãFcãã¡ã€ã³å
ã§å€©ç¶ã«ãããããããªããåã¯ãåèšã·ã¹ãã€ã³æ®åºããFcãã¡ã€ã³å
ã®ã¢ããé
žçœ®æã«ãã£ãŠå°å
¥ããããšããããäŸãã°ãåèšFc ãã¡ã€ã³ã¯ãD265Cåã³ïŒåã¯V205Cã®çœ®æ (EUçªå·ä»ã) ãå«ãããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æåçµåéšåã¯ãããCD45 ROã«ãç¹ç°çã«çµåããããšãã§ããããã®ãããªå®æœåœ¢æ
ã§ã¯ãåèšADCã¯ãCD45 RO+现èã«ãã£ãŠãå
éšã«åã蟌ãŸããããšãããã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ¹æ³ã¯ãåèšæ£è
ãé è¡å¹¹çŽ°èãå«ã移æ€çãåããåã«ãåèšADCãåèšæ£è
ã«æäžããããšãå«ããäŸãã°ãåèšæ¹æ³ã¯ãåèšæ£è
ãé è¡å¹¹çŽ°èãå«ã移æ€çãåããçŽ3æ¥åã«ãåèšADCãåèšæ£è
ã«æäžããããšãå«ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ£è
ã¯ãè¡æ¶²çŸæ£ã代è¬é害ããããèªå·±å
ç«çŸæ£ã幹现èé害ãåã¯é床è€åå
ç«äžå
šç(SCID)ããæãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ£è
ã¯ã幹现èé害ïŒäŸãã°ãè¡æ¶²ããåã¯èªå·±å
ç«çŸæ£ãªã©ïŒãæãããäŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåèšæ£è
ã¯ãè¡æ¶²ããïŒäŸãã°ãçœè¡ç
åã¯ãªã³ãè
«ïŒãæãããå¥ã®äŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåèšæ£è
ã¯ãèªå·±å
ç«çŸæ£ïŒäŸãã°ãå€çºæ§ç¡¬åçåã¯åŒ·ç®çãªã©ïŒãæããã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãå
å æ§ã®CD45+ HSCã®éå£ã¯ãåèšããæ£è
ã«ãããŠãåèšADCãæäžããåŸãæžå°ããã
äžè¿°ã®æ
æ§ã®ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ¹æ³ã¯ãæŽã«ãåèšæ£è
ã«é è¡å¹¹çŽ°è移æ€çãæäžããããšããå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšADCãåèšæ£è
ã®è¡æ¶²ããå®è³ªçã«ã¯ãªã¢ã©ã³ã¹ãããåŸã«ãåèšç§»æ€çãåèšããæ£è
ã«æäžããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšé è¡å¹¹çŽ°è移æ€ã¯ãåçš®ç°ç³»ã®çŽ°èãå«ãã
çºæã®è©³çŽ°ãªèª¬æ
以äžã®ã»ã¯ã·ã§ã³ã§ã¯ãæäœããã®æå-çµåãã©ã°ã¡ã³ããåã¯æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã (ADC)ã«ã€ããŠèª¬æãããããããã移æ€ç察宿䞻ç (GVHD)ã«çœ¹æ£ããŠãããåã¯ãã®ãªã¹ã¯ãããæ£è ã«æäžããããšãããã䞊ã³ã«ã以äžã®ã»ã¯ã·ã§ã³ã§ã¯ãåèšæ£è ã«ããã®ãããªæ²»çå€ãæäžããæ¹æ³ãæäŸããã
以äžã®ã»ã¯ã·ã§ã³ã§ã¯ãæäœããã®æå-çµåãã©ã°ã¡ã³ããåã¯æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã (ADC)ã«ã€ããŠèª¬æãããããããã移æ€ç察宿䞻ç (GVHD)ã«çœ¹æ£ããŠãããåã¯ãã®ãªã¹ã¯ãããæ£è ã«æäžããããšãããã䞊ã³ã«ã以äžã®ã»ã¯ã·ã§ã³ã§ã¯ãåèšæ£è ã«ããã®ãããªæ²»çå€ãæäžããæ¹æ³ãæäŸããã
å®çŸ©ïŒœ
å¥æ®µã«èšèŒã®ãªãéããæ¬åºé¡ã§äœ¿çšããã以äžã®çšèªåã³ãã¬ãŒãºã¯ã以äžã®æå³ãæã€ããšãæå³ãããã
å¥æ®µã«èšèŒã®ãªãéããæ¬åºé¡ã§äœ¿çšããã以äžã®çšèªåã³ãã¬ãŒãºã¯ã以äžã®æå³ãæã€ããšãæå³ãããã
æ¬åºé¡ã§äœ¿çšãããå ŽåãçšèªãçŽãã¯ãèšèŒãããå€ãã10%é«ãå€åã¯äœãå€ããããäŸãã°ãçšèªãçŽ5 nMãã¯ã4.5 nMãã5.5 nMã®ç¯å²ã瀺ãã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãæäœãã¯ãç¹å®ã®æåã«ç¹ç°çã«çµåããããåã¯ç¹å®ã®æåãšå
ç«åŠçã«åå¿æ§ã§ãããå
ç«ã°ãããªã³ååã®ããšãæããæäœãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããã¢ãã¯ããŒãã«æäœãããªã¯ããŒãã«æäœããã«ãã¹ãã·ãã£ãã¯æäœïŒäŸãã°ããã€ã¹ãã·ãã£ãã¯æäœïŒãéºäŒåå·¥åŠçã«æäœããæäœãåã³ãã®ä»ã®æ¹å€ãã圢æ
ã®æäœïŒäŸãã°ãéå®ããããã®ã§ã¯ãªãããè±-å
ç«åæäœããã¡ã©æäœãããåæäœããã«ãã¹ãã·ãã£ãã¯æäœïŒ»äŸãã°ããã€ã¹ãã·ãã£ãã¯æäœïŒœããããã³ã³ãžã¥ã²ãŒãæäœïŒ»äŸãã°ããã€-ãããª-åã³ã¯ã¢ãã-ã¹ãã·ãã£ãã¯æäœããã€ã¢ããã£ãããªã¢ããã£ãåã³ããã©ããã£ïŒœã䞊ã³ã«æäœãã©ã°ã¡ã³ãå³ã¡ãæäœã®æåçµåãã©ã°ã¡ã³ãäŸãã°ãFab'ãF(ab')2ãFabãFvãrlgGãåã³scFvãã©ã°ã¡ã³ããªã©ïŒœãããããææã®æå-çµå掻æ§ã瀺ãéãå«ãŸããïŒããæãããããå¥æ®µã«èšèŒã®ãªãå Žåãçšèªãã¢ãã¯ããŒãã«æäœãïŒmAbïŒã¯ãã¿ãŒã²ããã»ã¿ã³ãã¯è³ªã«ç¹ç°çã«çµåããããšãã§ãããã€ã³ã¿ã¯ããªååã䞊ã³ã«æäœãã©ã°ã¡ã³ãïŒäŸãã°ãFabãF(ab')2ã®ãã©ã°ã¡ã³ããªã©ïŒãã®äž¡æ¹ãå«ãããšãæå³ããããæ¬åºé¡ã§äœ¿çšãããå ŽåãFabåã³F(ab')2ãã©ã°ã¡ã³ãã¯ãã€ã³ã¿ã¯ããªæäœã®Fcãã©ã°ã¡ã³ããæ¬ ãæäœãã©ã°ã¡ã³ããæãããããã®æäœãã©ã°ã¡ã³ãã®äŸããæ¬åºé¡ã§èšèŒããã
æ¬é瀺ã®æäœã¯ãéåžžãåé¢ãããŠãããåã¯çµæãã§ãããæ¬åºé¡ã§äœ¿çšãããå Žåããåé¢ãããŠããããšã¯ããããçºçŸãã现èåã¯çŽ°èå¹é€ãããåå®ãããåé¢ãããåã³ïŒåã¯ååããããããªããããïŒäŸãã°ãæäœïŒãæããéåžžãå°ãªããšã1ã€ã®ç²Ÿè£œå·¥çšã«ãã£ãŠãåé¢ãããæäœã調補ãããåŸã£ãŠããåé¢ãããæäœããšã¯ãç°ãªãæåç¹ç°æ§ãæããä»ã®æäœãå®è³ªçã«æããªããæäœãæå³ãããäŸãã°ãCD45ã«ç¹ç°çã«çµåãããåé¢ãããæäœã¯ãCD45以å€ã®æåã«ç¹ç°çã«çµåããæäœãå®è³ªçã«å«ãŸãªãã
äžè¬çã«ãæäœã¯ãæåçµåé åãå«ãééåã³è»œéãå«ããåééã¯ãééå¯å€é å(æ¬åºé¡ã§ã¯ãHCVRåã¯VHãšç¥ã)åã³ééå®åžžé åãå«ããåèšééå®åžžé åã¯ãCH1ãCH2åã³CH3ã®3ã€ã®ãã¡ã€ã³ãå«ããå軜éã¯ã軜éå¯å€é å(æ¬åºé¡ã§ã¯ãLCVRåã¯VLãšç¥ã)åã³è»œéå®åžžé åãå«ãã軜éå®åžžé åã¯ã1ã€ã®ãã¡ã€ã³(CL)ãå«ããåèšVHåã³VLé åã¯ãæŽã«ãçžè£æ§æ±ºå®é å(complementarity determining regions (CDR))ãšåŒã°ãããè¶
å¯å€æ§ã®é åã«åããããéªšæ Œé å(framework regions (FR))ãšåŒã°ãããããä¿åãããé åãç¹åšãããåVHåã³VLã¯ã3ã€ã®CDRãš4ã€ã®FRã§æ§æããããããã¯ãã¢ããæ«ç«¯ããã«ã«ããã·ã«æ«ç«¯ãŸã§ã以äžã®é ã§é
眮ããŠããïŒFR1ãCDR1ãFR2ãCDR2ãFR3ãCDR3ãFR4ãééåã³è»œéã®å¯å€é åã¯ãæåãšçžäºäœçšããçµåé åãå«ããæäœã®å®åžžé åã¯ã宿䞻çµç¹åã¯å åïŒäŸãã°ãå
ç«ç³»ã®çš®ã
ã®çŽ°èäŸãã°ããšãã§ã¯ã¿ãŒçŽ°èåã³å€å
žçè£äœç³»ã®ç¬¬äžæå(Clq)ãªã©ïŒãžã®å
ç«ã°ãããªã³ã®çµåãåªä»ããããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãæå-çµåãã©ã°ã¡ã³ããã¯ãã¿ãŒã²ããæåã«ç¹ç°çã«çµåããäœçšèœãä¿æãã1ã€ä»¥äžã®æäœã®ãã©ã°ã¡ã³ãããæå³ãããæäœã®æå-çµåæ©èœããå
šé·æäœã®ãã©ã°ã¡ã³ãã«ãã£ãŠæããããšãã§ãããåèšæäœãã©ã°ã¡ã³ãã¯ãäŸãã°ãFabãF(ab')2ãscFvããã€ã¢ããã£ãããªã¢ããã£ãã¢ãã£ããã£ãããããã£ãã¢ãã¿ããŒãåã¯ãã¡ã€ã³æäœã§ããããšããããæäœã®ãæå-çµåãã©ã°ã¡ã³ãããšããçšèªã«å
å«ãããçµåãã©ã°ã¡ã³ãã®äŸãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã以äžãæããããïŒ(i)Fabãã©ã°ã¡ã³ããVLãVHãCLåã³CH1ãã¡ã€ã³ãããªãäžäŸ¡ãã©ã°ã¡ã³ãïŒ(ii)F(ab')2ãã©ã°ã¡ã³ãããã³ãžé åã§ãžã¹ã«ãã£ãæ¶æ©ã«ãã£ãŠé£çµããã2ã€ã®Fabãã©ã°ã¡ã³ããå«ãäºäŸ¡ãã©ã°ã¡ã³ãïŒ(iii) VHåã³CH1ãã¡ã€ã³ãããªãFdãã©ã°ã¡ã³ãïŒ(iv)æäœã®åäžã¢ãŒã ã®VLåã³VHãã¡ã€ã³ãããªãFvãã©ã°ã¡ã³ãïŒ(v) VHåã³VLãã¡ã€ã³ãå«ãdAbïŒ(vi) VHãã¡ã€ã³ãããªãdAbãã©ã°ã¡ã³ã(äŸãã°ãWard et al., Nature 341:544-546ã1989ãåç
§ã®ããš)ïŒ(vii) VHåã¯VLãã¡ã€ã³ãããªãdAbïŒ(viii)åé¢ããçžè£æ§æ±ºå®é å(CDR)ïŒäžŠã³ã«(ix)åæãªã³ã«ãŒã«ãã£ãŠä»»æéžæçã«é£çµããããšããã2ã€ä»¥äž(äŸãã°ã2ã€ã3ã€ã4ã€ã5ã€ãåã¯6ã€)ã®åé¢ããCDRã®çµã¿åãããæŽã«ãFvãã©ã°ã¡ã³ãã®2ã€ã®ãã¡ã€ã³ïŒVLåã³VHïŒã¯ãå¥ã
ã®éºäŒåã«ãã£ãŠã³ãŒããããŠãããããããããçµæãæ¹æ³ã䜿çšããããšã§ããªã³ã«ãŒã«ãã£ãŠé£çµããŠããã®çµæãåäžã¿ã³ãã¯è³ªéïŒVLåã³VHé åã察ã«ãªã£ãŠäžäŸ¡ååã圢æããïŒãšããããšãã§ãã(åéFv(scFv)ãšããŠå
¬ç¥ã§ããïŒäŸãã°ãBird et al., Science 242:423-426, 1988 åã³ Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988ãåç
§ã®ããš)ããããã®æäœãã©ã°ã¡ã³ãããåœæ¥è
ã«å
¬ç¥ã®åŸæ¥ã®æè¡ã䜿çšããŠå
¥æããããšãã§ããåã³åèšãã©ã°ã¡ã³ãããã€ã³ã¿ã¯ããª(intact)æäœãšåãæ§åŒã§ãæçšæ§ã«ã€ããŠã¹ã¯ãªãŒãã³ã°ããããšãã§ãããæå-çµåãã©ã°ã¡ã³ãããçµæãDNAæè¡ãã€ã³ã¿ã¯ããªå
ç«ã°ãããªã³ã®é
µçŽ çãªåã¯ååŠçãªåæã«ãã£ãŠãåã¯ãããå Žåã«ã¯ãåœè©²æè¡åéã§å
¬ç¥ã®ååŠçããããåææé ã«ãã£ãŠãç£çããããšãã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãæ-CD45æäœãåã¯ãCD45ã«çµåããæäœãã¯ãåèšæäœããCD45ãã¿ãŒã²ãããšãã蚺æè¬å€åã³ïŒåã¯æ²»çè¬å€ãšããŠæçšã§ããããã«ãååãªèŠªåæ§ã§CD45ã«ç¹ç°çã«çµåããããšãã§ãããå°ãªããšãå
ç«ã°ãããªã³ååã®äžéšãäŸãã°ãéå®ããããã®ã§ã¯ãªãããééè¥ããã¯è»œéãåã¯ãã®ãªã¬ã³ãçµåéšåã®å°ãªããšã1ã€ã®çžè£æ§æ±ºå®é å(CDR)ãééè¥ããã¯è»œéã®å¯å€é åãééè¥ããã¯è»œéã®å®åžžé åãéªšæ Œé åãåã¯ãããã®ä»»æã®é åããå«ãã¿ã³ãã¯è³ªåã¯ããããå«æååããæå³ãããæ-CD45æäœãšããŠã¯ããŸãã10çªç®ã®ãã£ãããã¯ãã³ã»ã¿ã€ãIIIãã¡ã€ã³(10Fn3)ã®ãããªãæäœ-æ§ã¿ã³ãã¯è³ªã¹ãã£ããã©ã«ãïŒããã¯ãæäœCDRã«ãæ§é åã³æº¶åªã¢ã¯ã»ã¹å¯èœæ§ã«ãããŠé¡äŒŒããŠãããBCãDEãåã³FGæ§é ã«ãŒããå«ãïŒããæããããã10Fn3ãã¡ã€ã³ã®äžæ¬¡æ§é ã¯ãIgGééã®å¯å€é åã®äžæ¬¡æ§é ã«é¡äŒŒããŠãããåœæ¥è
ã¯ãäŸãã°ã10Fn3ã®BCãDEãåã³FGã«ãŒãã®æ®åºããæ-CD45ã¢ãã¯ããŒãã«æäœã®CDRH-1ãCDRH-2åã¯CDRH-3é åã«ç±æ¥ããæ®åºãšçœ®ãæããããšã«ãã£ãŠãæ-CD45ã¢ãã¯ããŒãã«æäœã®CDRãããã£ãããã¯ãã³ã»ã¹ãã£ããã©ã«ãã®äžã«æ¥ãæšããããšãã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœåã¯ãã®æå-çµåéšåã¯ãããCD45ã¢ã€ãœãã©ãŒã CD45ROã«çµåããããšãã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªããã€ã¹ãã·ãã£ãã¯æäœ(bispecific antibody)ãã¯ãåäžã®åã¯ç°ãªãæåäžã«ããããšããããå°ãªããšã2çš®ã®ç°ãªãæåãåã¯2çš®ã®ç°ãªããšãããŒãã«çµåããããšãã§ãããäŸãã°ãã¢ãã¯ããŒãã«æäœããã°ãã°ãããæäœãè±-å
ç«åæäœãããåæäœãåã¯ãã¡ã©æäœããæããäŸãã°ãçµåç¹ç°æ§ã®ãã¡ã®1ã€ããé è¡å¹¹çŽ°èè¡šé¢æåïŒäŸãã°ãCD45ïŒã«ãããšãããŒãã«åããããšãã§ããä»æ¹ããç¹ã«çŽ°èå¢æ®ãå¢åŒ·ããã·ã°ãã«äŒéçµè·¯ã«é¢äžããã¬ã»ãã¿ãŒåã¯ã¬ã»ãã¿ãŒã»ãµããŠãããã®ãããªãæ§ã
ãªé è¡å¹¹çŽ°èè¡šé¢æååã¯å¥ã®çŽ°èè¡šé¢ã¿ã³ãã¯è³ªã«ãããšãããŒãã«ç¹ç°çã«çµåãããããšãã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ããã®çµåç¹ç°æ§ããåäžã®ã¿ãŒã²ããæåäžã®ããŠããŒã¯ãªãéè€ããªããšãããŒãã«åããããšããã(å³ã¡ããã€ãã©ãããã¯æäœ[biparatopic antibody])ã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãçžè£æ§æ±ºå®é åã(CDR)ã¯ãæäœã®è»œéåã³ééå¯å€ãã¡ã€ã³ã®äž¡æ¹ã«èŠåºãããè¶
å¯å€é åã®ããšããããå¯å€ãã¡ã€ã³ã®ããé«åºŠã«ä¿åãããéšåã¯ãéªšæ Œé å(FR)ãšåŒã°ãããæäœã®è¶
å¯å€é åãè¡šãã¢ããé
žã®äœçœ®ã¯ãæèåã³åœè©²æè¡åéã§å
¬ç¥ã®çš®ã
ã®å®çŸ©ã«äŸåããŠãå€åããããšããããå¯å€ãã¡ã€ã³å
ã®ããã€ãã®äœçœ®ã¯ããã€ããªããè¶
å¯å€äœçœ®ãšèŠãªãããããšãããããããã®äœçœ®ã¯ãããçµã®åºæºã®äžã§ã¯è¶
å¯å€é åå
ã«ãããšèŠãªãããããšããããäžæ¹ãå¥ã®çµã®åºæºã®äžã§ã¯è¶
å¯å€é åå€ã«ãããšèŠãªãããããšãããããããã®äœçœ®ã®1ã€ä»¥äžã¯ãŸããæ¡åŒµè¶
å¯å€é åã«ãããŠèŠåºãããããšããããæ¬åºé¡ã«èšèŒãããæäœã¯ããããã®ãã€ããªããè¶
å¯å€äœçœ®ã«ãæ¹å€ãå«ãããšããããçæ¥ã®ééåã³è»œéã®å¯å€ãã¡ã€ã³ã¯ããããããäž»ã«Î²-ã·ãŒãæ§é ããšãã3ã€ã®CDRã«ãã£ãŠé£çµããïŒCDRã¯ãβ-ã·ãŒãæ§é ãé£çµããå Žåã«ãã£ãŠã¯ãã®äžéšã圢æãããã«ãŒãã圢æããïŒã4ã€ã®éªšæ Œé åãå«ããåã
ã®éäžã®CDRã¯ãFR1-CDR1-FR2-CDR2-FR3-CDR3-FR4ã®é åºã§ãéªšæ Œé åã«ãã£ãŠè¿æ¥ããŠäžç·ã«ãŸãšãŸãããããŠä»ã®æäœéç±æ¥ã®CDRãšå
±ã«ãæäœã®ã¿ãŒã²ããçµåéšäœã®åœ¢æã«å¯äžãã(Kabat et al., Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, MD., 1987ãåç
§ã®ããš)ãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãå
ç«ã°ãããªã³ã®ã¢ããé
žæ®åºã®çªå·ä»ãã¯ãå¥æ®µã«ç€ºããªãéããKabatãã®å
ç«ã°ãããªã³ã®ã¢ããé
žæ®åºã®çªå·ä»ãã·ã¹ãã ã«åŸã£ãŠè¡ã(ããããéå®ããããã®ã§ã¯ãªãããIMGTåã³Chothiaçãå«ããä»»æã®æäœã®çªå·ä»ãã¹ããŒã ãå©çšããããšããã)ã
çšèªãFcãããFcé åãããFcãã¡ã€ã³ããåã³ãIgG Fcãã¡ã€ã³ãã¯ãæ¬åºé¡ã§äœ¿çšãããå ŽåãIgGååã®ããã€ã³æ¶åã«ãã£ãŠåŸãããçµæ¶åå¯èœãªãã©ã°ã¡ã³ãã«é¢ããå
ç«ã°ãããªã³ïŒäŸãã°ãIgGååïŒã®äžéšãæããåèšFcé åã¯ããžã¹ã«ãã£ãçµåã«ãã£ãŠé£çµãããIgGååã®2æ¬ã®ééã®Cæ«ç«¯åŽã®ååãå«ããããã¯ãæåçµå掻æ§ãæããªãããç³éšåã䞊ã³ã«è£äœåã³FcRnã¬ã»ãã¿ãŒçãå«ãFcã¬ã»ãã¿ãŒã«å¯Ÿããçµåéšäœãå«ãïŒäžèšåç
§ïŒãäŸãã°ãFcé åã¯ã第2ã®å®åžžãã¡ã€ã³CH2(äŸãã°ãããIgG1ã®EUäœçœ®231ãã340ã®æ®åº)åã³ç¬¬3ã®å®åžžãã¡ã€ã³CH3(äŸãã°ãããIgG1ã®EUäœçœ®341ãã447ã®æ®åº)ãå«ããæ¬åºé¡ã§äœ¿çšãããå ŽåãåèšFcé åã¯ãããã¯ãŒã»ãã³ãžé å(lower hinge region)ã(äŸãã°ãããIgG1ã®EUäœçœ®233ãã239ã®æ®åº)ãå«ãã
Fcã¯ãåé¢ããããã®é åãåã¯æäœãæäœãã©ã°ã¡ã³ããè¥ããã¯Fcèåã¿ã³ãã¯è³ªã®æèã«ããããã®é åããæãããšããããå€åããéå®ããããã®ã§ã¯ãªãããEUäœçœ®270ã272ã312ã315ã356ãåã³358çãå«ããFcãã¡ã€ã³å
ã®å€ãã®äœçœ®ã§èŠ³å¯ãããŠããŠãããåŸã£ãŠãæ¬åºé¡ã§æ瀺ãããé
åãšåœè©²æè¡åéã§ç¥ãããŠããé
åãšã®éã«ããããªå·®ç°ãååšããããšããããåŸã£ãŠããéçåIgG Fcãã¡ã€ã³ãåã¯ãWT IgG Fcãã¡ã€ã³ãã¯ãä»»æã®å€©ç¶ã«ååšããIgG Fcé å(å³ã¡ãä»»æã®ã¢ã¬ã«)ãæããããIgG1ãIgG2ãIgG3åã³IgG4ã®ééã®é
åã¯ãå€ãã®é
åããŒã¿ããŒã¹äžã«èŠã€ããããšãã§ããäŸãã°ãUniprotããŒã¿ããŒã¹(www.uniprot.org)ã§ã¯ããããããã¢ã¯ã»ã·ã§ã³çªå·P01857(IGHG1_human)ãP01859(IGHG2_human)ãP01860(IGHG3_human)åã³P01861(IGHG1_human)ã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãæ¹å€ããFcé åãåã¯ãããªã¢ã³ãFcé åãã¯ãFcãã¡ã€ã³å
ã®ä»»æã®äœçœ®ã«å°å
¥ãããã1ã€ä»¥äžã®ã¢ããé
žçœ®æãæ¬ å€±ãæ¿å
¥åã¯æ¹å€ãå«ãIgG Fcãã¡ã€ã³ãæããããç¹å®ã®æ
æ§ã§ã¯ãããªã¢ã³ãIgG Fcãã¡ã€ã³ã¯ã1ã€ä»¥äžã®ã¢ããé
žçœ®æãå«ãŸãªãéçåFcãã¡ã€ã³ãšæ¯èŒããŠãFcã¬ã³ãRåã³ïŒåã¯C1qã«å¯Ÿããçµå芪åæ§ãæžå°ããåã¯ç¡ããªããšããçµæãç£ãã1ã€ä»¥äžã®ã¢ããé
žçœ®æãå«ããæŽã«ãFcçµåçžäºäœçšã¯ãæ§ã
ãªãšãã§ã¯ã¿ãŒæ©èœåã³äžæµã®ã·ã°ãã«äŒéã€ãã³ãïŒæäœäŸåæ§çŽ°èåªä»æ§çŽ°èå·å®³(antibody dependent cell-mediated cytotoxicity (ADCC))åã³è£äœäŸåæ§çŽ°èå·å®³(complement dependent cytotoxicity (CDC))çãå«ããããããã«éå®ãããªãïŒã«ãšã£ãŠå¿
é ã§ãããåŸã£ãŠãããç¹å®ã®æ
æ§ã§ã¯ãããªã¢ã³ãFcãã¡ã€ã³ãå«ãæäœ(äŸãã°ãæäœãèåã¿ã³ãã¯è³ªãåã¯ã³ã³ãžã¥ã²ãŒã)ã¯ã1ã€ä»¥äžã®ã¢ããé
žçœ®æãæ¬ å€±ãæ¿å
¥ãåã¯æ¹å€ãå«ãŸãªã (äŸãã°ãFcé åå
ã®å¯Ÿå¿ããäœçœ®ã«å€©ç¶ã«ååšããã¢ããé
žæ®åºãå«ããæ¹å€ããŠããªãFcé å)ãä»ã®ç¹ã§ã¯åãã¢ããé
žé
åãæããã察å¿ããæäœãšæ¯èŒããŠãå°ãªããšã1皮以äžã®Fcãªã¬ã³ãïŒäŸãã°ãFcã¬ã³ãRïŒã«å¯Ÿããçµå芪åæ§ãå€ããããšãããã
ããªã¢ã³ãFcãã¡ã€ã³ã¯ãããããæ§æããã¢ããé
žæ¹å€ã«åŸã£ãŠå®çŸ©ããããFcé åã«é¢ããŠæ¬åºé¡ã§è°è«ãããå
šãŠã®ã¢ããé
žçœ®æã«ã€ããŠãçªå·ä»ãã¯ãåžžã«Kabatã«ãããããªEUã€ã³ããã¯ã¹ã«åŸããåŸã£ãŠãäŸãã°ãD265Cã¯ã芪Fcãã¡ã€ã³ã«å¯ŸããŠãEUäœçœ®265ã®ã¢ã¹ãã©ã®ã³é
ž(D)ãã·ã¹ãã€ã³(C)ã§çœ®æãããFcããªã¢ã³ãã§ãããåæ§ã«ãäŸãã°ãD265C/L234A/L235Aã¯ã芪Fcãã¡ã€ã³ã«å¯ŸããŠãEUäœçœ®265(DããCãž)ã234(LããAãž)ãåã³235(LããAãž)ã«çœ®æãæããFcããªã¢ã³ããå®çŸ©ãããããªã¢ã³ãã¯ãŸããå€ç°EUã¢ããé
žäœçœ®ã«ãããããã®æçµçãªã¢ããé
žçµæã«åŸã£ãŠæå®ãããããšããããäŸãã°ãL234A/L235Aå€ç°ã¯ããLALAããšåŒã¶ããšããããæŽãªãäŸãšããŠãE233P.L234V.L235A.delG236(236ã®æ¬ 倱)å€ç°ã¯ããEPLVLAdelGããšåŒã¶ããšããããæŽã«å¥ã®äŸãšããŠãI253A.H310A.H435Aå€ç°ã¯ããIHHããšåŒã¶ããšãããã眮æã瀺ãé åºã¯ä»»æã§ããããšã«çæããããã
çšèªãFcã¬ã³ãã»ã¬ã»ãã¿ãŒãåã¯ãFcã¬ã³ãRãã¯ãæ¬åºé¡ã§äœ¿çšãããå ŽåãIgGæäœFcé åã«çµåãããåã³Fcã¬ã³ãRéºäŒåã«ãã£ãŠã³ãŒããããã¿ã³ãã¯è³ªã®ãã¡ããªãŒã®ä»»æã®ã¡ã³ããŒãæããããã«ãããŠã¯ããã®ãã¡ããªãŒã¯ãéå®ããããã®ã§ã¯ãªãããFcã¬ã³ãRI (CD64)ïŒäŸãã°ãã¢ã€ãœãã©ãŒã Fcã¬ã³ãRIaãFcã¬ã³ãRIbãåã³Fcã¬ã³ãRIcãªã©ïŒïŒFcã¬ã³ãRII (CD32)ïŒäŸãã°ãã¢ã€ãœãã©ãŒã Fcã¬ã³ãRIIaäŸãã°ãã¢ãã¿ã€ãH131åã³R131ãFcã¬ã³ãRIIbäŸãã°ãFcã¬ã³ãRIIb-1 åã³ Fcã¬ã³ãRIIb-2ã䞊ã³ã«Fcã¬ã³ãRIIcãªã©ïŒïŒäžŠã³ã«Fcã¬ã³ãRIII (CD16)ïŒäŸãã°ãã¢ã€ãœãã©ãŒã Fcã¬ã³ãRIIIaäŸãã°ãã¢ãã¿ã€ãV158åã³F158䞊ã³ã«Fcã¬ã³ãRIIIbäŸãã°ãã¢ãã¿ã€ãFcã¬ã³ãRIIIb-NA1åã³Fcã¬ã³ãRIIIb-NA2ã䞊ã³ã«ä»»æã®æªçºèŠã®ããFcã¬ã³ãRåã¯Fcã¬ã³ãRã®ã¢ã€ãœãã©ãŒã è¥ããã¯ã¢ãã¿ã€ãããå«ããFcã¬ã³ãRã¯ãä»»æã®çåœäœïŒäŸãã°ãéå®ããããã®ã§ã¯ãªããããããããŠã¹ãã©ããããŠãµã®åã³ãµã«ãªã©ïŒã«ç±æ¥ããããšããããããŠã¹Fcã¬ã³ãRã¯ãéå®ããããã®ã§ã¯ãªãããFcã¬ã³ãRI (CD64)ãFcã¬ã³ãRII (CD32)ãFcã¬ã³ãRIII (CD16)ãåã³Fcã¬ã³ãRIII-2 (CD16-2)ã䞊ã³ã«ä»»æã®æªçºèŠã®ããŠã¹Fcã¬ã³ãRåã¯Fcã¬ã³ãRã®ã¢ã€ãœãã©ãŒã è¥ããã¯ã¢ãã¿ã€ãããå«ãã
çšèªããšãã§ã¯ã¿ãŒæ©èœãã¯ãæ¬åºé¡ã§äœ¿çšãããå ŽåãFcãã¡ã€ã³ãšFcã¬ã»ãã¿ãŒãšã®çžäºäœçšããçãããçååŠçãªäºè±¡ãæãããšãã§ã¯ã¿ãŒæ©èœãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããADCCãADCPãåã³CDCãæãããããæ¬åºé¡ã§äœ¿çšãããããšãã§ã¯ã¿ãŒçŽ°èãã¯ã1ã€ä»¥äžã®Fcã¬ã»ãã¿ãŒãçºçŸãããåã³1ã€ä»¥äžã®ãšãã§ã¯ã¿ãŒæ©èœãåªä»ãããå
ç«ã·ã¹ãã ã®çŽ°èãããããšãã§ã¯ã¿ãŒçŽ°èãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããåçããã¯ããã¡ãŒãžã奜äžçãæš¹ç¶çŽ°èã奜é
žçããã¹ã现èãè¡å°æ¿(platelets)ãB现èã倧é¡ç²ãªã³ãçãã©ã³ã²ã«ãã³ã¹çŽ°èãããã¥ã©ã«ã»ãã©ãŒ(NK)现èãåã³ã¬ã³ãã»ãã«ã¿T现èããæããããã䞊ã³ã«ä»»æã®çåœäœïŒäŸãã°ãéå®ããããã®ã§ã¯ãªããããããããŠã¹ãã©ããããŠãµã®åã³ãµã«ïŒã«ç±æ¥ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªããµã€ã¬ã³ã(silent)ããããµã€ã¬ã³ã¹å(silenced)ãåã¯ããµã€ã¬ã³ã·ã³ã°(silencing)ãã¯ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®Fcã¬ã³ãã»ã¬ã»ãã¿ãŒ(FcγR)ãžã®çµåãšæ¯èŒããŠãFcã¬ã³ãã»ã¬ã»ãã¿ãŒ(FcγR)ãžã®çµåãæžå°ãããæ¬åºé¡ã«èšèŒãããæ¹å€ããFcé åãæããæäœãæãïŒäŸãã°ãBLIã§æž¬å®ããå ŽåãäŸãã°ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®FcγRãžã®çµåãšæ¯èŒããŠãFcγRãžã®çµåã®æžå°ããå°ãªããšã70%ãå°ãªããšã80%ãå°ãªããšã90%ãå°ãªããšã95%ãå°ãªããšã98%ãå°ãªããšã99%ãåã¯100%ãã§ãã)ãããã€ãã®å®æœåœ¢æ
ã§ã¯ãFcãµã€ã¬ã³ã¹å(Fc silenced)æäœã¯ãFcγRã«ãæ€åºå¯èœãªçµåã瀺ããªããæ¹å€ããFcé åãæããæäœã®FcγRãžã®çµåããåœæè¡åéã§å
¬ç¥ã®æ§ã
ãªæè¡ïŒäŸãã°ãéå®ããããã®ã§ã¯ãªããã平衡æ¹æ³ïŒ»äŸãã°ãé
µçŽ çµåå
ç«åžçã¢ãã»ã€(ELISA)ïŒKinExAãRathanaswami et al. Analytical Biochemistry, Vol. 373:52-60, 2008ïŒã©ãžãªã€ã ãã¢ãã»ã€(RIA)ãåã¯è¡šé¢ãã©ãºã¢ã³å
±é³Žã¢ãã»ã€è¥ããã¯ä»ã®ã¡ã«ããºã ã®åæ
ã«åºã¥ãã¢ãã»ã€ïŒ»äŸãã°ãBIACORETM解æè¥ããã¯OctetTM解æ(forteBIO)ã䞊ã³ã«ä»ã®æ¹æ³ïŒ»äŸãã°ãéæ¥ççµåã¢ãã»ã€ã競åççµåã¢ãã»ã€ãèå
å
±é³Žãšãã«ã®ãŒç§»å(FRET)ãã²ã«é»æ°æ³³ååã³ã¯ãããã°ã©ãã£ãŒïŒäŸãã°ãã²ã«ãéïŒãªã©ïŒœïŒã䜿çšããŠã枬å®ããããšãã§ããããããã®åã³ä»ã®æ¹æ³ã¯ã1ã€ä»¥äžã®è©äŸ¡ããæ§ææåäžã«ããæšèãå©çšããããšããããåã³ïŒåã¯ãæ§ã
ãªæ€åºæ¹æ³ïŒäŸãã°ãéå®ããããã®ã§ã¯ãªãããçºè²æ§æšèãèå
æ§æšèãçºå
æ§æšèãåã¯åäœäœæšèãªã©ïŒã䜿çšããããšããããçµå芪åæ§åã³åæ
ã«é¢ããŠã¯ãPaul, W. E., ed., Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999)ïŒããã¯ãæäœ-å
ç«åçžäºäœçšã«çŠç¹ãåœãŠãŠããïŒã«ã詳现ã«èšèŒãããŠããã競åççµåã¢ãã»ã€ã®äžäŸã¯ãæšèæåãšç®çã®æäœãšããé-æšèã®æåã®éãå¢ãããªããããã®ååšäžã§ãã€ã³ãã¥ããŒã·ã§ã³ããããšãåã³åèšæšèæåã«çµåããæäœãæ€åºããããšããå«ãã©ãžãªã€ã ãã¢ãã»ã€ã§ããããã®ããŒã¿ãããã¹ãã£ããã£ãŒãã»ãããã解æã«ãããç¹å®ã®æåã«å¯Ÿããç®çã®æäœã®èŠªåæ§åã³çµåãªã-ã¬ãŒã(off-rate)ã決å®ããããšãããã第2ã®æäœãšã®ç«¶åããã©ãžãªã€ã ãã¢ãã»ã€ã䜿çšããŠã枬å®ããããšãããããã®å Žåãåèšæåããæšèååç©ã«ã³ã³ãžã¥ã²ãŒãããç®çã®æäœãšãé-æšèã®ç¬¬2ã®æäœã®éãå¢ãããªããããã®ååšäžã§ãã€ã³ãã¥ããŒã·ã§ã³ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãæ¹å€ããŠããªãFcé åãå«ãåãæäœãã¯ãåæããã¢ããé
žçœ®æ(äŸãã°ãD265CãH435A ãL234Aãåã³ïŒåã¯L235A)ãæ¬ ãããä»ã®ç¹ã§ã¯ãæ¯èŒãããFcãæ¹å€ããæäœãšãåãã¢ããé
žé
åãæããæäœãæãã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãã³ã³ãã£ã·ã§ãã³ã°ããããåã³ãã³ã³ãã£ã·ã§ãã³ã°ãã¯ãé è¡å¹¹çŽ°èãå«ã移æ€çãåããããšã«åããŠãæ£è
ã«å¯ŸããŠæºåãããããã»ã¹ã®ããšãæãããã®ãããªæé ã«ãã£ãŠãé è¡å¹¹çŽ°èã®ç§»æ€çã®ççã¯ä¿é²ããã(äŸãã°ãã³ã³ãã£ã·ã§ãã³ã°æé åã³ç¶ããŠè¡ã£ãé è¡å¹¹çŽ°è移æ€ã®åŸã«ãæ£è
ããåé¢ããè¡æ¶²ãµã³ãã«å
ã®çåå¯èœãªé è¡å¹¹çŽ°èã®éãæç¶çã«å¢å€§ããŠããããšããæšæž¬ããã)ãæ¬åºé¡ã«èšèŒãããæ¹æ³ã«åŸã£ãŠãé è¡å¹¹çŽ°èãçºçŸããæåïŒäŸãã°ãCD45äŸãã°ãGNNK+ CD45ãªã©ïŒã«çµåãåŸãADCãæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ããæ£è
ã«æäžããããšã«ãã£ãŠãé è¡å¹¹çŽ°è移æ€çæ³ã«åããŠãåèšæ£è
ãã³ã³ãã£ã·ã§ãã³ã°ããããšããããæ¬åºé¡ã«èšèŒãããããã«ãåèšæäœããè¬ç©-æäœã³ã³ãžã¥ã²ãŒãã圢æããããã«ã现èæ¯çŽ ã«å
±æçµåçã«ã³ã³ãžã¥ã²ãŒããããããšããããäžèšã®æåã®1皮以äžã«çµåãåŸããADCãæäœããã®æå-çµåãã©ã°ã¡ã³ããåã¯è¬ç©-æäœã³ã³ãžã¥ã²ãŒãããé è¡å¹¹çŽ°è移æ€çæ³ãå¿
èŠãšããæ£è
ã«æäžããããšã¯ãäŸãã°ãå
å æ§ã®é è¡å¹¹çŽ°èãéžæçã«æžå°ãããŠãããã«ãã£ãŠãå€å æ§ã®é è¡å¹¹çŽ°èã®ç§»æ€çã«ãã£ãŠåãããã空ããã§ããããšã«ãããé è¡å¹¹çŽ°è移æ€çãççããããšãä¿é²ããããšãããã
çšèªãæžå°ããããã¯ãCD45-çºçŸçŽ°èã«å¯Ÿããæ-CD45æäœåã¯ADCã®å¹æã«é¢ããæèã«ãããŠãCD45-çºçŸçŽ°èã®æ°ãæžå°ãããããšãåã¯é€å»ããããšããæå³ããã
æ¬åºé¡ã§äºæçã«äœ¿çšããããçšèªãæ²»çæå¹éãåã¯ãæ²»çæå¹çšéãã¯ãæ£è
ã«1ååã¯è€æ°åã®çšéãæäžãããšãã«ãææã®æ²»çãæäŸãããæ²»çè¬å€ãïŒäŸãã°ãæ-CD45 ADCïŒã®éåã¯çšéãæããæ²»çè¬å€ã®ãæ²»çæå¹éãã¯ããã®éãåäœã«ãããŠææã®å¿çãåŒãèµ·ããããšãã§ããããã«ãåäœã®çŸæ£ã®ç¶æ
ã幎霢ãæ§å¥ãåã³äœéãªã©ã®èŠå ã«å¿ããŠãå€åããããšããããçšèªãæ²»çæå¹éãã¯ã察象ïŒäŸãã°ãæ£è
ïŒããæ²»çãããããšã«å¹æãããéãå«ããæ²»çéã瀺ãããã°ãæäžãã¹ãæ¬çºæã®çµæç©ã®æ£ç¢ºãªéãã幎霢ãäœéãè
«çãµã€ãºãææåã¯è»¢ç§»ã®çšåºŠãæ£è
ïŒå¯Ÿè±¡ïŒã®çç¶ã«ãããå人差ãèæ
®ããŠãå»åž«ã¯æ±ºããããšãã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåããåæžæããšã¯ã身äœäžã®æäœè¬ç©ã®è¡æŒ¿äžæ¿åºŠãã察象ïŒäŸãã°ããã察象ïŒã«ãããŠãåååã¯50%æžå°ããã®ã«èŠããæéãããããã®50%ã®è¡æž
äžæ¿åºŠã®äœäžã¯ãè¬ç©ã埪ç°ããŠããéãåæ ããŠããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãã³ã³ãžã¥ã²ãŒããã¯ã1ã€ã®ååïŒäŸãã°ãæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ããªã©ïŒã®åå¿æ§å®èœåºãšãå¥ã®ååïŒäŸãã°ãæ¬åºé¡ã«èšèŒããã现èæ¯çŽ ãªã©ïŒã®é©åãªåå¿æ§å®èœåºãšã®ãååŠçãªçµåã«ãã£ãŠåœ¢æãããååç©ãæããã³ã³ãžã¥ã²ãŒãã¯ãäºãã«çµåãã2ã€ã®ååéã«ããªã³ã«ãŒãå«ãããšããããã³ã³ãžã¥ã²ãŒãã®åœ¢æã«çšããããšãã§ãããªã³ã«ãŒã®äŸãšããŠã¯ãããããå«æãªã³ã«ãŒïŒäŸãã°ã倩ç¶ã«ååšããåã¯å€©ç¶ã«ååšããªãã¢ããé
žãäŸãã°ãD-ã¢ããé
žãå«æãããªã³ã«ãŒïŒãæããããããªã³ã«ãŒããæ¬åºé¡ã«èšèŒããããåã³åœè©²æè¡åéã§å
¬ç¥ã§ãããçš®ã
ã®ã¹ãã©ããžãŒïŒstrategiesïŒã䜿çšããŠèª¿è£œããããšãããããã®äžã®åå¿æ§æåã«äŸåããŠããªã³ã«ãŒããäŸãã°ãé
µçŽ çå æ°Žå解ãå
å解ãé
žæ§æ¡ä»¶äžã§ã®å æ°Žå解ãå¡©åºæ§æ¡ä»¶äžã§ã®å æ°Žå解ãé
žåããžã¹ã«ãã£ãéå
ãæ±æ žåæãåã¯ææ©éå±åæã«ãã£ãŠãåæããããšããã(äŸãã°ãLeriche et al., Bioorg. Med. Chem., 20:571-582, 2012ãåç
§ã®ããš)ã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãã«ãããªã³ã°åå¿ãã¯ãäºãã«åå¿ããã®ã«é©ãã2ã€ä»¥äžã®çœ®æåºãåå¿ããŠãããããã®çœ®æåºã«çµåããååãã©ã°ã¡ã³ãã(äŸãã°ãå
±æçµåçã«)çµåãããååŠçãªéšåæ§é ã圢æããååŠåå¿ãæããã«ãããªã³ã°åå¿ã«ã¯ã现èæ¯çŽ ïŒäŸãã°ãåœè©²æè¡åéã§å
¬ç¥ã®åã¯æ¬åºé¡ã«èšèŒããã现èæ¯çŽ ïŒã§ãããã©ã°ã¡ã³ãã«çµåããåå¿æ§çœ®æåºããæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãïŒäŸãã°ãåœè©²æè¡åéã§å
¬ç¥ã®è¥ããã¯æ¬åºé¡ã«èšèŒããããCD45ã«çµåãããæäœããã®æå-çµåãã©ã°ã¡ã³ããåã¯ç¹ç°çãªæ-CD45æäœïŒã§ãããã©ã°ã¡ã³ãã«çµåãã奜é©ãªåå¿æ§çœ®æåºãšåå¿ããåå¿ãå«ãŸããã奜é©ãªåå¿æ§çœ®æåºã®äŸãšããŠã¯ãæ±æ žïŒæ±é»å察(äŸãã°ãç¹ã«ãããªãŒã«ïŒããã¢ã«ãã«å¯Ÿãã¢ãã³ïŒã«ã«ããã«å¯Ÿãåã¯ããªãŒã«ïŒÎ±, β-äžé£œåã«ã«ããã«å¯Ÿç)ããžãšã³ïŒãžãšããã£ã«å¯Ÿ(äŸãã°ããšããããã¢ãžãïŒã¢ã«ãã³å¯Ÿ)çãæãããããã«ãããªã³ã°åå¿ãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããããªãŒã«ã»ã¢ã«ãã«åãããããã·ã«ã»ã¢ã«ãã«åãã¢ãã³ã»ã¢ã«ãã«åãã¢ãã³çž®åãã¢ããåããšã¹ãã«åããžã¹ã«ãã£ã圢æãç°åä»å (äŸãã°ãç¹ã«ã[4+2]Diels-Alderç°åä»å ã[3+2]Huisgenç°åä»å )ãè³éŠææ±æ žçœ®æãè³éŠææ±é»å眮æãåã³åœè©²æè¡åéã§ç¥ãããŠãããåã¯æ¬åºé¡ã«èšèŒãããä»ã®åå¿æ§åŒãæããããã
æ¬åºé¡ã§äœ¿çšãããå ŽåããCRU(競åçåççãŠããã(competitive repopulating unit))ãã¯ãin vivo移æ€åŸã«æ€åºããåŸããé·æççãã幹现èã«é¢ãã枬å®ã®åäœã®ããšãæãã
æ¬åºé¡ã§äœ¿çšãããå ŽåãçšèªããããŒ(donor)ãã¯ãã¬ã·ããšã³ãã«çŽ°èåã¯ãã®åŸä»£ãæäžããåã«ããã®1ã€ä»¥äžã®çŽ°èãåé¢ããããåã¯åç©ãæããåèš1ã€ä»¥äžã®çŽ°èã¯ãäŸãã°ãé è¡å¹¹çŽ°èã®éå£ã§ããããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªããã€ã¢ããã£ãã¯ã2ã€ã®ããªããããéãå«ãäºäŸ¡æäœãæããããã§ãåã
ã®ããªããããéã¯ãåãããããéäžã®VHåã³VLãã¡ã€ã³ã®ååå
äŒåãäžå¯èœã§ãããããçããªã³ã«ãŒ(äŸãã°ã5ã€ã®ã¢ããé
žããæ§æããããªã³ã«ãŒ)ã«ãã£ãŠé£çµãããVHåã³VLãã¡ã€ã³ãå«ãããã®æ§æã«ãã£ãŠãããããã®ãã¡ã€ã³ã¯ãå¥ã®ããªããããéäžã®çžè£çãã¡ã€ã³ãšå¯Ÿã«ãªã£ãŠããã¢äºéäœæ§é ã圢æãããåŸã£ãŠãçšèªãããªã¢ããã£ãã¯ã3ã€ã®ããããéãå«ãäžäŸ¡æäœãæãããã®åã
ã¯ãåãããããéå
ã®VHåã³VLãã¡ã€ã³ã®ååå
äŒåãå¯èœã«ããã«ã¯éåžžã«çããããªã³ã«ãŒ(äŸãã°ã1ãã2ã¢ããé
žããæ§æããããªã³ã«ãŒ)ã«ãã£ãŠé£çµããã1ã€ã®VHãã¡ã€ã³åã³1ã€ã®VLãã¡ã€ã³ãå«ãããã®ããã«ããŠæ§æãããããããã¯ããã®çæ¥ã®æ§é ã«æããããŸããããã«ãéåžžã¯ãé£æ¥ããããããéã®VHãã¡ã€ã³åã³VLãã¡ã€ã³ã空éçã«äºãã«è¿æ¥ããããã«ãäžéäœåãã(äŸãã°ãHolliger et al., Proc. Natl. Acad. Sci. USA 90:6444-48, 1993ãåç
§)ã
æ¬åºé¡ã§äœ¿çšãããå Žåããäºéå¯å€ãã¡ã€ã³å
ç«ã°ãããªã³(dual variable domain immunoglobulin)ã(ãDVD-Igã)ã¯ãå䟡ã®ããã¥ã¢ã«-ã¿ãŒã²ãã£ã³ã°ã®åå€(a tetravalent, dual-targeting single agent)ãçæããããã«ããªã³ã«ãŒãä»ããŠã2ã€ã®ã¢ãã¯ããŒãã«æäœã®ã¿ãŒã²ããçµåå¯å€ãã¡ã€ã³ãçµåãããæäœãæã(äŸãã°ãGu et al., Meth. Enzymol., 502:25-41, 2012ããåç
§)ã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãå
å æ§ãã¯ãããæ£è
ã®ãããªç¹å®ã®çåœäœã«å€©ç¶ã«èŠåºãããååã现èãçµç¹ãåã¯èåš(äŸãã°ãé è¡å¹¹çŽ°èãåã¯å·šæ žçãè¡å°æ¿(thrombocyte)ãè¡å°æ¿(platelet)ãèµ€è¡çããã¹ã现èã骚é«èœçïŒmyeoblastïŒã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢çŽ°èãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ã»ãã©ãŒçŽ°èãT-ãªã³ãçãåã¯B-ãªã³ãçã®ãããªé è¡ç³»åã®çŽ°è)ã®ãããªç©è³ªãèšèŒããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãççèœå(engraftment potential)ãã¯ãé è¡å¹¹çŽ°èåã³é è¡åé§çŽ°èãçµç¹ã«åå®çããèœåãæãããã«äœ¿çšããããã®ãããªçŽ°èãèªç¶ã«åŸªç°ããŠããããåã¯ç§»æ€ã«ãã£ãŠæäŸããããã«é¢ãããªããåèšçšèªã¯ã现èã®çµç¹ããŒãã³ã°åã³æ³šç®ããçµç¹å
ãžã®çŽ°èã®ã³ãããŒåœ¢æã®ãããªãççãåãå·»ãããåã¯ççã«è³ãå
šãŠã®äºè±¡ãå
å«ãããççã®å¹çåã¯ççã®å²åã¯ãåœæ¥è
ã«å
¬ç¥ã®ä»»æã®èšåºçã«èš±å®¹ããããã©ã¡ãŒã¿ãçšããŠè©äŸ¡åã¯å®éããããšãã§ããäŸãã°ã競åçåççãŠããã(competitive repopulating unit)(CRU)ãè©äŸ¡ããããšïŒå¹¹çŽ°èãããŒãã³ã°ãããã³ãããŒåœ¢æããããåã¯ççããçµç¹ã«ãããŠãããŒã«ãŒãåã蟌ãŸããããšè¥ããã¯çºçŸããããšïŒåã¯ãçŸæ£ã®é²è¡ãé è¡å¹¹çŽ°èåã³é è¡åé§çŽ°èã®çåãè¥ããã¯ã¬ã·ããšã³ãã®çåã«ããã察象ã®é²è¡ãè©äŸ¡ããããšããå«ãŸããããšããããççã¯ã移æ€åŸã®æ«æ¢¢è¡äžã®çœè¡ç现èæ°ã枬å®ããããšã«ãã£ãŠãå€å®ããããšãã§ãããççã¯ã骚é«åžåŒãµã³ãã«ã«ããããããŒçŽ°èã«ãã骚é«çŽ°èã®å埩çã枬å®ããããšã«ãã£ãŠè©äŸ¡ããããšãã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãå€å æ§(exogenous)ãã¯ãããã®æ£è
ã®ãããªç¹å®ã®çåœäœã«å€©ç¶ã«ã¯èŠåºãããªãååã现èãçµç¹ãåã¯èåš(äŸãã°ãé è¡å¹¹çŽ°èãåã¯å·šæ žçãè¡å°æ¿(thrombocyte)ãè¡å°æ¿(platelet)ãèµ€è¡çããã¹ã现èã骚é«èœçïŒå¥œå¡©åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢çŽ°èãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ã»ãã©ãŒçŽ°èãT-ãªã³ãçãåã¯B-ãªã³ãçã®ãããªé è¡ç³»åã®çŽ°è)ã®ãããªç©è³ªãèšèŒãããã¬ã·ããšã³ãçåœäœïŒäŸãã°ãã¬ã·ããšã³ãæ£è
ïŒã«ãšã£ãŠå€å æ§ã§ããç©è³ªã¯ãåèšç©è³ªã®ç±æ¥ã§ãããããŒçåœäœïŒäŸãã°ããããŒå¯Ÿè±¡ïŒã®äžã«å€©ç¶ã«ååšããããšããããäŸãã°ãåçš®ç°ç³»ã®çŽ°è移æ€çã¯ãã¬ã·ããšã³ãã«å¯ŸããŠå€å æ§ã§ãããããããŒã«å¯ŸããŠã¯çæ¥ã§ãããå€å æ§ç©è³ªã«ã¯ãå€éšäŸçµŠæºããçåœäœã«åã¯ããããæœåºããå¹é€ç©ã«æäŸããããã®ãå«ãŸããã
çšèªãå®å
šé·æäœãåã³ãã€ã³ã¿ã¯ããªæäœãã¯ãæ¬åºé¡ã§ã¯ããã®å®è³ªçã«ã€ã³ã¿ã¯ããªåœ¢æ
ã®æäœãæãããã«äºæçã«äœ¿çšãããæ¬åºé¡ã§å®çŸ©ããããããªæäœãã©ã°ã¡ã³ãã§ã¯ãªãããã®ããã«ãIgG æäœã«ã€ããŠã¯ãã€ã³ã¿ã¯ããªæäœã¯ãå¯å€é åãå®åžžé åãåã³Fcé åãããããå«ã2ã€ã®ééã䞊ã³ã«å¯å€é åãåã³å®åžžé åãããããå«ã2ã€ã®è»œéããå«ããããå
·äœçã«ã¯ãã€ã³ã¿ã¯ããªIgGã¯ã軜éå¯å€é å(VL)åã³è»œéå®åžžé å(CL)ãããããå«ã2ã€ã®è»œéãå«ãã䞊ã³ã«ééå¯å€é å(VH)åã³3ã€ã®ééå®åžžé å(CH1, CH2,åã³CH3)ãããããå«ã2ã€ã®ééãå«ããCH2åã³CH3ã¯ãééã®Fcé åãè¡šãã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãéªšæ Œé åãåã¯ãFWé åãã¯ãæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®CDRã«é£æ¥ããã¢ããé
žæ®åºãå«ãã FWé åã®æ®åºã¯ãäŸãã°ãããæäœãããåæäœãã¢ãã¯ããŒãã«æäœãæäœãã©ã°ã¡ã³ããFabãã©ã°ã¡ã³ããåéæäœãã©ã°ã¡ã³ããscFvãã©ã°ã¡ã³ããæäœãã¡ã€ã³ãåã³ãã€ã¹ãã·ãã£ãã¯æäœãªã©ã«ååšããããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãå
ç«çŽ°èãã¯ãéå®ããããã®ã§ã¯ãªãããè¡æ¶²åŠçãªèµ·æºãæã¡ããã€ããã®å
ç«åå¿ã«ãããŠåœ¹å²ãæãã现èãå«ãããšãæå³ããããå
ç«çŽ°èãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããT现èåã³ããã¥ã©ã«ã»ãã©ãŒ(NK)现èãæãããããããã¥ã©ã«ã»ãã©ãŒçŽ°èã¯ãåœè©²æè¡åéã§ããç¥ãããŠããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãããã¥ã©ã«ã»ãã©ãŒçŽ°èãšããŠã¯ãNK-92现èã®ãããªçŽ°èæ ªãæãããããNK现èæ ªã®æŽãªãäŸãšããŠã¯ãNKGãYTãNK-YSãHANK-1ãYTS现èãåã³NKL现èãæãããããå
ç«çŽ°èã¯ãåçš®ç°ç³»åã¯èªå·±ã§ããããšãããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãå
é€çŽ°èã¯ãT现èã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãé è¡å¹¹çŽ°èã(ãHSCã)ãšã¯ãèªå·±è€è£œããèœåãåã³é¡ç²ç(äŸãã°ãå骚é«çã奜äžçïŒå¥œé
žçã奜塩åºç)ãèµ€è¡ç(äŸãã°ã網ç¶èµ€è¡çãèµ€è¡ç)ãè¡å°æ¿(thrombocyte)(äŸãã°ãå·šæ žèœçãè¡å°æ¿(platelet)ç£çå·šæ žçãè¡å°æ¿(platelets))ãåç(äŸãã°ãåçããã¯ããã¡ãŒãž)ãæš¹ç¶çŽ°èããã¯ãã°ãªã¢ãç ŽéªšçŽ°èãåã³ãªã³ãç(äŸãã°ãNK现èãB现èåã³T现è)ãå«ãããããã«éå®ãããªãå€æ§ãªç³»åãå«ãæçè¡æ¶²çŽ°èã«ååããèœåããæããæªæçè¡æ¶²çŽ°èãæãããã®ãããªçŽ°èã¯ãCD34+现èãå«ãããšããããCD34+现èã¯ãCD34现èè¡šé¢ããŒã«ãŒãçºçŸããæªæç现èã§ãããããã§ã¯ãCD34+现èã¯ãäžèšã«å®çŸ©ããã幹现èã®ç¹æ§ãæãã现èã®äºéå£ãå«ããšèããããŠããããäžæ¹ããŠã¹ã§ã¯ãHSCã¯CD34-ã§ãããæŽã«ãHSCã¯ãŸããé·æåççHSC(LT-HSC)åã³çæåççHSC(ST-HSC)ãæããLT-HSCåã³ST-HSCã¯ãæ©èœçãªå¯èœæ§åã³çŽ°èè¡šé¢ããŒã«ãŒã®çºçŸã«åºã¥ããŠåºå¥ããããäŸãã°ãããHSCã¯ãCD34+ãCD38-ãCD45RA-ãCD90+ãCD49F+ãåã³lin-(CD2ãCD3ãCD4ãCD7ãCD8ãCD10ãCD11BãCD19ãCD20ãCD56ãCD235Açãå«ãæçç³»åããŒã«ãŒã«ã€ããŠãã¬ãã£ã)ã§ãããããŠã¹ã§ã¯ã骚é«LT-HSCã¯ãCD34-ãSCA-1+ãC-kit+ãCD135-ãSlamfl/CD150+ãCD48-ãåã³lin-(Ter119ãCD11bãGr1ãCD3ãCD4ãCD8ãB220ãIL7raçãå«ãæçç³»åããŒã«ãŒã«ã€ããŠãã¬ãã£ã)ã§ããããäžæ¹ãST-HSCã¯ãCD34+ãSCA-1+ãC-kit+ãCD135-ãSlamfl/CD150+ãåã³lin-(Ter119ãCD11bãGr1ãCD3ãCD4ãCD8ãB220ãIL7raçãå«ãæçç³»åããŒã«ãŒã«ã€ããŠãã¬ãã£ã)ã§ãããå ããŠãST-HSCã¯ããã¡ãªã¹ã¿ã·ã¹æ¡ä»¶äžã§ãLT-HSCãããéæ¢æ§ãäœããå¢æ®æ§ãé«ããããããLT-HSCã¯ãèªå·±è€è£œèœãããé«ã(å³ã¡ãLT-HSCã¯ãæ人æãéããŠçåããã¬ã·ããšã³ãã代ã
ä»ããŠé£ç¶çã«ç§»æ€ããããšãã§ãã)ã®ã«å¯ŸããST-HSCã¯ãèªå·±è€è£œèœãéãããŠãã(å³ã¡ãST-HSCã¯ãéãããæéã®ã¿çåããé£ç¶ããŠç§»æ€ããããšã¯ã§ããªã)ããããã®HSCã®äœãããæ¬åºé¡ã«èšèŒãããæ¹æ³ã«ãããŠäœ¿çšããåŸããST-HSCã¯ãããããé«åºŠã«å¢æ®æ§ã§ãããããæ
ãååããåŸä»£ãããè¿
éã«çãåŸãã®ã§ãç¹ã«æçšã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãé è¡å¹¹çŽ°èã®æ©èœçãªå¯èœæ§ãã¯ã1)å€èœæ§(multi-potency)ïŒããã¯ãéå®ããããã®ã§ã¯ãªãããé¡ç²çäŸãã°ãå骚é«çã奜äžçïŒå¥œé
žçã奜塩åºçãèµ€è¡çäŸãã°ã網ç¶èµ€è¡çãèµ€è¡çãè¡å°æ¿(thrombocyte)äŸãã°ãå·šæ žèœçãè¡å°æ¿(platelet)ç£çå·šæ žçãè¡å°æ¿(platelets)ãåçäŸãã°ãåçããã¯ããã¡ãŒãžïŒœãæš¹ç¶çŽ°èããã¯ãã°ãªã¢ãç ŽéªšçŽ°èãåã³ãªã³ãçäŸãã°ãNK现èãB-现èåã³T-现èçãå«ããè€æ°ã®æ§ã
ãªè¡æ¶²ç³»åã«ååããèœåãæãïŒã2)èªå·±è€è£œïŒããã¯ãæ¯çŽ°èãšåçã®å¯èœæ§ãæããåšçŽ°èãçããããé è¡å¹¹çŽ°èã®èœåãæããæŽã«ããã®èœåã¯æ¶èããããšãªãåã
ã®çåæéãéããŠç¹°ãè¿ãèµ·ããããïŒã䞊ã³ã«3)é è¡å¹¹çŽ°èåã¯ãã®åŸä»£ãã移æ€ã¬ã·ããšã³ãã«åå°å
¥ããããšãé è¡å¹¹çŽ°èãããã«ããŒãã³ã°ããçç£çã§æç¶çãªé è¡ãå確ç«ããäœçšèœããå«ããé è¡å¹¹çŽ°èã®æ©èœçãªç¹æ§ãæãã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãããæäœãã¯ãããçæ®ç³»åå
ç«ã°ãããªã³é
åã«ç±æ¥ããå¯å€é ååã³å®åžžé åãæããæäœãå«ãããšãæå³ããããããæäœã¯ãããçæ®ç³»åå
ç«ã°ãããªã³é
åã«ãã£ãŠã³ãŒããããŠããªãã¢ããé
žæ®åº(äŸãã°ãin vitroã§ã®ã©ã³ãã ãªè¥ããã¯éšäœç¹ç°çãªå€ç°èªçºã«ãã£ãŠå°å
¥ãããå€ç°ãåã¯in vivoã§ã®éºäŒååæ§æè¥ããã¯äœçŽ°èå€ç°ã«ãã£ãŠå°å
¥ãããå€ç°)ãå«ãããšããããããããæ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãããæäœãã«ãããŠã¹çã®å¥ã®åºä¹³åç©çš®ã®çæ®ç³»åã«ç±æ¥ããCDRé
åãããã®éªšæ Œé
åäžã«ç§»æ€ããæäœãå«ãŸããããšããæå³ããŠããªããããæäœãããã现èã«ãããŠ(äŸãã°ãçµæãçºçŸã«ãã£ãŠ)ãåã¯æ©èœçã«åæ§æããããå
ç«ã°ãããªã³(äŸãã°ãééåã³ïŒåã¯è»œé)éºäŒåãçºçŸãåŸãé-ããåç©åã¯åæ žè¥ããã¯çæ žçŽ°èã«ãã£ãŠãç£çããããšããããããæäœãåéæäœã§ããå Žåãããã¯çæ¥ã®ããæäœã«ã¯èŠåºãããªããªã³ã«ãŒã»ãããããå«ãããšããããäŸãã°ãFvã¯ã2åããçŽ8åã®ã°ãªã·ã³åã¯ä»ã®ã¢ããé
žæ®åºã®ãããªãªã³ã«ãŒã»ãããããå«ãããšãããããªã³ã«ãŒã»ããããã¯åèšééã®å¯å€é ååã³åèšè»œéã®å¯å€é åãé£çµããããã®ãããªãªã³ã«ãŒã»ããããã¯ãããèµ·æºã§ãããšèŠãªããããããæäœããããå
ç«ã°ãããªã³é
åã«ç±æ¥ããæäœã©ã€ãã©ãªã䜿çšãããã¡ãŒãžã»ãã£ã¹ãã¬ã€æ³ãå«ããåœè©²æè¡åéã§å
¬ç¥ã®çš®ã
ã®æ¹æ³ã«ãã£ãŠäœè£œããããšããããããæäœã¯ãŸããæ©èœçãªå
å æ§ã®å
ç«ã°ãããªã³ãçºçŸããããšã¯ã§ããªãããããå
ç«ã°ãããªã³éºäŒåãçºçŸããããšãã§ãããã©ã³ã¹ãžã§ããã¯ã»ããŠã¹ã䜿çšããŠç£çããããšããã(äŸãã°ãPCTå
¬éçªå·WO 1998/24893; WO 1992/01047; WO 1996/34096; WO 1996/33735;ç±³åœç¹èš±ç¬¬5,413,923å·;第5,625,126å·;第5,633,425å·;第5,569,825å·;第5,661,016å·;第5,545,806å·;第5,814,318å·;第5,885,793å·;第5,916,771å·;åã³ç¬¬5,939,598å·ãåç
§ã®ããš)ã
ãããåãæäœãšã¯ãé-ããå
ç«ã°ãããªã³ã«ç±æ¥ããé
åãæå°éã«å«ãæäœããããåŸã£ãŠãé-ããïŒäŸãã°ãããŠã¹ïŒæäœã®ãããåãäœã¯ãé-ããæäœã«ç±æ¥ããé
åãæå°éã«å«ãæäœã§ãããFWé åã®å
šãŠåã¯å®è³ªçã«å
šãŠã¯ãããå
ç«ã°ãããªã³é
åã®FWé åã§ããããšããããããåæäœã¯ãŸããå
ç«ã°ãããªã³å®åžžé å(Fc)ã®å°ãªããšãäžéšãå
žåçã«ã¯ããå
ç«ã°ãããªã³ã»ã³ã³ã»ã³ãµã¹é
åã®å°ãªããšãäžéšããå«ãããšããããæäœãããåããæ¹æ³ã¯ãåœè©²æè¡åéã§å
¬ç¥ã§ãããåã³ãäŸãã°ãRiechmannããNature 332:323-7,1988ïŒç±³åœç¹èš±ç¬¬5,530,101å·;第5,585,089å·;第5,693,761å·;第5,693,762å·;åã³ç¬¬6,180,370å·ã«èšèŒãããŠããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªããã¡ã©ãæäœãšã¯ãé-ããå
ç«ã°ãããªã³ïŒäŸãã°ãã©ããåã¯ããŠã¹æäœïŒã«ç±æ¥ããå¯å€é
ååã³ããå
ç«ã°ãããªã³å®åžžé åïŒå
žåçã«ã¯ããå
ç«ã°ãããªã³é³åããéžã¶ïŒããæããæäœãããããã¡ã©æäœãäœæããæ¹æ³ã¯ãåœè©²æè¡åéã§å
¬ç¥ã§ãããMorrison, 1985, Science 229(4719):1202-7; Oi et al., 1986, BioTechniques 4:214-221; Gillies et al., 1985, J. Immunol. Methods 125:191-202; U.S. Pat. Nos. 5,807,715; 4,816,567; åã³ 4,816,397ãåç
§ã
çšèªãè±-å
ç«åãããïŒâde-immunized"ïŒãåã¯ãè±-å
ç«åïŒ"de-immunization"ïŒããšã¯ãæ¬åºé¡ã§äœ¿çšãããå Žåãéçåæ§ç¯ç©ãããã«ãããŠé-å
ç«åæ§ã«ããããšã«ãã£ãŠãåã¯ããæžåŒ±ããå
ç«åæ§ã«ããããšã«ãã£ãŠãå
ã®åèšéçåæ§ç¯ç©(åã¯èŠªæäœ)ãæ¹å€ããããšã«é¢ãããè±-å
ç«åæäœã¯ãé-ããèµ·æºã®éšå(äŸãã°ãéªšæ Œé ååã³ïŒåã¯CDR)ãå«ããæ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãè±-å
ç«åãããæäœãã¯ã察象ã®å
ç«ã·ã¹ãã ã掻æ§åããªãããã«ãå€ç°ã«ãã£ãŠè±-å
ç«åããæäœãæã(äŸãã°ãNanus et al., J. Urology 170:S84-S89ã2003ïŒWO98/52976ïŒWO00/34317)ã
æ¬åºé¡ã§äœ¿çšãããå Žåããè¬ç©å¯Ÿæäœæ¯(drug-to-antibody ratio)ãåã¯ãDARãã¯ãæäœã«ã³ã³ãžã¥ã²ãŒããã现èæ¯çŽ (äŸãã°ãã¢ãããã·ã³)ã®æ°ãæããäžè¬çã«ãADCã®DARã¯1ãã8ã®ç¯å²ã§ããããšãããããæäœã®çµåéšäœã®æ°ã«ãã£ãŠãããé«ãæèŒãå¯èœã§ãããåŸã£ãŠãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§èšèŒãããæ-CD45 ADCã¯ã1ã2ã3ã4ã5ã6ã7ãåã¯8ã®DARãæããã
æ¬åºé¡ã§äœ¿çšãããå Žåãé è¡å¹¹çŽ°è移æ€ããå¿
èŠãšãããæ£è
ã¯ã1皮以äžã®è¡æ¶²çŽ°èã®åã«æ¬ é¥åã¯æ¬ æã瀺ãæ£è
ã䞊ã³ã«å¹¹çŽ°èé害ãèªå·±å
ç«çŸæ£ããããåã¯æ¬åºé¡ã«èšèŒãããä»ã®ç
æ
ãæããæ£è
ãå«ããé è¡å¹¹çŽ°èã¯ãäžè¬ã«ã1)å€èœæ§(multi-potency)ãåŸã£ãŠãéå®ããããã®ã§ã¯ãªãããé¡ç²çïŒäŸãã°ãå骚é«çã奜äžçïŒå¥œé
žçã奜塩åºç)ãèµ€è¡ç(äŸãã°ã網ç¶èµ€è¡çãèµ€è¡ç)ãè¡å°æ¿(thrombocyte)(äŸãã°ãå·šæ žèœçãè¡å°æ¿(platelet)ç£çå·šæ žçãè¡å°æ¿(platelets))ãåç(äŸãã°ãåçããã¯ããã¡ãŒãž)ãæš¹ç¶çŽ°èããã¯ãã°ãªã¢ãç ŽéªšçŽ°èãåã³ãªã³ãç(äŸãã°ãNK现èãB-现èåã³T-现è)çãå«ããè€æ°ã®æ§ã
ãªè¡æ¶²ç³»åã«ååããããšãã§ããã2)èªå·±è€è£œãåŸã£ãŠãæ¯çŽ°èãšåçã®å¯èœæ§ãæããåšçŽ°èãçããããããšãã§ããã䞊ã³ã«3)移æ€ã¬ã·ããšã³ãã«åå°å
¥ããããšãé è¡å¹¹çŽ°èãããã«ããŒãã³ã°ããçç£çã§æç¶çãªé è¡ãå確ç«ããäœçšèœãã瀺ããåŸã£ãŠãé è¡ç³»åã®1皮以äžã®çŽ°èåã«ãããŠæ¬ é¥ãããåã¯æ¬ æããæ£è
ã«ãin vivoã§ãæ¬ é¥ãããåã¯æ¬ æãã现èã®éå£ãåæ§æããããã«ãé è¡å¹¹çŽ°èãæäžããããšããããäŸãã°ãåèšæ£è
ã¯ãããã«çœ¹æ£ããŠããããšããããåèšæ¬ æã¯ãããæ§çŽ°èéå£ãéžæçã«åã¯éç¹ç°çã«æžå°ãããååŠçæ³å€åã¯ä»ã®è¬å€ãæäžããããšã«ãã£ãŠåŒãèµ·ããããããšããããæŽã«ãåã¯ãã®ä»£ãããšããŠãåèšæ£è
ã¯éç¶èµ€è¡ç貧è¡ããµã©ã»ãã¢ããã¡ã³ã³ã貧è¡ãåçäžè¯æ§è²§è¡ãåã³ãŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀çã®ç°åžžãã¢ã°ããã³ç(äŸãã°ãé-æªæ§ç°åžžãã¢ã°ããã³ç)ã«çœ¹æ£ããŠããããšããããåèšå¯Ÿè±¡ã¯ãã¢ããã·ã³ã»ãã¢ãããŒãŒé床è€åå
ç«äžå
šç(ADA SCID)ãHIV/AIDSãç°ææ§çœè³ªãžã¹ãããã£ãŒããã€ã¢ã¢ã³ã-ãã©ãã¯ãã¡ã³è²§è¡ãåã³ã·ã¥ã¯ãã¯ãã³-ãã€ã¢ã¢ã³ãçå矀ã«çœ¹æ£ããŠãã察象ã§ããããšããããåèšå¯Ÿè±¡ã¯éºäŒæ§ã®è¡æ¶²é害(äŸãã°ãéç¶èµ€è¡ç貧è¡)åã¯èªå·±å
ç«çŸæ£ãæããããåã¯ãã®åœ±é¿ãåããŠããããšããããæŽã«ãåã¯ãã®ä»£ãããšããŠãåèšå¯Ÿè±¡ã¯ãç¥çµèœçŽ°èè
«åã¯è¡æ¶²ããçã®æªæ§è
«çãæããããåã¯ãã®åœ±é¿ãåããŠããããšããããäŸãã°ãåèšå¯Ÿè±¡ã¯ãçœè¡ç
ããªã³ãè
«åã¯éªšé«è
«ãæããŠããããšããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå¯Ÿè±¡ã¯ãæ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«åã¯é-ããžãã³ã»ãªã³ãè
«(non-Hodgkinâs lymphoma)ãæãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå¯Ÿè±¡ã¯éªšé«ç°åœ¢æçå矀ãæãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå¯Ÿè±¡ã¯ã匷ç®çãå€çºæ§ç¡¬åçã朰çæ§å€§è
žçãã¯ããŒã³ç
ãIåç³å°¿ç
çã®èªå·±å
ç«çŸæ£ãåã¯æ¬åºé¡ã«èšèŒãããå¥ã®èªå·±å
ç«æ§ã®ç
æ
ãæãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå¯Ÿè±¡ã¯ããã¡ã©æåã¬ã»ãã¿ãŒT-现è(CART)çæ³ãå¿
èŠãšãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå¯Ÿè±¡ã¯ã代è¬æ§è²¯èµé害ãæããããåã¯ãã®åœ±é¿ãåããŠãããåèšå¯Ÿè±¡ã¯ãã°ãªã³ãŒã²ã³èç©çãã ã³å€ç³çããŽãŒã·ã§ç
ãããŒã©ãŒç
ãã¹ãã£ã³ãŽè質çãç°ææ§çœè³ªãžã¹ãããã£ãŒããããªã矀ããéžæããã代è¬é害ãåã¯æ¬åºé¡ã«é瀺ãããæ²»çåã³çæ³ããæ©æµãåŸãããšãã§ããä»»æã®ä»ã®çŸæ£åã¯é害ïŒéå®ããããã®ã§ã¯ãªãããé床è€åå
ç«äžå
šçããŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀ãé«å
ç«ã°ãããªã³Mçå矀ããã§ãã£ã¢ãã¯-æ±ç
ãéºäŒæ§ãªã³ãçµç¹ççã倧çç³éªšç
ã骚圢æäžå
šçã貯èµçŸæ£ããµã©ã»ãã¢ã»ã¡ãžã£ãŒãéç¶èµ€è¡ççãå
šèº«æ§ç¡¬åçãå
šèº«æ§ãšãªããããŒãã¹ãå€çºæ§ç¡¬åçãè¥å¹Žæ§é¢ç¯ãªãŠããïŒã䞊ã³ã«"Bone Marrow Transplantation for Non-Malignant disease"ãASH Education Bookã1:319-338(2000)ïŒãã®é瀺ã¯ãé è¡å¹¹çŽ°è移æ€çæ³ãåŠæ¹ããããšã«ãã£ãŠæ²»çãããå¯èœæ§ã®ããç
æ
ã«é¢ãããã®ã§ããããã®å
šäœãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã«èšèŒãããŠããçŸæ£åã¯é害ãã«çœ¹æ£ããŠãããåã¯ãã®åœ±é¿ãåããŠããããšããããæŽã«ãåã¯ãã®ä»£ãããšããŠãé è¡å¹¹çŽ°è移æ€ããå¿
èŠãšãããæ£è
ã¯ãåè¿°ã®ç
æ
ã®ãã¡ã®1çš®ã«çœ¹æ£ããŠããåã¯çœ¹æ£ããŠããªãæ£è
ïŒããã«ãããããããå·šæ žçãè¡å°æ¿(thrombocyte)ãè¡å°æ¿(platelet)ãèµ€è¡çããã¹ã现èã骚é«èœçã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢ãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ã»ãã©ãŒçŽ°èãT-ãªã³ãçãåã³B-ãªã³ãççã®é è¡ç³»åå
ã®1皮以äžã®å
å æ§ã®çŽ°èåã®ã¬ãã«ã®äœäžïŒ»äŸãã°ããã®ä»ã®ç¹ã§ã¯å¥åº·ã§ãã察象ã®ã¬ãã«ãšæ¯èŒããŠãäœäžïŒœã瀺ãïŒã§ããããšããããåœæ¥è
ã®äžã®ããè
ã¯ãäŸãã°ãåœè©²æè¡åéã§å
¬ç¥ã®æé ã®äžã§ãç¹ã«ããããŒã»ãµã€ãã¡ããªãŒåã³èå
掻æ§å现èéžå¥(FACS)æ¹æ³ã«ãã£ãŠãåèšã®çŽ°èååã¯ä»ã®è¡æ¶²çŽ°èã®åã®ãã¡ã®1皮以äžã®ãã®ã®ã¬ãã«ãããã®ä»ã®ç¹ã§ã¯å¥åº·ã§ãã察象ã«å¯ŸããŠãäœäžããŠãããã©ããã容æã«æ±ºå®ããããšãã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãã¢ãã¯ããŒãã«æäœãïŒmAbïŒã¯ãä»»æã®çæ žçç©ãåæ žçç©ãåã¯ãã¡ãŒãžã»ã¯ããŒã³ãå«ãåäžã®ã¯ããŒã³ããåŸãããæäœãæãã䞊ã³ã«ãããç£çããæ¹æ³ã®ããšã§ã¯ãªããæ¬é瀺ã§æçšãªã¢ãã¯ããŒãã«æäœãããã€ããªããŒããçµæããåã³ãã¡ãŒãžã»ãã£ã¹ãã¬ã€æè¡ãåã¯ãããã®çµåãã䜿çšããããšãå«ããåœæè¡åéã§å
¬ç¥ã®å€çš®å€æ§ãªæè¡ã䜿çšããŠèª¿è£œããããšãã§ãããå¥æ®µã«ç€ºããªããã°ãçšèªãã¢ãã¯ããŒãã«æäœãã¯ãã¿ãŒã²ããã»ã¿ã³ãã¯è³ªã«ç¹ç°çã«çµåããããšãã§ãããã€ã³ã¿ã¯ããªåååã³æäœãã©ã°ã¡ã³ãïŒäŸãã°ãFabåã³F(ab')2ãã©ã°ã¡ã³ãçãå«ãïŒã®äž¡æ¹ãå«ãããšãæå³ãããæ¬åºé¡ã§äœ¿çšãããå ŽåãFabåã³F(ab')2ãã©ã°ã¡ã³ãã¯ãã€ã³ã¿ã¯ããªæäœã®Fcãã©ã°ã¡ã³ããæ¬ ãæäœãã©ã°ã¡ã³ããæãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæäœãã©ã°ã¡ã³ãã¯ãFcé åãå«ãã
æ¬åºé¡ã§äœ¿çšãããå Žåããäžæ§æäœ(neutral antibody)ãã¯ãã¬ã»ãã¿ãŒã®ãªã¬ã³ããžã®çµååã¯é
µçŽ ã®åºè³ªãšã®çžäºäœçšçãå«ããåå¥ã®ã¿ãŒã²ããåã¯ç¹å®ã®ã¿ãŒã²ãã(äŸãã°ãCD45)ã®æŽ»æ§ãææã«äžåãé®æãé»å®³ãç¡å¹åãæžå°åã¯åŠšå®³ããããšãã§ããªãæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ããããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãã¬ã·ããšã³ããã¯ãé è¡å¹¹çŽ°èã®éå£ãå«ã移æ€ççã®ç§»æ€çãåããæ£è
ãæããã¬ã·ããšã³ãã«æäžããã移æ€çŽ°èã¯ãäŸãã°ãèªå®¶ãåç³»ãåã¯åçš®ç°ç³»çŽ°èã§ããããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªããµã³ãã«ãã¯ã察象ããæ¡åãããæ€äœ(äŸãã°ãè¡æ¶²ãè¡æ¶²æå(äŸãã°ãè¡æž
åã¯è¡æŒ¿)ãå°¿ãåŸæ¶²ãçŸæ°Žãè³èé«æ¶²ãçµç¹(äŸãã°ãèç€åã¯çç®)ãèµæ¶²ã絚æ¯è絚æ¯ãµã³ãã«ãåã³çŽ°è)ãæãã
æ¬åºé¡ã§äœ¿çšãããå ŽåãçšèªãscFvãã¯ãæäœç±æ¥ã®ééã®å¯å€ãã¡ã€ã³ãšè»œéã®å¯å€ãã¡ã€ã³ãšãçµåããŠ1æ¬ã®éã圢æããŠãããåéFvæäœãæããscFvãã©ã°ã¡ã³ãã¯ããªã³ã«ãŒã«ãã£ãŠåé¢ããããæäœè»œéã®å¯å€é å(VL) (äŸãã°ãCDR-L1ãCDR-L2ãåã³ïŒåã¯CDR-L3)åã³æäœééã®å¯å€é å(VH) (äŸãã°ãCDR-H1ãCDR-H2ãåã³ïŒåã¯CDR-H3)ãå«ãåäžã®ããªããããéãå«ããscFvãã©ã°ã¡ã³ãã®VLé ååã³VHé åãé£çµãããªã³ã«ãŒã¯ãã¿ã³ãã¯è³ªãæ§æããã¢ããé
žããæ§æãããããããã»ãªã³ã«ãŒã§ããããšãããã代æ¿ã®ãªã³ã«ãŒããã¿ã³ãã¯è³ªå解ã«å¯ŸããscFvãã©ã°ã¡ã³ãã®èæ§ãå¢å€§ãããããã«(äŸãã°ãD-ã¢ããé
žãå«æãããªã³ã«ãŒ)ãscFvãã©ã°ã¡ã³ãã®æº¶è§£æ§ãå¢å€§ãããããã«(äŸãã°ãããªãšãã¬ã³ã»ã°ãªã³ãŒã«å«æãªã³ã«ãŒåã¯ç¹°ãè¿ãã®ã°ãªã·ã³åã³ã»ãªã³æ®åºãå«æããããªããããçã®èŠªæ°Žæ§ãªã³ã«ãŒ)ãåèšååã®çç©ç©çåŠçå®å®æ§ãæ¹åããããã«(äŸãã°ãååå
åã¯ååéãžã¹ã«ãã£ãçµåã圢æããã·ã¹ãã€ã³æ®åºãå«æãããªã³ã«ãŒ)ãåã¯åèšscFvãã©ã°ã¡ã³ãã®å
ç«åæ§ã匱ããããã«(äŸãã°ãã°ãªã³ã·ã«åéšäœãå«æãããªã³ã«ãŒ)ã䜿çšããããšããããæ¬åºé¡ã«èšèŒãããscFvååã®å¯å€é åããããããç±æ¥ããæäœååããã¢ããé
žé
åãå€åããããã«ãæ¹å€ããããšãã§ããããšããŸããåœæ¥è
ã¯ç解ãããäŸãã°ãscFvã®äœçšèœïŒå¯Ÿå¿ããæäœãèªèããæåã«çµåããäœçšèœïŒãä¿ååã¯å¢åŒ·ããããã«ãã¢ããé
žæ®åºã§ã®ä¿åç眮æåã¯å€åããããããã¯ã¬ãªããåã¯ã¢ããé
žçœ®æã(äŸãã°ãCDRåã³ïŒåã¯éªšæ Œæ®åºã«ãããŠ)è¡ãããšãããã
ãç¹ç°çãªçµåãåã¯ãç¹ç°çã«çµåããããšããçšèªã¯ãæ¬åºé¡ã§äœ¿çšãããå Žåãæäœããã¿ã³ãã¯è³ªãåºãèªèãåã³çµåãããšãããããã寧ãç¹ç°çãªã¿ã³ãã¯è³ªæ§é (ãšãããŒã)ãèªèãåã³çµåããäœçšèœã®ããšããããæäœããšãããŒããAãã«ç¹ç°çã§ããå ŽåãæšèãããAããšåèšæäœãšãå«æããåå¿ç©äžã«ããšãããŒãA(åã¯éé¢ã®éæšèA)ãå«æããååãååšãããšãåèšæäœã«çµåããæšèAã®éãæžå°ãããäŸãã°ãæäœã¯ãããåèšæäœããæšèãããŠããå Žåã察å¿ããéæšèæäœã«ãã£ãŠããã®ã¿ãŒã²ãããã競åçã«è§£é¢ããããšããããªãã°ãã¿ãŒã²ããã«ãç¹ç°çã«çµåãããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæäœã¯ã¿ãŒã²ããïŒäŸãã°ãCD45ïŒã«ç¹ç°çã«çµåããïŒããåèšæäœãåèšã¿ãŒã²ããã«å¯ŸããŠãå°ãªããšãçŽ10-4 MãçŽ10-5 MãçŽ10-6MãçŽ10-7 MãçŽ10-8 MãçŽ10-9MãçŽ10-10 MãçŽ10-11 MãçŽ10-12Måã¯æªæºïŒæªæºã¯10-12æªæºã§ããæ°åãæå³ãããäŸãã°ã10-13ïŒã®KDãæããå Žåã§ããïŒã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§äœ¿çšãããå ŽåãçšèªãCD45ãžã®ç¹ç°ççµåãåã¯ãCD45ã«ç¹ç°çã«çµåãããã¯ãCD45ã«çµåããè¡šé¢ãã©ãºã¢ã³å
±é³Žã«ãã£ãŠæž¬å®ããå Žåã1.0Ã10-7 M以äžã®è§£é¢å®æ°(KD)ãæããæäœãæãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãKDããæšæºçãªãã€ãªã¬ã€ã€ãŒå¹²æžæ³(Bio-Layer Interferometry) (BLI)ã«åŸã£ãŠæž¬å®ãããããããåèšæäœã¯ãé
åãé¢é£ããŠãã2皮以äžã®æåã«ç¹ç°çã«çµåããããšãã§ããããšãç解ãããããäŸãã°ã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæäœã¯ãCD45ã®ããåã³é-ãã(äŸãã°ãããŠã¹åã¯é-ããã®éé·é¡)ãªã«ãœãã°ã®äž¡æ¹ã«ç¹ç°çã«çµåããããšããããåŸã£ãŠãæ¬åºé¡ã§äœ¿çšãããå ŽåããããCD45ã«ç¹ç°çã«çµåããããšã¯ãããCD45(åã³ãããããã1皮以äžã®é-ããçš®ã«ç±æ¥ããCD45)ãšçµåããããé-CD45ã¿ã³ãã¯è³ªãšã¯å®è³ªçã«çµåããªãæäœããããã奜ãŸããã¯ãåèšæäœã¯ã1x10-7M以äžã®KDã5x10-8 M以äžã®KDã3x10-8M以äžã®KDã1x10-8 M以äžã®KDãåã¯5x10-9M以äžã®KDã§ãããCD45ã«çµåãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãããCD45ã®æ§ã
ãªã¢ã€ãœãã©ãŒã ïŒäŸãã°ãCD45RA (Uniprot Accession No: P08575-8; é
åçªå·(SEQ ID NO): 2)ãCD45RO (NCBI Accession No: NP_563578.2; é
åçªå·(SEQ ID NO): 1)ãCD45RB (NCBI Accession No: XP_006711537.1; é
åçªå·(SEQ ID NO): 3)ãCD45RC (Uniprot Accession No. P08575-10; é
åçªå·(SEQ ID NO): 4)ãCD45RAB (NCBI Accession No: XP_006711535.1; é
åçªå·(SEQ ID NO): 5)ãCD45RBC (NCBI Accession No: XP_006711536.1; é
åçªå·(SEQ ID NO): 6)åã³CD45RABC (NCBI Accession No. NP_002829.3; é
åçªå·(SEQ ID NO): 7)ïŒã®å
ã®åã
1çš®ã®çŽ°èå€ãã¡ã€ã³ã«ãç¹ç°çã«çµåããããšãã§ãããåŸã£ãŠãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã®æäœã¯ãæ±-ç¹ç°çãªæ-CD45æäœïŒå³ã¡ãå
šãŠã®ããCD45ã¢ã€ãœãã©ãŒã ã®çŽ°èå€é åã«ç¹ç°çã«çµåããæäœïŒã§ããã
æ¬åºé¡ã§äœ¿çšãããå Žåãèªå¥ã幹现èé害ãã¯ã察象ã®ã¿ãŒã²ããçµç¹ãã³ã³ãã£ã·ã§ãã³ã°ããããšã«ãã£ãŠãåã³ïŒåã¯ã¿ãŒã²ããçµç¹äžã®å
å æ§ã®å¹¹çŽ°èéå£ãé€å»ããããšã«ãã£ãŠ(äŸãã°ã察象ã®éªšé«çµç¹ããå
å æ§ã®é è¡å¹¹çŽ°èéå£åã¯é è¡åé§çŽ°èéå£ãé€å»ããããšã«ãã£ãŠ)ãåã³ïŒåã¯å¯Ÿè±¡ã®ã¿ãŒã²ããçµç¹äžã«å¹¹çŽ°èãççãããåã¯ç§»æ€ããããšã«ãã£ãŠãæ²»çåã¯æ²»çããåŸãä»»æã®çŸæ£ãé害ãåã¯çç¶ãåºãæããäŸãã°ãã¿ã€ãIç³å°¿ç
ã¯ãé è¡å¹¹çŽ°è移æ€ã«ãã£ãŠæ²»çãããããšã瀺ãããŠãããæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã«åŸã£ãã³ã³ãã£ã·ã§ãã³ã°ãæçã§ããããšã瀺ãããŠãããæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠæ²»çããåŸãæŽãªãé害ã«ã¯ãéå®ããããã®ã§ã¯ãªãããéç¶èµ€è¡ç貧è¡ããµã©ã»ãã¢ããã¡ã³ã³ã貧è¡ãåçäžè¯æ§è²§è¡ããŠã£ã¹ã³ããâã¢ã«ããªããçå矀ãADA SCIDãHIV/AIDSãç°ææ§çœè³ªãžã¹ãããã£ãŒããã€ã¢ã¢ã³ãâãã©ãã¯ãã¡ã³è²§è¡ãåã³ã·ã¥ã¯ãã¯ãã³âãã€ã¢ã¢ã³ãçå矀ãæãããããæ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°åã³ïŒåã¯é è¡å¹¹çŽ°èã®ç§»æ€ã®æ¹æ³ãçšããŠæ²»çããããšãã§ããæŽãªãçŸæ£ã«ã¯ãéºäŒæ§è¡æ¶²é害(äŸãã°ãéç¶èµ€è¡ç貧è¡)åã³åŒ·ç®çãå€çºæ§ç¡¬åçã朰çæ§å€§è
žçãåã³ã¯ããŒã³ç
çã®èªå·±å
ç«çŸæ£ãå«ãŸãããæ¬åºé¡ã«èšèŒãããã³ã³ãã£ã·ã§ãã³ã°åã³ïŒåã¯ç§»æ€æ¹æ³ã䜿çšããŠæ²»çããåŸãæŽãªãçŸæ£ã«ã¯ãæªæ§è
«ç(äŸãã°ãç¥çµèœçŽ°èè
«)ãåã¯è¡æ¶²ãã(äŸãã°ãçœè¡ç
ããªã³ãè
«ãåã³éªšé«è
«)ãå«ãŸãããäŸãã°ãåèšããã¯ãæ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«ãåã¯é-ããžãã³ã»ãªã³ãè
«(non-Hodgkinâs lymphoma)ã§ããããšããããæ¬åºé¡ã«èšèŒãããã³ã³ãã£ã·ã§ãã³ã°åã³ïŒåã¯ç§»æ€æ¹æ³ãçšããŠæ²»çå¯èœãªæŽãªãçŸæ£ã«ã¯ã骚é«ç°åœ¢æçå矀ãå«ãŸãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšå¯Ÿè±¡ã¯ã代è¬æ§è²¯èµé害ãæããããåã¯ããã«ãã£ãŠåœ±é¿ãåããŠãããäŸãã°ãåèšå¯Ÿè±¡ã¯ãã°ãªã³ãŒã²ã³èç©çãã ã³å€ç³çããŽãŒã·ã§ç
ãããŒã©ãŒç
ãã¹ãã£ã³ãŽè質çãç°ææ§çœè³ªãžã¹ãããã£ãŒãããéžæããã代è¬æ§é害ãåã¯æ¬åºé¡ã«é瀺ãããæ²»çåã³çæ³ããæ©æµãåããããšãã§ããä»»æã®ä»ã®çŸæ£åã¯é害ïŒéå®ããããã®ã§ã¯ãªãããé床è€åå
ç«äžå
šçããŠã£ã¹ã³ããâã¢ã«ããªããçå矀ãé«å
ç«ã°ãããªã³M(IgM)çå矀ããã§ãã£ã¢ãã¯âæ±ç
ãéºäŒæ§ãªã³ãçµç¹ççã倧çç³éªšç
ã骚圢æäžå
šçã貯èµçŸæ£ããµã©ã»ãã¢ã»ã¡ãžã£ãŒãéç¶èµ€è¡ççãå
šèº«æ§ç¡¬åçãå
šèº«æ§ãšãªããããŒãã¹(systemic lupus erythematosus)ãå€çºæ§ç¡¬åçãè¥å¹Žæ§é¢ç¯ãªãŠããïŒã䞊ã³ã«"Bone Marrow Transplantation for Non-Malignant disease"ãASH Education Bookã1:319-338(2000)ïŒæ¬é瀺ã¯ãé è¡å¹¹çŽ°è移æ€çç©ãæäžããçæ³ã«ãã£ãŠæ²»çãããå¯èœæ§ã®ããç
æ
ã«é¢ãããã®ã§ããããã®å
šäœãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã«èšèŒãããŠããçŸæ£åã¯é害ãã«çœ¹æ£ããŠãããåã¯åœ±é¿ãåããŠããããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªã察象ãåã³ãæ£è
ãã¯ãæ¬åºé¡ã«èšèŒãããç¹å®ã®çŸæ£åã¯çç¶ã«å¯ŸããŠæ²»çãåãããããã®ãããªçåœäœããããäŸãã°ãããæ£è
ã®ãããªæ£è
ã¯ãå€å æ§ã®é è¡å¹¹çŽ°èã®ççãä¿é²ãããããã«ãé è¡å¹¹çŽ°è移æ€çæ³ã®åã«æ²»çãåããããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãèªå¥ãè¡æ¶²ããå®è³ªçã«ã¯ãªã¢ã©ã³ã¹ããããã¯ãæ²»çè¬å€ïŒäŸãã°ãæ-CD45æäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ããªã©ïŒãæ£è
ã«æäžããåŸã®æç¹ã§ãã£ãŠãåèšæ£è
ããåé¢ãããè¡æ¶²ãµã³ãã«äžã®åèšæ²»çè¬å€ã®æ¿åºŠããåèšæ²»çè¬å€ãåŸæ¥ã®æ¹æ³ã«ãã£ãŠæ€åºã§ããªããããªãã®ã§ããå Žå(äŸãã°ãåèšæ²»çè¬å€ããåèšæ²»çè¬å€ãæ€åºããããã«äœ¿çšãããããã€ã¹åã¯ã¢ãã»ã€ã®ãã€ãºéŸå€ãè¶
ããŠæ€åºã§ããªããããªå Žå)ã®ããšããããåœè©²æè¡åéã§ç¥ãããŠãããæ§ã
ãªææ³ïŒåœè©²æè¡åéã§ç¥ãããŠããåã¯æ¬åºé¡ã«èšèŒãããELISAããŒã¹ã®æ€åºã¢ãã»ã€ãªã©ïŒã䜿çšããŠãæäœãåã¯æäœãã©ã°ã¡ã³ãããæ€åºããããšããããæäœãåã¯æäœãã©ã°ã¡ã³ããæ€åºããããã«äœ¿çšããåŸãæŽãªãã¢ãã»ã€ãšããŠã¯ããšãããåœè©²æè¡åéã§å
¬ç¥ã®ãå
ç«æ²éæ³åã³ã€ã ãããããã»ã¢ãã»ã€ãæããããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªããã©ã³ã¹ãã§ã¯ã·ã§ã³ãã¯ããšã¬ã¯ãããã¬ãŒã·ã§ã³ããªããã§ã¯ã·ã§ã³ããªã³é
žã«ã«ã·ãŠã æ²æ®¿ãDEAE-ããã¹ãã©ã³ã»ãã©ã³ã¹ãã§ã¯ã·ã§ã³çã®ãããªãåæ žå®¿äž»çŽ°èåã¯çæ žå®¿äž»çŽ°èã«å€å æ§ã®DNAãå°å
¥ããããã«äžè¬çã«äœ¿çšããããä»»æã®å€çš®å€æ§ãªæè¡ã®ããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãæ²»çãããåã¯ãæ²»çãã¯ãçŸæ£çç¶ã®é節床åã³ïŒåã¯é »åºŠãæžå°ãããããšãçŸæ£çç¶åã³ïŒåã¯åèšçç¶ã®æ ¹æ¬çãªåå ãåãé€ãããšãçŸæ£çç¶åã³ïŒåã¯ãã®æ ¹æ¬çãªåå ã®é »åºŠåã¯å¯èœæ§ãæžå°ãããããšã䞊ã³ã«çŸæ£ã«ãã£ãŠçŽæ¥çåã¯éæ¥çã«åŒãèµ·ããããæå·ãæ¹ååã¯ä¿®åŸ©ããããšãããããæçãªåã¯ææã®èšåºçãªçµæãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããæ¬åºé¡ã«èšèŒããããããªæäœã³ã³ãã£ã·ã§ãã³ã°çæ³åã³ç¶ããŠè¡ãé è¡å¹¹çŽ°èã®ç§»æ€çæ³åŸã«ãæ£è
ã«ãããŠå€å æ§ã®é è¡çŽ°èã®ççãä¿é²ãããããšãæãããããæŽãªãæçãªçµæãšããŠã¯ãé è¡å¹¹çŽ°è移æ€ãå¿
èŠãšããŠããæ£è
ã«ãããŠãã³ã³ãã£ã·ã§ãã³ã°çæ³åã³ç¶ããŠå€å æ§ã®é è¡å¹¹çŽ°èã®ç§»æ€çãåèšæ£è
ã«æäžããåŸãé è¡å¹¹çŽ°èã®çŽ°èæ°ãå¢å ããããšåã¯çžå¯Ÿæ¿åºŠãå¢å ããããšããæãããããæ¬åºé¡ã«èšèŒãããçæ³ã®æçãªçµæãšããŠã¯ãŸããã³ã³ãã£ã·ã§ãã³ã°çæ³åã³ç¶ããŠè¡ãé è¡å¹¹çŽ°è移æ€çæ³ã®åŸãé è¡ç³»åã®1皮以äžã®çŽ°èïŒå·šæ žçãè¡å°æ¿(thrombocyte)ãè¡å°æ¿(platelet)ãèµ€è¡çããã¹ã现èã骚é«èœçã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢çŽ°èãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ã»ãã©ãŒçŽ°èãT-ãªã³ãçãåã¯B-ãªã³ãççïŒã®çŽ°èæ°ãå¢å ããããšåã¯çžå¯Ÿæ¿åºŠãå¢å ããããšããæããããããšããããæŽãªãæçãªçµæãšããŠã¯ããã现è (äŸãã°ãCD45+çœè¡ç
现è)åã¯èªå·±å
ç«çŽ°è(äŸãã°ãèªå·±æåãšäº€å·®åå¿ããT-现èã¬ã»ãã¿ãŒãçºçŸããCD45+ T-现èçã®CD45+èªå·±å
ç«ãªã³ãç) ã®éå£çã®ãçŸæ£ãåŒãèµ·ãã现èéå£ãã®éãæžå°ããããšããæããããããšããããæ¬é瀺ã®æ¹æ³ãé害ãäºé²ããããšã察象ãšããéããçšèªãäºé²ãããã¯ãçŸæ£ã®ç¶æ
ãå®å
šã«é»æ¢ãããããšãå¿
èŠãšããªãããšãç解ããããããããæ¬åºé¡ã§äœ¿çšãããå Žåãäºé²ãããšããçšèªã¯ãçŸæ£ã«æåæ§ãããéå£ãåå®ããçŸæ£ã®çºçåã«æ¬é瀺ã®ååç©ãæäžããããšçããåœæ¥è
ãã§ããããšããããåèšçšèªã¯ãçŸæ£ã®ç¶æ
ãå®å
šã«åé¿ãããããšãæå³ãããã®ã§ã¯ãªãã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªãããªã¢ã³ããåã³ãèªå°äœãã¯ãäºæçã«äœ¿çšããããããŠæ¬åºé¡ã«èšèŒãããååç©ããããããã¿ã³ãã¯è³ªãåã¯ä»ã®åºè³ªã®å€©ç¶ã«ååšãããåæã®ãåã³ååæã®ã¢ããã°(analogues)ã®ããšããããæ¬åºé¡ã«èšèŒãããååç©ããããããã¿ã³ãã¯è³ªãåã¯ä»ã®ç©è³ªã®ããªã¢ã³ãåã¯èªå°äœã¯ãå
ã®ç©è³ªã®çç©åŠç掻æ§ãä¿æåã¯æ¹åããããšãããã
æ¬åºé¡ã§äœ¿çšãããå Žåãçšèªããã¯ã¿ãŒãã¯ããã©ã¹ãããDNAãã¯ã¿ãŒããã©ã¹ãããRNAãã¯ã¿ãŒããŠã€ã«ã¹ãåã¯ä»ã®å¥œé©ãªã¬ããªã³ã³çã®ãæ žé
žãã¯ã¿ãŒãå«ããæ¬åºé¡ã«èšèŒãããçºçŸãã¯ã¿ãŒã¯ãããªãã¯ã¬ãªããé
åã䞊ã³ã«ãäŸãã°ãã¿ã³ãã¯è³ªãçºçŸãããåã³ïŒåã¯åºä¹³åç©çŽ°èã®ã²ãã ã®äžã«ãããã®ããªãã¯ã¬ãªããé
åãçµã¿èŸŒãŸããããã«äœ¿çšãããæŽãªãé
åãšã¬ã¡ã³ããå«ãããšããããæ¬é瀺ã®æäœåã³æäœãã©ã°ã¡ã³ããçºçŸãããã®ã«çšããããšãã§ããç¹å®ã®ãã¯ã¿ãŒãšããŠã¯ãéºäŒå転åãæ瀺ããããã¢ãŒã¿é ååã³ãšã³ãã³ãµãŒçã®ã調ç¯é
åãå«ããã©ã¹ããããæãããããæäœåã³æäœãã©ã°ã¡ã³ããçºçŸãããããã®ä»ã®æçšãªãã¯ã¿ãŒã¯ããããã®éºäŒåã®ç¿»èš³å²åãå¢åŒ·ããããåã¯éºäŒå転åããçããmRNAã®å®å®æ§åã¯æ žå€ãžã®ç§»è¡ãæ¹åããããªãã¯ã¬ãªããé
åãå«ãããããã®é
åèŠçŽ ãšããŠã¯ãäŸãã°ãçºçŸãã¯ã¿ãŒäžã«ããéºäŒåãå¹ççã«è»¢åããããã«ããã5'åã³3'é翻蚳é ååã³ããªã¢ããã«åã·ã°ãã«éšäœããæããããããšããããæ¬åºé¡ã«èšèŒãããçºçŸãã¯ã¿ãŒã¯ãŸãããã®ãããªãã¯ã¿ãŒãå«ã现èãéžæããããã®ããŒã«ãŒãã³ãŒãããããªãã¯ã¬ãªãããå«ãããšãããã奜é©ãªããŒã«ãŒã®äŸãšããŠã¯ãã¢ã³ãã·ãªã³ãã¯ãã©ã ãã§ãã³ãŒã«ãã«ããã€ã·ã³ãåã³ããŠã«ã»ãªã¹ãªã·ã³(nourseothricin)çã®æçç©è³ªã«å¯Ÿããèæ§ãã³ãŒãããéºäŒåããæããããã
æ¬åºé¡ã§äœ¿çšãããçšèªãã¢ã·ã«ãã¯ã-C(=O)Rãæããããã§ãæ¬åºé¡ã§å®çŸ©ããããã«ãRã¯æ°ŽçŽ (ãã¢ã«ãããã)ãC1-C12ã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12ã¢ã«ããã«ãC3-C7ã«ã«ãã·ã¯ãªã«ãC6-C20ã¢ãªãŒã«ã5-10å¡ãããã¢ãªãŒã«ãåã¯5-10å¡ãããã·ã¯ãªã«ã§ãããé-éå®çãªäŸãšããŠã¯ããã«ãã«ãã¢ã»ãã«ãããããã€ã«ããã³ãŸã€ã«ãåã³ã¢ã¯ãªãã€ã«ãæããããã
æ¬åºé¡ã§äœ¿çšãããçšèªãC1-C12ã¢ã«ãã«ãã¯ã1ãã12åã®ççŽ ååãæããçŽéåã¯åå²ã®é£œåçåæ°ŽçŽ ãæããå
žåçãªC1-C12ã¢ã«ãã«åºãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã-ã¡ãã«ã-ãšãã«ã-n-ãããã«ã-n-ããã«ã-n-ãã³ãã«ãåã³-n-ããã·ã«ãæããããïŒäžæ¹ãåå²C1-C12ã¢ã«ãã«ãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã-ã€ãœãããã«ã-sec-ããã«ã-ã€ãœããã«ã-tert-ããã«ã-ã€ãœãã³ãã«ãåã³2-ã¡ãã«ããã«ãæãããããC1-C12ã®ã¢ã«ãã«åºã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
æ¬åºé¡ã§äœ¿çšãããçšèªãã¢ã«ã±ãã«ãã¯ãäžé£œåã®å°ãªããšã1ã€ã®éšäœãå³ã¡ãççŽ -ççŽ ãsp2äºéçµåããæãããéåžžã®ã第2çŽã®ãåã¯ç¬¬3çŽã®ççŽ ååãå«ãC2-C12çåæ°ŽçŽ ãæããäŸãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã以äžãæããããïŒãšãã¬ã³åã¯ããã«ã-ã¢ãªã«ã-1-ãããã«ã-2-ãããã«ã-ã€ãœããã¬ãã«ã-1-ãã³ããã«ã-2-ãã³ããã«ã-3-ã¡ãã«-1-ãããã«ã-2-ã¡ãã«-2-ãããã«ã-2,3-ãžã¡ãã«-2-ãããã«ãªã©ãæãããããã¢ã«ã±ãã«åºã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
æ¬åºé¡ã§äœ¿çšããããã¢ã«ããã«ãã¯ãäžé£œåã®å°ãªããšã1ã€ã®éšäœãå³ã¡ãççŽ -ççŽ ãspäžéçµåãæãããéåžžã®ã第2çŽã®ãåã¯ç¬¬3çŽã®ççŽ ååãå«ãC2-C12çåæ°ŽçŽ ãæããäŸãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããã¢ã»ãã¬ã³åã³ãããã«ã®ã«ãæãããããã¢ã«ããã«åºã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
æ¬åºé¡ã§äœ¿çšããããã¢ãªãŒã«ãã¯ãC6-C20ççŽ ç°è³éŠæåºãæããã¢ãªãŒã«åºã®äŸãšããŠã¯ãéå®ããããã®ã§ã¯ãªããããã§ãã«ããããã«åã³ã¢ã³ãã©ã»ãã«ãæãããããã¢ãªãŒã«åºã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
æ¬åºé¡ã§äœ¿çšããããã¢ãªãŒã«ã¢ã«ãã«ãã¯ãççŽ ååïŒå
žåçã«ã¯æ«ç«¯åã¯sp3ççŽ ååïŒã«çµåããæ°ŽçŽ ååã®1ã€ãã¢ãªãŒã«ã»ã©ãžã«ã«ã§çœ®æãããŠãããéç°ç¶ã¢ã«ãã«ã»ã©ãžã«ã«ãæããå
žåçãªã¢ãªãŒã«ã¢ã«ãã«åºãšããŠã¯ãéå®ããããã®ã§ã¯ãªããããã³ãžã«ã2-ãã§ãã«ãšã¿ã³-1-ã€ã«ã2-ãã§ãã«ãšãã³-1-ã€ã«ããããã«ã¡ãã«ã2-ãããã«ãšã¿ã³-1-ã€ã«ã2-ãããã«ãšãã³-1-ã€ã«ãããããã³ãžã«ã2-ããããã§ãã«ãšã¿ã³-1-ã€ã«ãªã©ãæãããããåèšã¢ãªãŒã«ã¢ã«ãã«åºã¯6ãã20åã®ççŽ ååãå«ã¿ãäŸãã°ãã¢ãªãŒã«ã¢ã«ãã«åºã®ã¢ã«ãã«éšåæ§é ïŒäŸãã°ãã¢ã«ã«ãã«ãã¢ã«ã±ãã«åã¯ã¢ã«ããã«åºçãæããããïŒã¯1ãã6åã®ççŽ ååã§ãããã¢ãªãŒã«éšåæ§é ã¯5ãã14åã®ççŽ ååã§ãããã¢ã«ã«ãªã«åºã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
æ¬åºé¡ã§äœ¿çšããããã·ã¯ãã¢ã«ãã«ãã¯ã飜åççŽ ç°ã©ãžã«ã«ãæããããã¯åç°åŒåã¯äºç°åŒã§ããããšããããã·ã¯ãã¢ã«ãã«åºãšããŠã¯ãåç°ãšããŠ3ãã7åã®ççŽ ååãæããç°ãåã¯äºç°ãšããŠ7ãã12åã®ççŽ ååãæããç°ãæãããããåç°åŒã·ã¯ãã¢ã«ãã«åºã®äŸãšããŠã¯ãã·ã¯ããããã«ãã·ã¯ãããã«ãã·ã¯ããã³ãã«ãã·ã¯ãããã·ã«ãã·ã¯ããããã«ãåã³ã·ã¯ããªã¯ãã«ãæãããããã·ã¯ãã¢ã«ãã«åºã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
æ¬åºé¡ã§äœ¿çšããããã·ã¯ãã¢ã«ã±ãã«ãã¯äžé£œåççŽ ç°ã©ãžã«ã«ãæããããã¯åç°åŒåã¯äºç°åŒã§ããããšããããã·ã¯ãã¢ã«ã±ãã«åºãšããŠã¯ãåç°ãšããŠ3ãã6åã®ççŽ ååãæããç°ãåã¯äºç°ãšããŠ7ãã12åã®ççŽ ååãæããç°ãæãããããåç°åŒã·ã¯ãã¢ã«ã±ãã«åºã®äŸãšããŠã¯ã1-ã·ã¯ããã³ã-1-ãšãã«ã1-ã·ã¯ããã³ã-2-ãšãã«ã1-ã·ã¯ããã³ã-3-ãšãã«ã1-ã·ã¯ãããã¹-1-ãšãã«ã1-ã·ã¯ãããã¹-2-ãšãã«ãåã³1-ã·ã¯ãããã¹-3-ãšãã«ãæãããããã·ã¯ãã¢ã«ã±ãã«åºã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
æ¬åºé¡ã§äœ¿çšãããããããã¢ã©ã«ãã«ãã¯ãççŽ ååïŒå
žåçã«ã¯æ«ç«¯åã¯sp3ççŽ ååïŒã«çµåããæ°ŽçŽ ååã®1ã€ããããã¢ãªãŒã«ã»ã©ãžã«ã«ã§çœ®æãããŠãããéç°ç¶ã¢ã«ãã«ã»ã©ãžã«ã«ãæããå
žåçãªãããã¢ãªãŒã«ã¢ã«ãã«åºãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã2-ãã³ãºã€ãããŸãªã«ã¡ãã«ã2-ããªã«ãšãã«çãæãããããåèšãããã¢ãªãŒã«ã¢ã«ãã«åºã¯6ãã20åã®ççŽ ååãå«ã¿ãäŸãã°ããããã¢ãªãŒã«ã¢ã«ãã«åºã®ã¢ã«ãã«éšåæ§é (ã¢ã«ã«ãã«ãã¢ã«ã±ãã«åã¯ã¢ã«ããã«åºçãæãããã)ã¯1ãã6åã®ççŽ ååã§ããã䞊ã³ã«ãããã¢ãªãŒã«éšåæ§é ã¯5ãã14åã®ççŽ ååã§ãã䞊ã³ã«NãOãPãåã³Sããéžæããã1ãã3åã®ãããååã§ãããåèšãããã¢ãªãŒã«ã¢ã«ãã«åºã®ãããã¢ãªãŒã«éšåæ§é ã¯ã3ãã7åã®ç°å¡(2ãã6åã®ççŽ åå)ãæããåç°ã§ããããšããããåã¯7ãã10åã®ç°å¡(4ãã9åã®ççŽ åå䞊ã³ã«NãOãPãåã³Sããéžæããã1ãã3åã®ãããåå)ãæããäºç°ã§ããããšãããïŒäŸãã°ïŒäºç°[4,5]ã[5,5]ã[5,6]ãåã¯[6,6]ã·ã¹ãã ïŒã
æ¬åºé¡ã§äœ¿çšãããããããã¢ãªãŒã«ãåã³ããããã·ã¯ãã¢ã«ãã«ãã¯ãããããè³éŠæåã¯é-è³éŠæç°ã·ã¹ãã ãæããããã§1ã€ä»¥äžã®ç°ååã¯ããããååãäŸãã°çªçŽ ãé
žçŽ ãåã³ç¡«é»ã§ããããããã¢ãªãŒã«åã¯ãããã·ã¯ãã¢ã«ãã«ã»ã©ãžã«ã«ã¯ã2ãã20åã®ççŽ åååã³NãOãPãåã³Sããéžæããã1ãã3åã®ãããååãå«ãããããã¢ãªãŒã«åã¯ãããã·ã¯ãã¢ã«ãã«ã¯ã3ãã7åã®ç°å¡(2ãã6åã®ççŽ åå䞊ã³ã«NãOãPãåã³Sããéžæããã1ãã3åã®ãããåå)ãæããåç°ã§ããããšããããåã¯7ãã10åã®ç°å¡(4ãã9åã®ççŽ åå䞊ã³ã«NãOãPãåã³Sããéžæããã1ãã3åã®ãããåå)ãæããäºç°ã§ããããšãããïŒäŸãã°ïŒäºç°[4,5]ã[5,5]ã[5,6]ãåã¯[6,6]ã·ã¹ãã ïŒããããã¢ãªãŒã«åã³ãããã·ã¯ãã¢ã«ãã«ã¯ã眮æãããŠããªããåã¯çœ®æãããŠããããšãããã
ãããã¢ãªãŒã«åã³ãããã·ã¯ãã¢ã«ãã«åºã¯ãPaquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968), ç¹ã«1, 3, 4, 6, 7, åã³ 9ç« ; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), ç¹ã«13, 14, 16, 19, åã³ 28å·»; 䞊ã³ã« J. Am. Chem. Soc. (1960) 82:5566ãã«èšèŒãããŠããã
ãããã¢ãªãŒã«åºã®äŸãšããŠã¯ãäŸãã°ãéå®ããããã®ã§ã¯ãªãããããªãžã«ããã¢ãŸãªã«ãããã©ãããããªãã§ãã«ãããªããžãã«ããã©ãã«ãããšãã«ããããªã«ããã©ãŸãªã«ãã€ãããŸãªã«ãããã©ãŸãªã«ããã³ãŸãã©ãã«ããã¢ããã¿ã¬ãã«ãã€ã³ããªã«ãã€ã³ãã¬ãã«ããããªãã«ãã€ãœãããªãã«ããã³ãºã€ãããŸãªã«ãã€ãœããµãŸãªã«ããã©ãžãã«ãããªããžãã«ãã€ã³ããªãžãã«ãã€ãœã€ã³ããªã«ã3H-ã€ã³ããªã«ã1H-ã€ã³ããŸãªã«ãããªãã«ã4H-ãããªãžãã«ããã¿ã©ãžãã«ãããããªãžãã«ãããããµãªãã«ããããŸãªãã«ãã·ã³ããªãã«ããããªãžãã«ã4aH-ã«ã«ããŸãªã«ãã«ã«ããŸãªã«ããã§ãã³ããªãžãã«ãã¢ã¯ãªãžãã«ãããªããžãã«ããã§ãã³ãããªãã«ããã§ããžãã«ããã§ããã¢ãžãã«ããã©ã¶ãã«ããã§ãããµãžãã«ãã€ãœã¯ãããã«ãã¯ãããã«ãã€ãããŸãªãžãã«ãã€ãããŸãªãã«ããã©ãŸãªãžãã«ããã©ãŸãªãã«ããã³ãŸããªã¢ãŸãªã«ããã³ãŸã€ãœãªããµãŸãªã«ãåã³ã€ãµããã€ã«ãæããããã
ãããã·ã¯ãã¢ã«ãã«ã®äŸãšããŠã¯ãäŸãã°ãéå®ããããã®ã§ã¯ãªããããžãããããªãžã«ãããã©ãããããªãžã«(ãããªãžã«)ãããã©ãããããªãã§ãã«ããããªãžãã«ã4-ãããªããã«ããããªãžãã«ã2-ãããªããã«ãããã©ããããã©ãã«ãããã©ããããã©ãã«ããã¹-ããã©ããããã©ãã«ãããã©ããããããªãã«ãããã©ãããã€ãœãããªãã«ããã«ããããããªãã«ããªã¯ã¿ãããã€ãœãããªãã«ãããã©ãžãã«ãããã¯ãªãžãã«ãåã³ã¢ã«ããªãã«ãæããããã
éå®ã§ã¯ãªãäŸãšããŠãççŽ çµåãããã¢ãªãŒã«é¡åã³ãããã·ã¯ãã¢ã«ãã«é¡ã¯ãããªãžã³ã®2ã3ã4ã5ãè¥ããã¯6äœãããªããžã³ã®3ã4ã5ãè¥ããã¯6äœãããªããžã³ã®2ã4ã5ãè¥ããã¯6äœããã©ãžã³ã®2ã3ã5ãè¥ããã¯6äœããã©ã³ãããã©ããããã©ã³ãããªãã©ã³ãããªãã§ã³ããããŒã«è¥ããã¯ããã©ããããããŒã«ã®2ã3ã4ãè¥ããã¯5äœããªããµãŸãŒã«ãã€ãããŸãŒã«è¥ããã¯ãã¢ãŸãŒã«ã®2ã4ãè¥ããã¯5äœãã€ãœãªããµãŸãŒã«ããã©ãŸãŒã«ãè¥ããã¯ã€ãœãã¢ãŸãŒã«ã®3ã4ãè¥ããã¯5äœãã¢ãžãªãžã³ã®2ãè¥ããã¯3äœãã¢ãŒããžã³ã®2ã3è¥ããã¯4äœããããªã³ã®2ã3ã4ã5ã6ã7ãè¥ããã¯8äœãåã¯ã€ãœãããªã³ã®1ã3ã4ã5ã6ã7ãè¥ããã¯8äœãã§çµåãããæŽã«ããå
žåçã«ã¯ãççŽ çµåãããç°é¡ãšããŠã¯ã2-ããªãžã«ã3-ããªãžã«ã4-ããªãžã«ã5-ããªãžã«ã6-ããªãžã«ã3-ããªããžãã«ã4-ããªããžãã«ã5-ããªããžãã«ã6-ããªããžãã«ã2-ããªããžãã«ã4-ããªããžãã«ã5-ããªããžãã«ã6-ããªããžãã«ã2-ãã©ãžãã«ã3-ãã©ãžãã«ã5-ãã©ãžãã«ã6-ãã©ãžãã«ã2-ãã¢ãŸãªã«ã4-ãã¢ãŸãªã«ãåã¯5-ãã¢ãŸãªã«ãæããããã
éå®ã§ã¯ãªãäŸãšããŠãçªçŽ çµåãããã¢ãªãŒã«é¡åã³ãããã·ã¯ãã¢ã«ãã«é¡ã¯ãã¢ãžãªãžã³ãã¢ãŒããžã³ããããŒã«ããããªãžã³ã2-ãããªã³ã3-ãããªã³ãã€ãããŸãŒã«ãã€ãããŸãªãžã³ã2-ã€ãããŸãªã³ã3-ã€ãããŸãªã³ããã©ãŸãŒã«ããã©ãŸãªã³ã2-ãã©ãŸãªã³ã3-ãã©ãŸãªã³ããããªãžã³ãããã©ãžã³ãã€ã³ããŒã«ãã€ã³ããªã³ã1H-ã€ã³ããŸãŒã«ã®1äœã§ãã€ãœã€ã³ããŒã«åã¯ã€ãœã€ã³ããªã³ã®2äœãã¢ã«ããªã³ã®4äœãåã³ã«ã«ããŸãŒã«åã¯ããŒã¿ã»ã«ã«ããªã³ã®9äœãã§çµåãããæŽã«ããå
žåçã«ã¯ãçªçŽ çµåãããç°é¡ãšããŠã¯ã1-ã¢ãžãªãžã«ã1-ã¢ãŒããžã«(1-azetedyl)ã1-ãããªã«ã1-ã€ãããŸãªã«ã1-ãã©ãŸãªã«ãåã³1-ãããªãžãã«ãæããããã
æ¬åºé¡ã§äœ¿çšãããã䞊ã³ã«äžèšã®ã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã¢ãªãŒã«ãã¢ãªãŒã«ã¢ã«ãã«ãã·ã¯ãã¢ã«ãã«ããããã¢ãªãŒã«ããããã·ã¯ãªã«ãªã©ã®äœããã«é©çšããããã眮æãããããšã¯ã1å以äžã®æ°ŽçŽ ååãããããç¬ç«ããŠçœ®æåºã§çœ®æãããŠããããšãæå³ãããåã
ã®çœ®æåºã®å®çŸ©ã«ãã£ãŠå¥æ®µã«å¶çŽãããªãéããåè¿°ã®ååŠçéšåæ§é ã¯ãäŸãã°ã"ã¢ã«ãã«"ã"ã¢ã«ãã¬ã³"ã"ãããã¢ã«ãã«"ã"ãããã¢ã«ãã¬ã³"ã"ã¢ã«ã±ãã«"ã"ã¢ã«ã±ãã¬ã³"ã"ãããã¢ã«ã±ãã«"ã"ãããã¢ã«ã±ãã¬ã³"ã"ã¢ã«ããã«"ã"ã¢ã«ããã¬ã³"ã"ãããã¢ã«ããã«"ã"ãããã¢ã«ããã¬ã³"ã"ã·ã¯ãã¢ã«ãã«"ã"ã·ã¯ãã¢ã«ãã¬ã³"ã"ãããã·ã¯ãã¢ã«ãã«"ããããã·ã¯ãã¢ã«ãã¬ã³"ã"ã¢ãªãŒã«"ã"ã¢ãªãŒã¬ã³"ã"ãããã¢ãªãŒã«"ãåã³ "ãããã¢ãªãŒã¬ã³" åºã¯ãä»»æéžæçã«çœ®æãããŠãããå
žåçãªçœ®æåºãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã-X, -R, -OH, -OR, -SH, -SR, NH2, -NHR, -N(R)2, -N+(R)3, -CX3, -CN, -OCN, -SCN, -NCO, -NCS, -NO, -NO2, -N3, -NC(=O)H, -NC(=O)R, -C(=O)H, -C(=O)R, -C(=O)NH2, -C(=O)N(R)2, -SO3-, -SO3H, -S(=O)2R, -OS(=O)2OR, -S(=O)2NH2, -S(=O)2N(R)2, -S(=O)R, -OP(=O)(OH)2, -OP(=O)(OR)2, -P(=O)(OR)2, -PO3, -PO3H2, -C(=O)X, -C(=S)R, -CO2H, -CO2R, -CO2-, -C(=S)OR, -C(=O)SR, -C(=S)SR, -C(=O)NH2, -C(=O)N(R)2, -C(=S)NH2, -C(=S)N(R)2, -C(=NH)NH2, åã³ -C(=NR)N(R)2ããæããããïŒããã§ãåXã¯ãFãClãBrãåã³Iãããããããã®å Žåæ¯ã«ã€ããŠç¬ç«ã«éžæãããïŒåã³ãåRã¯ãC1-C12ã¢ã«ãã«ãC6-C20ã¢ãªãŒã«ãC3-C14ãããã·ã¯ãã¢ã«ãã«åã¯ãããã¢ãªãŒã«ãä¿è·åºåã³ãããã©ãã¯éšåæ§é ãããããããã®å Žåæ¯ã«ã€ããŠç¬ç«ã«éžæããããåºããä»»æéžæçã«çœ®æãããããšèšèŒãããŠããå Žåã¯ã©ããªå Žåã§ãããã®åºã¯ãããããã®å Žåæ¯ã«ã€ããŠç¬ç«ã«ã1å以äžã®äžèšã®çœ®æåºã§çœ®æãããããšããããåèšçœ®æã¯ãé£æ¥ãã眮æåºãéç°ïŒäŸãã°ãé£æ¥ããå®èœæ§çœ®æåºã®éç°ãªã©ïŒãããŠãäŸãã°ãã©ã¯ã¿ã ãã©ã¯ãã³ãç°ç¶ç¡æ°Žç©ãã¢ã»ã¿ãŒã«ãããã¢ã»ã¿ãŒã«ãããªã¢ã»ã¿ãŒã«ãã¢ãããŒã«ãåã³ããã¢ãããŒã«ã圢æããéç°ã«ãã£ãŠãäŸãã°ãä¿è·åºãšãªãããã«åœ¢æãããããšããç¶æ³ããå«ãããšãããã
ããã©ãžã«ã«ã®åœåèŠåã«ã¯ãç¶æ³ã«å¿ããŠãã¢ã-ã©ãžã«ã«åã¯ãž-ã©ãžã«ã«ã®äœãããå«ãŸãããããšãç解ããŠããå¿
èŠããããäŸãã°ã眮æåºãååã®æ®ãã®éšåãžã®2ã€ã®çµåã®äœçœ®ãå¿
èŠãšããå Žåãåèšçœ®æåºã¯ãž-ã©ãžã«ã«ã§ãããšç解ããããäŸãã°ã2ã€ã®çµåã®äœçœ®ãå¿
èŠãšããã¢ã«ãã«ãšããŠèå¥ããã眮æåºãšããŠã¯ã-CH2-ã-CH2CH2-ã-CH2CH(CH3)CH2-ãçã®ãž-ã©ãžã«ã«ãæãããããä»ã®ã©ãžã«ã«åœåèŠåã¯ãåèšã©ãžã«ã«ããã¢ã«ãã¬ã³ãããã¢ã«ã±ãã¬ã³ãããã¢ãªãŒã¬ã³ããããããã·ã¯ãã¢ã«ãã¬ã³ãçã®ãããªãž-ã©ãžã«ã«ã§ããããšãæ確ã«ç€ºãã
眮æåºããž-ã©ãžã«ã«ãšããŠç€ºããã(å³ã¡ãååã®æ®ãã®éšåãžã®2ã€ã®çµåã®äœçœ®ãæãã)å Žåã¯ãã€ã§ããåèšçœ®æåºã¯ãå¥æ®µã«æããªãéããä»»æã®æ¹åæ§é
眮ã§çµåããããšãã§ããããšãç解ããããã
ãç°æ§ (Isomerism)ããšã¯ãåäžã®åååŒãæãããããã®ååã®çµåã®é
åãåã¯ãã®ååã®ç©ºéé
眮ãç°ãªãååç©ãæå³ããããã®ååã®ç©ºéé
眮ãç°ãªãç°æ§äœããç«äœç°æ§äœããšåŒã¶ãäºãã«é¡åé¢ä¿ã«ãªãç«äœç°æ§äœãããžã¢ã¹ãã¬ãªããŒããšåŒã¶ãåã³äºãã«éãåãããããšãã§ããªããé¡åé¢ä¿ã«ããç«äœç°æ§äœãããšãã³ããªããŒããšåŒã³ãæã«ã¯ãå
åŠç°æ§äœããšåŒã¶ã
4ã€ã®é-åäžçœ®æåºã«çµåããççŽ ååãããã©ã«äžå¿ããšåŒã¶ãããã©ã«ç°æ§äœããšã¯ãå°ãªããšã1ã€ã®ãã©ã«äžå¿ãæããååç©ãæå³ããã1ã€ä»¥äžã®ãã©ã«äžå¿ãæããååç©ã¯ãåã
ã®ãžã¢ã¹ãã¬ãªããŒãšããŠãåã¯ããžã¢ã¹ãã¬ãªããŒæ··åç©(diastereomeric mixture)ããšåŒã°ãããžã¢ã¹ãã¬ãªããŒã®æ··åç©ãšããŠååšããããšãããã1ã€ã®ãã©ã«äžå¿ãååšããå Žåãç«äœç°æ§äœã¯ããã®ãã©ã«äžå¿ã®çµ¶å¯Ÿé
眮(Råã¯S)ã«ãã£ãŠç¹åŸŽä»ããããšãã§ããã絶察é
眮ãšã¯ãåèšãã©ã«äžå¿ã«çµåãã眮æåºã®ç©ºéé
眮ããããæ€èšãããã©ã«äžå¿ã«çµåãã眮æåºããCahnãIngoldåã³Prelogã®é
åèŠåã«åŸã£ãŠã©ã³ã¯ä»ãããã(Cahn et al., Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116)ããã©ãªãã£ãŒãå察ã§ããåã
ã®ãšãã³ããªããŒåœ¢æ
ãçéã§å«ãæ··åç©ãããã©ã»ãæ··åç©ããšåŒã¶ã
æ¬æ现æžåã³ç¹èš±è«æ±ã®ç¯å²ã«é瀺ãããååç©ã¯ã1ã€ä»¥äžã®äžæäžå¿ãå«ãããšããããåã³ãåååç©ã®ç°ãªããžã¢ã¹ãã¬ãªããŒåã³ïŒåã¯ãšãã³ããªããŒãååšããããšãããããã®æ现æžåã³ç¹èš±è«æ±ã®ç¯å²ã«ãããŠãä»»æã®ååç©ã«ã€ããŠã®èšèŒã¯ãå¥æ®µã®èšèŒããªãéããå
šãŠã®ãšãã³ããªããŒããžã¢ã¹ãã¬ãªããŒåã³ãããã®æ··åç©ãå«ãããšãæå³ãããæŽã«ããã®æ现æžåã³ç¹èš±è«æ±ã®ç¯å²ã«ãããŠãä»»æã®ååç©ã«ã€ããŠã®èšèŒã¯ãå¥æ®µã®èšèŒããªãéããåã
ã®ãšãã³ããªããŒã䞊ã³ã«åèšãšãã³ããªããŒã®ä»»æã®æ··åç©ãã©ã»ãäœåã¯ä»ã®ãã®ãå«ãããšãæå³ãããååç©ã®æ§é ãç¹å®ã®ãšãã³ããªããŒãšããŠæããå Žåãæ¬åºé¡ã®é瀺ã¯ããã®ç¹å®ã®ãšãã³ããªããŒã«éå®ãããªãããšãç解ãããããåŸã£ãŠãæ¬é瀺ã®åã
ã®æ§é åŒã®ãšãã³ããªããŒãå
åŠç°æ§äœãåã³ãžã¢ã¹ãã¬ãªããŒããæ¬åºé¡ã§äŒå³ããããæ¬æ现æžã«ãããŠãåèšååç©ã®æ§é åŒã¯ã䟿å®äžãããã€ãã®å Žåã«ãããŠãç¹å®ã®ç°æ§äœãè¡šãããæ¬é瀺ã¯ã幟äœç°æ§äœãäžæççŽ ã«åºã¥ãå
åŠç°æ§äœãç«äœç°æ§äœãäºå€ç°æ§äœçã®ãããªå
šãŠã®ç°æ§äœãå«ã¿ãå
šãŠã®ç°æ§äœãåãã¬ãã«ã®æŽ»æ§ãæããããã§ã¯ãªãããšãç解ãããããããã®ååç©é¡ã¯ãç°ãªãäºå€ç°æ§äœåœ¢æ
ã§ååšããããšããããæ¬é瀺ã«ããååç©ã¯ãå¥æ®µã®èšèŒããªãéããå
šãŠã®äºå€ç°æ§äœåœ¢æ
ãå«ãããšãæå³ãããååç©ã®æ§é ãç¹å®ã®äºå€ç°æ§äœãšããŠæããå Žåãæ¬åºé¡ã®é瀺ã¯ããã®ç¹å®ã®äºå€ç°æ§äœã«éå®ãããªãããšãç解ãããã¹ãã§ããã
æ¬åºé¡ã«èšèŒãããä»»æã®åŒã®ååç©ã¯ãé©çšå¯èœã§ããã°ãååç©èªäœã䞊ã³ã«ãããã®å¡©ãåã³ãããã®æº¶åªåç©ãå«ããäŸãã°ãå¡©ã¯ãã¢ããªã³ãšæ¬é瀺ã®ååç©äžã®æ£ã«è·é»ããåº(äŸãã°ãã¢ãã)ãšã®éã§åœ¢æãããããšãããã奜é©ãªã¢ããªã³ãšããŠã¯ãå¡©åç©ãèåç©ïŒããããïŒããšãŠåç©ãç¡«é
žå¡©ãéç¡«é
žå¡©ãã¹ã«ãã¡ãã³é
žå¡©ïŒã¹ã«ãã¡ã¡ãŒãïŒãç¡é
žå¡©ããªã³é
žå¡©ãã¯ãšã³é
žå¡©ãã¡ã¿ã³ã¹ã«ãã³é
žå¡©ãããªãã«ãªãé
¢é
žå¡©ãã°ã«ã¿ãã³é
žå¡©ãã°ã«ã¯ãã³é
žå¡©ãã°ã«ã¿ã«é
žå¡©ããªã³ãŽé
žå¡©ããã¬ã€ã³é
žå¡©ãã³ãã¯é
žå¡©ãããã«é
žå¡©ãé
ç³é
žå¡©ããã·ã«é
žå¡©ããµãªãã«é
žå¡©ãä¹³é
žå¡©ãããã¿ã¬ã³ã¹ã«ãã³é
žå¡©åã³é
¢é
žå¡©ïŒäŸãããªãã«ãªãé
¢é
žå¡©ïŒãæãããããçšèªãè¬åŠçã«èš±å®¹å¯èœãªã¢ããªã³ãã¯ãè¬åŠçã«èš±å®¹å¯èœãªå¡©ã圢æããããã®å¥œé©ãªã¢ããªã³ããããåæ§ã«ãå¡©ã¯ãã«ããªã³ãšæ¬é瀺ã®ååç©äžã®è² ã«è·é»ããåº(äŸãã°ãã«ã«ããã·ã¬ãŒã)ãšã®éã§åœ¢æãããããšãããã奜é©ãªã«ããªã³ãšããŠã¯ããããªãŠã ã»ã€ãªã³ãã«ãªãŠã ã»ã€ãªã³ããã°ãã·ãŠã ã»ã€ãªã³ãã«ã«ã·ãŠã ã»ã€ãªã³ãåã³ããã©ã¡ãã«ã¢ã³ã¢ããŠã ã»ã€ãªã³ãªã©ã®ã¢ã³ã¢ããŠã ã»ã«ããªã³ãæãããããããã€ãã®å¥œé©ãªçœ®æã¢ã³ã¢ããŠã ã»ã€ãªã³ã®äŸãšããŠã¯ã以äžããèªå°ããããã®ãæããããïŒãšãã«ã¢ãã³ããžãšãã«ã¢ãã³ããžã·ã¯ãããã·ã«ã¢ãã³ãããªãšãã«ã¢ãã³ãããã«ã¢ãã³ããšãã¬ã³ãžã¢ãã³ããšã¿ããŒã«ã¢ãã³ããžãšã¿ããŒã«ã¢ãã³ãããã©ãžã³ããã³ãžã«ã¢ãã³ããã§ãã«ãã³ãžã«ã¢ãã³ãã³ãªã³ãã¡ã°ã«ãã³ãåã³ããã¡ã¿ãã³ããªãžã³åã³ã¢ã«ã®ãã³ãªã©ã®ã¢ããé
žãæ¬é瀺ã®ååç©ã¯ãŸãã第åçŽçªçŽ ååãå«æããå¡©ãå«ãã
奜é©ãªç¡æ©ã¢ããªã³ã®äŸãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã以äžã®ç¡æ©é
žããèªå°ããããã®ãæããããïŒå¡©é
žãèåæ°ŽçŽ é
žããšãŠåæ°ŽçŽ é
žãç¡«é
žãäºç¡«é
žãç¡é
žãäºç¡é
žããªã³(phosphoric)åã³ãªã³(phosphorous)ã奜é©ãªææ©ã¢ããªã³ã®äŸãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã以äžã®ææ©é
žããèªå°ããããã®ãæããããïŒ2-ã¢ã»ããã·å®æ¯éŠé
žãé
¢é
žãã¢ã¹ã³ã«ãã³é
žãã¢ã¹ãã©ã®ã³é
žãå®æ¯éŠé
žãã«ã³ãã¡ãŒã¹ã«ãã³é
žãæ¡ç®é
žãã¯ãšã³é
žããšããé
žããšã¿ã³ãžã¹ã«ãã³é
žããšã¿ã³ã¹ã«ãã³é
žãããã«é
žãã°ã«ã±ããã³é
žãã°ã«ã³ã³é
žãã°ã«ã¿ãã³é
žãã°ãªã³ãŒã«é
žãããããã·ãã¬ã€ã³é
žãããããã·ããã¿ã¬ã³ã»ã«ã«ãã³é
žãã€ã»ããªã³é
žãä¹³é
žãã©ã¯ãããªã³é
žãã©ãŠãªã³é
žããã¬ã€ã³é
žããªã³ãŽé
žãã¡ã¿ã³ã¹ã«ãã³é
žãã ãã³é
žããªã¬ã€ã³é
žãã·ã¥ãŠé
žããã«ããã³é
žããã¢é
žããã³ããã³é
žããã§ãã«é
¢é
žããã§ãã«ã¹ã«ãã³é
žãããããªã³é
žããã«ãã³é
žããµãªãã«é
žãã¹ãã¢ãªã³é
žãã³ãã¯é
žãã¹ã«ãã¡ãã«é
žãé
ç³é
žããã«ãšã³ã¹ã«ãã©ã³é
žãåã³åèé
žã奜é©ãªããªããŒææ©ã¢ããªã³ã®äŸãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã以äžã®ããªããŒé
žããèªå°ããããã®ãæããããïŒã¿ã³ãã³é
žãã«ã«ããã·ã¡ãã«ã»ã»ã«ããŒã¹ã
æŽã«ãæ¬é瀺ã®ååç©ïŒäŸãã°ãåèšååç©ã®å¡©ïŒã¯ãæ°Žåç©ã®è¥ããã¯éæ°Žåç©(ç¡æ°Ž)ã®åœ¢æ
ã§ãåã¯ä»ã®æº¶åªååãšã®æº¶åªåç©ãšããŠååšããããšããããæ°Žåç©ã®é-éå®çãªäŸãšããŠã¯ãäžæ°Žåç©ãäºæ°Žåç©ãªã©ãæããããã溶åªåç©ã®é-éå®çãªäŸãšããŠã¯ããšã¿ããŒã«æº¶åªåç©ãã¢ã»ãã³æº¶åªåç©ãªã©ãæãããããã溶åªåç©ãã¯ãååŠéè«çãªéåã¯é-ååŠéè«çãªéã®äœããã®æº¶åªãå«æããã溶åªãä»å ããã圢æ
ãæå³ãããããã€ãã®ååç©ã¯ãçµæ¶æ§ã®åºçžäžã«ãåºå®ããã¢ã«æ¯çã®æº¶åªååãææããåŸåãæããããã«ãã£ãŠæº¶åªåç©ã圢æããããããŠãåèšæº¶åªãæ°Žã§ããå Žåã圢æããã溶åªåç©ã¯æ°Žåç©ã§ããïŒåã³åèšæº¶åªãã¢ã«ã³ãŒã«ã§ããå Žåã圢æããã溶åªåç©ã¯ã¢ã«ã³ã©ãŒãã§ãããæ°Žåç©ã¯ã1ååã®ç©è³ªãš1åå以äžã®æ°Žã®çµåãã«ãã£ãŠåœ¢æããããã®äžã§ã¯ãæ°ŽãH2OãšããŠã®ååç¶æ
ãä¿æãããæ°Žåç©ãšã¯ãäŸãã°ãäžæ°Žåç©ãäºæ°Žåç©ãäžæ°Žåç©ãªã©ãæãã
æŽã«ãæ¬åºé¡ã«é瀺ããåŒãè¡šãååç©åã¯ãã®å¡©ã«ã€ããŠãçµæ¶å€åãååšããããšããããä»»æã®çµæ¶åœ¢æ
ãçµæ¶åœ¢æ
ã®æ··åç©ãåã¯ãããã®ç¡æ°Žç©è¥ããã¯æ°Žåç©ããæ¬é瀺ã®ç¯å²ã«å«ãŸããããšã«çæããããã
æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)
æ¬åºé¡ã«èšèŒãããããã«ãCD45ã«çµåããæäœåã³ãã®æåçµåãã©ã°ã¡ã³ãã¯ã现èæ¯çŽ ååïŒå³ã¡ã现èæ¯çŽ ïŒã«ã³ã³ãžã¥ã²ãŒãïŒçµåïŒããããšããããããã«ãã£ãŠãæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã圢æãããæ¬åºé¡ã§äœ¿çšãããå Žåãçšèªã现èæ¯çŽ ããã现èæ¯çŽ éšåæ§é ãåã³ãè¬ç©ãããäºæçã«äœ¿çšããã
æ¬åºé¡ã«èšèŒãããããã«ãCD45ã«çµåããæäœåã³ãã®æåçµåãã©ã°ã¡ã³ãã¯ã现èæ¯çŽ ååïŒå³ã¡ã现èæ¯çŽ ïŒã«ã³ã³ãžã¥ã²ãŒãïŒçµåïŒããããšããããããã«ãã£ãŠãæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã圢æãããæ¬åºé¡ã§äœ¿çšãããå Žåãçšèªã现èæ¯çŽ ããã现èæ¯çŽ éšåæ§é ãåã³ãè¬ç©ãããäºæçã«äœ¿çšããã
ç¹ã«ãæ¬åºé¡ã«é瀺ãããADCã¯ã现èæ¯çŽ éšåæ§é (äŸãã°ããã³ãŸãžã¢ãŒãã³éšåæ§é äŸãã°ãããããã³ãŸãžã¢ãŒãã³(PBD)ãåã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³(IGN)ã«ã³ã³ãžã¥ã²ãŒããã(å³ã¡ããªã³ã«ãŒã«ãã£ãŠå
±æçµåãã)ãCD45ã«çµåããæäœ(ãã®æåçµåãã©ã°ã¡ã³ããå«ã)ãå«ã¿ãããã§ãåèšçŽ°èæ¯çŽ éšåæ§é ã¯ãæäœéšåæ§é ã«ã³ã³ãžã¥ã²ãŒãããŠããªãå Žåã现èå·å®³æ§å¹æåã¯çŽ°èå¢æ®æå¶å¹æãæãããæ§ã
ãªå®æœåœ¢æ
ã§ã¯ã现èæ¯çŽ éšåæ§é ã¯ãã³ã³ãžã¥ã²ãŒãäžã§çµåããŠããå Žåã现èå·å®³æ§ãæžå°ããŠããåã¯å
šãç¡ããªã£ãŠããããåèšãªã³ã«ãŒããåæãããåŸã«çŽ°èå·å®³æ§ãåã³çºæ®ããããã«ãªããæ§ã
ãªå®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ éšåæ§é ã¯ãåèšãªã³ã«ãŒããåæãããããšç¡ãã«ã现èæ¯æ§ãç¶æãããããã€ãã®å®æœåœ¢æ
ã§ã¯ã现èæ¯çŽ ååã¯ãæ¬åºé¡ã«é瀺ãããŠããããã«ã现èå
éšã«åã蟌ãŸããæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã«ã³ã³ãžã¥ã²ãŒãããããã®çµæãåèšæäœãåã¯ãã®ãã©ã°ã¡ã³ãã现èå
ã«åã蟌ãŸããåŸãåèšçŽ°èæ¯çŽ ã¯ããã®çŽ°èå
ã®ã¿ãŒã²ããã«ã¢ã¯ã»ã¹ããããšããããåã³ãäŸãã°ãè¡æ¶²çŽ°èæ»ãåªä»ããããšããããåŸã£ãŠãæ¬é瀺ã®ADCã¯ãäžè¬çãªåŒ
Ab-(Z-L-Cy)nã
ã§ããããšããããããã§ãæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ã(Ab)ã¯ãååŠçãªéšåæ§é (Z)ãä»ããŠããªã³ã«ãŒ(L)ã«ã³ã³ãžã¥ã²ãŒãïŒå ±æçµåïŒãã现èæ¯çŽ éšåæ§é (Cy)ã«ã³ã³ãžã¥ã²ãŒãïŒå ±æçµåïŒããããšãããã
Ab-(Z-L-Cy)nã
ã§ããããšããããããã§ãæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ã(Ab)ã¯ãååŠçãªéšåæ§é (Z)ãä»ããŠããªã³ã«ãŒ(L)ã«ã³ã³ãžã¥ã²ãŒãïŒå ±æçµåïŒãã现èæ¯çŽ éšåæ§é (Cy)ã«ã³ã³ãžã¥ã²ãŒãïŒå ±æçµåïŒããããšãããã
åŸã£ãŠãåèšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã¯ãæŽæ°nã«ãã£ãŠç€ºããããããªå€æ°ã®è¬ç©éšåæ§é ã«ã³ã³ãžã¥ã²ãŒãããããšããããããã§ãæŽæ°nã¯æäœåœããã®çŽ°èæ¯çŽ ã®å¹³ååæ°ãè¡šããããã§ãæŽæ°nã¯ãäŸãã°çŽ1ããçŽ20ã®ç¯å²ã§ããããšããããä»»æã®æ°ã®çŽ°èæ¯çŽ ãæ-CD45æäœã«ã³ã³ãžã¥ã²ãŒãããããšããããäŸãã°ã1ã2ã3ã4ã5ã6ã7ãåã¯8åãããã€ãã®å®æœåœ¢æ
ã§ã¯ãnã¯ãçŽ1ããçŽ5ãçŽ1ããçŽ4ãçŽ1ããçŽ3ãåã¯çŽ2ããçŽ5ãåã¯çŽ3ããçŽ5ã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãnã¯çŽ1ãçŽ2ãçŽ3ãåã¯çŽ4ã§ãããã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿ã«ããADCã®èª¿è£œç©äžã®æäœåœããã®è¬ç©éšåæ§é ã®å¹³ååæ°ãã質éåæãELISAã¢ãã»ã€ãåã³HPLCã®ãããªåŸæ¥ã®æ段ã«ãã£ãŠæããã«ããããšãã§ãããnã«é¢ããADCã®å®éçãªååžã決å®ããããšãã§ãããå Žåã«ãã£ãŠã¯ãéçžHPLCåã¯é»æ°æ³³åã®ãããªæ段ã«ãã£ãŠãnãç¹å®ã®æ°å€ã§ããå質ãªADCããä»ã®è¬ç©æèŒéãæããADCãããåé¢ããã粟補ãããåã³ç¹æ§è©äŸ¡ããããšãã§ããã
ããã€ãã®æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã«ã€ããŠãnã¯ããã®æäœäžã®çµå(attachment)éšäœã®æ°ã«ãã£ãŠå¶éãããããšããããäŸãã°ãçµå(attachment)ãã·ã¹ãã€ã³ã®ããªãŒã«ã§ããå Žåãæäœã¯1åã ãåã¯æ°åã®ã·ã¹ãã€ã³ã®ããªãŒã«åºãæã€ãåã¯ãªã³ã«ãŒãçµåãã(attached)ã®ã«ååãªåå¿æ§ããã€ããªãŒã«åºã1åã ãåã¯æ°åæã€ãäžè¬ã«ãæäœã¯ãè¬ç©éšåæ§é ã«çµåããããšãã§ããéé¢åã³åå¿æ§ã·ã¹ãã€ã³åºãå€ãã¯å«ãŸãªãïŒäž»ã«ãæäœäžã®ã·ã¹ãã€ã³ã®ããªãŒã«æ®åºã¯ããžã¹ã«ãã£ãæ¶æ©ãšããŠååšãããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæäœãããžããªãã¬ã€ããŒã«(DTT)åã¯ããªã«ã«ããã«ãšãã«ãã¹ãã£ã³(TCEP)ãªã©ã®éå
å€ã§éå
ããŠãéšåçéå
æ¡ä»¶äžåã¯å
šéå
æ¡ä»¶äžã§ãåå¿æ§ã·ã¹ãã€ã³ã®ããªãŒã«åºãçæãããããšããããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãããé«ãè¬ç©ã®æèŒãäŸãã°ãn>5ãã«ãã£ãŠãããç¹å®ã®æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã®åéãäžæº¶æ§ãæ¯æ§ãåã¯çŽ°èééæ§ã®åªå€±ããåŒãèµ·ããããããšãããã
ããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿ã®éã«ãçè«äžã®æ倧ãããå°ãªãè¬ç©éšåæ§é ããæäœã«ã³ã³ãžã¥ã²ãŒããããæäœã¯ãäŸãã°ã以äžã«è«ããããã«ãè¬ç©-ãªã³ã«ãŒäžéäœåã¯ãªã³ã«ãŒè©Šè¬ãšåå¿ããªããªãžã³æ®åºãå«ãããšããããæãåå¿æ§ã®é«ããªãžã³åºã®ã¿ãã¢ãã³åå¿æ§ãªã³ã«ãŒè©Šè¬ãšåå¿ããããšãã§ãããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæäœããå€æ§æ¡ä»¶äžã«äŸãããªãžã³åã¯ã·ã¹ãã€ã³ã®ãããªåå¿æ§æ±æ žåºãè¡šã«é²åºãããã
ADCã®æèŒ(è¬ç©ïŒæäœæ¯)ããçš®ã
ã®æ¹æ³ã§ïŒäŸãã°ã(i)æäœã«å¯Ÿãããè¬ç©-ãªã³ã«ãŒäžéäœåã¯ãªã³ã«ãŒè©Šè¬ã®ã¢ã«éå°ãå¶éããããšã(ii)ã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿ã®æéåã¯æž©åºŠãå¶éããããšã(iii)ã·ã¹ãã€ã³ã®ããªãŒã«ä¿®é£Ÿã®ããã«ãéšåçãªåã¯å¶éçãªéå
æ¡ä»¶äžã«ããããšã(iv)ãªã³ã«ãŒ-è¬ç©çµå(attachment)ã®æ°åã³ïŒåã¯äœçœ®ãã³ã³ãããŒã«ããããã«ãã·ã¹ãã€ã³æ®åºã®æ°åã³äœçœ®ãæ¹å€ããããã«ãæäœã®ã¢ããé
žé
åãçµæãæè¡ã«ãã£ãŠæäœããããšãã«ãã£ãŠïŒãã³ã³ãããŒã«ããããšãããã
æ-CD45æäœ
æ¬é瀺ã¯ãCD45ã«çµåããããšãå¯èœã§ãããæäœããã®æå-çµåãã©ã°ã¡ã³ãåã³ãªã¬ã³ããæ²»çè¬å€ãšããŠäœ¿çšãã(i) 1皮以äžã®ãããã®æåãçºçŸãã现èãç¹åŸŽãšãããããåã³èªå·±å ç«çŸæ£ãçŽæ¥çã«æ²»çãããåã³(ii) 移æ€çæ³ãå¿ èŠãšããæ£è ã«ãããŠã移æ€ããé è¡å¹¹çŽ°èãççããããšãä¿é²ããããšããçºèŠã«ãéšåçã«åºã¥ãããããã®æ²»ç掻æ§ã¯ãäŸãã°ã现èïŒäŸãã°ããã现èãèªå·±å ç«çŽ°èåã¯é è¡å¹¹çŽ°èãªã©ïŒã®è¡šé¢ã«çºçŸããŠããCD45ã«ãæäœããã®æå-çµåãã©ã°ã¡ã³ããåã³ïŒåã¯ãªã¬ã³ããçµåããããšã«ãã£ãŠããããŠãã®åŸã«çŽ°èæ»ãèªå°ãããããšã«ãã£ãŠãåŒãèµ·ããããããšããããå å æ§ã®é è¡å¹¹çŽ°èãæžå°ãããããšã«ãã£ãŠã移æ€ããé è¡å¹¹çŽ°èãããŒãã³ã°ããããšãã§ããããããæäŸãããããšããããåã³ããã®åŸãçç£çãªé è¡ã確ç«ããããšãããããã®ããã«ããŠã移æ€ããé è¡å¹¹çŽ°èã¯ãæ£è ïŒäŸãã°ãæ¬åºé¡ã«èšèŒããã幹现èé害ã«çœ¹æ£ããŠããããæ£è ãªã©ïŒå ã§ãããŸãççããããšãã§ããã
æ¬é瀺ã¯ãCD45ã«çµåããããšãå¯èœã§ãããæäœããã®æå-çµåãã©ã°ã¡ã³ãåã³ãªã¬ã³ããæ²»çè¬å€ãšããŠäœ¿çšãã(i) 1皮以äžã®ãããã®æåãçºçŸãã现èãç¹åŸŽãšãããããåã³èªå·±å ç«çŸæ£ãçŽæ¥çã«æ²»çãããåã³(ii) 移æ€çæ³ãå¿ èŠãšããæ£è ã«ãããŠã移æ€ããé è¡å¹¹çŽ°èãççããããšãä¿é²ããããšããçºèŠã«ãéšåçã«åºã¥ãããããã®æ²»ç掻æ§ã¯ãäŸãã°ã现èïŒäŸãã°ããã现èãèªå·±å ç«çŽ°èåã¯é è¡å¹¹çŽ°èãªã©ïŒã®è¡šé¢ã«çºçŸããŠããCD45ã«ãæäœããã®æå-çµåãã©ã°ã¡ã³ããåã³ïŒåã¯ãªã¬ã³ããçµåããããšã«ãã£ãŠããããŠãã®åŸã«çŽ°èæ»ãèªå°ãããããšã«ãã£ãŠãåŒãèµ·ããããããšããããå å æ§ã®é è¡å¹¹çŽ°èãæžå°ãããããšã«ãã£ãŠã移æ€ããé è¡å¹¹çŽ°èãããŒãã³ã°ããããšãã§ããããããæäŸãããããšããããåã³ããã®åŸãçç£çãªé è¡ã確ç«ããããšãããããã®ããã«ããŠã移æ€ããé è¡å¹¹çŽ°èã¯ãæ£è ïŒäŸãã°ãæ¬åºé¡ã«èšèŒããã幹现èé害ã«çœ¹æ£ããŠããããæ£è ãªã©ïŒå ã§ãããŸãççããããšãã§ããã
ããCD45(mRNA NCBIåç
§é
åïŒNM_080921.3, ã¿ã³ãã¯è³ªNCBIåç
§é
åïŒ NP_563578.2)ã«çµåããããšãã§ããæäœåã³æå-çµåãã©ã°ã¡ã³ãããæ¬åºé¡ã«é瀺ãããçµæç©åã³æ¹æ³ãšäœµããŠäœ¿çšããŠãäŸãã°ãé è¡å¹¹çŽ°è移æ€çæ³ãå¿
èŠãšããæ£è
ã«ãããé è¡å¹¹çŽ°è移æ€çã®ççãä¿é²ããããšããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœãåã¯ãã®æåçµåéšåã¯ãè±-å
ç«åããæ-CD45æäœãåã¯ãã®æåçµåéšåã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœãåã¯ãã®æåçµåéšåã¯ããã¡ã©ã®æ-CD45æäœãåã¯ãã®æåçµåéšåã§ãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœãåã¯ãã®æåçµåéšåã¯ãããåæ-CD45æäœãåã¯ãã®æåçµåéšåã§ãããä»ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœãåã¯ãã®æåçµåéšåã¯ãå®å
šã«ããæ-CD45æäœãåã¯ãã®æåçµåéšåã§ããã
CD45ã¯ãTåã³B现èæåã¬ã»ãã¿ãŒãä»ããã·ã°ãã«äŒéã«å¿
é ã®é è¡çŽ°èç¹ç°çãªè貫éåã¿ã³ãã¯è³ªããã·ã³ã»ãã¹ãã¡ã¿ãŒãŒã§ãããCD45ã«ã¯ã倧ããªçŽ°èå€ãã¡ã€ã³ãåã³ãã¹ãã¡ã¿ãŒãŒãå«ã现è質ãã¡ã€ã³ãããããè€æ°ã®CD45ã®ã¢ã€ãœãã©ãŒã ãã1次転åç©äžã®34åã®ãšã¯ãœã³ãéžæçã¹ãã©ã€ã·ã³ã°(alternative splicing)ãåããããšããçããããšã¯ãœã³4, 5, 6åã³æãã7ã®ã¹ãã©ã€ã·ã³ã°ã«ãã£ãŠè€æ°ã®CD45ã®å€æ§æ§ãçãããCD45éºäŒåã¯ãæ§ã
ã«äžŠã¹æ¿ãããããã®ããããã6çš®é¡ã®ã¢ã€ãœãã©ãŒã ããããã§ãæãè¯ãåå®ãããŠãããåèšã¢ã€ãœãã©ãŒã ã¯ãRA(Uniprotã¢ã¯ã»ãã·ã§ã³çªå·: P08575-8ïŒé
åçªå·(SEQ ID NO): 31)ãRO(NCBIã¢ã¯ã»ãã·ã§ã³çªå·: NP_563578.2ïŒé
åçªå·(SEQ ID NO): 32)ãRB(NCBIã¢ã¯ã»ãã·ã§ã³çªå·: XP_006711537.1ïŒé
åçªå·(SEQ ID NO): 33)ãRAB(NCBIã¢ã¯ã»ãã·ã§ã³çªå·: XP_006711535.1ïŒé
åçªå·(SEQ ID NO): 34)ãRBC(NCBIã¢ã¯ã»ãã·ã§ã³çªå·: XP_006711536.1ïŒé
åçªå·(SEQ ID NO): 35)ãåã³RABC(NCBIã¢ã¯ã»ãã·ã§ã³çªå·NP_002829.3ïŒé
åçªå·(SEQ ID NO): 36)ã§ãã (Hermiston et al. 2003 âCD45: a critical regulator of signaling thresholds in immune cells.â Annu Rev Immunol. 2:107-137.)ãCD45RAã¯ããã€ãŒãT现èäžã«çºçŸããŠããã䞊ã³ã«CD45ROã¯ã掻æ§ååã³ã¡ã¢ãªãŒT现èãäžéšã®B现èãµãã»ããã掻æ§ååçïŒãã¯ããã¡ãŒãžãåã³é¡ç²çäžã«çºçŸããŠãããCD45RBã¯ãæ«æ¢¢B现èããã€ãŒãT现èãèžè
ºçŽ°èäžã«çºçŸããŠããŠããã¯ããã¡ãŒãžãåã³æš¹ç¶çŽ°èäžã«ã¯åŒ±ãçºçŸããŠãããéžæçãªãšã¯ãœã³ã®çºçŸã¯ã以äžãè¡šïŒã«èšèŒããCD45ã®ã¢ã€ãœãã©ãŒã ãšããŠã芳å¯ãããã
éžæçã¹ãã©ã€ã·ã³ã°ã«ãã£ãŠãCD45ã¿ã³ãã¯è³ªã®æ§ã
ãªã¢ã€ãœãã©ãŒã (äŸãã°ãCD45RAãCD45RABãCD45RABC)ã§çºçŸãããåã
ã®ãšããœã³åã¯ãšããœã³ã®çµåããããããããã察ç
§çã«ãCD45ROã¯ããšã¯ãœã³4ãã6ã®çºçŸãæ¬ ãããšã¯ãœã³1ãã3åã³7ãã34ã®çµåãããçæãããããšã¯ãœã³7ãåèšã¿ã³ãã¯è³ªããæé€ããããšã¯ãœã³1ãã3åã³8ãã34ãäžç·ã«ã¹ãã©ã€ã·ã³ã°ããããšãããšããã³ã¹ããããE3-8ãšåã¥ãããããã®ã¿ã³ãã¯è³ªã¯ãmRNAã¬ãã«ã§ã¯æ€åºãããŠããããçŸåšã®ãšãããããŒã»ãµã€ãã¡ããªãŒã«ãã£ãŠã¯åå®ãããŠããªãã
CD45ROã¯ãçŸåšãé è¡å¹¹çŽ°èã§çºçŸããå¯äžã®æ¢ç¥ã®CD45ã¢ã€ãœãã©ãŒã ã§ãããCD45RAåã³CD45RABCã¯ãæ€åºãããŠããªãããé è¡å¹¹çŽ°èã®è¡šçŸåããé€å€ãããŠãããCD45RBã¯èå
ã®é è¡å¹¹çŽ°èã«çºçŸããŠããããæ人ã®éªšé«é è¡å¹¹çŽ°èã«ã¯ååšããªããšãããããŠã¹ã§è¡ãããç 究ããã®ãšããã³ã¹ããããç¹ã«ãCD45RCã«ã¯ãã¢ãžã¢äººéå£å
ã§èªããããããšã¯ãœã³6ã®å€åãé«ãå²åã§ãã(CD45RCã®ãšã¯ãœã³6ã®å€åã¯ãæ¥æ¬äººéå£ã®çŽ25%ã«èªãããã)ããã®å€åã«ãã£ãŠãCD45ROã®é«çºçŸåã³CD45RAãCD45RBãåã³CD45RCã®ã¬ãã«ã®äœäžããããããããæŽã«ãCD45RAããªã¢ã³ã(äŸãã°ãCD45RABåã³CD45RACç)ã¯ãèªå·±å
ç«çŸæ£ãšé¢é£ããŠãããšã¯ãœã³4ã®å€åã瀺ãã
é è¡å¹¹çŽ°èäžã«CD45ROãååšããããšãåã³ä»ã®å
ç«çŽ°è(äŸãã°ãTåã³Bãªã³ãçãµãã»ãã䞊ã³ã«çš®ã
ã®éªšé«æ§çŽ°èç)äžã®CD45ROã®çºçŸãæ¯èŒçéå®çã§ããããšã«ãã£ãŠãCD45ROã¯ãé è¡å¹¹çŽ°è移æ€ãå¿
èŠãšããæ£è
ãžã®ã³ã³ãã£ã·ã§ãã³ã°çæ³ã®ããã®ãç¹ã«éåžžã«é©ããã¿ãŒã²ããã«ãªããCD45ROã¯ããšããœã³4ã5ãåã³6ã®çºçŸãæ¬ ãã®ã¿ã§ããã®ã§ãå
ç«åãšããŠããã䜿çšããããšã«ãã£ãŠãæ±CD45Abåã³CD45RO-ç¹ç°çãªæäœãã¹ã¯ãªãŒãã³ã°ããããšãå¯èœã«ãªãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããADCãçµæç©ãåã³æ¹æ³ã«ãããŠäœ¿çšããããæ-CD45æäœãåã¯ãã®æåçµåéšåã¯ãCD45ã®å
šãŠã®ã¢ã€ãœãã©ãŒã ã«çµåãããæ±-CD45æäœãåã¯ãã®æåçµåéšåã§ãããä»ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããADCãçµæç©ãåã³æ¹æ³ã«ãããŠäœ¿çšããããæ-CD45æäœãåã¯ãã®æåçµåéšåã¯ã1皮以äžã®ããCD45ã®åè¿°ã®ã¢ã€ãœãã©ãŒã ïŒäŸãã°ã1皮以äžã®CD45RAãCD45RBãCD45RCãCD45ROãCD45RABãCD45 RBCãåã³CD45 RABCïŒã«ç¹ç°çã«çµåãããã¢ã€ãœãã©ãŒã ç¹ç°çãªæ-CD45æäœã§ããã
æ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æ¹æ³ãšå
±ã«äœ¿çšããããšãããæ-CD45æäœã¯ãæ-CD45æäœãåã³ãã®æå-çµåéšåãå«ããæäœã®æå-çµåéšåã¯åœè©²åéã§åšç¥ã§ãããåèšæäœã®æå-çµåé åã«åºã¥ããŠå®¹æã«æ§ç¯ããããšãã§ãããäŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããã³ã³ãã£ã·ã§ãã³ã°æ¹æ³ãšäœµããŠäœ¿çšããæ-CD45æäœã¯ãã¢ãã¯ããŒãã«æäœè¥ããã¯ãã®æå-çµåãã©ã°ã¡ã³ããããªã¯ããŒãã«æäœè¥ããã¯ãã®æå-çµåãã©ã°ã¡ã³ããããåæäœè¥ããã¯ãã®æå-çµåãã©ã°ã¡ã³ããå®å
šããæäœè¥ããã¯ãã®æå-çµåãã©ã°ã¡ã³ãããã¡ã©æäœè¥ããã¯ãã®æå-çµåãã©ã°ã¡ã³ãããã€ã¹ãã·ãã£ãã¯æäœ(bispecific antibody)è¥ããã¯ãã®æå-çµåãã©ã°ã¡ã³ããäºéå¯å€å
ç«ã°ãããªã³ã»ãã¡ã€ã³ãäžæ¬éFvåå(scFv)ããã€ã¢ããã£ãããªã¢ããã£ãããããã£ãæäœ-æ§ã¿ã³ãã¯è³ªã¹ãã£ããã©ã«ããFvãã©ã°ã¡ã³ããFabãã©ã°ã¡ã³ããF(ab')2ååãåã¯ã¿ã³ãã di-scFvãã§ããããšããããæ¬åºé¡ã«èšèŒãããADCåã¯æ¹æ³ã«ãããŠå
šäœçã«åã¯éšåçã«äœ¿çšããããšãããäŸç€ºçãªæ-CD45æäœãã以äžã§æäŸããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœã¯ãBIOLEGEND(ç»é²åæš)(ãµã³ãã£ãšãŽãCA)ãã賌å
¥å¯èœãªã¯ããŒã³HI30ã§ãããè¥ããã¯ããã«ç±æ¥ãããåã¯ãããã®ããåããªã¢ã³ãã§ãããæäœã®ããåã¯ãéããæäœã®éªšæ Œæ®åºåã³å®åžžé åæ®åºããåœæè¡åéã§å
¬ç¥ã®æé ã«åŸã£ãŠ(äŸãã°ã以äžã®å®æœäŸïŒã«èšèŒãããããã«)çæ®ç³»åããæäœã®ãã®ã§çœ®æããããšã«ãã£ãŠè¡ãããšãã§ãããæ¬åºé¡ã«èšèŒãããæ¹æ³ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãæ-CD45æäœab10558, EP322Y, MEM-28, ab10559, 0.N.125, F10-89-4, HIe-1, 2B11, YTH24.5, PD7/26/16, F10-89-4, 1B7, ab154885, B-A11, phosphor S1007, ab170444, EP350, Y321, GA90, D3/9, X1 6/99, åã³ LT45ïŒãããã¯ABCAM(ç»é²åæš)(ã±ã³ããªããžãMA)ãã賌å
¥å¯èœã§ããïŒã䞊ã³ã«ãããã®ããåããªã¢ã³ãããæãããããæ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æé ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãæ-CD45æäœHPA000440ïŒããã¯ãSIGMA-ALDRICH(ç»é²åæš)(ã»ã³ãã»ã«ã€ã¹ãMO)ãã賌å
¥å¯èœã§ããïŒãåã³ãã®ããåããªã¢ã³ããæãããããæ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æ¹æ³ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãããŠã¹ã»ã¢ãã¯ããŒãã«æäœBC8ïŒããã¯ãäŸãã°ãMatthews et al., Blood 78:1864-1874, 1991ã«èšèŒãããŠããŠããã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã䞊ã³ã«ãã®ããåããªã¢ã³ããæãããããæ¬åºé¡ã«èšèŒãããæ¹æ³ãšäœµããŠäœ¿çšããããšãããæŽãªãæ-CD45æäœãšããŠã¯ãã¢ãã¯ããŒãã«æäœYAML568ïŒããã¯ãäŸãã°ãGlatting et al., J. Nucl. Med. 8:1335-1341, 2006ã«èšèŒãããŠããŠããã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã䞊ã³ã«ãã®ããåããªã¢ã³ããæãããããæ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æé ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãã¢ãã¯ããŒãã«æäœYTH54.12åã³YTH25.4ïŒããã¯ãäŸãã°ãBrenner et al., Ann. N.Y. Acad. Sci. 996:80-88, 2003ã«èšèŒãããŠããŠããã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã䞊ã³ã«ãã®ããåããªã¢ã³ããæãããããæ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æ¹æ³ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãUCHL1, 2H4, SN130, MD4.3, MBI, åã³ MT2ïŒãããã¯ãäŸãã°ãBrown et al., Immunology 64:331-336, 1998ã«èšèŒãããŠããŠããã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã䞊ã³ã«ãã®ããåããªã¢ã³ããæãããããæ¬åºé¡ã«èšèŒãããæ¹æ³ãšäœµããŠäœ¿çšããããšãããæŽãªãæ-CD45æäœãšããŠã¯ãã¢ã¡ãªã«ã³ã»ã¿ã€ãã»ã«ã«ãã£ãŒã»ã³ã¬ã¯ã·ã§ã³(American Type Culture Collection (ATCC))ã®ã¢ã¯ã»ãã·ã§ã³çªå·RA3-6132ãRA3-2C2ãåã³TIB122ããç£çããããåã³æŸåºãããæ-CD45æäœã䞊ã³ã«ã¢ãã¯ããŒãã«æäœC363.16Aãåã³13/2ïŒãããã¯ãäŸãã°ãJohnson et al., J. Exp. Med. 169:1179-1184, 1989ã«èšèŒãããŠããŠããã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã䞊ã³ã«ãã®ããåããªã¢ã³ããæãããããæ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æ¹æ³ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãã¢ãã¯ããŒãã«æäœAHN-12.1ãAHN-12ãAHN-12.2ãAHN-12.3ãAHN-12.4ãHLe-1ãåã³KC56(T200) ïŒãããã¯ãäŸãã°ãHarvath et al., J. Immunol. 146:949-957, 1991ã«èšèŒãããŠããŠããã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã䞊ã³ã«ãã®ããåããªã¢ã³ããæããããã
æ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æé ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãäŸãã°ãç±³åœç¹èš±çªå·7,265,212ïŒããã¯ãäŸãã°ããšããããæ-CD45æäœ39E11ã16C9ãåã³1G10ãèšèŒããïŒã«èšèŒãããŠããæ-CD45æäœïŒç±³åœç¹èš±çªå·7,160,987ïŒããã¯ãäŸãã°ãATCCã¢ã¯ã»ãã·ã§ã³çªå·HB-11873ãç£çããåã³æŸåºããæ-CD45æäœïŒäŸãã°ãã¢ãã¯ããŒãã«æäœ6G3çïŒãèšèŒããïŒã«èšèŒãããŠããæ-CD45æäœïŒåã³ç±³åœç¹èš±çªå·6,099,838ïŒããã¯ãäŸãã°ãæ-CD45æäœMT3ã䞊ã³ã«ATCCã¢ã¯ã»ãã·ã§ã³çªå·HB220ïŒMB23G2ãšãåŒã°ããïŒåã³HB223ãç£çããåã³æŸåºããæäœãèšèŒããïŒã«èšèŒãããŠããæ-CD45æäœã䞊ã³ã«US 2004/0096901åã³US 2008/0003224ïŒãããã¯ãäŸãã°ãATCCã¢ã¯ã»ãã·ã§ã³çªå·PTA-7339ãç£çããåã³æŸåºããæ-CD45æäœïŒäŸãã°ãã¢ãã¯ããŒãã«æäœ17.1çïŒãèšèŒããïŒã«èšèŒãããŠããæ-CD45æäœããæããããïŒãããã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã
æ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æé ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãATCCã¢ã¯ã»ãã·ã§ã³çªå·MB4B4ãMB23G2ã14.8ãGAP 8.3ã74-9-3ãI/24.D6ã9.4ã4B2ãM1/9.3.4.HL.2ããçæåã³æŸåºãããæäœã䞊ã³ã«ãããã®ããååã³ïŒåã¯èŠªåæ§æçããªã¢ã³ããæããããã芪åæ§æçããäŸãã°ãæ¬åºé¡ã«èšèŒãããããåã¯åœè©²åéã§å
¬ç¥ã®in vitroãã£ã¹ãã¬ã€æè¡(äŸãã°ã以äžã®å®æœäŸïŒã«èšèŒããããããªãã¡ãŒãžã»ãã£ã¹ãã¬ã€)ã䜿çšããŠå®æœããããšãããã
æ¬åºé¡ã«èšèŒãããæ£è
ã³ã³ãã£ã·ã§ãã³ã°æé ãšäœµããŠäœ¿çšããããšããããæŽãªãæ-CD45æäœãšããŠã¯ãæ-CD45æäœT29/33ãæããããããã¯ãäŸãã°ãMorikawa et al., Int. J. Hematol. 54:495-504, 1991ã«èšèŒãããïŒãã®é瀺ã¯ãæ-CD45æäœã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã
ããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãã¢ããã¹ã¿ãã(è¥ããã¯ãå
¬ç¥ã®90Y-BC8ãIomab-BãBC8ïŒäŸãã°ãUS20170326259ãWO2017155937ãåã³Orozco et al. Blood.127.3 (2016): 352-359.ã«èšèŒããã)ãåã¯BC8-B10(äŸãã°ãLi et al. PloS one 13.10 (2018): e0205135ã«èšèŒããã)ããéžæãããïŒãããã®åã
ã¯ãåç
§ã«ããåã蟌ãŸããïŒãä»ã®æ-CD45æäœã¯ãäŸãã°ãWO2003/048327, WO2016/016442, US2017/0226209, US2016/0152733, US9,701,756; US2011/0076270, å㯠US7,825,222ã«èšèŒãããŠããïŒãããã®åã
ã¯ãåç
§ã«ããåã蟌ãŸããïŒã
äŸãã°ã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãã¢ããã¹ã¿ããã®çµåé åã«å¯Ÿå¿ããçµåé åïŒäŸãã°CDRãå¯å€é åïŒãå«ããã¢ããã¹ã¿ããã®ééå¯å€é å(VH)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO)ïŒ 10ã«èšèŒããïŒè¡šïŒãåç
§ïŒãã¢ããã¹ã¿ããã®è»œéå¯å€é å(VL)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO)ïŒ 11ã«èšèŒããïŒè¡šïŒãåç
§ïŒãããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœãåã¯ãã®æå-çµåéšåã¯ãé
åçªå·(SEQ ID NO)ïŒ 10ã«èšèŒã®ã¢ããé
žæ®åºãå«ãå¯å€ééãåã³é
åçªå·(SEQ ID NO)ïŒ 11ã«èšèŒã®è»œéå¯å€é åãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãã¢ããã¹ã¿ããã®CDR1ãCDR2åã³CDR3ãå«ãééã䞊ã³ã«ã¢ããã¹ã¿ããã®CDR1ãCDR2åã³CDR3ãå«ã軜éå¯å€é åãå«ãã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœã¯ãã¢ãã¯ããŒãã«æäœ104ã®å¯å€é åãå«ãã104ã¯ãããŠã¹CD45.2ã¢ã€ãœãã©ãŒã (BioLegend, San Diego, CA)ã«çµåãããåžè²©ãããŠããæ-CD45æäœã§ãããåã³mAb Ly-5.2ãšããŠãç¥ãããŠãããããã€ãã®å®æœåœ¢æ
ã§ã¯ã104ã®å¯å€é åã¯ãFcãã¡ã€ã³å
ã«ã1ã€ä»¥äžã®ã¢ããé
žçœ®æãå«ãããIgGå®åžžé åãšçµåãããäŸãã°ãããã€ãã®å®æœåœ¢æ
ã§ã¯ã104ã®å¯å€é åã¯ãFcãã¡ã€ã³å
ã®S239Cåã³N297Aã®çœ®æãå«ãããIgGå®åžžé åãšçµåãããããã€ãã®å®æœåœ¢æ
ã§ã¯ã104ã®å¯å€é åã¯ãFcãã¡ã€ã³å
ã®S239Cåã³IHH (å³ã¡ãI253AãH310Aåã³H435A)ã®çœ®æãå«ãããIgGå®åžžé åãšçµåããã
äŸãã°ã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ã104 S239C/IHHã®çµåé åã«å¯Ÿå¿ããçµåé åïŒäŸãã°CDRãå¯å€é åïŒãå«ãã104 S239C/IHHã®ééã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 12ã«èšèŒããïŒè¡šïŒåç
§ïŒã104 S239C/IHHã®è»œéã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 13ã«èšèŒããïŒè¡šïŒåç
§ïŒãããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœãåã¯ãã®æå-çµåéšåã¯ãé
åçªå·(SEQ ID NO): 12ã«èšèŒãããã¢ããé
žæ®åºãå«ãééãåã³é
åçªå·(SEQ ID NO): 13ã«èšèŒãããã¢ããé
žæ®åºãå«ã軜éããå«ãã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãã¢ãã¯ããŒãã«æäœAbAã®CDRé ååã³ïŒåã¯å¯å€é åãå«ããAbAã®ééå¯å€é å(VH)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 14ã«èšèŒããïŒè¡šïŒãåç
§ïŒãAbAã®VH CDRãã¡ã€ã³ã»ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 15(VH CDR1)ãé
åçªå·(SEQ ID NO): 16(VH CDR2)ãåã³é
åçªå·(SEQ ID NO): 17(VH CDR3)ã«èšèŒãããAbAã®è»œéå¯å€é å(VL)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 18ã«èšèŒãããAbAã®VL CDRãã¡ã€ã³ã»ã¢ããé
žé
åããé
åçªå·(SEQ ID NO):19(VL CDR1); é
åçªå·(SEQ ID NO):20(VL CDR2)ãåã³é
åçªå·(SEQ ID NO): 21(VL CDR3)ã«èšèŒãããåŸã£ãŠãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«ãããŠæäŸãããæ-CD45æäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãé
åçªå·(SEQ ID NO): 14ã«èšèŒã®ã¢ããé
žé
åãå«ãééå¯å€é åãåã³é
åçªå·(SEQ ID NO):18ã«èšèŒã®ã¢ããé
žé
åãå«ã軜éå¯å€é åããå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã¯ãé
åçªå·(SEQ ID NO):15ã16ãåã³17ã«èšèŒãããã¢ããé
žé
åãå«ãCDR1ãCDR2ãåã³CDR3ãå«ãééã䞊ã³ã«é
åçªå·(SEQ ID NO):19ã20ãåã³21ã«èšèŒãããã¢ããé
žé
åãå«ãCDR1ãCDR2ãåã³CDR3ãå«ã軜éå¯å€é åããå«ãã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãã¢ãã¯ããŒãã«æäœAbBã®CDRé ååã³ïŒåã¯å¯å€é åãå«ããAbBã®ééå¯å€é å(VH)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 22ã«èšèŒããïŒè¡šïŒãåç
§ïŒãAbBã®VH CDRãã¡ã€ã³ã»ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 23(VH CDR1)ãé
åçªå·(SEQ ID NO): 24(VH CDR2)ãåã³é
åçªå·(SEQ ID NO): 25(VH CDR3)ã«èšèŒãããAbBã®è»œéå¯å€é å(VL)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 26ã«èšèŒãããAbBã®VL CDRãã¡ã€ã³ã»ã¢ããé
žé
åããé
åçªå·(SEQ ID NO):27(VL CDR1); é
åçªå·(SEQ ID NO):28(VL CDR2)ãåã³é
åçªå·(SEQ ID NO): 29(VL CDR3)ã«èšèŒãããåŸã£ãŠãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«ãããŠæäŸãããæ-CD45æäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãé
åçªå·(SEQ ID NO): 22ã«èšèŒã®ã¢ããé
žé
åãå«ãééå¯å€é åãåã³é
åçªå·(SEQ ID NO):26ã«èšèŒã®ã¢ããé
žé
åãå«ã軜éå¯å€é åããå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã¯ãé
åçªå·(SEQ ID NO):23ã24ãåã³25ã«èšèŒãããã¢ããé
žé
åãå«ãCDR1ãCDR2ãåã³CDR3ãå«ãééã䞊ã³ã«é
åçªå·(SEQ ID NO):27ã28ãåã³29ã«èšèŒãããã¢ããé
žé
åãå«ãCDR1ãCDR2ãåã³CDR3ãå«ã軜éå¯å€é åããå«ãã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãã¢ãã¯ããŒãã«æäœAbCã®CDRé ååã³ïŒåã¯å¯å€é åãå«ããAbCã®ééå¯å€é å(VH)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 30ã«èšèŒããïŒè¡šïŒãåç
§ïŒãAbCã®VH CDRãã¡ã€ã³ã»ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 31(VH CDR1)ãé
åçªå·(SEQ ID NO): 32(VH CDR2)ãåã³é
åçªå·(SEQ ID NO): 33(VH CDR3)ã«èšèŒãããAbCã®è»œéå¯å€é å(VL)ã¢ããé
žé
åããé
åçªå·(SEQ ID NO): 34ã«èšèŒãããAbCã®VL CDRãã¡ã€ã³ã»ã¢ããé
žé
åããé
åçªå·(SEQ ID NO):35(VL CDR1); é
åçªå·(SEQ ID NO):36(VL CDR2)ãåã³é
åçªå·(SEQ ID NO): 37(VL CDR3)ã«èšèŒãããåŸã£ãŠãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«ãããŠæäŸãããæ-CD45æäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãé
åçªå·(SEQ ID NO): 30ã«èšèŒã®ã¢ããé
žé
åãå«ãééå¯å€é åãåã³é
åçªå·(SEQ ID NO):34ã«èšèŒã®ã¢ããé
žé
åãå«ã軜éå¯å€é åããå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã¯ãé
åçªå·(SEQ ID NO):31ã32ãåã³33ã«èšèŒãããã¢ããé
žé
åãå«ãCDR1ãCDR2ãåã³CDR3ãå«ãééã䞊ã³ã«é
åçªå·(SEQ ID NO):35ã36ãåã³37ã«èšèŒãããã¢ããé
žé
åãå«ãCDR1ãCDR2ãåã³CDR3ãå«ã軜éå¯å€é åããå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãæ¬åºé¡ã«èšèŒãããæ-CD45æäœã®ééãåã³ãæ¬åºé¡ã«èšèŒãããæ-CD45æäœã®è»œéå¯å€é åããå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã¯ãæ¬åºé¡ã«èšèŒãããæ-CD45æäœã®CDR1ãCDR2åã³CDR3ããå«ãééãåã³æ¬åºé¡ã«èšèŒãããæ-CD45æäœã®CDR1ãCDR2åã³CDR3ããå«ã軜éå¯å€é åãå«ãã
å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãæ¬åºé¡ã®æ-CD45æäœãšãå°ãªããšã95%ã®åäžæ§ãäŸãã°ãæ¬åºé¡ã®æ-CD45æäœãšãå°ãªããšã95%ã96%ã97%ã98%ã99%ãåã¯100%ã®åäžæ§ããæããã¢ããé
žé
åãå«ããééå¯å€é åãå«ããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæäœã¯ãæ¬åºé¡ã®æ-CD45æäœãåã¯ãã®ããªã¢ã³ãã®éé(HC)å¯å€ãã¡ã€ã³ãå«ãæ¹å€ããéé(HC)å¯å€é åãå«ãããã®ããªã¢ã³ãã¯ã(i)1,2,3,4åã¯5åã®ã¢ããé
žã®çœ®æãä»å åã¯æ¬ æã«ãããŠãåèšæ-CD45æäœãšã¯ç°ãªãïŒ(ii)ããããã5,4,3,2è¥ããã¯1åã®ã¢ããé
žã®çœ®æãä»å åã¯æ¬ æã«ãããŠãåèšæ-CD45æäœãšã¯ç°ãªãïŒ(iii) 1-5ã1-3ã1-2ã2-5è¥ããã¯3-5åã®ã¢ããé
žã®çœ®æãä»å åã¯æ¬ æã«ãããŠãåèšæ-CD45æäœãšã¯ç°ãªããåã³ïŒåã¯(iv)åèšæ-CD45æäœã«å¯ŸããŠãå°ãªããšãçŽ75%ã80%ã85%ã90%ã95%ã96%ã97%ã98%è¥ããã¯99%åäžã§ãããã¢ããé
žé
åãå«ããããã§ã(i)ãã(iv)ã®äœãã«ãããŠããã¢ããé
žçœ®æã¯ãä¿åçã¢ããé
žçœ®æãåã¯é-ä¿åçã¢ããé
žçœ®æãã§ããããšãããïŒäžŠã³ã«ããã§ãåèšæ¹å€ããééå¯å€é åã¯ãåèšæäœã®CD45çµåç¹ç°æ§ãä¿æããªãããåèšæ-CD45æäœã®ééå¯å€é åã«å¯ŸããŠãçç©åŠçãªæŽ»æ§ãå¢å ããããšãããã
æŽãªãæ-CD45æäœã¯ãåœéç¹èš±åºé¡çªå·PCT/US2019/058973åã³PCT/US2019/058971ãã«èšèŒãããŠããïŒãã®åã
ã®å
šäœã®å
容ã¯ãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã
æŽãªãæ-CD45æäœãåã³ãã®æå-çµåéšåã¯ãéå®ããããã®ã§ã¯ãªãããæ¬åºé¡ã«èšèŒãããæäœãåå®ããæ¹æ³ïŒäŸãã°ãæäœã©ã€ãã©ãªã®ãã€ã»ã¹ã«ãŒãããã»ã¹ã¯ãªãŒãã³ã°ããã¡ãŒãžã»ãã£ã¹ãã¬ã€ãèšç®ã¢ããªã³ã°ãªã©)ãªã©ã®ãåšç¥ã®æ¹æ³ãçšããŠçæããããšãããã
äžè¿°ã®ååè¡ç©ã®é瀺ã¯ããã®å
šäœãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸãããæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ãšäœµçšãããããšãããæäœåã³æå-çµåãã©ã°ã¡ã³ããšããŠã¯ãäžèšã®æäœåã³ãã®æå-çµåãã©ã°ã¡ã³ãã䞊ã³ã«äžèšãããã®é-ããæäœåã³æå-çµåãã©ã°ã¡ã³ãã®ããåããªã¢ã³ããåã³äžèšæäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã®ãšãããŒããšåããšãããŒãã«çµåããæäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãïŒäŸãã°ã競åçCD45çµåã¢ãã»ã€ã«ãã£ãŠè©äŸ¡ããå ŽåïŒããæããããã
Fc-æ¹å€æäœ
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã§æäŸããããæ-CD45æäœåã¯ãã®æåçµåéšåã¯ãæäœå®åžžé åãäŸãã°ãFcé å(äŸãã°ãã¿ã³ãã scFvã(scFv)2ããžã¢ããã£ãŒ(diaodies)ç)ããæ¬ ããä»ã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã§æäŸããããæ-CD45æäœåã¯æåçµåéšåã¯ã1ã€ä»¥äžã®æäœå®åžžé å(äŸãã°ã1ã€ä»¥äžã®CH1ãCH2ãåã¯CH3)ãå«ããããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã§æäŸããããæ-CD45æäœåã¯ãã®æåçµåéšåã¯ã1ã€ä»¥äžã®Fcé åãå«ãã
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã§æäŸããããæ-CD45æäœåã¯ãã®æåçµåéšåã¯ãæäœå®åžžé åãäŸãã°ãFcé å(äŸãã°ãã¿ã³ãã scFvã(scFv)2ããžã¢ããã£ãŒ(diaodies)ç)ããæ¬ ããä»ã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã§æäŸããããæ-CD45æäœåã¯æåçµåéšåã¯ã1ã€ä»¥äžã®æäœå®åžžé å(äŸãã°ã1ã€ä»¥äžã®CH1ãCH2ãåã¯CH3)ãå«ããããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã§æäŸããããæ-CD45æäœåã¯ãã®æåçµåéšåã¯ã1ã€ä»¥äžã®Fcé åãå«ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§æäŸããããæ-CD45æäœåã¯ãã®æåçµåéšåã¯ãçæ¥ã®åã¯éçåã®Fcé åãå«ããä»ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããæäœåã¯çµåãã©ã°ã¡ã³ãã¯ãåæžæãå¢å ããããåã¯ADCCãå¢å ãããè¥ããã¯æžå°ããããã®ã®ãããªãåèšæäœåã³ïŒåã¯ãã©ã°ã¡ã³ãã®ç¹æ§ãå€åããããFcé åå
ã®æ¹å€åã³ïŒåã¯å€ç°ããå«ãããšããããæ¬åºé¡ã§æäŸãããFc-æ¹å€æäœåã³ADCã«ãã£ãŠãå
å æ§ã®é è¡å¹¹çŽ°èãéžæçã«æžå°ãããããšãå¯èœã«ãªãã ãã§ãªããå€å æ§ã®é è¡å¹¹çŽ°è移æ€çã«å¯Ÿãã现èå·å®³æ§å¹æãæžå°ããããã«ãã£ãŠãé è¡å¹¹çŽ°è移æ€çã®ççãæŽã«ä¿é²ããã
æ¬åºé¡ã«èšèŒããããæäœãåã¯çµåãã©ã°ã¡ã³ãã¯ãåèšæäœåã³ïŒåã¯ãã©ã°ã¡ã³ãã®ç¹æ§ãå€åãããæ¹å€åã³ïŒåã¯å€ç°ïŒäŸãã°ãåæžæãå¢å€§ããããåã¯ADCCãå¢å€§ãããè¥ããã¯äœäžããããæ¹å€åã³ïŒåã¯å€ç°ïŒãå«ãããšãããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ã1ã€ä»¥äžã®æŸå°æ§æšèã¢ããé
žãå«ãæäœãæäŸããããæŸå°æ§æšèãããæäœã¯ã蚺æåã³æ²»çã®äž¡æ¹ã®ç®çã®ããã«äœ¿çšããåŸã(å¥ã®ç¹åŸŽãšããŠãæŸå°æ§æšèãããååã«ã³ã³ãžã¥ã²ãŒãããããšãå¯èœã§ãã)ãããªããããã®æšèã«é¢ããéå®ãããªãäŸãšããŠã¯ã3Hã14Cã15Nã35Sã90Yã99Tcåã³125Iã131Iåã³186Reãæãããããããããã«éå®ãããªããæŸå°æ§æšèã¢ããé
žåã³é¢é£ããããèªå°äœã調補ããããã®æ¹æ³ã¯åœè©²æè¡åéã§å
¬ç¥ã§ãã(äŸãã°ãJunghans et al.ãCancer Chemotherapy and Biotherapy 655-686ã第2çãChafneråã³Longoç·šãLippincott Raven(1996)åã³ç±³åœç¹èš±ç¬¬4,681,581å·ãç±³åœç¹èš±ç¬¬4,735,210å·ãç±³åœç¹èš±ç¬¬5,101,827å·ãç±³åœç¹èš±ç¬¬5,102,990U.S. RE35,500å·ïŒœãç±³åœç¹èš±ç¬¬5,648,471å·ãç±³åœç¹èš±ç¬¬5,697,902å·ãåç
§ã®ããš)ãäŸãã°ãæŸå°æ§åäœäœããã¯ãã©ãã³Tã®æ¹æ³ã«ãã£ãŠã³ã³ãžã¥ã²ãŒããããããšãããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœãåã¯ãã®çµåãã©ã°ã¡ã³ãã¯ãæ¹å€ããFcé åãå«ããããã§ãåèšæ¹å€ããFcé åã¯ãéçåFcé åã«å¯ŸããŠå°ãªããšã1ã€ã®ã¢ããé
žæ¹å€ãå«ã¿ããã®çµæãåèšååã¯ãFcã¬ã³ãR(FcγR)ã«å¯Ÿãã芪åæ§åã¯çµåãå€ãããåèšFcé åå
ã®ããç¹å®ã®ã¢ããé
žäœçœ®ã¯ãFcγRãšçŽæ¥æ¥è§Šãããçµæ¶åŠçç 究ã«ãã£ãŠåãã£ãŠãããå
·äœçã«ã¯ãã¢ããé
ž234ïœ239(ãã³ãžé å)ãã¢ããé
ž265ïœ269(B/Cã«ãŒã)ãã¢ããé
ž297ïœ299(C'/Eã«ãŒã)ãåã³ã¢ããé
ž327ïœ332(F/G)ã«ãŒãã§ããã(Sondermann et alã2000 Natureã406: 267-273åç
§)ãããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããæäœã¯ãæ§é çãªåã³çµæ¶åŠçãªè§£æã«åºã¥ããŠãFcγRãšçŽæ¥çã«æ¥è§Šãããå°ãªããšã1ã€ã®æ®åºãæ¹å€ãããããªã¢ã³ãFcé åãå«ãããšãããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ-CD45æäœïŒåã¯ãã®ãã©ã°ã¡ã³ãïŒã®Fcé åã¯ãKabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, NH1, MD (1991) (æ¬åºé¡ã«æ確ã«åç
§ã«ããåã蟌ãŸãã)ã«ãããããªEUã€ã³ããã¯ã¹ã«ããã¢ããé
ž265ã§ã®ã¢ããé
žçœ®æãå«ãããKabatã«ãããããªEUã€ã³ããã¯ã¹ãã¯ãããIgG1 EUæäœã®çªå·ä»ããããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265Aå€ç°ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯D265Cå€ç°ãå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœïŒåã¯ãã®ãã©ã°ã¡ã³ãïŒã®Fcé åã¯ãäŸãã°Kabatã«ãããããªEUã€ã³ããã¯ã¹ã«ããã¢ããé
ž234ã§ã®ã¢ããé
žçœ®æãå«ãã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265ãV205ãH435ãI253ãåã³ïŒåã¯H310ã®ã¢ããé
žäœçœ®ã«å€ç°ãå«ããäŸãã°ããããã®äœçœ®ã§ã®ç¹ç°çãªå€ç°ãšããŠã¯ãD265CãV205CãH435AãI253Aãåã³ïŒåã¯H310Aãæããããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234Aå€ç°ãå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœ(åã¯ãã®ãã©ã°ã¡ã³ã)ã®Fcé åã¯ãKabatã«ãããããªEUã€ã³ããã¯ã¹ã«ããã¢ããé
ž235ã§ã®ã¢ããé
žçœ®æãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL235Aå€ç°ãå«ããæŽã«å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234Aåã³L235Aå€ç°ãå«ããæŽãªãå®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234Aãåã³L235Aå€ç°ãå«ããæŽã«æŽãªãå®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234AãL235Aãåã³H435Aå€ç°ãå«ããæŽãªãå®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265Cåã³H435Aå€ç°ãå«ãã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãS239ã«å€ç°ãåç¬ã§ãåã¯æ¬åºé¡ã«èšèŒãããä»ã®Fcã«å ããŠãå«ããäŸç€ºçãªå®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãS239Cå€ç°ãå«ãã
æŽã«å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234Aåã³L235Aå€ç°ïŒæ¬åºé¡ã§ã¯ããL234A.L235Aãåã¯ãLALAããšãåŒã¶ïŒãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234Aåã³L235Aå€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªããæŽãªãå®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234Aãåã³L235Aå€ç°(æ¬åºé¡ã§ã¯ããD265C.L234A.L235AããšãåŒã¶)ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234Aãåã³L235Aå€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªãããŸãæŽãªãå®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234AãL235Aãåã³H435Aå€ç°(æ¬åºé¡ã§ã¯ããD265C.L234A.L235A.H435AããšãåŒã¶)ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234AãL235Aãåã³H435Aå€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªããæŽãªãå®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265Cåã³H435Aå€ç°(æ¬åºé¡ã§ã¯ããD265C.H435AããšãåŒã¶)ãå«ããæŽã«å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265AãS239CãL234Aãåã³L235Aå€ç°(æ¬åºé¡ã§ã¯ããD265A.S239C.L234A.L235AããšãåŒã¶)ãå«ããæŽã«å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265AãS239CãL234Aãåã³L235Aå€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãN297Gãåã³H435Aå€ç°(æ¬åºé¡ã§ã¯ããD265C.N297G.H435AããšãåŒã¶)ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãN297Qãåã³H435Aå€ç°(æ¬åºé¡ã§ã¯ããD265C.N297Q.H435AããšãåŒã¶)ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãE233PãL234VãL235Aåã³delG236(236ã®æ¬ 倱)å€ç°(æ¬åºé¡ã§ã¯ããE233P.L234V.L235A.delG236ãåã¯ãEPLVLAdelGããšãåŒã¶)ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãE233PãL234VãL235Aåã³delG236(236ã®æ¬ 倱)å€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãE233PãL234VãL235AãdelG236(236ã®æ¬ 倱)åã³H435Aå€ç°(æ¬åºé¡ã§ã¯ããE233P.L234V.L235A.delG236.H435Aãåã¯ãEPLVLAdelG.H435AããšãåŒã¶)ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãE233PãL234VãL235AãdelG236(236ã®æ¬ 倱)åã³H435Aå€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234AãL235AãS239Cåã³D265Aå€ç°ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234AãL235AãS239Cåã³D265Aå€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãH435AãL234AãL235Aãåã³D265Cå€ç°ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãH435AãL234AãL235Aãåã³D265Cå€ç°ãå«ããããã§ãåèšFcé åã¯ãP329Gå€ç°ãå«ãŸãªãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãæ¹å€ããFcé åãæãããã®çµæãåèšæäœã§ã¯ãin vitroãšãã§ã¯ã¿ãŒæ©èœã¢ãã»ã€ã«ãããŠãFcã¬ã»ãã¿ãŒ(FcR)ãžã®çµåããæ¹å€ããŠããªãFcé åãå«ãåãæäœã®åèšFcRãžã®çµåãšæ¯èŒããŠãæžå°ããŠããšãã§ã¯ã¿ãŒæ©èœãæžå°ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãæ¹å€ããFcé åãæãããã®çµæãåèšæäœã§ã¯ãin vitroãšãã§ã¯ã¿ãŒæ©èœã¢ãã»ã€ã«ãããŠãFcã¬ã³ãã»ã¬ã»ãã¿ãŒ(FcγR)ãžã®çµåããæ¹å€ããŠããªãFcé åãå«ãåãæäœã®åèšFcγRãžã®çµåãšæ¯èŒããŠãæžå°ããŠããšãã§ã¯ã¿ãŒæ©èœãæžå°ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcγRã¯ãFcγR1ã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcγRã¯ãFcγR2Aã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcγRã¯ãFcγR2Bã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcγRã¯ãFcγR2Cã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcγRã¯ãFcγR3Aã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcγRã¯ãFcγR3Bã§ãããä»ã®å®æœåœ¢æ
ã§ã¯ãçµåã®æžå°ã¯ãFcγRãžã®æäœçµåã§ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®åèšFcγRãžã®çµåãšæ¯èŒããŠãå°ãªããšã70%ã®æžå°ãå°ãªããšã80%ã®æžå°ãå°ãªããšã90%ã®æžå°ãå°ãªããšã95%ã®æžå°ãå°ãªããšã98%ã®æžå°ãå°ãªããšã99%ã®æžå°ãåã¯100%ã®æžå°ã§ãããä»ã®å®æœåœ¢æ
ã§ã¯ãçµåã®æžå°ã¯ãFcγRãžã®æäœçµåã§ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®åèšFcγRãžã®çµåãšæ¯èŒããŠãå°ãªããšã70%ãã100%ã®æžå°ãå°ãªããšã80%ãã100%ã®æžå°ãå°ãªããšã90%ãã100%ã®æžå°ãå°ãªããšã95%ãã100%ã®æžå°ãåã¯å°ãªããšã98%ãã100%ã®æžå°ã§ããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãæ¹å€ããFcé åãæãããã®çµæãåèšæäœã§ã¯ãin vitroãµã€ãã«ã€ã³æŸåºã¢ãã»ã€ã«ãããŠãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ãµã€ãã«ã€ã³æŸåºãšæ¯èŒããŠãå°ãªããšã50%ã®ãµã€ãã«ã€ã³æŸåºã«æžå°ããŠããµã€ãã«ã€ã³æŸåºãæžå°ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ããµã€ãã«ã€ã³æŸåºã®æžå°ã¯ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ãµã€ãã«ã€ã³æŸåºãšæ¯èŒããŠããµã€ãã«ã€ã³æŸåºã®å°ãªããšã70%ã®æžå°ãå°ãªããšã80%ã®æžå°ãå°ãªããšã90%ã®æžå°ãå°ãªããšã95%ã®æžå°ãå°ãªããšã98%ã®æžå°ãå°ãªããšã99%ã®æžå°ãåã¯100%ã®æžå°ã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ããµã€ãã«ã€ã³æŸåºã®æžå°ã¯ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ãµã€ãã«ã€ã³æŸåºãšæ¯èŒããŠããµã€ãã«ã€ã³æŸåºã®å°ãªããšã70%ãã100%ã®æžå°ãå°ãªããšã80%ãã100%ã®æžå°ãå°ãªããšã90%ãã100%ã®æžå°ãå°ãªããšã95%ãã100%ã®æžå°ã§ãããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ããµã€ãã«ã€ã³æŸåºã¯å
ç«çŽ°èã«ããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãæ¹å€ããFcé åãæãããã®çµæãåèšæäœã§ã¯ãin vitroãã¹ã现èè±é¡ç²ã¢ãã»ã€ã«ãããŠãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ãã¹ã现èè±é¡ç²ãšæ¯èŒããŠãå°ãªããšã50%ã®ãã¹ã现èè±é¡ç²ã«æžå°ããŠããã¹ã现èè±é¡ç²ãæžå°ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ããã¹ã现èè±é¡ç²ã®æžå°ã¯ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ãã¹ã现èè±é¡ç²ãšæ¯èŒããŠããã¹ã现èè±é¡ç²ã®å°ãªããšã70%ã®æžå°ãå°ãªããšã80%ã®æžå°ãå°ãªããšã90%ã®æžå°ãå°ãªããšã95%ã®æžå°ãå°ãªããšã98%ã®æžå°ãå°ãªããšã99%ã®æžå°ãåã¯100%ã®æžå°ã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ããã¹ã现èè±é¡ç²ã®æžå°ã¯ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ãã¹ã现èè±é¡ç²ãšæ¯èŒããŠããã¹ã现èè±é¡ç²ã®å°ãªããšã70%ãã100%ã®æžå°ãå°ãªããšã80%ãã100%ã®æžå°ãå°ãªããšã90%ãã100%ã®æžå°ãå°ãªããšã95%ãã100%ã®æžå°ã§ããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãæ¹å€ããFcé åãæãããã®çµæãåèšæäœã§ã¯ãin vitroæäœäŸåæ§çŽ°èãã¡ãŽãµã€ããŒã·ã¹ã»ã¢ãã»ã€(antibody dependent cell phagocytosis (ADCP) assay)ã«ãããŠãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ADCPãšæ¯èŒããŠãå°ãªããšã50%ã®æäœäŸåæ§çŽ°èãã¡ãŽãµã€ããŒã·ã¹ïŒADCPïŒã«æžå°ããŠãADCPãæžå°ãããåã¯åé¿ããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãADCPã®æžå°ã¯ãæ¹å€ããŠããªãFcé åãå«ãåãæäœã®ãµã€ãã«ã€ã³æŸåºãšæ¯èŒããŠããµã€ãã«ã€ã³æŸåºã®å°ãªããšã70%ã®æžå°ãå°ãªããšã80%ã®æžå°ãå°ãªããšã90%ã®æžå°ãå°ãªããšã95%ã®æžå°ãå°ãªããšã98%ã®æžå°ãå°ãªããšã99%ã®æžå°ãåã¯100%ã®æžå°ã§ããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããæ-HCæäœïŒäŸãã°ãæ-CD45æäœïŒã¯ã以äžã®æ¹å€åã¯ä»¥äžã®æ¹å€ã®çµã¿åããã®ãã¡ã®1ã€ãå«ãFcé åãå«ãïŒD265A, D265C, D265C / H435A, D265C / LALA, D265C / LALA / H435A, D265A / S239C / L234A / L235A / H435A, D265A / S239C / L234A / L235A, D265C / N297G, D265C / N297G / H435A, D265C (EPLVLAdelG *), D265C (EPLVLAdelG ) / H435A, D265C / N297Q / H435A, D265C / N297Q, EPLVLAdelG / H435A, EPLVLAdelG / D265C, EPLVLAdelG / D265A, N297A, N297G, å㯠N297Qã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã®æ-CD45æäœã¯ã以äžã®æ¹å€åã¯ä»¥äžã®æ¹å€ã®çµã¿åããã®ãã¡ã®1ã€ãå«ãFcé åãå«ãïŒD265A, D265C, D265C / H435A, D265C / LALA, D265C / LALA / H435A, D265C / N297G, D265C / N297G / H435A, D265C (IgG2*), D265C (IgG2) / H435A, D265C / N297Q / H435A, D265C / N297Q, EPLVLAdelG / H435A, N297A, N297G, å㯠N297Qã
æ¹å€ããFcé åãšFcã¬ã³ãã»ã¬ã»ãã¿ãŒãšã®éã®çµååã¯èŠªåæ§ããåœæè¡åéã§å
¬ç¥ã®æ§ã
ãªæè¡ïŒäŸãã°ãéå®ããããã®ã§ã¯ãªããã平衡æ¹æ³ïŒ»äŸãã°ãé
µçŽ çµåå
ç«åžçã¢ãã»ã€(ELISA)ïŒKinExAãRathanaswami et al. Analytical Biochemistry, Vol. 373:52-60, 2008ïŒã©ãžãªã€ã ãã¢ãã»ã€(RIA)ãåã¯è¡šé¢ãã©ãºã¢ã³å
±é³Žã¢ãã»ã€è¥ããã¯ä»ã®ã¡ã«ããºã ã®åæ
ã«åºã¥ãã¢ãã»ã€ïŒ»äŸãã°ãBIACORE(ç»é²åæš)解æè¥ããã¯Octet(ç»é²åæš)解æ(forteBIO)ã䞊ã³ã«ä»ã®æ¹æ³ïŒ»äŸãã°ãéæ¥ççµåã¢ãã»ã€ã競åççµåã¢ãã»ã€ãèå
å
±é³Žãšãã«ã®ãŒç§»å(FRET)ãã²ã«é»æ°æ³³ååã³ã¯ãããã°ã©ãã£ãŒïŒäŸãã°ãã²ã«ãéïŒãªã©ïŒœïŒã䜿çšããŠã枬å®ããããšãããããããã®åã³ä»ã®æ¹æ³ã¯ã1ã€ä»¥äžã®è©äŸ¡ããæ§ææåäžã«ããæšèãå©çšããããšããããåã³ïŒåã¯ãæ§ã
ãªæ€åºæ¹æ³ïŒäŸãã°ãéå®ããããã®ã§ã¯ãªãããçºè²æ§æšèãèå
æ§æšèãçºå
æ§æšèãåã¯åäœäœæšèãªã©ïŒã䜿çšããããšããããçµå芪åæ§åã³åæ
ã«é¢ããŠã¯ãPaul, W. E., ed., Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999)ïŒããã¯ãæäœ-å
ç«åçžäºäœçšã«çŠç¹ãåœãŠãŠããïŒã«ã詳现ã«èšèŒãããŠããã競åççµåã¢ãã»ã€ã®äžäŸã¯ãæšèæåãšç®çã®æäœãšããé-æšèã®æåã®éãå¢ãããªããããã®ååšäžã§ãã€ã³ãã¥ããŒã·ã§ã³ããããšãåã³åèšæšèæåã«çµåããæäœãæ€åºããããšããå«ãã©ãžãªã€ã ãã¢ãã»ã€ã§ããããã®ããŒã¿ãããã¹ãã£ããã£ãŒãã»ãããã解æã«ãããç¹å®ã®æåã«å¯Ÿããç®çã®æäœã®èŠªåæ§åã³çµåãªã-ã¬ãŒã(off-rate)ã決å®ããããšãããã第2ã®æäœãšã®ç«¶åããã©ãžãªã€ã ãã¢ãã»ã€ã䜿çšããŠã枬å®ããããšãããããã®å Žåãåèšæåããæšèååç©ã«ã³ã³ãžã¥ã²ãŒãããç®çã®æäœãšãé-æšèã®ç¬¬2ã®æäœã®éãå¢ãããªããããã®ååšäžã§ãã€ã³ãã¥ããŒã·ã§ã³ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããFcæ¹å€(äŸãã°ãD265CãL234AãL235Aãåã³ïŒåã¯H435A)ãæããæäœã¯ãFcã¬ã³ãã»ã¬ã»ãã¿ãŒãžã®çµåããæ¹å€ããŠããªãFcé åãå«ãåãæäœã®åèšFcã¬ã³ãã»ã¬ã»ãã¿ãŒãžã®çµåãšæ¯èŒããŠãå°ãªããšã70%ã®æžå°ãå°ãªããšã80%ã®æžå°ãå°ãªããšã90%ã®æžå°ãå°ãªããšã95%ã®æžå°ãå°ãªããšã98%ã®æžå°ãå°ãªããšã99%ã®æžå°ãåã¯100%ã®æžå°ã§ããïŒäŸãã°ããã€ãªã¬ã€ã€ãŒå¹²æžæ³(biolayer Interferometry)(BLI)ã§è©äŸ¡ããå ŽåïŒã
ãããªãçè«ã«ãææãããããšãæãŸãªãããFcã¬ã³ãã»ã¬ã»ãã¿ãŒãšã®Fcé åçµåçžäºäœçšã¯ãçš®ã
ã®ãšãã§ã¯ã¿ãŒæ©èœåã³äžæµã®ã·ã°ãã«äŒéã€ãã³ãïŒäŸãã°ãéå®ããããã®ã§ã¯ãªãããæäœäŸåæ§çŽ°èåªä»æ§çŽ°èå·å®³(antibody dependent cell-mediated cytotoxicity (ADCC))åã³è£äœäŸåæ§çŽ°èå·å®³(complement dependent cytotoxicity (CDC))ãªã©ïŒã«å¿
é ã§ãããšèãããããåŸã£ãŠãããç¹å®ã®æ
æ§ã§ã¯ãæ¹å€ããFcé åãå«ãæäœ(äŸãã°ãL234AãL235Aãåã³ïŒåã¯D265Cå€ç°ãå«ã)ã§ã¯ããšãã§ã¯ã¿ãŒæ©èœãå®è³ªçã«æžå°ããŠãããåã¯æ¶å€±ããŠããããšãã§ã¯ã¿ãŒæ©èœããåœæè¡åéã§å
¬ç¥ã®çš®ã
ã®æ¹æ³ã䜿çšããŠïŒäŸãã°ãç®çã®æäœã«å¯Ÿãã现èå¿çäŸãã°ããã¹ã现èè±é¡ç²åã¯ãµã€ãã«ã€ã³æŸåºïŒœã枬å®ããããšã«ãã£ãŠïŒã¢ãã»ã€ããããšããããäŸãã°ãåœæè¡åéã§ã®æšæºçãªæ¹æ³ãçšããŠãFcæ¹å€æäœãããã®in vitroã§ãã¹ã现èè±é¡ç²ãèªçºããäœçšèœãåã¯ãã®ãµã€ãã«ã€ã³æŸåºïŒäŸãã°ãããæ«æ¢¢è¡åæ žçŽ°èã«ããæŸåºãããïŒãèªçºããäœçšèœãã«ã€ããŠãã¢ãã»ã€ããããšãããã
åŸã£ãŠã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãåæžæã®äœäžïŒäŸãã°ãæ¹å€ããŠããªãFcé åãæããæäœãšæ¯èŒããŠïŒãããããå€ç°ãå«ããçãåæžæãæããæäœã¯ãæäœãç寿åœã®æ²»çè¬ãšããŠæ©èœããããšãæåŸ
ããããããç¹å®ã®äŸã§ã¯ïŒäŸãã°ãæäœãæäžããç¶ããŠHSCãæäžãããšããæ¬åºé¡ã«èšèŒãããã³ã³ãã£ã·ã§ãã³ã°ã»ã¹ãããã§ã¯ïŒãæçã§ããããšããããçæ³çã«ã¯ãå
å æ§ã®å¹¹çŽ°èãšã¯ç°ãªããäžè¬ã«ã¿ãŒã²ããæåïŒäŸãã°ãCD45ïŒãçºçŸããŠããããåèšæ-CD45æäœã®ã¿ãŒã²ããã§ã¯ãªãHSCãæäžããåã«ãåèšæäœã¯å®è³ªçã«ã¯ãªã¢ã©ã³ã¹ãããã¹ãã§ããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ã435ïŒKabatã«ããEUã€ã³ããã¯ã¹ïŒã®äœçœ®ã§ã®å€ç°ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšå€ç°ã¯H435Aå€ç°ã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããæ-CD45æäœã¯ã(äŸãã°ãããã«ãããŠ)çŽ24æé以äžãçŽ23æé以äžãçŽ22æé以äžãçŽ21æé以äžãçŽ20æé以äžãçŽ19æé以äžãçŽ18æé以äžãçŽ17æé以äžãçŽ16æé以äžãçŽ15æé以äžãçŽ14æé以äžãçŽ13æé以äžãçŽ12æé以äžãåã¯çŽ11æé以äžã®åæžæãæããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããæ-CD45æäœã¯ã1ãã5æéã5ãã10æéã10ãã15æéã15ãã20æéãåã¯20ãã25æéã®åæžæ(äŸãã°ãããã«ããã)ãæããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœã®åæžæã¯ãçŽ5ãã7æéïŒçŽ5ãã9æéïŒçŽ5ãã11æéïŒçŽ5ãã13æéïŒçŽ5ãã15æéïŒçŽ5ãã20æéïŒçŽ5ãã24æéïŒçŽ7ãã24æéïŒçŽ9ãã24æéïŒçŽ11ãã24æéïŒçŽ12ãã22æéïŒçŽ10ãã20æéïŒçŽ8ãã18æéïŒåã¯çŽ14ãã24æéã§ããã
ããã€ãã®æ
æ§ã§ã¯ãåèšFcé åã¯ãåæžæãæžå°ããããåã³åèšæäœã®ãšãã§ã¯ã¿ãŒæ©èœãäœäžãããã2ã€ä»¥äžã®å€ç°ãå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãåæžæã®æžå°ãããããå€ç°ãåã³FcγRãšçŽæ¥çã«æ¥è§Šããããšãã§ãã(äŸãã°ãæ§é çãªåã³çµæ¶åŠçãªè§£æã«åºã¥ã)å°ãªããšã1ã€ã®æ®åºã®å€ç°ããå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãH435Aå€ç°ãL234Aå€ç°ãåã³L235Aå€ç°ããå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãH435Aå€ç°åã³D265Cå€ç°ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãH435Aå€ç°ãL234Aå€ç°ãL235Aå€ç°ãåã³D265Cå€ç°ãå«ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã¯ãæ¬æäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®Fcãã¡ã€ã³ã«ãããã·ã¹ãã€ã³æ®åºãä»ããŠã现èæ¯çŽ (äŸãã°ãPBD)ã«ã³ã³ãžã¥ã²ãŒããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšã·ã¹ãã€ã³æ®åºã¯ãåèšæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®Fcãã¡ã€ã³ã«ãããå€ç°ã«ãã£ãŠå°å
¥ããããäŸãã°ãåèšã·ã¹ãã€ã³æ®åºã¯ãCys118ãCys239ãåã³Cys265ãããªã矀ããéžæãããããšãããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæ-CD45æäœïŒåã¯ãã®ãã©ã°ã¡ã³ãïŒã®Fcé åã¯ãKabatã«ãããããªEUã€ã³ããã¯ã¹ã«ããã¢ããé
ž265ã§ã®ã¢ããé
žçœ®æãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265Cå€ç°ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265Cåã³H435Aå€ç°ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234Aãåã³L235Aå€ç°ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãD265CãL234AãL235Aãåã³H435Aå€ç°ãå«ããäžè¿°ã®å€ç°ã«å ããŠãåã¯ä»£ããã«ãããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãS239Cå€ç°ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234Aå€ç°ãL235Aå€ç°ãS239Cå€ç°åã³D265Aå€ç°ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãS239Cåã³H435Aå€ç°ãå«ããå¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãL234Aå€ç°ãL235Aå€ç°ãåã³S239Cå€ç°ãå«ããæŽã«å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãH435Aå€ç°ãL234Aå€ç°ãL235Aå€ç°ãåã³S239Cå€ç°ãå«ããæŽã«å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšFcé åã¯ãH435Aå€ç°ãL234Aå€ç°ãL235Aå€ç°ãS239Cå€ç°åã³D265Aå€ç°ãå«ãã
ç¹ã«ãFcã®ã¢ããé
žäœçœ®ã¯ãå¥æ®µã«ç€ºããªãéããEUçªå·ä»ãã€ã³ããã¯ã¹ãåç
§ããŠããã
æ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ãšçµã¿åãããŠäœ¿çšããããšãããæäœåã³æåçµåãã©ã°ã¡ã³ããšããŠã¯ãäžèšã®æäœåã³ãã®æåçµåãã©ã°ã¡ã³ãã䞊ã³ã«äžèšã®é-ããæäœåã³æå-çµåãã©ã°ã¡ã³ãã®ããªã¢ã³ããåã³(äŸãã°ã競åçæåçµåã¢ãã»ã€ã«ãã£ãŠè©äŸ¡ããå Žåã«)äžèšã®æäœåã³ãã®æåçµåãã©ã°ã¡ã³ããšåããšãããŒãã«çµåããæäœåã¯æåçµåãã©ã°ã¡ã³ãããæããããã
æ¬é瀺ã®æäœã¯ãæŽã«æãå ããŠãäŸãã°(Dall'Acqua et al.(2006)J Biol Chem 281: 23514-24)ã(Zalevsky et al.(2010)Nat Biotechnol 28: 157-9)ã(Hinton et al.(2004)J Biol Chem 279: 6213-6)ã(Hinton et al.(2006)J Immunol 176: 346-56)ã(Shields et al.(2001)J Biol Chem 276: 6591-604)ã(Petkova et al.(2006)Int Immunol 18: 1759-69)ã(Datta-Mannan et al.(2007)Drug Metab Dispos 35: 86-94)ã(Vaccaro et al.(2005)Nat Biotechnol 23: 1283-8)ã(Yeung et al. (2010)Cancer Res 70: 3269-77)åã³(Kim et al. (1999)Eur J Immunol 29: 2819-25)ã«èšèŒã®Fcå€ç°ã®ãããªFcå€ç°ãæŽã«å°å
¥ããããšã«ãã£ãŠãæäœã®åæžæãæŽã«èª¿ç¯ããããšãããã䞊ã³ã«äœçœ®250ã252ã253ã254ã256ã257ã307ã376ã380ã428ã434åã³435ãå«ãããšããããåç¬ã§åã¯çµã¿åãããŠäœè£œããåŸãäŸç€ºçãªå€ç°ã¯ãT250QãM252Yã1253AãS254TãT256EãP2571ãT307AãD376VãE380AãM428LãH433KãN434SãN434AãN434HãN434FãH435Aåã³H435Rå€ç°ã§ããã
æäœãæäœããŠæ¬åºé¡ã®äœããã®Fcæ¹å€ãå
¥ããæ¹æ³ã¯ãåœæè¡åéã§åšç¥ã§ããããããã®æ¹æ³ãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããåèšæäœåã¯å°ãªããšãåèšæäœã®å®åžžé åãã³ãŒãããã調補ããDNAååã«é¢ãããéšäœç¹ç°ç(åã¯ãªãªãŽãã¯ã¬ãªãããåªä»ãã)å€ç°èªçºãPCRå€ç°èªçºãåã³ã«ã»ããå€ç°èªçºãã«ãã調補ãæãããããéšäœç¹ç°çå€ç°èªçºã¯ãåœæè¡åéã§åšç¥ã§ããïŒäŸãã°ãCarter et al., Nucleic Acids Res., 13:4431-4443 (1985) åã³ Kunkel et al., Proc. Natl. Acad. Sci. USA, 82:488 (1987)ãåç
§ïŒãPCRå€ç°èªçºããŸããåºçºããªããããã®ã¢ããé
žé
åããªã¢ã³ããäœè£œããã®ã«é©ããŠãããHiguchi, in PCR Protocols, pp. 177-183 (Academic Press, 1990); åã³ Vallette et al., Nuc. Acids Res. 17:723-733 (1989)ãåç
§ãé
åããªã¢ã³ãã調補ããããã®å¥ã®æ¹æ³ïŒã«ã»ããå€ç°èªçºïŒã¯ãWells et al., Gene, 34:315-323 (1985)ã«èšèŒãããŠããæè¡ã«åºã¥ãã
æäœãåå®ããæ¹æ³
é è¡å¹¹çŽ°èãçºçŸããCD45ã«çµåããããšãã§ãããæäœãåã¯æäœãã©ã°ã¡ã³ãã®ã©ã€ãã©ãªããã€ã¹ã«ãŒãããã»ã¹ã¯ãªãŒãã³ã°ããããã®æ¹æ³ã䜿çšããŠããããèªå·±å ç«çŸæ£ãæ²»çããããã«ãåã³æ¬åºé¡ã«èšèŒããããããªé è¡å¹¹çŽ°èçæ³ãå¿ èŠãšããæ£è (äŸãã°ãããæ£è )ãã³ã³ãã£ã·ã§ãã³ã°ããããã«ãæçšãªæ-CD45æäœãåå®ããããšãããããã®ãããªæ¹æ³ã䜿çšããŠãæ¬åºé¡ã«èšèŒãããAb1ã®æ¹è¯åãåå®ããããšãããããã®ãããªæ¹æ³ãšããŠã¯ãåœæè¡åéã§å ¬ç¥ã®in vitroãã£ã¹ãã¬ã€æè¡ãäŸãã°ããšãããããã¡ãŒãžã»ãã£ã¹ãã¬ã€ããã¯ããªã¢ã»ãã£ã¹ãã¬ã€ãé µæ¯ãã£ã¹ãã¬ã€ãåºä¹³åç©çŽ°èãã£ã¹ãã¬ã€ããªããœãŒã ã»ãã£ã¹ãã¬ã€ãmRNAãã£ã¹ãã¬ã€ãåã³cDNAãã£ã¹ãã¬ã€ãªã©ããæããããã
é è¡å¹¹çŽ°èãçºçŸããCD45ã«çµåããããšãã§ãããæäœãåã¯æäœãã©ã°ã¡ã³ãã®ã©ã€ãã©ãªããã€ã¹ã«ãŒãããã»ã¹ã¯ãªãŒãã³ã°ããããã®æ¹æ³ã䜿çšããŠããããèªå·±å ç«çŸæ£ãæ²»çããããã«ãåã³æ¬åºé¡ã«èšèŒããããããªé è¡å¹¹çŽ°èçæ³ãå¿ èŠãšããæ£è (äŸãã°ãããæ£è )ãã³ã³ãã£ã·ã§ãã³ã°ããããã«ãæçšãªæ-CD45æäœãåå®ããããšãããããã®ãããªæ¹æ³ã䜿çšããŠãæ¬åºé¡ã«èšèŒãããAb1ã®æ¹è¯åãåå®ããããšãããããã®ãããªæ¹æ³ãšããŠã¯ãåœæè¡åéã§å ¬ç¥ã®in vitroãã£ã¹ãã¬ã€æè¡ãäŸãã°ããšãããããã¡ãŒãžã»ãã£ã¹ãã¬ã€ããã¯ããªã¢ã»ãã£ã¹ãã¬ã€ãé µæ¯ãã£ã¹ãã¬ã€ãåºä¹³åç©çŽ°èãã£ã¹ãã¬ã€ããªããœãŒã ã»ãã£ã¹ãã¬ã€ãmRNAãã£ã¹ãã¬ã€ãåã³cDNAãã£ã¹ãã¬ã€ãªã©ããæããããã
çç©åŠçã«é¢é£ããååã«çµåããæäœãåã¯æåçµåãã©ã°ã¡ã³ããåé¢ããããã«ãã¡ãŒãžã»ãã£ã¹ãã¬ã€ã䜿çšããããšã¯ãäŸãã°ãFelici et al., Biotechnol. Annual Rev. 1:149-183, 1995; Katz, Annual Rev. Biophys. Biomol. Struct. 26:27-45, 1997; åã³ Hoogenboom et al., Immunotechnology 4:1-20, 1998ãã§ã¬ãã¥ãŒãããŠããŠããããããã®åã
ã®é瀺ã¯ãin vitroãã£ã¹ãã¬ã€æè¡ã«é¢é£ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸãããKay, Perspect. Drug Discovery Des. 2:251-268, 1995 åã³ Kay et al., Mol. Divers. 1:139-140, 1996ã«èšèŒãããããã«ãã©ã³ãã åããã³ã³ããããªã¢ã«ã»ããããã»ã©ã€ãã©ãªãæ§ç¯ããŠã现èè¡šé¢æåã«çµåããããªãããããéžæããããšãè¡ãããŠããŠããããããã®åã
ã®é瀺ã¯ãæåçµåååã®çºèŠã«é¢é£ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸãããã¿ã³ãã¯è³ªé¡(äŸãã°ãå€éäœã¿ã³ãã¯è³ªé¡)ããæ©èœçååãšããŠããã¡ãŒãžã»ãã£ã¹ãã¬ã€ããããšããããŸãã§ããŠããŠãã(äŸãã°ãEP 0349578; EP 4527839;åã³EP 0589877ã䞊ã³ã«Chiswell and McCafferty, Trends Biotechnol. 10:80-84 1992ãåç
§ããããã®åã
ã®é瀺ã¯ãæåçµåååãçºèŠããããã«in vitroãã£ã¹ãã¬ã€æè¡ã䜿çšããããšã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒãæŽã«ãæ©èœçæäœãã©ã°ã¡ã³ã(äŸãã°ãFabåã³scFvãã©ã°ã¡ã³ã)ããin vitroãã£ã¹ãã¬ã€ã»ãã©ãŒãããã§ãçºçŸãããããšãè¡ãããŠããŠãã(äŸãã°ãMcCafferty et al., Nature 348:552-554, 1990; Barbas et al., Proc. Natl. Acad. Sci. USA 88:7978-7982, 1991; åã³ Clackson et al., Nature 352:624-628, 1991ãåç
§ããããã®åã
ã®é瀺ã¯ãæåçµåååãçºèŠããããã®in vitroãã£ã¹ãã¬ã€ã»ãã©ãããã©ãŒã ã«é¢é£ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒãããæ-CD45æäœããäŸãã°ãHuMAb-ããŠã¹ç»é²åæšåã¯XenoMouseTMã«ãããŠç£çãããããšãããããšãããããããã®æè¡ã䜿çšããŠãé è¡å¹¹çŽ°èãçºçŸããCD45ã«çµåããããšãã§ããã次ãã§ãé è¡å¹¹çŽ°è移æ€çæ³ãå¿
èŠãšããæ£è
(äŸãã°ãããæ£è
)ã«ãããŠå
å æ§ã®é è¡å¹¹çŽ°èãæžå°ãããããã«äœ¿çšããããšãã§ãããæäœé¡ãæäœãåã¯ãã©ã°ã¡ã³ãã®èŠªåæ§ãåå®ãããåã³æ¹åãããããšãããã
in vitroãã£ã¹ãã¬ã€æè¡ã«å ããŠãèšç®ã¢ããªã³ã°æè¡ã䜿çšããŠãé è¡å¹¹çŽ°èãçºçŸããæåïŒäŸãã°ãCD45ïŒã«çµåããããšãã§ããæäœããèšèšãããåã³åå®ããããšããããäŸãã°ãèšç®ã¢ããªã³ã°æè¡ã䜿çšããŠãåœæ¥è
ã®ããè
ã¯ãé è¡å¹¹çŽ°èãçºçŸããæåïŒäŸãã°ãCD45ïŒã«ããç¹ç°çãªãšãããŒãïŒäŸãã°ãåèšæåã®çŽ°èå€ã®ãšãããŒãïŒã«çµåããããšãã§ããååãæ±ããŠãæäœãåã¯æäœãã©ã°ã¡ã³ãã®ã©ã€ãã©ãªãin silicoã§ã¹ã¯ãªãŒãã³ã°ããããšãããã
æŽãªãæè¡ã䜿çšããŠãé è¡å¹¹çŽ°èãçºçŸããCD45ã«çµåããããšãã§ãããåã³ãäŸãã°ãã¬ã»ãã¿ãŒåªä»ãšã³ããµã€ããŒã·ã¹ã«ãã£ãŠãåèšçŽ°èãäžã«åã蟌ãããšãã§ãããæäœãåã¯æäœãã©ã°ã¡ã³ããåå®ããããšããããäŸãã°ãäžèšã®in vitroãã£ã¹ãã¬ã€æè¡ããCD45ã«çµåãããåã³ç¶ããŠäžã«åã蟌ãŸãããæäœãåã¯ãã®æäœãã©ã°ã¡ã³ããæ±ããŠã¹ã¯ãªãŒãã³ã°ããããšã«ãé©åãããããšãããããã¡ãŒãžã»ãã£ã¹ãã¬ã€ã¯ããã®ã¹ã¯ãªãŒãã³ã°ã»ãã©ãã€ã ãšçµã¿åãããŠäœ¿çšããããšããããããªæè¡ã®1ã€ã®ä»£è¡šã§ãããé è¡å¹¹çŽ°èã®äžã«åã蟌ãŸããããšãããæ-CD45æäœãåã¯æäœãã©ã°ã¡ã³ããåå®ããããã«ãåœæ¥è
ã®ããè
ã¯ãWilliams et al., Leukemia 19:1432-1438, 2005ã«èšèŒããããã¡ãŒãžã»ãã£ã¹ãã¬ã€æè¡ã䜿çšããããšãããïŒãã®é瀺ã¯ããã®å
šäœãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒãäŸãã°ãåœæè¡åéã§å
¬ç¥ã®å€ç°èªçºæ¹æ³ã䜿çšããŠãæäœãæäœãã©ã°ã¡ã³ãïŒäŸãã°ããšãããscFvãã©ã°ã¡ã³ããFabãã©ã°ã¡ã³ãããã€ã¢ããã£ãããªã¢ããã£ãåã³10Fn3ãã¡ã€ã³ïŒãåã¯ãªã¬ã³ãïŒãããã¯ãã©ã³ãã åã¢ããé
žã«ã»ãããäŸãã°ãCDRè¥ããã¯ãã®ç䟡é åãåã¯æäœè¥ããã¯æäœãã©ã°ã¡ã³ãã®1ã€ä»¥äžãè¥ããã¯å
šãŠã®äžã«ïŒœå«æããïŒãã³ãŒãããçµæããã¡ãŒãžã»ã©ã€ãã©ãªãç£çããããšãã§ãããåèšæäœåã¯æäœãã©ã°ã¡ã³ãã®éªšæ Œé åããã³ãžãFcãã¡ã€ã³ãåã³ä»ã®é åããäŸãã°ãããçæ®ç³»åæäœé
ååã¯ããçæ®ç³»åæäœãšæ¯èŒããŠå
ãã«éãé
åãæããããã«ããããšã«ãã£ãŠãããã«ãããŠé-å
ç«åæ§ã§ããããã«èšèšããããšãããã
æ¬åºé¡ã«èšèŒããããåã¯åœæè¡åéã§å
¬ç¥ã®ãã¡ãŒãžã»ãã£ã¹ãã¬ã€æè¡ã䜿çšããŠããã¡ãŒãžç²åã«å
±æçµåããã©ã³ãã åæäœãåã¯æäœãã©ã°ã¡ã³ããå«ããã¡ãŒãžã»ã©ã€ãã©ãªããCD45ãšã€ã³ãã¥ããŒãããïŒäŸãã°ããŸãæåã«ãé-ç¹ç°çãªã¿ã³ãã¯è³ªçµåã瀺ãæäœãåã¯æäœãã©ã°ã¡ã³ããã³ãŒããããã¡ãŒãžãé€å»ããããã«ãåã³Fcãã¡ã€ã³ã«çµåããæäœåã¯ãã®ãã©ã°ã¡ã³ããã³ãŒããããã¡ãŒãžãé€å»ããããã«ãåèšãã¡ãŒãžã»ã©ã€ãã©ãªãããããã³ã°è¬å€ïŒ»äŸãã°ãä¹³ã¿ã³ãã¯è³ªããŠã·è¡æž
ã¢ã«ããã³ãåã³ïŒåã¯IgGãªã©ïŒœãšã€ã³ãã¥ããŒãããã䞊ã³ã«æ¬¡ã«ãåèšãã¡ãŒãžã»ã©ã€ãã©ãªããCD45ãçºçŸããã现èïŒäŸãã°ãé è¡å¹¹çŽ°èïŒã®éå£ãšã€ã³ãã¥ããŒãããïŒãæ-CD45æäœãåã¯æäœãã©ã°ã¡ã³ãã现èè¡šé¢ã®åçš®æåã«çµåãããåã³ç¶ããŠãåèšé è¡å¹¹çŽ°èã«ãã£ãŠäžã«åã蟌ãŸãããã®ã«ååãªæéïŒäŸãã°ã4âã§30åãã6æéãäŸãã°ã4âã§1æéãªã©ïŒãåèšãã¡ãŒãžã»ã©ã€ãã©ãªãåèšé è¡å¹¹çŽ°èãšã€ã³ãã¥ããŒãããããšããããç¶ããŠãäŸãã°ãå·ãã(4â)pH 2.8ã®0.1 Mã°ãªã·ã³ã»ãããã¡ãŒã§æŽãããšã«ãã£ãŠãé è¡å¹¹çŽ°èã«çµåããããšãåã³é è¡å¹¹çŽ°èã«ãã£ãŠäžã«åã蟌ãŸããããšãã®ç®çã«ãšã£ãŠãåèšCD45ã«å¯ŸããŠååãªèŠªåæ§ã瀺ããªããæäœãåã¯æäœãã©ã°ã¡ã³ããå«ããã¡ãŒãžããé€å»ããããšããããåèšé è¡å¹¹çŽ°èãäžã«åã蟌ãã ãæäœãåã¯ãã®æäœãã©ã°ã¡ã³ãã«çµåãããã¡ãŒãžããäŸãã°ãåèšçŽ°èã溶解ãããã®çŽ°èå¹é€å¹å°ããäžã«åã蟌ãŸãããã¡ãŒãžãååããããšã«ãã£ãŠãåå®ããããšãããã次ãã§ãäŸãã°ãåœæè¡åéã§å
¬ç¥ã®æ¹æ³ã䜿çšããŠããã¯ããªã¢çŽ°èãååãããã¡ãŒãžãšå
±ã«2ÃYTå¹å°äžã§ã€ã³ãã¥ããŒãããããšã«ãã£ãŠãåèšãã¡ãŒãžããã¯ããªã¢çŽ°èäžã§å¢å¹
ããããšãããã次ãã§ããã®å¹å°ããååãããã¡ãŒãžããäŸãã°ããã¡ãŒãžã»ã²ãã å
ã«æ¿å
¥ãããæäœåã¯æäœãã©ã°ã¡ã³ããã³ãŒãããéºäŒåã®æ žé
žé
åã決å®ããããšã«ãã£ãŠãåå®ããããšãããããã®ã³ãŒããããæäœåã¯æäœãã©ã°ã¡ã³ãããç¶ããŠã(äŸãã°ããã®æäœãã©ã°ã¡ã³ããäŸãã°ãscFvãã©ã°ã¡ã³ãã«ã€ããŠã¯)ååŠåæããããšã«ãã£ãŠãåã¯(äŸãã°ãå
šé·æäœã«ã€ããŠã¯)çµæãçºçŸããããšã«ãã£ãŠãæ°ãã«èª¿è£œããããšãããã
調補ããæäœãåã¯æäœãã©ã°ã¡ã³ããäžã«åã蟌ã蚱容éããäŸãã°ãåœæè¡åéã§å
¬ç¥ã®æŸå°æ§æ žçš®å
éšå蟌ã¢ãã»ã€ã䜿çšããŠãè©äŸ¡ããããšããããäŸãã°ãæ¬åºé¡ã«èšèŒããããåã¯åœæè¡åéã§å
¬ç¥ã®in vitroãã£ã¹ãã¬ã€æè¡ãçšããŠåå®ããæ-CD45æäœãåã¯æäœãã©ã°ã¡ã³ãããæŸå°æ§åäœå
çŽ ïŒäŸãã°ã18F, 75Br,77Br, 122I, 123I, 124I, 125I, 129I, 131I, 211At, 67Ga, 111In, 99Tc, 169Yb, 186Re, 64Cu, 67Cu, 177Lu, 77As, 72As, 86Y, 90Y, 89Zr, 212Bi, 213Bi, å㯠225AcïŒãçµã¿èŸŒãŸããããšã«ãããæ©èœçã«ããããšããããäŸãã°ãæŸå°æ§ããã²ã³ïŒäŸãã°ã18F, 75Br,77Br, 122I, 123I, 124I, 125I, 129I, 131I, 211AtçïŒããæ±é»åæ§ããã²ã³è©Šè¬ãå«ãããŒãºïŒäŸãã°ãããªã¹ãã¬ã³ã»ããŒãºïŒ(äŸãã°ããšãŒãåããŒãºãThermo Fisher Scientific, Inc., Cambridge, MA)ã䜿çšããŠãæäœãåã¯æäœãã©ã°ã¡ã³ãã®äžã«çµã¿èŸŒãŸããããšããããæŸå°æ§æšèããæäœããã®ãã©ã°ã¡ã³ãåã¯ADCããäžã«åã蟌ãŸããã®ã«ååãªæé(äŸãã°ã4âã§30åãã6æéãäŸãã°ã4âã§1æéç)ãé è¡å¹¹çŽ°èãšå
±ã«ã€ã³ãã¥ããŒãããããšãããã次ãã§ãïŒäŸãã°ãå·ãã(4â)pH 2.8ã®0.1 Mã°ãªã·ã³ã»ãããã¡ãŒã䜿çšããŠïŒåèšçŽ°èãæŽæµããŠãäžã«åã蟌ãŸããªãã£ãæäœåã¯ãã®ãã©ã°ã¡ã³ããé€å»ãããäžã«åã蟌ãŸããæäœãåã¯æäœãã©ã°ã¡ã³ãããåŸãããé è¡å¹¹çŽ°èããæŸåºãããæŸå°ç·(äŸãã°ãγç·)ãæ€åºããååããæŽæµãããã¡ãŒããæŸåºãããæŸå°ç·(äŸãã°ãγç·)ãšæ¯ã¹ãããšã«ãã£ãŠãåå®ããããšããããåèšã®å
éšå蟌ã¢ãã»ã€ã䜿çšããŠãADCãç¹åŸŽä»ããããšãããã
æäœããäŸãã°ãç±³åœç¹èš±ç¬¬4,816,567å·ã«èšèŒãããããã«ãçµæãæ¹æ³åã³çµæç©ã䜿çšããŠç£çããããšãããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããæ-CD45æäœãã³ãŒãããåé¢ãããæ žé
žãæäŸãããããã®ãããªæ žé
žã¯ãæ¬æäœã®VLãå«ãã¢ããé
žé
ååã³ïŒåã¯æ¬æäœã®VHãå«ãã¢ããé
žé
å(äŸãã°ãæ¬æäœã®è»œéåã³ïŒåã¯éé)ãã³ãŒãããããšããããæŽãªãå®æœåœ¢æ
ã§ã¯ããã®ãããªæ žé
žãå«ã1皮以äžã®ãã¯ã¿ãŒ(äŸãã°ãçºçŸãã¯ã¿ãŒ)ãæäŸããããæŽãªãå®æœåœ¢æ
ã§ã¯ããã®ãããªæ žé
žãå«ã宿䞻现èãæäŸãããã1ã€ã®ãã®ãããªå®æœåœ¢æ
ã§ã¯ã宿䞻现èã¯ä»¥äžãå«ã(äŸãã°ã以äžã§åœ¢è³ªè»¢æãããŠãã)ïŒ(1)æ¬æäœã®VLãå«ãã¢ããé
žé
ååã³æ¬æäœã®VHãå«ãã¢ããé
žé
åãã³ãŒãããæ žé
žãå«ããã¯ã¿ãŒãåã¯(2)æ¬æäœã®VLãå«ãã¢ããé
žé
åãã³ãŒãããæ žé
žãå«ã第1ã®ãã¯ã¿ãŒåã³æ¬æäœã®VHãå«ãã¢ããé
žé
åãã³ãŒãããæ žé
žãå«ã第2ã®ãã¯ã¿ãŒã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšå®¿äž»çŽ°èã¯ãçæ žçç©ãäŸãã°ãã£ã€ããŒãºã»ãã ã¹ã¿ãŒåµå·£(CHO)现èåã¯ãªã³ã系现è(äŸãã°Y0ãNS0ãSp20现è)ã§ããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ-CLL-1æäœãäœè£œããæ¹æ³ãæäŸãããããã§ãåèšæ¹æ³ã¯ãäžèšã«æäŸããããããªæäœãã³ãŒãããæ žé
žãå«ã宿䞻现èããåèšæäœã®çºçŸã«é©ããæ¡ä»¶äžã§ãå¹é€ããããšããåã³ä»»æéžæçã«ãåèšå®¿äž»çŽ°è(åã¯å®¿äž»çŽ°èå¹é€å¹å°)ããåèšæäœãååããããšããå«ãã
æ-CD45æäœãçµæãçã«ç£çããããã«ãæäœãã³ãŒãããæ žé
ž(äŸãã°ãäžèšã®ãããªæ žé
ž)ããåé¢ãããããŠå®¿äž»çŽ°èäžã§æŽã«ã¯ããŒãã³ã°ããåã³ïŒåã¯çºçŸãããããã«ã1皮以äžã®ãã¯ã¿ãŒã«æ¿å
¥ããããã®ãããªæ žé
žã¯ãåŸæ¥ã®æé ã䜿çšããŠ(äŸãã°ãæ¬æäœã®ééåã³è»œéãã³ãŒãããéºäŒåã«ç¹ç°çã«çµåãåŸããªãªãŽãã¯ã¬ãªããã»ãããŒãã䜿çšããããšã«ãã£ãŠ)容æã«åé¢ããããšãã§ããåã³ã·ãŒã¯ãšã³ã·ã³ã°ãããããšãã§ããã
æäœãã³ãŒããããã¯ã¿ãŒãã¯ããŒãã³ã°ããåã¯çºçŸãããã®ã«é©ãã宿䞻现èãšããŠã¯ãæ¬åºé¡ã«èšèŒãããåæ žçç©åã¯çæ žçç©çŽ°èãæãããããäŸãã°ãæäœããç¹ã«ã°ãªã³ã·ã«ååã³Fcãšãã§ã¯ã¿ãŒæ©èœãå¿
èŠãšããªãå Žåã«ããã¯ããªã¢äžã§ç£çãããŠãè¯ãããã¯ããªã¢äžã§æäœãã©ã°ã¡ã³ãåã³ããªãããããçºçŸãããããšã«ã€ããŠã¯ãäŸãã°ãç±³åœç¹èš±ç¬¬5,648,237ã5,789,199ãåã³5,840,523å·ãåç
§ã®ããšïŒCharlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254ãåç
§ã®ããšãããã«ã¯ã倧è
žèäžã§æäœãã©ã°ã¡ã³ããçºçŸãããããšãèšèŒãããŠããïŒãçºçŸãããåŸãåèšæäœãããã¯ããªã¢çŽ°èããŒã¹ãããå¯æº¶æ§ç»åãšããŠåé¢ããæŽã«ç²Ÿè£œããŠãè¯ãã
宿䞻ãšããŠãèæ€åç©çŽ°èã䜿çšããããšãã§ãããäŸãã°ãæžæ¿æ¶²äžã§å¢æ®ããããã«é©åããåºä¹³åç©çŽ°èæ ªãæçšã§ããããšããããæçšãªåºä¹³åç©å®¿äž»çŽ°èæ ªã®ä»ã®äŸã¯ãSV40ã§åœ¢è³ªè»¢æãããµã«è
èCV1æ ª(COS-7)ïŒããèæ§è
è现èæ ª(äŸãã°ãGraham et al., J. Gen Virol. 36:59 (1977)ã«èšèŒããããããª293åã¯293现è)ïŒãããŒã»ãã ã¹ã¿ãŒè
è现è(BHK)ïŒããŠã¹ã»ã»ã«ããªçŽ°è(äŸãã°ãMather, Biol. Reprod. 23:243-251 (1980)ã«èšèŒããããããªTM4现è)ïŒãµã«è
è现è(CV1)ïŒã¢ããªã«ã»ãããªã¶ã«è
è现è(VERO-76)ïŒããåå®®é žãã现è(HELA)ïŒã€ãè
è现è(MDCK)ïŒãããã¡ããŒã»ã©ããèè现è(BRL 3A)ïŒããèºçŽ°è(W138)ïŒããèè现è(Hep G2)ïŒããŠã¹ä¹³ãã(MMT 060562)ïŒTRI现è(äŸãã°ãMather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982)ã«èšèŒããã)ïŒMRC 5现èïŒåã³FS4现èãã§ãããä»ã®æçšãªåºä¹³åç©å®¿äž»çŽ°èæ ªãšããŠã¯ããã£ã€ããŒãºã»ãã ã¹ã¿ãŒåµå·£(CHO)现èïŒDHFR-CHO现è(Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980))çãå«ã)ïŒåã³éªšé«è
«çŽ°èæ ª(äŸãã°ãY0ãNS0åã³Sp2/0ç)ãæãããããæäœç£çã«é©ããããç¹å®ã®åºä¹³åç©å®¿äž»çŽ°èæ ªã«é¢ããã¬ãã¥ãŒã«ã€ããŠã¯ãäŸãã°ãYazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003)ãåç
§ã®ããšã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšå®¿äž»çŽ°èã¯çæ žçç©ãäŸãã°ããã£ã€ããŒãºã»ãã ã¹ã¿ãŒåµå·£(CHO)现èåã¯ãªã³ã系现è(äŸãã°ãY0ãNS0ãSp20现è)ã§ããã
现èæ¯çŽ
æ¬åºé¡ã«èšèŒãããŠããããã«ãæ-CD45æäœãåã³ãã®æåçµåãã©ã°ã¡ã³ãã¯ã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒã(çµå)ããããšããããäŸãã°ã现èæ¯çŽ ã¯ãæ¬åºé¡ã«èšèŒããããããªãã³ãŸãžã¢ãŒãã³éšåæ§é (äŸãã°ãPBDåã¯IGN)ãå«ãã
æ¬åºé¡ã«èšèŒãããŠããããã«ãæ-CD45æäœãåã³ãã®æåçµåãã©ã°ã¡ã³ãã¯ã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒã(çµå)ããããšããããäŸãã°ã现èæ¯çŽ ã¯ãæ¬åºé¡ã«èšèŒããããããªãã³ãŸãžã¢ãŒãã³éšåæ§é (äŸãã°ãPBDåã¯IGN)ãå«ãã
ããããã³ãŸãžã¢ãŒãã³é¡(PBDs)
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã«èšèŒãããCD45ã«çµåãããæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãããããã³ãŸãžã¢ãŒãã³(ãPBDã)ã§ãã现èæ¯çŽ ã«ãåã¯PBDãå«ã现èæ¯çŽ ã«ãã³ã³ãžã¥ã²ãŒãããããšããããPBDé¡ã¯ãããç¹å®ã®æŸç·èã«ãã£ãŠç£çããã倩ç¶ç©ã§ãããé åéžæçãªDNAã¢ã«ãã«åååç©ã§ããããšã瀺ãããŠããŠãããPBD现èæ¯çŽ é¡ãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããã¢ã³ãã©ãã€ã·ã³ãäºéäœPBDé¡ãåã³ãäŸãã°ãHartley, J.A. (2011). âThe development of pyrrolobenzodiazepines as antitumor agents.â Expert Opin. Inv. Drug, 20(6), 733-744; åã³ Antonow, D.; Thurston, D.E. (2011) âSynthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs).â Chem. Rev. 111: 2815-2864ã®äžã§é瀺ãããŠãããã®ãæããããã
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã«èšèŒãããCD45ã«çµåãããæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãããããã³ãŸãžã¢ãŒãã³(ãPBDã)ã§ãã现èæ¯çŽ ã«ãåã¯PBDãå«ã现èæ¯çŽ ã«ãã³ã³ãžã¥ã²ãŒãããããšããããPBDé¡ã¯ãããç¹å®ã®æŸç·èã«ãã£ãŠç£çããã倩ç¶ç©ã§ãããé åéžæçãªDNAã¢ã«ãã«åååç©ã§ããããšã瀺ãããŠããŠãããPBD现èæ¯çŽ é¡ãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããã¢ã³ãã©ãã€ã·ã³ãäºéäœPBDé¡ãåã³ãäŸãã°ãHartley, J.A. (2011). âThe development of pyrrolobenzodiazepines as antitumor agents.â Expert Opin. Inv. Drug, 20(6), 733-744; åã³ Antonow, D.; Thurston, D.E. (2011) âSynthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs).â Chem. Rev. 111: 2815-2864ã®äžã§é瀺ãããŠãããã®ãæããããã
PBDsã¯ã以äžã®äžè¬çãªæ§é ã§ããïŒ
ãããã®ååç©ã¯ã眮æåºã®æ°ãçš®é¡ãåã³äœçœ®ã«ãããŠãè³éŠæïŒãAãïŒç°åã³ãããïŒãCãïŒç°ã®äž¡æ¹ã«ãããŠã䞊ã³ã«Cç°ã®é£œå床ã«ãããŠãç°ãªãããžã¢ãŒãã³B-ç°ã«ãããŠãN10-C11äœã«ã¯ãã€ãã³ïŒN=CïŒãã«ã«ãããŒã«ã¢ãã³ïŒNH-CHïŒOHïŒïŒãåã¯ã«ã«ãããŒã«ã¢ãã³ã»ã¡ãã«ã»ãšãŒãã«ïŒNH-CH(OMe)ïŒã®ãã¡ã®ãäœãããååšããããã®äœçœ®ã¯ãDNAã¢ã«ãã«åã®åå ãšãªã芪é»åæ§ã®éšåæ§é ã§ãããæ¢ç¥ã®å€©ç¶ç©PBDsã¯ãå
šãŠããã©ã«C11aäœã«(S)æ§é ãæã¡ãCç°ããAç°ã«åãã£ãŠèŠãå Žåã«ãå³å·»ãã®ããããçããŠããããã®ãããBåDNAã®å°æºïŒminor grooveïŒãæããç䟡ããªãã¯ã¹æ§é ã«é©ãã3次å
圢ç¶ïŒappropriate three-dimensional shape for isohelicity with the minor groove of B-form DNAïŒã«ãªããçµåéšäœã«ãŽã£ãããšãã£ããããããã«ãªãïŒKohn, In Antibiotics III. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, Acc. Chem. Res., 19, 230-237 (1986))ã«èšèŒãããŠãããåèšå°æºïŒminor grooveïŒã«ä»å ç©ã圢æããPBDsã®äœçšèœã«ãããDNAã®ããã»ã·ã³ã°ã¯åŠšå®³ãããæ-è
«ç掻æ§ãããããããããšãããã
å¯ææ§ã¢ã«ãã¬ã³ã»ãªã³ã«ãŒãä»ããŠã2ã€ã®PBDãŠãããããC8-ããããã·ã«å®èœåºãä»ããŠçµåãããããšã«ããããããã®ååã®çç©åŠç掻æ§ãåäžãããããšãã§ããããšãã以åã«é瀺ãããŠããŠããïŒBose, D. S., et al., J. Am. Chem. Soc., 114, 4939-4941 (1992); Thurston, D. E., et al., J. Org. Chem., 61, 8141-8147 (1996)ïŒãPBDäºéäœã¯ãããªã³ãããŒã 5'-Pu-GATC-Py-3'éå
éæ¶æ©ã®ãããªãé
åéžæçãªDNAæå·ã圢æãããšèãããïŒSmellie, M., et al., Biochemistry, 42, 8232-8239 (2003); Martin, C., et al., Biochemistry, 44, 4135-4147ïŒãããããäž»ã«ãããã®çç©æŽ»æ§ã«é¢äžãããšèãããããæå©ãªäºéäœããããã³ãŸãžã¢ãŒãã³ååç©ã¯ãGregson et al. (Chem. Commun. 1999, 797-798; "compound 1", and by Gregson et al. (J. Med. Chem. 2001, 44, 1161-1174; "compound 4a")ã«èšèŒãããŠããããã®ååç©ã¯ãSG2000ãšããŠãç¥ãããŠããŠãæ§é åŒã¯ä»¥äžã§ããïŒ
ã
äžè¬çã«ããããªãžã³ã»ã¢ã«ã±ã³éšåæ§é ãžã®æ¹å€ã«ãã£ãŠãçµåãããéšåæ§é ïŒããæ
ã«ãæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãïŒãžã®å
±æçµåã«äœ¿ããããã³ãã«ãæäŸãããïŒæ¬åºé¡ã«èšèŒãããŠããããã«ãããããã-L-Z'åã³-L-Z-AbïŒãæãã¯ããªã³ã«ãŒããN10ã®äœçœ®ã«çµåãããããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®æ§é åŒã«ãã£ãŠè¡šãããããããã³ãŸãžã¢ãŒãã³äºéäœã§ããïŒ
ããã§ãnã¯ã2ãã5ãŸã§ã®æŽæ°ã§ãããnã3ã§ãããã®åŒã®ååç©ã¯ãDSB-120ãšããŠç¥ãããŠãã(Bose et al., J. Am. Chem. Soc. 1992, 114, 4939-4941)ã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®æ§é åŒã«ãã£ãŠè¡šãããããããã³ãŸãžã¢ãŒãã³äºéäœã§ããïŒ
ããã§ãnã¯ã2ãã5ãŸã§ã®æŽæ°ã§ãããnã3ã§ãããã®åŒã®ååç©ã¯ãSJG-136ãšããŠç¥ãããŠãã(Gregson et al., J. Med. Chem. 2001, 44, 737 - 748)ãnã5ã§ãããã®åŒã®ååç©ã¯ãDRG-16ãšããŠç¥ãããŠãã(Gregson et al., Med. Chem. 2004;47:1161-1174)ã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®æ§é åŒã«ãã£ãŠè¡šãããããããã³ãŸãžã¢ãŒãã³äºéäœã§ããïŒ
ããã§ãæ³¢ç·ã¯ãæ¬åºé¡ã«èšèŒãããADCã®ãªã³ã«ãŒãžã®ãå
±æçµå (covalent attachment)ã®äœçœ®ã瀺ãããã®PBDã«åºã¥ãADCã¯ãäŸãã°ãSutherland et al., Blood 2013 122:1455-1463ã«é瀺ãããããã¯ããã®å
šäœããæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®æ§é åŒã«ãã£ãŠè¡šãããPBDäºéäœã§ããïŒ
ããã§ãnã¯ã3åã¯5ã§ãããåã³ããã§ãæ³¢ç·ã¯ãæ¬åºé¡ã«èšèŒãããADCã®ãªã³ã«ãŒãžã®ãå
±æçµå(covalent attachment)ã®äœçœ®ã瀺ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®æ§é åŒ(I)ã«ãã£ãŠè¡šãããPBDäºéäœã§ããïŒ
ã
ããã§ãæ³¢ç·ã¯ãæ¬åºé¡ã«èšèŒãããADCã®ãªã³ã«ãŒãžã®ãå ±æçµå (covalent attachment)ã®äœçœ®ã瀺ãã
ããã§ãæ³¢ç·ã¯ãæ¬åºé¡ã«èšèŒãããADCã®ãªã³ã«ãŒãžã®ãå ±æçµå (covalent attachment)ã®äœçœ®ã瀺ãã
ã€ã³ããªããã³ãŸãžã¢ãŒãã³é¡(IGNs)
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã«èšèŒããããCD45ã«çµåããæäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãã€ã³ããªããã³ãŸãžã¢ãŒãã³(ãIGNã)ã§ãã现èæ¯çŽ ã«ãåã¯IGNãå«ã现èæ¯çŽ ã«ãã³ã³ãžã¥ã²ãŒãããããšããããããã€ãã®å®æœåœ¢æ ã§ã¯ãIGN现èæ¯çŽ ã¯ãã€ã³ããªããã³ãŸãžã¢ãŒãã³äºéäœåã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³åœäºéäœã§ããã
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ¬åºé¡ã«èšèŒããããCD45ã«çµåããæäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã¯ãã€ã³ããªããã³ãŸãžã¢ãŒãã³(ãIGNã)ã§ãã现èæ¯çŽ ã«ãåã¯IGNãå«ã现èæ¯çŽ ã«ãã³ã³ãžã¥ã²ãŒãããããšããããããã€ãã®å®æœåœ¢æ ã§ã¯ãIGN现èæ¯çŽ ã¯ãã€ã³ããªããã³ãŸãžã¢ãŒãã³äºéäœåã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³åœäºéäœã§ããã
ã€ã³ããªããã³ãŸãžã¢ãŒãã³äºéäœã¯ããã现èã«å¯ŸããŠãin vitroã®å¹æãé«ãïŒäœpMã¬ã³ãžIC50å€ïŒãæ¯èŒçæ°ããã±ãã«ã«ã»ã¯ã©ã¹ïŒchemical classïŒã®çŽ°èæ¯çŽ ã§ãããPBDäºéäœã®SJG-136ãšåæ§ã«ãIGNäºéäœã¯ãDNAã®å°æºïŒminor grooveïŒã«çµåããåèšäºéäœäžã®2ã€ã®ã€ãã³å®èœåºãä»ããŠãã°ã¢ãã³æ®åºã«å
±æçµåãããã®çµæãDNAã®ã¯ãã¹ãªã³ãã³ã°ããããããããIGNäºéäœ(IGN 6ïŒPBDéšåæ§é ã®ã¡ãã¬ã³åºããã§ãã«ç°ã«çœ®ãæãã)ã¯ãããããDNA IGNãšã®ä»å ç©åœ¢æãããéãé床ã§ããããã«ãSJG-136ãšæ¯èŒããŠãin vitroã§ãïœ10å以äžé«ãå¹æã瀺ãã(äŸãã°ãMiller et al., "A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity" Mol. Cancer Ther. 2016, 15(8), 1870-1878ããåç
§)ã察ç
§çã«ãIGNåœäºéäœã¯ãåäžã®åå¿æ§ã®ã€ã³ããªããã³ãŸãžã¢ãŒãã³ã®ã€ãã³ãå«ãïŒäºéäœçŽ°èæ¯çŽ äžã®ç¬¬2ã®ã€ã³ããªããã³ãŸãžã¢ãŒãã³ã¯ãéå
ïŒã¢ãã³ïŒåœ¢æ
ã§ååšãããåŸã£ãŠãIGNåœäºéäœã¯ãåèšäºéäœäžã«ååšããåäžã®ã€ãã³éšåæ§é ãä»ããŠãDNAãã¢ã«ãã«åãããåã³DNAãã¯ãã¹ãªã³ã¯ããªãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®æ§é ã®åŒãæããIGNåœäºéäœã§ããïŒ
ã
ããã§ãæ³¢ç·ã¯ãåèšãªã³ã«ãŒã®çµåäœçœ®ã瀺ãã
ããã§ãæ³¢ç·ã¯ãåèšãªã³ã«ãŒã®çµåäœçœ®ã瀺ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ã现èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããŠã以äžã®æ§é ãæããïŒ
ã
ãã®çŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãæ¬åºé¡ã§ã¯DGN549ãšãããåã³ADC IMGN632äžã«ååšãããäž¡è
ã¯ãäŸãã°ãåœéç¹èš±åºé¡ WO2017004026ã«é瀺ãããŠããïŒããã¯ãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®æ§é ã®åŒãæããã€ã³ããªããã³ãŸãžã¢ãŒãã³åœäºéäœã§ããã
ããã§ãæ³¢ç·ã¯ãåèšãªã³ã«ãŒã®çµåäœçœ®ã瀺ãããã®IGNåœäºéäœã®çŽ°èæ¯çŽ ã¯ãæ¬åºé¡ã§ã¯DGN462ãšãããäŸãã°ãç±³åœç¹èš±åºé¡å
¬é第20170080102å·ã«ãããŠé瀺ãããŠããïŒããã¯ãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãååŠçéšåæ§é Zãå«ã¿ãCy-L-ZãšããŠäžç·ã«ãªã£ãŠããŠã以äžã®æ§é ãæããïŒ
ããã§ãæ³¢ç·ã¯ãåèšæäœïŒäŸãã°ãæ-CD45æäœåã¯ãã®ãã©ã°ã¡ã³ãïŒãžã®çµåäœçœ®(point of attachment)ã瀺ãããã®çŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãADC IMGN779äžã«ååšããäŸãã°ãç±³åœç¹èš±åºé¡å
¬é第20170080102å·ã«ãããŠé瀺ãããŠããïŒããã¯ãæ¬åºé¡ã«åç
§ã«ããã以åã«åã蟌ãŸããïŒã
ãªã³ã«ãŒ
æ¬åºé¡ã§äœ¿çšãããçšèªããªã³ã«ãŒãã¯ãæ-CD45æäœåã¯ãã®ãã©ã°ã¡ã³ã(Ab)ã现èæ¯çŽ (äŸãã°PBD)ã«å ±æçµåãããŠãæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã圢æãããå ±æçµååã¯ååéãå«ã2䟡ã®ååŠçãªéšåæ§é ãæå³ããã
æ¬åºé¡ã§äœ¿çšãããçšèªããªã³ã«ãŒãã¯ãæ-CD45æäœåã¯ãã®ãã©ã°ã¡ã³ã(Ab)ã现èæ¯çŽ (äŸãã°PBD)ã«å ±æçµåãããŠãæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ã圢æãããå ±æçµååã¯ååéãå«ã2䟡ã®ååŠçãªéšåæ§é ãæå³ããã
åèšæäœåã³åèšè¬ç©éšåæ§é ã®å
±æçµå(covalent attachment)ã¯ãåèšãªã³ã«ãŒã2ã€ã®åå¿æ§å®èœåºãæããããšãèŠæ±ããïŒå³ã¡åå¿æ§ã®æå³ã§ã®äºäŸ¡ã§ããïŒããããããæ žé
žãè¬ç©ãæ¯çŽ ãæäœããããã³ãåã³ã¬ããŒã¿ãŒåºçã®2ã€ä»¥äžã®æ©èœçãªåã¯çç©åŠçã«æŽ»æ§ãªéšåæ§é ãçµåãããã®ã«åœ¹ç«ã€äºäŸ¡ã®ãªã³ã«ãŒè©Šè¬ãç¥ãããŠããããããã®ã³ã³ãžã¥ã²ãŒããåŸãæ¹æ³ã«ã€ããŠã¯èšèŒãããŠãã(Hermanson,G.T.(1996)Bioconjugate Techniques; Academic Press: New Yorkãp.234-242)ã
åŸã£ãŠãçŸåšã®ãªã³ã«ãŒã¯ã2ã€ã®åå¿æ§æ«ç«¯ãæããã1ã€ã¯ãæäœã«ã³ã³ãžã¥ã²ãŒãããããã®ãã®ã§ããããã1ã€ã¯ã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããããã®ãã®ã§ãããåèšãªã³ã«ãŒã®æäœã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿æ§æ«ç«¯(æ¬åºé¡ã§ã¯ãZ'ãšããŠå®çŸ©ããåå¿æ§éšåæ§é )ã¯ãå
žåçã«ã¯ãäŸãã°ãåèšæäœã«ããã·ã¹ãã€ã³ã»ããªãŒã«åºåã¯ãªãžã³ã»ã¢ãã³åºãçµãŠãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããããšãã§ããååŠçãªéšåæ§é ã§ãããåŸã£ãŠãå
žåçã«ã¯ããã€ã±ã«ã»ã¢ã¯ã»ãã¿ãŒ(ãã¬ã€ããã®ãããª)ã®ãããªããªãŒã«åå¿æ§åºãã¯ãããããã¢ããšãŒãè¥ããã¯R-ã¹ã«ãã¡ãã«åºã®ãããªè±é¢åºãåã¯ã«ã«ããã·ã«åºã®ãããªã¢ãã³åå¿æ§åºã§ãããåèšæäœã«ãåèšãªã³ã«ãŒãã³ã³ãžã¥ã²ãŒããããããšã«ã€ããŠã¯ãæ¬åºé¡äžä»¥äžã«ãã詳ãã説æããã
åèšãªã³ã«ãŒã®çŽ°èæ¯çŽ ã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿æ§æ«ç«¯ã¯ãå
žåçã«ã¯ãåèšçŽ°èæ¯çŽ ååå
ã®åå¿æ§çœ®æåºãšã®çµåã圢æããããšã«ãã£ãŠãåèšçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããããšãã§ããååŠçãªéšåæ§é ã§ãããé-éå®çãªäŸãšããŠã¯ãäŸãã°ãåèšãªã³ã«ãŒã«ããã«ã«ããã·ã«åºåã¯å¡©åºæ§ã¢ãã³åºãçµç±ããŠããããããåèšçŽ°èæ¯çŽ ã«ããå¡©åºæ§ã¢ãã³åºåã¯ã«ã«ããã·ã«åºãšã¢ããçµåã圢æããããšãåã¯ãåèšçŽ°èæ¯çŽ ã«ããOHåºã®åã¯SHåºã®ã¢ã«ãã«åãçµãŠããããããšãŒãã«ãã¹ã«ãã£ãåã¯ããã«é¡ãããã®ã圢æããããšããæããããã
åèšçšèªããªã³ã«ãŒãããã³ã³ãžã¥ã²ãŒããã圢æ
ã®ãªã³ã«ãŒã説æããéã«äœ¿çšããå Žåãåå¿æ§æ«ç«¯ã®äžæ¹åã¯äž¡æ¹ã¯ãåèšãªã³ã«ãŒåã³ïŒåã¯åèšçŽ°èæ¯çŽ éã®ã䞊ã³ã«åèšãªã³ã«ãŒåã³ïŒåã¯åèšæäœè¥ããã¯ãã®æåçµåãã©ã°ã¡ã³ãéã®ãçµåã圢æãããŠããã®ã§ãååšããªã(äŸãã°ãæ¬åºé¡ã®ä»¥äžã«èšèŒãããããã«ãåå¿æ§éšåæ§é Zâ²ãååŠçãªéšåæ§é Zã«å€æãããŠãã)ããåã¯åå¿éäžã«ãã(äŸãã°ãã«ã«ãã³é
žã®ã«ã«ããã«ã ãã«ãªã£ãŠããç)ããã®ãããªã³ã³ãžã¥ã²ãŒããããåå¿ããæ¬åºé¡äžä»¥äžã«æŽã«èšèŒããã
çš®ã
ã®ãªã³ã«ãŒã䜿çšããŠãèšèŒãããæäœãæå-çµåãã©ã°ã¡ã³ããåã³ãªã¬ã³ããã现èæ¯çŽ ååã«ã³ã³ãžã¥ã²ãŒããããããšããããäžè¬çã«ã¯ãæ¬é瀺ã«é©ãããªã³ã«ãŒã¯ã埪ç°äžã¯å®è³ªçã«å®å®çã§ãããããã®ã¿ãŒã²ãã现èã®äžã§åã¯è¿åã§ãåèšçŽ°èæ¯çŽ ãæŸåºããããšãå¯èœã«ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬é瀺ã«é©ãããããç¹å®ã®ãªã³ã«ãŒãããåæå¯èœãåã¯ãé-åæå¯èœããšããŠã«ããŽãªãŒåããããšããããäžè¬ã«ãåæå¯èœãªãªã³ã«ãŒã¯ãççåŠçãªç°å¢ã«å¿ããŠåæããã1ã€ä»¥äžã®å®èœåºãå«ããäŸãã°ãåæå¯èœãªãªã³ã«ãŒã«ã¯ã现èå
é
µçŽ (äŸãã°ãã«ããã·ã³B)ã®ååšäžã§å解ããé
µçŽ åºè³ª(äŸãã°ãããªã³-ã¢ã©ãã³)ã现èã³ã³ããŒãã¡ã³ãã®é
žæ§ç°å¢äžã§å解ããé
žæ§-åæå¯èœåº(äŸãã°ããã€ãããŸã³(hydrozone))ãåã¯çŽ°èå
ã®éå
ç°å¢äžã§å解ããéå
å¯èœãªåº(äŸãã°ããžã¹ã«ãã£ã)ããå«ãŸããããšãããã察ç
§çã«ãäžè¬çã«ãé-åæå¯èœãªãªã³ã«ãŒã¯ãã¿ãŒã²ãã现èå
ã§ãåèšADCã®æäœéšåæ§é ãå解(äŸãã°ããªãœãœãŒã å解)ãããäžã§ãåèšADCããæŸåºãããã
é-åæå¯èœãªãªã³ã«ãŒ
æ¬åºé¡ã§ã®äœ¿çšã«é©ãããé-åæå¯èœãªãªã³ã«ãŒã¯ãçµåã -(C=O)-, C1-C12ã¢ã«ãã¬ã³ãC1-C12ãããã¢ã«ãã¬ã³ãC2-C12ã¢ã«ã±ãã¬ã³ãC2-C12ãããã¢ã«ã±ãã¬ã³ãC2-C12ã¢ã«ããã¬ã³ãC2-C12ãããã¢ã«ããã¬ã³ãC3-C12 ã·ã¯ãã¢ã«ãã¬ã³ããããã·ã¯ãã¢ã«ãã¬ã³ãã¢ãªãŒã¬ã³ããããã¢ãªãŒã¬ã³ãåã³ãããã®çµåãããéžæããã1ã€ä»¥äžã®åºãæŽã«å«ãããšãããããããŠããããã®åã ã¯ãä»»æéžæçã«çœ®æãããŠããããšããããåã³ïŒåã¯1ã€ä»¥äžã®ãããååïŒäŸãã°ãSãNãåã¯OïŒã1ã€ä»¥äžã®ççŽ ååã®ä»£ããã«å«ãããšãããããã®ãããªåºã®é-éå®çãªäŸãšããŠã¯ãã¢ã«ãã¬ã³(CH2)p, (C=O)(CH2)r,åã³ããªãšãã¬ã³ã°ãªã³ãŒã«(PEG; (CH2CH2O)q)ããŠãããã-(NHCH2CH2)u-ããããã§ãpãqãrãtãåã³uã®åã ã¯ã1ãã12ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæãããããæããããã
æ¬åºé¡ã§ã®äœ¿çšã«é©ãããé-åæå¯èœãªãªã³ã«ãŒã¯ãçµåã -(C=O)-, C1-C12ã¢ã«ãã¬ã³ãC1-C12ãããã¢ã«ãã¬ã³ãC2-C12ã¢ã«ã±ãã¬ã³ãC2-C12ãããã¢ã«ã±ãã¬ã³ãC2-C12ã¢ã«ããã¬ã³ãC2-C12ãããã¢ã«ããã¬ã³ãC3-C12 ã·ã¯ãã¢ã«ãã¬ã³ããããã·ã¯ãã¢ã«ãã¬ã³ãã¢ãªãŒã¬ã³ããããã¢ãªãŒã¬ã³ãåã³ãããã®çµåãããéžæããã1ã€ä»¥äžã®åºãæŽã«å«ãããšãããããããŠããããã®åã ã¯ãä»»æéžæçã«çœ®æãããŠããããšããããåã³ïŒåã¯1ã€ä»¥äžã®ãããååïŒäŸãã°ãSãNãåã¯OïŒã1ã€ä»¥äžã®ççŽ ååã®ä»£ããã«å«ãããšãããããã®ãããªåºã®é-éå®çãªäŸãšããŠã¯ãã¢ã«ãã¬ã³(CH2)p, (C=O)(CH2)r,åã³ããªãšãã¬ã³ã°ãªã³ãŒã«(PEG; (CH2CH2O)q)ããŠãããã-(NHCH2CH2)u-ããããã§ãpãqãrãtãåã³uã®åã ã¯ã1ãã12ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæãããããæããããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒLã¯ã1ã€ä»¥äžã®ãçµåã-(C=O)-ã-C(O)NH- åºã-OC(O)NH-åºãC1-C12ã¢ã«ãã¬ã³ãC1-C12ãããã¢ã«ãã¬ã³ãC2-C12 ã¢ã«ã±ãã¬ã³ãC2-C12ãããã¢ã«ã±ãã¬ã³ãC2-C12ã¢ã«ããã¬ã³ãC2-C12 ãããã¢ã«ããã¬ã³ãC3-C12ã·ã¯ãã¢ã«ãã¬ã³ããããã·ã¯ãã¢ã«ãã¬ã³ãã¢ãªãŒã¬ã³ããããã¢ãªãŒã¬ã³ãqã1ãã12ã®æŽæ°ã§ãã-(CH2CH2O)q- åºãåã¯æº¶è§£æ§å¢åŒ·åºãå«ãïŒããã§ãåã
ã®C1-C12ã¢ã«ãã¬ã³ãC1-C12ãããã¢ã«ãã¬ã³ãC2-C12ã¢ã«ã±ãã¬ã³ãC2-C12 ãããã¢ã«ã±ãã¬ã³ãC2-C12 ã¢ã«ããã¬ã³ãC2-C12 ãããã¢ã«ããã¬ã³ãC3-C12 ã·ã¯ãã¢ã«ãã¬ã³ããããã·ã¯ãã¢ã«ãã¬ã³ãã¢ãªãŒã¬ã³ãåã¯ãããã¢ãªãŒã¬ã³ã¯ãã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã«ãã«ã»ãããã¢ãªãŒã«ãã¢ãããã¢ã³ã¢ããŠã ãã¢ã·ã«ãã¢ã·ã«ãªãã·ãã¢ã·ã«ã¢ãããã¢ããã«ã«ããã«ãã¢ã«ã³ãã·ã«ã«ããã«ããŠã¬ã€ããã«ã«ãã¡ãŒããã¢ãªãŒã«ããããã¢ãªãŒã«ãã¹ã«ãã£ãã«ãã¹ã«ãã©ãã«ãããããã·ã«ãã¢ã«ã³ãã·ãã¹ã«ãã¡ãã«ãããã²ã³ãã«ã«ããã·ãããªããã¡ãã«ãã·ã¢ããããããã·ãã¡ã«ã«ãããåã³ãããããããªã矀ãããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã1ãã5åã®çœ®æåºã§ãä»»æéžæçã«çœ®æãããããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåã
ã®C1-C12ã¢ã«ãã¬ã³ãC1-C12ãããã¢ã«ãã¬ã³ãC2-C12ã¢ã«ã±ãã¬ã³ãC2-C12ãããã¢ã«ã±ãã¬ã³ãC2-C12 ã¢ã«ããã¬ã³ãC2-C12 ãããã¢ã«ããã¬ã³ãC3-C12 ã·ã¯ãã¢ã«ãã¬ã³ããããã·ã¯ãã¢ã«ãã¬ã³ãã¢ãªãŒã¬ã³ãåã¯ãããã¢ãªãŒã¬ã³ã«ã¯ãä»»æéžæçã«ãOãSåã³Nããéžæããã1ã€ä»¥äžã®ãããååãå²ã蟌ãããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåã
ã®C1-C6ã¢ã«ãã¬ã³ãC1-C12ãããã¢ã«ãã¬ã³ãC2-C12ã¢ã«ã±ãã¬ã³ãC2-C12 ãããã¢ã«ã±ãã¬ã³ãC2-C12 ã¢ã«ããã¬ã³ãC2-C12 ãããã¢ã«ããã¬ã³ãC3-C12 ã·ã¯ãã¢ã«ãã¬ã³ããããã·ã¯ãã¢ã«ãã¬ã³ãã¢ãªãŒã¬ã³ãåã¯ãããã¢ãªãŒã¬ã³ã«ã¯ãä»»æéžæçã«ãOãSåã³Nããéžæããã1ã€ä»¥äžã®ãããååãå²ã蟌ãããšãããã䞊ã³ã«ã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã«ãã«ã»ãããã¢ãªãŒã«ãã¢ãããã¢ã³ã¢ããŠã ãã¢ã·ã«ãã¢ã·ã«ãªãã·ãã¢ã·ã«ã¢ãããã¢ããã«ã«ããã«ãã¢ã«ã³ãã·ã«ã«ããã«ããŠã¬ã€ããã«ã«ãã¡ãŒããã¢ãªãŒã«ããããã¢ãªãŒã«ãã¹ã«ãã£ãã«ãã¹ã«ãã©ãã«ãããããã·ã«ãã¢ã«ã³ãã·ãã¹ã«ãã¡ãã«ãããã²ã³ãã«ã«ããã·ãããªããã¡ãã«ãã·ã¢ããããããã·ãã¡ã«ã«ãããåã³ãããããããªã矀ãããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã1ãã5åã®çœ®æåºã§ãä»»æéžæçã«çœ®æãããããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšé-åæå¯èœãªãªã³ã«ãŒã¯ã-(CH2)n-ãŠããããå«ããããã§ãnã¯ã2ãã12ãäŸãã°2ãã6ãã®æŽæ°ã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšé-åæå¯èœãªãªã³ã«ãŒã¯ã-(CH2)n-ãå«ããããã§ãnã¯ã1ã2ã3ã4ã5ãåã¯6ã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšé-åæå¯èœãªãªã³ã«ãŒã¯ãnã¯6ã§ããã以äžã®åŒã«ãã£ãŠè¡šãããã-(CH2)n-ã§ããïŒ
ã
åæå¯èœãªãªã³ã«ãŒ
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ããšçŽ°èæ¯çŽ (äŸãã°ãPBD)ãã³ã³ãžã¥ã²ãŒããããªã³ã«ãŒã¯ã现èå ã®æ¡ä»¶äžã«ãããŠãåæå¯èœã§ããããã®çµæãåèšãªã³ã«ãŒã®åæã«ããã现èå ç°å¢ã«ãããŠãåèšæäœããåèšçŽ°èæ¯çŽ ãŠããããæŸåºããããåæå¯èœãªãªã³ã«ãŒã¯ãå±æç°å¢ïŒäŸãã°ã现èå€åã³çŽ°èå ç°å¢ïŒ»äŸãã°ãpHãéå é»äœãåã¯é µçŽ æ¿åºŠïŒœïŒã«ãããéããå©çšããŠãã¿ãŒã²ãã现èå ã§çŽ°èæ¯çŽ ã®æŸåºãåŒãèµ·ããããã«èšèšãããŠãããäžè¬çã«ãåæå¯èœãªãªã³ã«ãŒã¯ã埪ç°äžã«ãããŠæ¯èŒçå®å®ã§ãããã1皮以äžã®ã¡ã«ããºã (äŸãã°ãéå®ããããã®ã§ã¯ãªããããããã¢ãŒãŒããããããŒãŒãåã³ã°ã«ã¯ããããŒãŒã®æŽ»æ§ãªã©)ãéããŠã现èå ç°å¢ã«ãããŠãç¹ã«åæããããããæ¬åºé¡ã§äœ¿çšãããåæå¯èœãªãªã³ã«ãŒã¯ã埪ç°ããŠããè¡æŒ¿ã®äžã§ãåã³ïŒåã¯ã¿ãŒã²ãã现èã®å€åŽã§ãå®è³ªçã«å®å®ã§ããã䞊ã³ã«ã¿ãŒã²ãã现èã®å åŽã§ãåã¯ã¿ãŒã²ãã现èã®è¿åã§ãããå¹ççãªé床ã§åæãããããšãããã
ããã€ãã®å®æœåœ¢æ ã§ã¯ãæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ããšçŽ°èæ¯çŽ (äŸãã°ãPBD)ãã³ã³ãžã¥ã²ãŒããããªã³ã«ãŒã¯ã现èå ã®æ¡ä»¶äžã«ãããŠãåæå¯èœã§ããããã®çµæãåèšãªã³ã«ãŒã®åæã«ããã现èå ç°å¢ã«ãããŠãåèšæäœããåèšçŽ°èæ¯çŽ ãŠããããæŸåºããããåæå¯èœãªãªã³ã«ãŒã¯ãå±æç°å¢ïŒäŸãã°ã现èå€åã³çŽ°èå ç°å¢ïŒ»äŸãã°ãpHãéå é»äœãåã¯é µçŽ æ¿åºŠïŒœïŒã«ãããéããå©çšããŠãã¿ãŒã²ãã现èå ã§çŽ°èæ¯çŽ ã®æŸåºãåŒãèµ·ããããã«èšèšãããŠãããäžè¬çã«ãåæå¯èœãªãªã³ã«ãŒã¯ã埪ç°äžã«ãããŠæ¯èŒçå®å®ã§ãããã1皮以äžã®ã¡ã«ããºã (äŸãã°ãéå®ããããã®ã§ã¯ãªããããããã¢ãŒãŒããããããŒãŒãåã³ã°ã«ã¯ããããŒãŒã®æŽ»æ§ãªã©)ãéããŠã现èå ç°å¢ã«ãããŠãç¹ã«åæããããããæ¬åºé¡ã§äœ¿çšãããåæå¯èœãªãªã³ã«ãŒã¯ã埪ç°ããŠããè¡æŒ¿ã®äžã§ãåã³ïŒåã¯ã¿ãŒã²ãã现èã®å€åŽã§ãå®è³ªçã«å®å®ã§ããã䞊ã³ã«ã¿ãŒã²ãã现èã®å åŽã§ãåã¯ã¿ãŒã²ãã现èã®è¿åã§ãããå¹ççãªé床ã§åæãããããšãããã
奜é©ãªåæå¯èœãªãªã³ã«ãŒãšããŠã¯ãäŸãã°ãé
µçŽ çå æ°Žå解ãå
å解ãé
žæ§æ¡ä»¶äžã§ã®å æ°Žå解ãå¡©åºæ§æ¡ä»¶äžã§ã®å æ°Žå解ãé
žåããžã¹ã«ãã£ãéå
ãæ±æ žåæãåã¯ææ©éå±åæãã«ãã£ãŠåæããåŸããªã³ã«ãŒãæãããã (äŸãã°ãLeriche et al., Bioorg. Med. Chem., 20:571-582, 2012,ãåç
§ã®ããšããã®é瀺ã¯ãå
±æçµåçãªã³ã³ãžã¥ã²ãŒãã«é©ãããªã³ã«ãŒã«é¢é£ãããšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸãã)ã奜é©ãªåæå¯èœãªãªã³ã«ãŒã¯ãäŸãã°ãããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«åã¯ãžãããããªã©ã®ååŠçãªéšåæ§é ãå«ãããšãããã
é
žæ§æ¡ä»¶äžã§å æ°Žå解å¯èœãªãªã³ã«ãŒãšããŠã¯ãäŸãã°ãããã©ãŸã³é¡ãã»ãã«ã«ããŸã³é¡ãããªã»ãã«ã«ããŸã³é¡ãcis-ã¢ã³ãããã»ã¢ããé¡ããªã«ããšã¹ãã«é¡ãã¢ã»ã¿ãŒã«é¡ãã±ã¿ãŒã«é¡ããªã©ãæããããã(äŸãã°ãU.S. Pat. Nos. 5,122,368; 5,824,805; 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem. 264:14653-14661, ãåç
§ããããé瀺ã®ããããã¯ãå
±æçµåçãªã³ã³ãžã¥ã²ãŒãã«é©ãããªã³ã«ãŒã«é¢é£ãããšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸãã)ããã®ãããªãªã³ã«ãŒã¯ãäžæ§ã®pHæ¡ä»¶äžïŒäŸãã°ãè¡æ¶²äžïŒã§ã¯æ¯èŒçå®å®ã§ããããpH 5.5åã¯5.0(ãªãœãœãŒã ã®å¡ãã®pH)ããäžã§ã¯äžå®å®ã§ããã
éå
æ¡ä»¶äžã§åæå¯èœãªãªã³ã«ãŒãšããŠã¯ãäŸãã°ããžã¹ã«ãã£ããæãããããäŸãã°ãSATA(N-ã¹ã¯ã·ã³ã€ããžã«-S-ã¢ã»ãã«ããªã¢ã»ããŒã)ãSPDP (N-ã¹ã¯ã·ã³ã€ããžã«-3-(2-ããªãžã«ãžããª)ããããªããŒã)ãSPDB (N-ã¹ã¯ã·ã³ã€ããžã«-3-(2-ããªãžã«ãžããª)é
ªé
ž)åã³SMPT (N-ã¹ã¯ã·ã³ã€ããžã«-ãªãã·ã«ã«ããã«-α-ã¡ãã«-α-(2-ããªãžã«-ãžããª)ãã«ãšã³)ãSPDBåã³SMPTãçšããŠåœ¢æããããšãã§ãããžã¹ã«ãã£ãã»ãªã³ã«ãŒçãçš®ã
ã®ãžã¹ã«ãã£ãã»ãªã³ã«ãŒãåœè©²æè¡åéã«ãããŠå
¬ç¥ã§ããïŒäŸãã°ãThorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer (C. W. Vogel ed., Oxford U. Press, 1987. 以äžãåç
§ U.S. Pat. No. 4,880,935, ãã®é瀺ã¯ãå
±æçµåçãªã³ã³ãžã¥ã²ãŒãã«é©ãããªã³ã«ãŒã«é¢é£ãããšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸãã)ã
é
µçŽ çå æ°Žå解ãåãããªã³ã«ãŒã¯ãäŸãã°ã现èå
ãããããŒãŒåã¯ãããã¢ãŒãŒé
µçŽ ïŒäŸãã°ãéå®ããããã®ã§ã¯ãªããããªãœãœãŒã ã»ãããã¢ãŒãŒåã¯ãšã³ããœãŒã ã»ãããã¢ãŒãŒãæããããïŒã«ãã£ãŠåæãããããããå«æãªã³ã«ãŒã§ããããšãããã现èå
ã¿ã³ãã¯è³ªå解ã«ããæ²»çè¬å€ã®æŸåºãå©çšããããšã®1ã€ã®å©ç¹ã¯ãåèšè¬å€ã¯ãã³ã³ãžã¥ã²ãŒãããŠããå Žåã«å
žåçã«ã¯æžåŒ±ããŠããããšãåã³ã³ã³ãžã¥ã²ãŒãã®è¡æž
å®å®æ§ãå
žåçã«ã¯é«ãããšãã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãããããžã«ã»ãªã³ã«ãŒã¯ãå°ãªããšã2ã¢ããé
žé·ãåã¯å°ãªããšã3ã¢ããé
žé·ãã§ãããäŸç€ºçãªã¢ããé
žãªã³ã«ãŒãšããŠã¯ããžãããããããªãããããããã©ããããåã¯ãã³ã¿ãããããæããããã奜é©ãªããããã®äŸãšããŠã¯ãããªã³ãã¢ã©ãã³ãã·ãã«ãªã³ïŒCitïŒããã§ãã«ã¢ã©ãã³ããªãžã³ããã€ã·ã³ãåã³ã°ãªã·ã³ã®ãããªã¢ããé
žãå«æããããããããæãããããã¢ããé
žãªã³ã«ãŒæ§æèŠçŽ ãå«ãã¢ããé
žæ®åºãšããŠã¯ã倩ç¶ã®ã¢ããé
žæ®åºã䞊ã³ã«ãã€ããŒãªã¢ããé
žé¡åã³ã·ãã«ãªã³çã®é-倩ç¶ã®ã¢ããé
žã¢ããã°é¡ããæãããããäŸç€ºçãªãžããããé¡ãšããŠã¯ãããªã³-ã·ãã«ãªã³ (vc å㪠val-cit) åã³ ã¢ã©ãã³-ãã§ãã«ã¢ã©ãã³ (af å㯠ala-phe)ããæãããããäŸç€ºçãªããªããããé¡ãšããŠã¯ã°ãªã·ã³-ããªã³-ã·ãã«ãªã³ (gly-val-cit) åã³ ã°ãªã·ã³-ã°ãªã·ã³-ã°ãªã·ã³ (gly-gly-gly)ããæãããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒãšããŠã¯ããžããããïŒäŸãã°ãVal-Cit, Ala-Val, è¥ããã¯Phe-Lys, Val-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, å㯠Trp-Citãªã©ïŒããæãããããVal-Cit å㯠Phe-Lys ã®ãããªãžãããããå«ããªã³ã«ãŒã¯ãäŸãã°ãU.S. Pat. No. 6,214,345,ã«é瀺ãããŠããããã®é瀺ã¯ãå
±æçµåçãªã³ã³ãžã¥ã²ãŒãã«é©ãããªã³ã«ãŒã«é¢é£ãããšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãVal-Alaåã³Val-Citããéžæããããžãããããå«ãã
æ¬åºé¡ã«èšèŒãããæäœãæå-çµåãã©ã°ã¡ã³ããåã³ãªã¬ã³ããã现èæ¯çŽ ååã«ã³ã³ãžã¥ã²ãŒãããã®ã«é©ãããªã³ã«ãŒãšããŠã¯ã1,6-è±é¢ããã»ã¹ã«ãã£ãŠã现èæ¯çŽ ãæŸåºããããšãã§ãããªã³ã«ãŒããæããããããã®è±é¢ããã»ã¹ãå¯èœãªååŠçãªéšåæ§é ãšããŠã¯ãp-ã¢ãããã³ãžã«(PAB)åºã6-ãã¬ã€ãããããµã³é
žãpHæåæ§çé
žå¡©ãåã³Jain et al., Pharm. Res. 32:3526-3540, 2015ã«èšèŒãããŠãããããªä»ã®è©Šè¬ããæããããããã®é瀺ã¯ãå
±æçµåçãªã³ã³ãžã¥ã²ãŒãã«é©ãããªã³ã«ãŒã«é¢é£ãããšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒãšããŠã¯ãåè¿°ã®PABåã¯PABC(ãã©-ã¢ãããã³ãžã«ãªãã·ã«ã«ããã«)çã®ãèªå£(self-immolative)ãåºãæãããããããã¯ãäŸãã°ãCarl et al., J. Med. Chem. (1981) 24:479-480; Chakravarty et al (1983) J. Med. Chem. 26:638-644; US 6214345; US20030130189; US20030096743; US6759509; US20040052793; US6218519; US6835807; US6268488; US20040018194; W098/13059; US20040052793; US6677435; US5621002; US20040121940; W02004/032828)ãã«é瀺ãããŠããããã®ããã»ã¹ãå¯èœãªä»ã®ãã®ãããªååŠçãªéšåæ§é (ãèªå£ãªã³ã«ãŒã)ãšããŠã¯ãã¡ãã¬ã³ã»ã«ã«ãã¡ãŒãé¡åã³ãããã¢ãªãŒã«åºãäŸãã°ã¢ãããã¢ãŸãŒã«é¡ãã¢ããã€ãããŸãŒã«é¡ãã¢ããããªããžã³é¡ãªã©ãæããããããã®ãããªãããç°åŒèªå£(self-immolative)åºãå«ããªã³ã«ãŒã¯ãäŸãã°ãç±³åœç¹èš±åºé¡å
¬é20160303254 åã³ 20150079114ã䞊ã³ã«ç±³åœç¹èš±ç¬¬7,754,681; Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237; US 2005/0256030; de Groot et al (2001) J. Org. Chem. 66:8815-8830; åã³ US 7223837ã«é瀺ãããŠãããããã€ãã®å®æœåœ¢æ
ã§ã¯ããžããããããèªå£ãªã³ã«ãŒãšäœµããŠäœ¿çšããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒLã¯ã1ã€ä»¥äžã®ãããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãã¢ããé
žãæ倧10åã®ã¢ããé
žãããªããããããp-ã¢ãããã³ãžã«(PAB)åºããããç°åŒèªå£(self-immolative)åºãC1-C12 ã¢ã«ãã«ãC1-C12 ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ããããã¢ãªãŒã«ã-(C=O)-åºã-C(O)NH-åºã-OC(O)NH-åºãåã¯pã1ãã12ã®æŽæ°ã§ãã-(CH2CH2O)q-åºããå«ãïŒããã§ãåã
ã®C1-C12ã¢ã«ãã«ãC1-C12ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ãåã¯ãããã¢ãªãŒã«ã¯ãã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã«ãã«ã»ãããã¢ãªãŒã«ãã¢ãããã¢ã³ã¢ããŠã ãã¢ã·ã«ãã¢ã·ã«ãªãã·ãã¢ã·ã«ã¢ãããã¢ããã«ã«ããã«ãã¢ã«ã³ãã·ã«ã«ããã«ããŠã¬ã€ããã«ã«ãã¡ãŒããã¢ãªãŒã«ããããã¢ãªãŒã«ãã¹ã«ãã£ãã«ãã¹ã«ãã©ãã«ãããããã·ã«ãã¢ã«ã³ãã·ãã¹ã«ãã¡ãã«ãããã²ã³ãã«ã«ããã·ãããªããã¡ãã«ãã·ã¢ããããããã·ãã¡ã«ã«ãããåã³ãããããããªã矀ãããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã1ãã5åã®çœ®æåºã§ãä»»æéžæçã«çœ®æãããããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåã
ã®C1-C12 ã¢ã«ãã«ãC1-C12ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ãåã¯ãããã¢ãªãŒã«åºã«ã¯ãä»»æéžæçã«ãOãSåã³Nããéžæããã1ã€ä»¥äžã®ãããååãå²ã蟌ãããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåã
ã®C1-C12 ã¢ã«ãã«ãC1-C12ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ãåã¯ãããã¢ãªãŒã«åºã«ã¯ãä»»æéžæçã«ãOãSåã³Nããéžæããã1ã€ä»¥äžã®ãããååãå²ã蟌ãããšãããã䞊ã³ã«ã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã«ãã«ã»ãããã¢ãªãŒã«ãã¢ãããã¢ã³ã¢ããŠã ãã¢ã·ã«ãã¢ã·ã«ãªãã·ãã¢ã·ã«ã¢ãããã¢ããã«ã«ããã«ãã¢ã«ã³ãã·ã«ã«ããã«ããŠã¬ã€ããã«ã«ãã¡ãŒããã¢ãªãŒã«ããããã¢ãªãŒã«ãã¹ã«ãã£ãã«ãã¹ã«ãã©ãã«ãããããã·ã«ãã¢ã«ã³ãã·ãã¹ã«ãã¡ãã«ãããã²ã³ãã«ã«ããã·ãããªããã¡ãã«ãã·ã¢ããããããã·ãã¡ã«ã«ãããåã³ãããããããªã矀ãããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã1ãã5åã®çœ®æåºã§ãä»»æéžæçã«çœ®æãããããšãããã
åœæ¥è
ã¯ã1ã€ä»¥äžã®åèšããåºã¯ãäºäŸ¡(ãžã©ãžã«ã«)çš®ïŒäŸãã°ãC1-C12ã¢ã«ãã¬ã³çïŒã®åœ¢æ
ã§ååšããããšããããšèªèããã§ãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒLã¯ãéšåæ§é *-L1L2-** ãå«ããããã§ïŒ
L1ã¯ååšããªããåã¯-(CH2)mNR1C(=O)-, -(CH2)mNR1-, -(CH2)mX3(CH2)m-,
ã§ããïŒ
L2ã¯ååšããªããåã¯-(CH2)m-, -NR1(CH2)m-, -(CH2)mNR1C(=O)(CH2)m-, -X4, -(CH2)mNR1C(=O)X4, -(CH2)mNR1C(=O)-, -((CH2)mO)n(CH2)m-, -((CH2)mO)n(CH2)mX3(CH2)m-, -NR1((CH2)mO)nX3(CH2)m-, -NR1((CH2)mO)n(CH2)mX3(CH2)m-, -X1X2C(=O)(CH2)m-, - (CH2)m(O(CH2)m)n-, -(CH2)mNR1(CH2)m-, -(CH2)mNR1C(=O)(CH2)mX3(CH2)m-, - (CH2)mC(=O)NR1(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)-, - (CH2)mNR1(CH2)mC(=O)X2X1C(=O)-, -(CH2)mX3(CH2)mC(=O)X2X1C(=O)-, - (CH2)mC(=O)NR1(CH2)m-, -(CH2)mC(=O)NR1(CH2)mX3(CH2)m-, -(CH2)mX3(CH2)mNR1C(=O)(CH2)m-, -(CH2)mX3(CH2)mC(=O)NR1(CH2)m-, - (CH2)mO)n(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)NR1(CH2)m(O(CH2)m)n-, - (CH2)m(O(CH2)m)nC(=O)-, -(CH2)mNR1(CH2)mC(=O)-, -(CH2)mC(=O)NR1(CH2)mNR1C(=O)-, -(CH2)m(O(CH2)m)nX3(CH2)m-, - (CH2)mX3((CH2)mO)n(CH2)m-, -(CH2)mX3(CH2)mC(=O)-, - (CH2)mC(=O)NR1(CH2)mO)n(CH2)mX3(CH2)m-, - (CH2)mX3(CH2)m(O(CH2)m)nNR1C(=O)(CH2)m-, -(CH2)mX3(CH2)m(O(CH2)m)nC(=O)-, -(CH2)mX3(CH2)m(O(CH2)m)n-, -(CH2)mC(=O)NR1(CH2)mC(=O)-, -(CH2)mC(=O)NR1(CH2)m(O(CH2)m)nC(=O)-, -((CH2)mO)n(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)NR1(CH2)mC(=O)NR1(CH2)m-, -(CH2)mNR1C(=O)(CH2)mNR1C(=O)(CH2) -(CH2)mX3(CH2)mC(=O)NR1-, -(CH2)mC(=O)NR1-, -(CH2)mX3-, -C(R1)2(CH2)m-, -(CH2)mC(R1)2NR1-, -(CH2)mC(=O)NR1(CH2)mNR1-, - (CH2)mC(=O)NR1(CH2)mNR1C(=O)NR1-, -(CH2)mC(=O)X2X1C(=O)-, - C(R1)2(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)NR1(CH2)mC(R1)2NR1-, - C(R1)2(CH2)mX3(CH2)m-, -(CH2)mX3(CH2)mC(R1)2NR1-, -C(R1)2(CH2)mOC(=O)NR1(CH2)m-, -(CH2)mNR1C(=O)O(CH2)mC(R1)2NR1-, -(CH2)mX3(CH2)mNR1-, -(CH2)mX3(CH2)m(O(CH2)m)nNR1-, -(CH2)mNR1-, -(CH2)mC(=O)NR1(CH2)m(O(CH2)m)nNR1-, -(CH2)m(O(CH2)m)nNR1-, -(CH2CH2O)n(CH2)m-, -(CH2)m(OCH2CH2)n;-(CH2)mO(CH2)m-, -(CH2)mS(=O)2-, - (CH2)mC(=O)NR1(CH2)mS(=O)2-, -(CH2)mX3(CH2)mS(=O)2-, -(CH2)mX2X1C(=O)-, -(CH2)m(O(CH2)m)nC(=O)X2X1C(=O)-, -(CH2)m(O(CH2)m)nX2X1C(=O)-, - (CH2)mX3(CH2)mX2X1C(=O)-, -(CH2)mX3(CH2)m(O(CH2)m)nX2X1C(=O)-, - (CH2)mX3(CH2)mC(=O)NR1(CH2)mNR1C(=O)-, -(CH2)mX3(CH2)mC(=O)NR1(CH2)mC(=O)-, -(CH2)mX3(CH2)mC(=O)NR1(CH2)m(O(CH2)m)nC(=O)-, -(CH2)mC(=O)X2X1C(=O)NR1(CH2)m-, -(CH2)mX3(O(CH2)m)nC(=O)-, -(CH2)mNR1C(=O)((CH2)mO)n(CH2)m-, -(CH2)m(O(CH2)m)nC(=O)NR1(CH2)m-, -(CH2)mNR1C(=O)NR1(CH2)m- è¥ãã㯠-(CH2)mX3(CH2)mNR1C(=O)-;
ã§ããïŒ
ããã§ãX1ã¯
ã§ããïŒ
X2ã¯
ã§ããïŒ
X3ã¯
ã§ããïŒåã³ã
X4ã¯
ã§ããïŒ
ããã§ã
R1ã¯ãHåã³C1-C6ã¢ã«ãã«ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
mã¯ã1ã2ã3ã4ã5ã6ã7ã8ã9ãåã³10ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
nã¯ã1ã2ã3ã4ã5ã6ã7ã8ã9ã10ã11ã12ã13ãåã³14ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒäžŠã³ã«ã
ããã§ã1åã®æå°(*)ã¯ã现èæ¯çŽ ïŒäŸãã°ãPBDïŒãžã®çµå(attachment)ã®äœçœ®ã瀺ãã2åã®æå°(**)ã¯ãåå¿æ§çœ®æåºZ'åã¯ååŠçãªéšåæ§é Zãžã®çµå(attachment)ã®äœçœ®ã瀺ããäœããL1ãšL2ã®äž¡æ¹ãååšããªãããšã¯ç¡ãã
L1ã¯ååšããªããåã¯-(CH2)mNR1C(=O)-, -(CH2)mNR1-, -(CH2)mX3(CH2)m-,
L2ã¯ååšããªããåã¯-(CH2)m-, -NR1(CH2)m-, -(CH2)mNR1C(=O)(CH2)m-, -X4, -(CH2)mNR1C(=O)X4, -(CH2)mNR1C(=O)-, -((CH2)mO)n(CH2)m-, -((CH2)mO)n(CH2)mX3(CH2)m-, -NR1((CH2)mO)nX3(CH2)m-, -NR1((CH2)mO)n(CH2)mX3(CH2)m-, -X1X2C(=O)(CH2)m-, - (CH2)m(O(CH2)m)n-, -(CH2)mNR1(CH2)m-, -(CH2)mNR1C(=O)(CH2)mX3(CH2)m-, - (CH2)mC(=O)NR1(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)-, - (CH2)mNR1(CH2)mC(=O)X2X1C(=O)-, -(CH2)mX3(CH2)mC(=O)X2X1C(=O)-, - (CH2)mC(=O)NR1(CH2)m-, -(CH2)mC(=O)NR1(CH2)mX3(CH2)m-, -(CH2)mX3(CH2)mNR1C(=O)(CH2)m-, -(CH2)mX3(CH2)mC(=O)NR1(CH2)m-, - (CH2)mO)n(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)NR1(CH2)m(O(CH2)m)n-, - (CH2)m(O(CH2)m)nC(=O)-, -(CH2)mNR1(CH2)mC(=O)-, -(CH2)mC(=O)NR1(CH2)mNR1C(=O)-, -(CH2)m(O(CH2)m)nX3(CH2)m-, - (CH2)mX3((CH2)mO)n(CH2)m-, -(CH2)mX3(CH2)mC(=O)-, - (CH2)mC(=O)NR1(CH2)mO)n(CH2)mX3(CH2)m-, - (CH2)mX3(CH2)m(O(CH2)m)nNR1C(=O)(CH2)m-, -(CH2)mX3(CH2)m(O(CH2)m)nC(=O)-, -(CH2)mX3(CH2)m(O(CH2)m)n-, -(CH2)mC(=O)NR1(CH2)mC(=O)-, -(CH2)mC(=O)NR1(CH2)m(O(CH2)m)nC(=O)-, -((CH2)mO)n(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)NR1(CH2)mC(=O)NR1(CH2)m-, -(CH2)mNR1C(=O)(CH2)mNR1C(=O)(CH2) -(CH2)mX3(CH2)mC(=O)NR1-, -(CH2)mC(=O)NR1-, -(CH2)mX3-, -C(R1)2(CH2)m-, -(CH2)mC(R1)2NR1-, -(CH2)mC(=O)NR1(CH2)mNR1-, - (CH2)mC(=O)NR1(CH2)mNR1C(=O)NR1-, -(CH2)mC(=O)X2X1C(=O)-, - C(R1)2(CH2)mNR1C(=O)(CH2)m-, -(CH2)mC(=O)NR1(CH2)mC(R1)2NR1-, - C(R1)2(CH2)mX3(CH2)m-, -(CH2)mX3(CH2)mC(R1)2NR1-, -C(R1)2(CH2)mOC(=O)NR1(CH2)m-, -(CH2)mNR1C(=O)O(CH2)mC(R1)2NR1-, -(CH2)mX3(CH2)mNR1-, -(CH2)mX3(CH2)m(O(CH2)m)nNR1-, -(CH2)mNR1-, -(CH2)mC(=O)NR1(CH2)m(O(CH2)m)nNR1-, -(CH2)m(O(CH2)m)nNR1-, -(CH2CH2O)n(CH2)m-, -(CH2)m(OCH2CH2)n;-(CH2)mO(CH2)m-, -(CH2)mS(=O)2-, - (CH2)mC(=O)NR1(CH2)mS(=O)2-, -(CH2)mX3(CH2)mS(=O)2-, -(CH2)mX2X1C(=O)-, -(CH2)m(O(CH2)m)nC(=O)X2X1C(=O)-, -(CH2)m(O(CH2)m)nX2X1C(=O)-, - (CH2)mX3(CH2)mX2X1C(=O)-, -(CH2)mX3(CH2)m(O(CH2)m)nX2X1C(=O)-, - (CH2)mX3(CH2)mC(=O)NR1(CH2)mNR1C(=O)-, -(CH2)mX3(CH2)mC(=O)NR1(CH2)mC(=O)-, -(CH2)mX3(CH2)mC(=O)NR1(CH2)m(O(CH2)m)nC(=O)-, -(CH2)mC(=O)X2X1C(=O)NR1(CH2)m-, -(CH2)mX3(O(CH2)m)nC(=O)-, -(CH2)mNR1C(=O)((CH2)mO)n(CH2)m-, -(CH2)m(O(CH2)m)nC(=O)NR1(CH2)m-, -(CH2)mNR1C(=O)NR1(CH2)m- è¥ãã㯠-(CH2)mX3(CH2)mNR1C(=O)-;
ã§ããïŒ
ããã§ãX1ã¯
X2ã¯
X3ã¯
X4ã¯
ããã§ã
R1ã¯ãHåã³C1-C6ã¢ã«ãã«ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
mã¯ã1ã2ã3ã4ã5ã6ã7ã8ã9ãåã³10ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
nã¯ã1ã2ã3ã4ã5ã6ã7ã8ã9ã10ã11ã12ã13ãåã³14ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒäžŠã³ã«ã
ããã§ã1åã®æå°(*)ã¯ã现èæ¯çŽ ïŒäŸãã°ãPBDïŒãžã®çµå(attachment)ã®äœçœ®ã瀺ãã2åã®æå°(**)ã¯ãåå¿æ§çœ®æåºZ'åã¯ååŠçãªéšåæ§é Zãžã®çµå(attachment)ã®äœçœ®ã瀺ããäœããL1ãšL2ã®äž¡æ¹ãååšããªãããšã¯ç¡ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒãšããŠã¯ãp-ã¢ãããã³ãžã«åº(PAB)ãå«ãã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšp-ã¢ãããã³ãžã«åºã¯ãåèšçŽ°èæ¯æ§è¬ç©ãšåèšãªã³ã«ãŒå
ã®ãããã¢ãŒãŒåæéšäœãšã®éã«ãé
眮ãããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšp-ã¢ãããã³ãžã«åºã¯ãp-ã¢ãããã³ãžã«ãªãã·ã«ã«ããã«ã»ãŠãããã®äžéšã§ããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšp-ã¢ãããã³ãžã«åºã¯ãp-ã¢ãããã³ãžã«ã¢ããã»ãŠãããã®äžéšã§ããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãPhe-Lys, Val-Lys, Phe-Ala, Phe-Cit, Val-Ala, Val-Cit, åã³ Val-Argããããªã矀ããéžæããããããããå«ããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ã1ã€ä»¥äžã®PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, å㯠Ala-PABããå«ãã
ããã€ãã®æ
æ§ã«ãããŠãåèšãªã³ã«ãŒã¯ã1皮以äžã®ããããããªãªãŽç³, -(CH2)p-, -(CH2CH2O)q-, -(C=O)(CH2)r-, -(C=O)(CH2CH2O)t-, -(NHCH2CH2)u-, -PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, å㯠Ala-PABããå«ããããã§ãpãqãrãtãåã³uã®åã
ã¯ã1ãã12ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãMCC (4-[N-ãã¬ã€ããã¡ãã«]ã·ã¯ããããµã³-1-ã«ã«ããã·ã¬ãŒããå«ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãPAB-Ala-Val-åã¯PAB-Cit-Val-ã-(C=O)(CH2)r-ãŠãããã-(C=O)(CH2CH2O)t-ãŠããããåã³-(NHCH2CH2)u-ãŠãããããå«ããããã§ãrãtãåã³uã¯ã1ãã12ãŸã§ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãPAB-Ala-Val-åã¯PAB-Cit-Val-ã-(C=O)(CH2)r-ãŠãããã-(C=O)(CH2CH2O)t-ãŠããããåã³-(NHCH2CH2)u-ãŠãããããå«ããããã§ãr=2ãt=8ãåã³u=1ã§ãããå
·äœçãªå®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãåŒ(II)ïŒ
ã§è¡šãããããšãããã
ããã§ãR1ã¯ãCH3(Ala) åã¯(CH2)3NH(CO)NH2(Cit) ã§ããã
ããã§ãR1ã¯ãCH3(Ala) åã¯(CH2)3NH(CO)NH2(Cit) ã§ããã
åœè©²æè¡åéã®åœæ¥è
ã¯ãæ¬åºé¡ã§é瀺ããããããªååŠçãªåºãéšåæ§é ãåã³ç¹åŸŽã®äœãã1ã€ä»¥äžããè€æ°ã®æ¹æ³ã«ãã£ãŠçµã¿åãããŠãæ¬åºé¡ã§é瀺ããããããªãæäœãšçŽ°èæ¯çŽ ãšãã³ã³ãžã¥ã²ãŒãããã®ã«æçšãªãªã³ã«ãŒã圢æããããšãããããšèªèããã§ãããã
ãªã³ã«ãŒ-现èæ¯çŽ åã³ãªã³ã«ãŒ-æäœã®ã³ã³ãžã¥ã²ãŒã·ã§ã³
ããç¹å®ã®å®æœåœ¢æ ã§ã¯ãåèšãªã³ã«ãŒãé©åãªæ¡ä»¶äžã§åèšçŽ°èæ¯çŽ ãšåå¿ãããŠããªã³ã«ãŒ-现èæ¯çŽ ã³ã³ãžã¥ã²ãŒãã圢æãããããç¹å®ã®å®æœåœ¢æ ã§ã¯ãåå¿æ§ã®åºããåèšçŽ°èæ¯çŽ åã¯ãªã³ã«ãŒã«ãããŠäœ¿çšããå ±æçµå(covalent attachment)ã圢æããã
ããç¹å®ã®å®æœåœ¢æ ã§ã¯ãåèšãªã³ã«ãŒãé©åãªæ¡ä»¶äžã§åèšçŽ°èæ¯çŽ ãšåå¿ãããŠããªã³ã«ãŒ-现èæ¯çŽ ã³ã³ãžã¥ã²ãŒãã圢æãããããç¹å®ã®å®æœåœ¢æ ã§ã¯ãåå¿æ§ã®åºããåèšçŽ°èæ¯çŽ åã¯ãªã³ã«ãŒã«ãããŠäœ¿çšããå ±æçµå(covalent attachment)ã圢æããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ãåŒ(I)ã«ããPBDåã¯ãã®èªå°äœã§ããã现èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãããç¶ããŠãé©åãªæ¡ä»¶äžã§ãCD45ã«çµåãããåèšæäœãèªå°äœåããæäœãåã¯ãããã®æåçµåãã©ã°ã¡ã³ããšåå¿ãããŠãADCã圢æãããæãã¯ãåèšãªã³ã«ãŒãããŸãæåã«ãCD45ã«çµåãããåèšæäœãèªå°äœåããæäœãåã¯ãããã®æåçµåãã©ã°ã¡ã³ããšåå¿ãããŠããªã³ã«ãŒ-æäœã³ã³ãžã¥ã²ãŒãã圢æãããããããåèšçŽ°èæ¯çŽ ãšåå¿ãããŠãADCã圢æããããã®ãããªã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿ãããããããã詳ãã説æããã
åèšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã«ããªã³ã«ãŒåã¯çŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒããå
±æçµå(covalent attachment)ãããããã«ãå€ãã®æ§ã
ãªåå¿ãå©çšããããšãã§ãããåèšæäœååäžã®å¥œé©ãªçµå(attachmentïŒã®äœçœ®ãšããŠã¯ãéå®ããããã®ã§ã¯ãªããããªãžã³ã®ã¢ãã³åºãã°ã«ã¿ãã³é
žåã³ã¢ã¹ãã©ã®ã³é
žã®éé¢ã«ã«ãã³é
žåºãã·ã¹ãã€ã³ã®ã¹ã«ããããªã«åºãåã³è³éŠæã¢ããé
žã®çš®ã
ã®éšåæ§é ãæãããããäŸãã°ããªã³ã«ãŒäžã®ã«ã«ããã·(åã¯ã¢ãã)åºãæäœéšåæ§é äžã®ã¢ãã(åã¯ã«ã«ããã·)åºã«çµåãããããã«ãé-ç¹ç°çãªå
±æçµåããã«ã«ããžã€ããåå¿ãçšããŠè¡ãããšããããæŽã«ããªã³ã«ãŒäžã®ã¢ããåºãæäœéšåæ§é äžã®ã¢ããåºã«çµåãããããã«ããžã¢ã«ãããåã¯ã€ãããšã¹ãã«ãªã©ã®äºå®èœåºæ§ã®è¬å€ã䜿çšããããšãããã现èæ¯çŽ ãæäœéšåæ§é ã«çµåãããããšã«ã¯ãã·ããå¡©åºåå¿ãå©çšããããšãå¯èœã§ããããã®æ¹æ³ã¯ãåèšæäœåã¯ãªã³ã«ãŒã®ã©ã¡ããã®ã°ãªã³ãŒã«åã¯æ°Žé
žåºãéãšãŠçŽ é
žé
žåãããããšãå«ã¿ããã®ããã«ããŠã¢ã«ãããã圢æããã次ãã§ããããããããããåèšãªã³ã«ãŒåã¯æäœãšåå¿ããããå
±æçµåã¯ãåèšã¢ã«ããããšã¢ããåºãšã®éã«ã·ããå¡©åºã圢æããããšãä»ããŠã圢æããããã€ãœããªã·ã¢ããŒãé¡ãã现èæ¯çŽ åã¯æäœéšåæ§é ããªã³ã«ãŒã«å
±æçµåããã(covalently attaching)ããã®ã«ãããªã³ã°å€ãšããŠäœ¿çšããããšããããä»ã®æè¡ã¯åœæ¥è
ã«ç¥ãããŠãããæ¬é瀺ã®ç¯å²å
ã§ããã
æ¬åºé¡ã«èšèŒããããæäœåã¯æåçµåãã©ã°ã¡ã³ããžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«æçšãªãªã³ã«ãŒãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã以äžã®è¡šïŒã«ç€ºããããªãåèšæäœãšåèšãªã³ã«ãŒã®åå¿æ§ã®ååŠçãªéšåæ§é ïŒæ¬åºé¡ã§ã¯ãåå¿æ§çœ®æåºãZ'ããšåŒã¶ïŒãšã®éã®ã«ãããªã³ã°åå¿ã«ãã£ãŠåœ¢æããããååŠçãªéšåæ§é Zãå«ããªã³ã«ãŒããæãããããæ³¢ç·ã¯ãåèšæäœåã¯æåçµåãã©ã°ã¡ã³ããåã³çŽ°èæ¯çŽ ååããžã®çµå(attachmentïŒã®äœçœ®ã瀺ãã
è¡šïŒïŒæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã圢æããéã®ã«ãããªã³ã°åå¿ã«ãã圢æãããäŸç€ºçãªååŠçãªéšåæ§é Zã
åœæ¥è
ã®äžã®ããè
ã¯ãåèšãªã³ã«ãŒã«çµåããåå¿æ§çœ®æåºZ'ãåã³åèšæäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã«ããåå¿æ§çœ®æåºããååŠçãªéšåæ§é Zãçæããå
±æçµåã«ãããªã³ã°åå¿ã«é¢äžãããã®ã§ããããšãèªèããåèšåå¿æ§çœ®æåºZ'ãèªèãããåŸã£ãŠãæ¬åºé¡ã«èšèŒãããæ¹æ³ãšäœµããããšã«ãããŠæçšãªæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã¯ãæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ããããªã³ã«ãŒåã¯çŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒããšåå¿ããããšã«ãã£ãŠåœ¢æãããããšããããæ¬åºé¡ã«èšèŒãããããã«ãåèšãªã³ã«ãŒåã¯çŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯åå¿æ§çœ®æåºZ'çãå«ã¿ãæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãäžã®åå¿æ§çœ®æåºãšã®åå¿ã«é©ããŠããŠãååŠçãªéšåæ§é Zã圢æããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãZ'ã¯ã-NR1C(=O)CH=CH2, -N3, -SH, -S(=O)2(CH=CH2), -(CH2)2S(=O)2(CH=CH2), -NR1S(=O)2(CH=CH2), -NR1C(=O)CH2R2, -NR1C(=O)CH2Br, -NR1C(=O)CH2I, -NHC(=O)CH2Br, -NHC(=O)CH2I, -ONH2, -C(O)NHNH2, -CO2H, -NH2, -NH(C=O), -NC(=S),
ã§ããïŒ
ããã§ã
R1ã¯ãHåã³C1-C6ã¢ã«ãã«ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
R2ã¯ã-S(CH2)nCHR3NHC(=O)R1ïŒ
R3ã¯ãR1åã¯-C(=O)OR1ïŒ
R4ã¯ãHãC1-C6ã¢ã«ãã«ãFãClãåã³-OHããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
R5ã¯ãH, C1-C6 ã¢ã«ãã«, F, Cl, -NH2, -OCH3, -OCH2CH3, -N(CH3)2, -CN, -NO2,åã³ -OHããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒäžŠã³ã«ã
R6ã¯ãHãC1-C6 ã¢ã«ãã«ãFã-C(=O)OHã§çœ®æããããã³ãžã«ãªãã·ã-C(=O)OHã§çœ®æããããã³ãžã«ã-C(=O)OHã§çœ®æãããC1-C4ã¢ã«ã³ãã·ãåã³-C(=O)OHã§çœ®æãããC1-C4ã¢ã«ãã«ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã
ããã§ã
R1ã¯ãHåã³C1-C6ã¢ã«ãã«ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
R2ã¯ã-S(CH2)nCHR3NHC(=O)R1ïŒ
R3ã¯ãR1åã¯-C(=O)OR1ïŒ
R4ã¯ãHãC1-C6ã¢ã«ãã«ãFãClãåã³-OHããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒ
R5ã¯ãH, C1-C6 ã¢ã«ãã«, F, Cl, -NH2, -OCH3, -OCH2CH3, -N(CH3)2, -CN, -NO2,åã³ -OHããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããïŒäžŠã³ã«ã
R6ã¯ãHãC1-C6 ã¢ã«ãã«ãFã-C(=O)OHã§çœ®æããããã³ãžã«ãªãã·ã-C(=O)OHã§çœ®æããããã³ãžã«ã-C(=O)OHã§çœ®æãããC1-C4ã¢ã«ã³ãã·ãåã³-C(=O)OHã§çœ®æãããC1-C4ã¢ã«ãã«ããããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã
è¡šïŒã«ç€ºãããããã«ãåèšãªã³ã«ãŒã«ãã奜é©ãªåå¿æ§çœ®æåºZ'ãåã³æäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã«ããåå¿æ§çœ®æåºã®äŸãšããŠã¯ãæ±æ žïŒæ±é»å察(äŸãã°ãããªãŒã«ïŒããã¢ã«ãã«å¯Ÿãã¢ãã³ïŒã«ã«ããã«å¯Ÿãåã¯ããªãŒã«ïŒÎ±, β-äžé£œåã«ã«ããã«å¯Ÿãªã©)ããžãšã³ïŒãžãšããã£ã«å¯Ÿ(äŸãã°ããšããããã¢ãžãïŒã¢ã«ãã³å¯Ÿãåã¯ãžãšã³ïŒÎ±,β-äžé£œåã«ã«ããã«å¯Ÿ)ãªã©ãæãããããååŠçãªéšåæ§é Zã圢æããããã®åå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããããªãŒã«ã»ã¢ã«ãã«åãããããã·ã«ã»ã¢ã«ãã«åãã¢ãã³ã»ã¢ã«ãã«åãã¢ãã³åã¯ããããã·ã«ã¢ãã³çž®åãããã©ãžã³åœ¢æãã¢ããåããšã¹ãã«åããžã¹ã«ãã£ã圢æãç°åä»å (äŸãã°ããšãããã[4+2]Diels-Alderç°åä»å ã[3+2]Huisgenç°åä»å )ãè³éŠææ±æ žçœ®æãè³éŠææ±é»å眮æãåã³åœè©²æè¡åéã§ç¥ãããŠãããåã¯æ¬åºé¡ã«èšèŒãããä»ã®åå¿æ§åŒãæãããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšåå¿æ§çœ®æåºZ'ã¯ãåèšæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãäžã®æ±æ žæ§å®èœåºãšã®åå¿ã«å¥œé©ãªæ±é»åæ§å®èœåºã§ããã
æ¬åºé¡ã§é瀺ããããã«ãæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãå
ã«ååšãåŸãåå¿æ§çœ®æåºãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã(i)N-æ«ç«¯ã¢ãã³åºã(ii)åŽéã¢ãã³åº(äŸãã°ããªãžã³)ã(iii)åŽéããªãŒã«åº(äŸãã°ãã·ã¹ãã€ã³)ãåã³(iv)ç³æ°Žé
žåºåã¯ã¢ããåº(ããã§ãåèšæäœã¯ã°ãªã³ã·ã«åãããŠãã)ãã®ãããªæ±æ žåºãæãããããæ¬åºé¡ã§é瀺ããããã«ãæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãå
ã«ååšãåŸãåå¿æ§çœ®æåºãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããã»ãªã³ãã¹ã¬ãªãã³ãåã³ããã·ã³æ®åºã®ããããã·ã«éšåæ§é ïŒãªãžã³æ®åºã®ã¢ããéšåæ§é ïŒã¢ã¹ãã©ã®ã³é
žåã³ã°ã«ã¿ãã³é
žæ®åºã®ã«ã«ããã·ã«éšåæ§é ïŒäžŠã³ã«ã·ã¹ãã€ã³æ®åºã®ããªãŒã«éšåæ§é ã䞊ã³ã«ãé-倩ç¶ã¢ããé
žã®ãããã«ã®ã«ãã¢ãžããããã¢ãªãŒã«(äŸãã°ããã«ãªãã¢ãªãŒã«)ããããããã¢ãªãŒã«(äŸãã°ããã«ãªããããã¢ãªãŒã«)ãããã¢ã«ãã«ãåã³ãããããã¢ã«ãã«éšåæ§é ãæãããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§é瀺ããããã«ãæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãå
ã«ååšããåå¿æ§çœ®æåºãšããŠã¯ãã¢ãã³åã¯ããªãŒã«éšåæ§é ãæãããããããç¹å®ã®æäœã¯ãéå
å¯èœãªééãžã¹ã«ãã£ãïŒå³ã¡ãã·ã¹ãã€ã³æ¶æ©ïŒãæãããæäœã¯ãDTT(ãžããªãã¬ã€ããŒã«)çã®éå
å€ã§åŠçããããšã«ãã£ãŠããªã³ã«ãŒè©Šè¬ãšã³ã³ãžã¥ã²ãŒã·ã§ã³ãããããã«ãåå¿æ§ã«ããããšãã§ãããåŸã£ãŠãåã·ã¹ãã€ã³æ¶æ©ã¯ãçè«çã«ã¯ã2ã€ã®åå¿æ§ããªãŒã«æ±æ žåºã圢æããããªãžã³ãš2-ã€ããããªã©ã³(ãã©ãŠãè©Šè¬)ãšã®åå¿ã«ãã£ãŠãæŽãªãæ±æ žåºãæäœäžã«å°å
¥ããŠãã¢ãã³ãããªãŒã«ã«è»¢åãããããšãã§ããã1åã2åã3åã4åãåã¯ãã以äžã®ã·ã¹ãã€ã³æ®åºãå°å
¥ããããšã«ãã£ãŠ(äŸãã°ã1å以äžã®é-çæ¥çãªã·ã¹ãã€ã³ã»ã¢ããé
žæ®åºãå«ãå€ç°æäœã調補ããããšã«ãã£ãŠ)ãåå¿æ§ããªãŒã«åºããæäœ(åã¯ãã®ãã©ã°ã¡ã³ã)ã«å°å
¥ããããšããããç±³åœç¹èš±ç¬¬7,521,541å·ã¯ãåå¿æ§ã·ã¹ãã€ã³ã»ã¢ããé
žãå°å
¥ããããšã«ããå·¥åŠçã«æäœããæäœãæ瀺ããŠããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã«çµåããåå¿æ§çœ®æåºZ'ã¯ãæäœäžã«ååšããæ±é»ååºãšåå¿æ§ã§ããæ±æ žåºã§ãããæäœäžã®æçšãªæ±é»ååºãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããã¢ã«ãããåã³ã±ãã³ã®ã«ã«ããã«åºãæãããããæ±æ žåºã®ãããååã¯ãæäœäžã®æ±é»ååºãšåå¿ããåèšæäœãšå
±æçµåã圢æããããšããããæçšãªæ±æ žåºãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããããã©ãžãããªãã·ã ãã¢ãããããããã·ã«ãããã©ãžã³ãããªã»ãã«ã«ããŸã³ãããã©ãžã³ã»ã«ã«ããã·ã¬ãŒããåã³ã¢ãªãŒã«ããã©ãžãããæããããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãååŠçãªéšåæ§é Zã¯ãæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãå
ã«ååšããåå¿æ§æ±æ žçœ®æåº(äŸãã°ãã¢ãã³åã³ããªãŒã«éšåæ§é )ãšåèšãªã³ã«ãŒã«çµåããåå¿æ§æ±é»å眮æåºZ'ãšã®éã®åå¿ã®çæç©ã§ãããäŸãã°ãZ'ã¯ããšãããããã€ã±ã«ã»ã¢ã¯ã»ãã¿ãŒ(äŸãã°ããã¬ã€ãã)ã掻æ§åãšã¹ãã«ãé»åæ¬ æã«ã«ããã«ååç©ãåã¯ã¢ã«ãããã§ããããšãããã
åå¿æ§çœ®æåºZ'ãšãã®çµæãšããŠåŸãããååŠçãªéšåæ§é Zã®ããã€ãã®ä»£è¡šçã§é-éå®çãªäŸããè¡šïŒã«ç€ºãã
äŸãã°ããªã³ã«ãŒ-æäœã³ã³ãžã¥ã²ãŒãåã³ADCã®åæã«å¥œé©ãªãªã³ã«ãŒãšããŠã¯ãéå®ããããã®ã§ã¯ãªãããåèšãªã³ã«ãŒã«çµåããåå¿æ§çœ®æåºZ'ïŒäŸãã°ããã¬ã€ããåã¯ããã¢ã«ãã«åºãªã©ïŒãæããããããããã¯ãè©Šè¬é¡ïŒäŸãã°ãç¹ã«ãã¹ã¯ã·ã³ã€ããžã«4-(N-ãã¬ã€ããã¡ãã«)-ã·ã¯ããããµã³-L-ã«ã«ããã·ã¬ãŒã(SMCC)ãN-ã¹ã¯ã·ã³ã€ããžã«ã»ãšãŒãã¢ã»ããŒã(SIA)ãã¹ã«ã-SMCCãm-ãã¬ã€ãããã³ãŸã€ã«-N-ããããã·ã¹ã¯ã·ã³ã€ããžã«ã»ãšã¹ãã«(MBS)ãã¹ã«ã-MBSãåã³ã¹ã¯ã·ã³ã€ããžã«ã»ãšãŒãã¢ã»ããŒããçã§ãããäŸãã°ãLiu et al., 18:690-697, 1979ã«èšèŒãããŠãããã®é瀺ã¯ãååŠçã«ã³ã³ãžã¥ã²ãŒããããããã®ãªã³ã«ãŒã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã«ãã£ãŠãåèšãªã³ã«ãŒã«çµåããããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ããªã³ã«ãŒLã«çµåããåå¿æ§çœ®æåºZ'ã¯ããã¬ã€ãããã¢ãžããåã¯ã¢ã«ãã³ã§ããããã¬ã€ããå«æãªã³ã«ãŒã®äŸã¯ãé-åæå¯èœãªãã¬ã€ããã«ããã€ã«-ããŒã¹ã®ãªã³ã«ãŒã§ãããããã¯ãã¢ãŠãªã¹ã¿ãã³ãªã©ã®åŸ®å°ç®¡ç Žå£å€ãã³ã³ãžã¥ã²ãŒãããã®ã«ç¹ã«æçšã§ããããã®ãããªãªã³ã«ãŒã¯Doronina et al., Bioconjugate Chem. 17:14-24, 2006ã«èšèŒãããŠããïŒãã®é瀺ã¯ãååŠçã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããããã®ãªã³ã«ãŒã«é¢ãããã®ãšããŠãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåå¿æ§çœ®æåºZ'ã¯-(C=O)-åã¯-NH(C=O)-ã§ããããã®çµæãåèšãªã³ã«ãŒã¯ãããããã-(C=O)-åã¯-NH(C=O)-åºãšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®ã¢ããåºãšã®åå¿ããçããã¢ããåã¯å°¿çŽ ã®éšåæ§é ã«ãã£ãŠãåèšæäœåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã«çµåããããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšåå¿æ§çœ®æåºZ'ã¯ãN-ãã¬ã€ããžã«åºãããã²ã³åN-ã¢ã«ãã«ã¢ããåºãã¹ã«ããã«ãªãã·N-ã¢ã«ãã«ã¢ããåºãã«ãŒãããŒãåºãããã²ã³åã¹ã«ããã«åºãããªãŒã«åºåã¯ãã®èªå°äœãå
éšã«ççŽ -ççŽ ã®äžéçµåãå«ãã¢ã«ããã«åºãïŒãããïŒã·ã¯ãã¢ã«ããã«åºããã·ã¯ã[6.1.0]ãã³-4-ã€ã³-9-ã€ã«åºïŒbicyclo[6.1.0]non-4-yn-9-yl groupïŒãå
éšã«ççŽ -ççŽ ã®äºéçµåãå«ãã¢ã«ã±ãã«åºãã·ã¯ãã¢ã«ã±ãã«åºãããã©ãžãã«åºãã¢ãžãåºããã¹ãã£ã³åºããããªã«ã»ãªãã·ãåºããããã³åºããããªã«ã»ã€ãã³åºããžã¢ãŸåºãã±ãã³åºã(O-ã¢ã«ãã«)ããããã·ã«ã¢ããåºãããã©ãžã³åºãããã²ã³åN-ãã¬ã€ããžã«åºã1,1-ãã¹(ã¹ã«ããã«ã¡ãã«)ã¡ãã«ã«ã«ããã«åºåã¯ãã®è±é¢èªå°äœãããã²ã³åã«ã«ããã«åºãåã¯ã¢ã¬ã³ã¢ããåºã§ããããããã¯ããããä»»æéžæçã«çœ®æãããããšããããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšåå¿æ§çœ®æåºã¯ãã·ã¯ãã¢ã«ã±ã³åºãã·ã¯ãã¢ã«ãã³åºãåã¯ä»»æéžæçã«çœ®æããã(ããã)ã·ã¯ãã¢ã«ããã«åºãå«ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãååŠçãªéšåæ§é Zããè¡šïŒããéžæãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãååŠçãªéšåæ§é Zã¯ã以äžã®ãšããã§ããïŒ
ã
ããã§ãSã¯ãããã®å¹¹çŽ°èåã¯T现èã®çŽ°èè¡šé¢äžã§çºçŸããæåã«ç¹ç°çã«çµåãããæäœã®åã¯ãã®æå-çµåãã©ã°ã¡ã³ãã®ãäžã«ååšããåå¿æ§çœ®æåºãè¡šãç¡«é»ååã§ããïŒäŸãã°ãã·ã¹ãã€ã³æ®åºã®-SHåºã«ç±æ¥ãã)ã
ããã§ãSã¯ãããã®å¹¹çŽ°èåã¯T现èã®çŽ°èè¡šé¢äžã§çºçŸããæåã«ç¹ç°çã«çµåãããæäœã®åã¯ãã®æå-çµåãã©ã°ã¡ã³ãã®ãäžã«ååšããåå¿æ§çœ®æåºãè¡šãç¡«é»ååã§ããïŒäŸãã°ãã·ã¹ãã€ã³æ®åºã®-SHåºã«ç±æ¥ãã)ã
åèšãªã³ã«ãŒãåŒ(II)ã®ãã®ã§ããããã€ãã®å®æœåœ¢æ
ã§ã¯ããªã³ã«ãŒ-åå¿æ§çœ®æåºã¯ãL-Z'ãšããŠäžç·ã«ãªã£ãŠãããåèšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ããšã³ã³ãžã¥ã²ãŒãããåã«ã以äžã®æ§é ãæããïŒ
ã
ããã§ãæ³¢ç·ã¯ãåèšçŽ°èæ¯çŽ ïŒäŸãã°ãPBDåã¯ãã®èªå°äœ) äžã®çœ®æåºãžã®çµå(attachmentïŒã®äœçœ®ã瀺ããåèšãªã³ã«ãŒã®æ«ç«¯ã®æ³¢ç·ã¯ãåèšçŽ°èæ¯çŽ ïŒäŸãã°ãPBDïŒãžã®çµå(attachmentïŒã®äœçœ®ã瀺ããããã€ãã®å®æœåœ¢æ ã§ã¯ãåèšãªã³ã«ãŒLåã³ååŠçãªéšåæ§é Zã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåŸãL-Z-AbãšããŠäžç·ã«ãªã£ãŠããã以äžã®æ§é ãæããïŒ
ããã§ãSã¯ãããã®å¹¹çŽ°èåã¯T现èã®çŽ°èè¡šé¢äžã§çºçŸããæåã«ç¹ç°çã«çµåãããæäœã®åã¯ãã®æåçµåãã©ã°ã¡ã³ãã®ãäžã«ååšããåå¿æ§çœ®æåºãè¡šãç¡«é»ååã§ããïŒäŸãã°ãã·ã¹ãã€ã³æ®åºã®-SHåºã«ç±æ¥ãã)ãåèšãªã³ã«ãŒã®æ«ç«¯ã®æ³¢ç·ã¯ãåèšçŽ°èæ¯çŽ ïŒäŸãã°ãPBDåã¯ãã®èªå°äœ)ãžã®çµå(attachmentïŒã®äœçœ®ã瀺ãã
ããã§ãæ³¢ç·ã¯ãåèšçŽ°èæ¯çŽ ïŒäŸãã°ãPBDåã¯ãã®èªå°äœ) äžã®çœ®æåºãžã®çµå(attachmentïŒã®äœçœ®ã瀺ããåèšãªã³ã«ãŒã®æ«ç«¯ã®æ³¢ç·ã¯ãåèšçŽ°èæ¯çŽ ïŒäŸãã°ãPBDïŒãžã®çµå(attachmentïŒã®äœçœ®ã瀺ããããã€ãã®å®æœåœ¢æ ã§ã¯ãåèšãªã³ã«ãŒLåã³ååŠçãªéšåæ§é Zã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåŸãL-Z-AbãšããŠäžç·ã«ãªã£ãŠããã以äžã®æ§é ãæããïŒ
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ãæ§é åŒ(I)ã§è¡šãããããããã³ãŸãžã¢ãŒãã³ã§ãããåã³åèšãªã³ã«ãŒã¯ããžã¢ãŒãã³ã»ã¢ããåºãžã®çµåã«ãã£ãŠçµå(attachmentïŒããããã®ãããªå®æœåœ¢æ
ã§ã¯ãåèšADCã¯ãåŒ(III)ã§è¡šãããããšãããïŒ
ã
ããã§ãåLãZãåã³Abã¯ãæ¬åºé¡ã§èª¬æãããã
ããã§ãåLãZãåã³Abã¯ãæ¬åºé¡ã§èª¬æãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåŒ(III)ã®ADCã®ãªã³ã«ãŒLã¯ãåæå¯èœãªãªã³ã«ãŒã§ãããããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšåæå¯èœãªãªã³ã«ãŒLã¯ã1ã€ä»¥äžã®ãããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãã¢ããé
žãæ倧10åã®ã¢ããé
žãããªããããããp-ã¢ãããã³ãžã«(PAB)åºããããç°åŒèªå£(self-immolative)åºãC1-C12 ã¢ã«ãã«ãC1-C12 ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ããããã¢ãªãŒã«ã-(C=O)-åºã-C(O)NH-åºã-OC(O)NH-åºãpã1ãã12ã®æŽæ°ã§ãã-(CH2CH2O)q-åºãåã¯æº¶è§£æ§å¢åŒ·åºãå«ãïŒ
ããã§ãåã ã®C1-C12 ã¢ã«ãã«ãC1-C12ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ãåã¯ãããã¢ãªãŒã«åºã¯ãã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã«ãã«ã»ãããã¢ãªãŒã«ãã¢ãããã¢ã³ã¢ããŠã ãã¢ã·ã«ãã¢ã·ã«ãªãã·ãã¢ã·ã«ã¢ãããã¢ããã«ã«ããã«ãã¢ã«ã³ãã·ã«ã«ããã«ããŠã¬ã€ããã«ã«ãã¡ãŒããã¢ãªãŒã«ããããã¢ãªãŒã«ãã¹ã«ãã£ãã«ãã¹ã«ãã©ãã«ãããããã·ã«ãã¢ã«ã³ãã·ãã¹ã«ãã¡ãã«ãããã²ã³ãã«ã«ããã·ãããªããã¡ãã«ãã·ã¢ããããããã·ãã¡ã«ã«ãããåã³ãããããããªã矀ãããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã1ãã5åã®çœ®æåºã§ãä»»æéžæçã«çœ®æãããããšãããïŒ
åã¯ãåã ã®C1-C12 ã¢ã«ãã«ãC1-C12ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ãåã¯ãããã¢ãªãŒã«åºã«ã¯ãä»»æéžæçã«ãOãSåã³Nããéžæããã1ã€ä»¥äžã®ãããååãå²ã蟌ãããšãããã
ããã§ãåã ã®C1-C12 ã¢ã«ãã«ãC1-C12ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ãåã¯ãããã¢ãªãŒã«åºã¯ãã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ã«ã«ãªã«ãã¢ã«ãã«ã»ãããã¢ãªãŒã«ãã¢ãããã¢ã³ã¢ããŠã ãã¢ã·ã«ãã¢ã·ã«ãªãã·ãã¢ã·ã«ã¢ãããã¢ããã«ã«ããã«ãã¢ã«ã³ãã·ã«ã«ããã«ããŠã¬ã€ããã«ã«ãã¡ãŒããã¢ãªãŒã«ããããã¢ãªãŒã«ãã¹ã«ãã£ãã«ãã¹ã«ãã©ãã«ãããããã·ã«ãã¢ã«ã³ãã·ãã¹ã«ãã¡ãã«ãããã²ã³ãã«ã«ããã·ãããªããã¡ãã«ãã·ã¢ããããããã·ãã¡ã«ã«ãããåã³ãããããããªã矀ãããããããã®å Žåæ¯ã«ç¬ç«ããŠéžæãããã1ãã5åã®çœ®æåºã§ãä»»æéžæçã«çœ®æãããããšãããïŒ
åã¯ãåã ã®C1-C12 ã¢ã«ãã«ãC1-C12ãããã¢ã«ãã«ãC2-C12ã¢ã«ã±ãã«ãC2-C12 ãããã¢ã«ã±ãã«ãC2-C12 ã¢ã«ããã«ãC2-C12 ãããã¢ã«ããã«ãC3-C12 ã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ãªãŒã«ãåã¯ãããã¢ãªãŒã«åºã«ã¯ãä»»æéžæçã«ãOãSåã³Nããéžæããã1ã€ä»¥äžã®ãããååãå²ã蟌ãããšãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãããããããªãªãŽç³ã-(CH2)p-, -(CH2CH2O)q-, -(C=O)(CH2)r-, -(C=O)(CH2CH2O)t-, -(NHCH2CH2)u-, -PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, å㯠Ala-PABãå«ããããã§ãpãqãrãtãåã³uã®åã
ã¯ã1ãã12ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæãããã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãPAB-Ala-Val- å㯠PAB-Cit-Val-, a-(C=O)(CH2)r- ãŠããã, -(C=O)(CH2CH2O)t- ãŠããã, åã³ -(NHCH2CH2)u- ãŠãããããå«ããããã§ã r=2ãt=8ãåã³u=1ã§ãããå
·äœçãªå®æœåœ¢æ
ã§ã¯ãåèšãªã³ã«ãŒã¯ãåŒ(II)ã§è¡šãããããšãããïŒ
ããã§ãR1 ã¯ãCH3(Ala)ãåã¯(CH2)3NH(CO)NH2(Cit)ãã§ããã
åèšçŽ°èæ¯çŽ ãåŒ(I)ã®ãã®ã§ãããåã³åèšãªã³ã«ãŒãåŒ(II)ã®ãã®ã§ãããããã§ãR1ãCH3ã§ãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒ-ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«åå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠãããåŒ(IV)ã§è¡šãããããšãããïŒ
ã
ãã®ç¹å®ã®çŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ããã·ãªã³(SG3249)ãšããŠç¥ãããŠãããäŸãã°ãHoward et al., ACS Med. Chem. Lett. 2016, 7(11), 983-987ïŒãã®é瀺ã¯ããã®å
šäœããæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã«èšèŒãããŠãããåŒ(IV)ã®ååç©ã¯ãæ¬åºé¡ã§é瀺ããæ-CD45æäœã«ã³ã³ãžã¥ã²ãŒããããšãåŒ(V)ã§è¡šãããšãã§ããïŒ
ã
ããã§ãAbã¯ãæ¬åºé¡ã§é瀺ããããããªæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã§ãããåã³Sã¯ãåèšæäœã®äžã«ååšãããåã¯åèšæäœã®äžã«å°å ¥ããããç¡«é»åå(äŸãã°ãã·ã¹ãã€ã³æ®åºããªãŒã«)ãè¡šãã
ããã§ãAbã¯ãæ¬åºé¡ã§é瀺ããããããªæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã§ãããåã³Sã¯ãåèšæäœã®äžã«ååšãããåã¯åèšæäœã®äžã«å°å ¥ããããç¡«é»åå(äŸãã°ãã·ã¹ãã€ã³æ®åºããªãŒã«)ãè¡šãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ ã¯ã以äžã®åŒã§è¡šãããããããã³ãŸãžã¢ãŒãã³äºéäœã§ããïŒ
ã
ããã§ãæ³¢ç·ã¯ãåèšãªã³ã«ãŒã®çµåäœçœ®(attachment point)ã瀺ãã
ããã§ãæ³¢ç·ã¯ãåèšãªã³ã«ãŒã®çµåäœçœ®(attachment point)ã瀺ãã
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããã以äžã®æ§é ãæããïŒ
ã
ãã®ç¹å®ã®çŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ã¿ãªãªã³ãšããŠç¥ãããŠãããäŸãã°ãADC ããã¹ããã·ããã»ã¿ãªãªã³(Vadastuximab talirine)(SGN-CD33A)ã«é¢é£ããŠãMantaj et al., Angewandte Chemie International Edition English 2017,56, 462-488ãã«èšèŒãããŠããããã®é瀺ã¯ããã®å
šäœãæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããã
æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã®èª¿è£œ
åŒ(V)ã®ADCã®ãããªãæ¬åºé¡ã«é瀺ãããåŒAb-(Z-L-Cy)nã®ADCã«ãããŠãæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ã(Ab)ã¯ãæ¬åºé¡ã«é瀺ããããããªãªã³ã«ãŒLåã³ååŠçãªéšåæ§é Zãä»ããŠã1å以äžã®çŽ°èæ¯æ§è¬ç©éšåæ§é (Cy;äŸãã°ãPBD)ïŒäŸãã°ãæäœãããçŽ1åããçŽ20åã®çŽ°èæ¯çŽ éšåæ§é ïŒã«ã³ã³ãžã¥ã²ãŒããããä»»æã®æ°ã®çŽ°èæ¯çŽ ããåèšæ-CD45æäœã«ã³ã³ãžã¥ã²ãŒãããããšãããïŒäŸãã°ã1ã2ã3ã4ã5ã6ã7ãåã¯8ïŒãããã€ãã®å®æœåœ¢æ ã§ã¯ãnã¯ãçŽ1ããçŽ5ãçŽ1ããçŽ4ãçŽ1ããçŽ3ãåã¯çŽ2ããçŽ5ãåã¯çŽ3ããçŽ5ãã§ãããããã€ãã®å®æœåœ¢æ ã§ã¯ãnã¯ãçŽ1ãçŽ2ãçŽ3ãåã¯çŽ4ãã§ããã
åŒ(V)ã®ADCã®ãããªãæ¬åºé¡ã«é瀺ãããåŒAb-(Z-L-Cy)nã®ADCã«ãããŠãæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ã(Ab)ã¯ãæ¬åºé¡ã«é瀺ããããããªãªã³ã«ãŒLåã³ååŠçãªéšåæ§é Zãä»ããŠã1å以äžã®çŽ°èæ¯æ§è¬ç©éšåæ§é (Cy;äŸãã°ãPBD)ïŒäŸãã°ãæäœãããçŽ1åããçŽ20åã®çŽ°èæ¯çŽ éšåæ§é ïŒã«ã³ã³ãžã¥ã²ãŒããããä»»æã®æ°ã®çŽ°èæ¯çŽ ããåèšæ-CD45æäœã«ã³ã³ãžã¥ã²ãŒãããããšãããïŒäŸãã°ã1ã2ã3ã4ã5ã6ã7ãåã¯8ïŒãããã€ãã®å®æœåœ¢æ ã§ã¯ãnã¯ãçŽ1ããçŽ5ãçŽ1ããçŽ4ãçŽ1ããçŽ3ãåã¯çŽ2ããçŽ5ãåã¯çŽ3ããçŽ5ãã§ãããããã€ãã®å®æœåœ¢æ ã§ã¯ãnã¯ãçŽ1ãçŽ2ãçŽ3ãåã¯çŽ4ãã§ããã
æ¬é瀺ã®ADCã¯ã以äžãå«ããåœæ¥è
ã«å
¬ç¥ã®ææ©ååŠåå¿ãæ¡ä»¶ãåã³è©Šè¬ã䜿çšããããã€ãã®çµè·¯ã«ãã£ãŠèª¿è£œããåŸãïŒ(1)æäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®åå¿æ§çœ®æåºãã2䟡ãªã³ã«ãŒè©Šè¬ãšåå¿ãããŠãæ¬åºé¡äžäžèšã®ãããªAb-Z-Lã圢æããããç¶ããŠã现èæ¯çŽ éšåæ§é Cyãšåå¿ãããïŒåã¯ã(2)现èæ¯çŽ éšåæ§é ã®åå¿æ§çœ®æåºãã2䟡ãªã³ã«ãŒè©Šè¬ãšåå¿ãããŠãCy-L-Z'ã圢æããããç¶ããŠãæ¬åºé¡äžäžèšã®ãããªæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®åå¿æ§çœ®æåºãšåå¿ãããŠãåŒAb-(Z-L-Cy)nã®ADCã圢æããããADCã調補ããããã®æŽãªãæ¹æ³ããæ¬åºé¡ã«èšèŒããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãåèšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã¯ã1ã€ä»¥äžã®ã¹ã«ããããªã«åºãæããããã«ååŠçã«ä¿®é£ŸããåŸã1ã€ä»¥äžã®ç³åº(carbohydrate groups)ãæããããšãããã次ãã§ãæ¬åºé¡äžäžèšã«èšèŒãããããã«ãã¹ã«ããããªã«åºã®ç¡«é»ååãä»ããŠã³ã³ãžã¥ã²ãŒããããããšã«ãã£ãŠãåèšADCã圢æããã
æŽã«å¥ã®å®æœåœ¢æ
ã§ã¯ãåèšæäœã¯ãé
žåãããŠã¢ã«ããã(-CHO)åºãæäŸãåŸã1ã€ä»¥äžã®ç³åº(carbohydrate groups)ãæããããšããã(äŸãã°ãLaguzza, et al., J. Med. Chem. 1989, 32(3), 548-55ãåç
§ã®ããš)ã次ãã§ãæ¬åºé¡äžäžèšã«èšèŒãããããã«ã察å¿ããã¢ã«ããããä»ããŠã³ã³ãžã¥ã²ãŒããããããšã«ãã£ãŠãåèšADCã圢æããã现èæ¯çŽ ãçµå(attachment)ãããåã¯äŒåãããããã®ã¿ã³ãã¯è³ªãæ¹å€ããä»ã®ãããã³ãŒã«ã¯ãColigan et al., Current Protocols in Protein Science, vol. 2, John Wiley & Sons (2002)ã«èšèŒãããŠããïŒæ¬åºé¡ã«åç
§ã«ããåã蟌ãŸããïŒã
æäœãå
ç«ã°ãããªã³åã¯ãã®ãã©ã°ã¡ã³ãçã®ã现èãã¿ãŒã²ããã«ããã¿ã³ãã¯è³ªã«ããªã³ã«ãŒ-è¬ç©éšåæ§é ãã³ã³ãžã¥ã²ãŒããããããã®æ¹æ³ã¯ãäŸãã°ãç±³åœç¹èš±ç¬¬5,208,020å·; ç±³åœç¹èš±ç¬¬6,441,163å·; WO2005037992; WO2005081711; åã³WO2006/034488ã«èšèŒãããŠããïŒãããã®å
šãŠã¯ããã®å
šäœãæ¬åºé¡ã«æ確ã«åç
§ã«ããåã蟌ãŸããïŒã
æãã¯ãåèšæäœåã³çŽ°èæ¯æ§è¬å€ãå«ãèåã¿ã³ãã¯è³ªããäŸãã°ãçµæãæè¡åã¯ããããåæã«ãã£ãŠãäœè£œããããšããããDNAã®é·ãã¯ãäºãã«é£æ¥ãããåã¯åèšã³ã³ãžã¥ã²ãŒãã®ææã®ç¹æ§ãç Žå£ããªããªã³ã«ãŒã»ãããããã³ãŒãããé åã«ãã£ãŠåé¢ããããåèšã³ã³ãžã¥ã²ãŒãã®2ã€ã®éšåãã³ãŒãããããããã®é åããå«ãããšãããã
å»è¬çµæç©
æ¬åºé¡ã«èšèŒãããADCããçš®ã ã®æè¬åœ¢æ ã§æ£è (äŸãã°ãèªå·±å ç«çŸæ£åã¯ããã«çœ¹æ£ããŠããããæ£è )ã«æäžããããšããããäŸãã°ãæ¬åºé¡ã«èšèŒãããADCããå ç«çŸæ£åã¯ããã«çœ¹æ£ããŠããæ£è ã«ã氎溶液ïŒäŸãã°ã1皮以äžã®è¬åŠçã«èš±å®¹å¯èœãªè³Šåœ¢å€ãå«ã氎溶液ãªã©ïŒã®åœ¢æ ã§æäžããããšããããæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ãšå ±ã«äœ¿çšããããã«å¥œé©ãªè¬åŠçã«èš±å®¹ããã賊圢å€ãšããŠã¯ãç²åºŠèª¿æŽå€ãæãããããåèšæ°Žæº¶æ¶²ããåœè©²æè¡åéã§å ¬ç¥ã®æè¡ã䜿çšããŠæ» èããããšãããã
æ¬åºé¡ã«èšèŒãããADCããçš®ã ã®æè¬åœ¢æ ã§æ£è (äŸãã°ãèªå·±å ç«çŸæ£åã¯ããã«çœ¹æ£ããŠããããæ£è )ã«æäžããããšããããäŸãã°ãæ¬åºé¡ã«èšèŒãããADCããå ç«çŸæ£åã¯ããã«çœ¹æ£ããŠããæ£è ã«ã氎溶液ïŒäŸãã°ã1皮以äžã®è¬åŠçã«èš±å®¹å¯èœãªè³Šåœ¢å€ãå«ã氎溶液ãªã©ïŒã®åœ¢æ ã§æäžããããšããããæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ãšå ±ã«äœ¿çšããããã«å¥œé©ãªè¬åŠçã«èš±å®¹ããã賊圢å€ãšããŠã¯ãç²åºŠèª¿æŽå€ãæãããããåèšæ°Žæº¶æ¶²ããåœè©²æè¡åéã§å ¬ç¥ã®æè¡ã䜿çšããŠæ» èããããšãããã
æ¬åºé¡ã«èšèŒããããããªADCãå«ãå»è¬è£œå€ã¯ããã®ãããªADCãã1皮以äžã®ä»»æéžæçãªè¬åŠçã«èš±å®¹å¯èœãªæ
äœãšæ··åããããšã«ãã£ãŠ(Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980))ãåçµä¹Ÿç¥è£œå€åã¯æ°Žæº¶æ¶²ã®åœ¢æ
ã§ã調補ãããè¬åŠçã«èš±å®¹å¯èœãªæ
äœã¯ãäžè¬ã«ã䜿çšããçšéåã³æ¿åºŠã§ãã¬ã·ããšã³ãã«å¯ŸããŠç¡æ¯æ§ã§ãããããã«ã¯ãéå®ããããã®ã§ã¯ãªããã以äžãæããããïŒãªã³é
žå¡©ãã¯ãšã³é
žå¡©ãåã³ä»ã®ææ©é
žãªã©ã®ãããã¡ãŒïŒã¢ã¹ã³ã«ãã³é
žåã³ã¡ããªãã³ãå«ãé
žåé²æ¢å€ïŒä¿åå€ïŒå¡©åãªã¯ã¿ãã·ã«ãžã¡ãã«ãã³ãžã«ã»ã¢ã³ã¢ããŠã ïŒå¡©åãããµã¡ãããŠã ïŒå¡©åãã³ã¶ã«ã³ããŠã ïŒå¡©åãã³ãŒãããŠã ïŒãã§ããŒã«ãããã«è¥ããã¯ãã³ãžã«ã»ã¢ã«ã³ãŒã«ïŒã¡ãã«è¥ããã¯ãããã«ã»ãã©ãã³çã®ã¢ã«ãã«ã»ãã©ãã³ïŒã«ãã³ãŒã«ïŒã¬ãŸã«ã·ããŒã«ïŒã·ã¯ããããµããŒã«ïŒ3-ãã³ã¿ããŒã«ïŒåã³m-ã¯ã¬ãŸãŒã«ãªã©ïŒïŒäœååé(çŽ10æ®åºæªæº)ããªããããïŒè¡æž
ã¢ã«ããã³ããŒã©ãã³ãè¥ããã¯å
ç«ã°ãããªã³ãªã©ã®ã¿ã³ãã¯è³ªïŒããªããã«ãããªãã³ãªã©ã®èŠªæ°Žæ§ããªããŒïŒã°ãªã·ã³ãã°ã«ã¿ãã³ãã¢ã¹ãã©ã®ã³ããã¹ããžã³ãã¢ã«ã®ãã³ãè¥ããã¯ãªãžã³ãªã©ã®ã¢ããé
žïŒã°ã«ã³ãŒã¹ããã³ããŒã¹ãè¥ããã¯ããã¹ããªã³ãªã©ã®ãåç³é¡ãäºç³é¡ãåã³ä»ã®ç³é¡ïŒEDTAãªã©ã®ãã¬ãŒãå€ïŒã·ã§ç³ããã³ãããŒã«ããã¬ãããŒã¹ãè¥ããã¯ãœã«ãããŒã«ãªã©ã®ç³é¡ïŒãããªãŠã ãªã©ã®å¡©åœ¢ææ§å¯Ÿã€ãªã³ïŒéå±é¯äœïŒäŸãã°ãZn-ã¿ã³ãã¯è³ªé¯äœïŒïŒäžŠã³ã«ïŒåã¯ããªãšãã¬ã³ã»ã°ãªã³ãŒã«ïŒPEGïŒãªã©ã®é-ã€ãªã³æ§çé¢æŽ»æ§å€ã
æäž
æ¬åºé¡ã«èšèŒãããADCããçµå£ãçµç®ãç®äžã錻è å ãéèå ãçèå ãçŒå ãåã¯éçµå£çã®æ§ã ãªçµè·¯ã«ãã£ãŠæäžããããšããããä»»æã®æäžã®ã±ãŒã¹ã«ãããŠãæäžã«æãé©ããçµè·¯ã¯ãæäžããç¹å®ã®æäœãåã¯æå-çµåãã©ã°ã¡ã³ããæ£è ãå»è¬è£œå€åæ¹æ³ãæäžæ¹æ³(äŸãã°ãæäžæå»åã³æäžçµè·¯)ãæ£è ã®å¹Žéœ¢ãäœéãæ§å¥ãæ²»çããçŸæ£ã®éç床ãæ£è ã®é£äºãåã³æ£è ã®ææ³é床ã«äŸåããã
æ¬åºé¡ã«èšèŒãããADCããçµå£ãçµç®ãç®äžã錻è å ãéèå ãçèå ãçŒå ãåã¯éçµå£çã®æ§ã ãªçµè·¯ã«ãã£ãŠæäžããããšããããä»»æã®æäžã®ã±ãŒã¹ã«ãããŠãæäžã«æãé©ããçµè·¯ã¯ãæäžããç¹å®ã®æäœãåã¯æå-çµåãã©ã°ã¡ã³ããæ£è ãå»è¬è£œå€åæ¹æ³ãæäžæ¹æ³(äŸãã°ãæäžæå»åã³æäžçµè·¯)ãæ£è ã®å¹Žéœ¢ãäœéãæ§å¥ãæ²»çããçŸæ£ã®éç床ãæ£è ã®é£äºãåã³æ£è ã®ææ³é床ã«äŸåããã
æ¬åºé¡ã«èšèŒãããADCãæäœãåã¯ãã®æå-çµåãã©ã°ã¡ã³ãã®æå¹çšéã¯ãäŸãã°ãåå(äŸãã°ãããŒã©ã¹)æäžãè€æ°åæäžãåã¯æç¶æäžãããã§ãäœéã«é¢ããŠçŽ0.001ããçŽ100 mg/kgã®ç¯å²ã«ããŠãåèšæäœããã®æå-çµåãã©ã°ã¡ã³ãã®æé©è¡äžæ¿åºŠ(äŸãã°ãçŽ0.0001ããçŽ5000 ÎŒg/mLã®è¡äžæ¿åºŠ)ã«ãªãããšããããåèšçšéãããããèªå·±å
ç«çŸæ£ã«çœ¹æ£ããŠãã察象ãåã¯é è¡å¹¹çŽ°è移æ€ãåããããšã«åããŠã³ã³ãã£ã·ã§ãã³ã°çæ³ãåããŠãã察象(äŸãã°ããã)ã«ã1æ¥ã1é±éãåã¯1ã¶æããã1å以äž(äŸãã°ã2ãã10å)ãæäžããããšããããé è¡å¹¹çŽ°è移æ€åã«ãããã³ã³ãã£ã·ã§ãã³ã°åŠçœ®ã®å Žåã§ã¯ãåèšADCãæäœãåã¯ãã®æåçµåãã©ã°ã¡ã³ãããå€å æ§ã®é è¡å¹¹çŽ°èã®ççãæé©ã«ä¿é²ãããæã«ãäŸãã°ãå€å æ§ã®é è¡å¹¹çŽ°è移æ€çãæäžãã1æéãã1é±é(äŸãã°ãçŽ1æéãçŽ2æéãçŽ3æéãçŽ4æéãçŽ5æéãçŽ6æéãçŽ7æéãçŽ8æéãçŽ9æéãçŽ10æéãçŽ11æéãçŽ12æéãçŽ13æéãçŽ14æéãçŽ15æéãçŽ16æéãçŽ17æéãçŽ18æéãçŽ19æéãçŽ20æéãçŽ21æéãçŽ22æéãçŽ23æéãçŽ24æéãçŽ2æ¥ãçŽ3æ¥ãçŽ4æ¥ãçŽ5æ¥ãçŽ6æ¥ãåã¯çŽ7æ¥)åã¯ãã以äžåã«ãåèšæ£è
ã«æäžããããšãããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.1 mg/kgããçŽ0.3 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.15 mg/kgããçŽ0.3 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.15 mg/kgããçŽ0.25 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.2 mg/kgããçŽ0.3 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.25 mg/kgããçŽ0.3 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.1 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.2 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžãããããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããæ-CD45æäœã®çšéã¯ãçŽ0.3 mg/kgã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãããæ£è
ã«æäžããããæ¬åºé¡ã«èšèŒãããæ-CD45 ADCã®çšéã¯ãçŽ0.001 mg/kgãã10 mg/kg, çŽ0.01 mg/kgãã9.5 mg/kg, çŽ0.1 mg/kgãã9 mg/kg, çŽ0.1 mg/kgãã8.5 mg/kg, çŽ0.1 mg/kgãã8 mg/kg, çŽ0.1 mg/kgãã7.5 mg/kg, çŽ0.1 mg/kgãã7 mg/kg, çŽ0.1 mg/kgãã6.5 mg/kg, çŽ0.1 mg/kgãã6 mg/kg, çŽ0.1 mg/kgãã5.5 mg/kg, çŽ0.1 mg/kgãã5 mg/kg, çŽ0.1 mg/kgãã4.5 mg/kg, çŽ0.1 mg/kgãã4 mg/kg, çŽ0.5 mg/kgãã3.5 mg/kg, çŽ0.5 mg/kgãã3 mg/kg, çŽ1 mg/kgãã10 mg/kg, çŽ1 mg/kgãã9 mg/kg, çŽ1 mg/kgãã8 mg/kg, çŽ1 mg/kgãã7 mg/kg, çŽ1 mg/kgãã6 mg/kg, çŽ1 mg/kgãã5 mg/kg, çŽ1 mg/kgãã4 mg/kg,åã¯ãçŽ1 mg/kgãã3 mg/kgãã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ²»çåã¯ã³ã³ãã£ã·ã§ãã³ã°ã®ããã«ãããæ£è
ã«æäžããããæ¬åºé¡ã«èšèŒãããæ-CD45 ADCã¯ã24æé以äžã22æé以äžã20æé以äžã18æé以äžã16æé以äžã14æé以äžã13æé以äžã12æé以äžã11æé以äžã10æé以äžã9æé以äžã8æé以äžã7æé以äžã6æé以äžãåã¯5æé以äžãã®åæžæãæããã1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ-HC ADCã®åæžæã¯ã5æéãã7æéïŒ5æéãã9æéïŒ15æéãã11æéïŒ5æéãã13æéïŒ5æéãã15æéïŒ5æéãã20æéïŒ5æéãã24æéïŒ7æéãã24æéïŒ9æéãã24æéïŒ11æéãã24æéïŒ12æéãã22æéïŒ10æéãã20æéïŒ8æéãã18æéïŒåã¯ã14æéãã24æéãã§ããã
1ã€ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§é瀺ããæ¹æ³ã«ãã£ãŠãã³ã³ãã£ã·ã§ãã³ã°ã®ããã«ADCã®æäžãåããæ£è
ã«ãããŠãèæ¯æ§ãæå°éã«æãããããäŸãã°ãããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§é瀺ããæ¹æ³ã«ãã£ãŠãçŽ24æéãçŽ48æéãçŽ72æéãåã¯çŽ96æéãè¶
ããŠãåèšæ£è
ã«ãããŠãèèã®ããŒã«ãŒã»ã¬ãã«ããæ¢ç¥ã®æ¯æ§ã¬ãã«æªæºã«çãŸãããã«ãªããä»ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§é瀺ããæ¹æ³ã«ãã£ãŠãçŽ24æéãçŽ48æéãçŽ72æéãåã¯çŽ96æéãè¶
ããŠãåèšæ£è
ã«ãããŠãèèã®ããŒã«ãŒã»ã¬ãã«ããåºæºç¯å²å
ã«çãŸãããã«ãªããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã§é瀺ããæ¹æ³ã«ãã£ãŠãèèã®ããŒã«ãŒã»ã¬ãã«ã®äžæããçŽ24æéãçŽ48æéãçŽ72æéãåã¯çŽ96æéãè¶
ããŠãåºæºç¯å²ãè¶
ããŠçŽ1.5åãã倧ãããåºæºç¯å²ãè¶
ããŠçŽ3åãã倧ãããåºæºç¯å²ãè¶
ããŠçŽ5åãã倧ãããåã¯åºæºç¯å²ãè¶
ããŠçŽ10åãã倧ãããã¯ãªããªããæ¯æ§è©Šéšã«äœ¿çšããããšãããèèã®ããŒã«ãŒã®äŸãšããŠã¯ãã¢ã©ãã³ã»ã¢ãããã©ã³ã¹ã¢ãããŒãŒ(ALT)ãä¹³é
žè±æ°ŽçŽ é
µçŽ (LDH)ãåã³ã¢ã¹ãã©ã®ã³é
žã¢ãããã©ã³ã¹ã¢ãããŒãŒ(AST)çãæãããããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ¬åºé¡ã«èšèŒãããããã«ADCãæäžããããšã«ãã£ãŠ(å³ã¡ãååçšéã®ä»£ããã«2åçšéã§æäžãã)ãèèã®ããŒã«ãŒ(äŸãã°ãASTãLDHãåã³ïŒåã¯ALT)ã¯äžéçã«å¢å ãããããã€ãã®äŸã§ã¯ãæ¯æ§ã瀺ãèèã®ããŒã«ãŒã¯é«ã¬ãã«ã«éããããšãããããããç¹å®ã®æéïŒäŸãã°ãçŽ12æéãçŽ18æéãçŽ24æéãçŽ36æéãçŽ48æéãçŽ72æéãçŽ3æ¥ãçŽ3.5æ¥ãçŽ4æ¥ãçŽ4.5æ¥ãçŽ5æ¥ãçŽ5.5æ¥ãçŽ6æ¥ãçŽ6.5æ¥ãçŽ7æ¥ãçŽ7.5æ¥ãåã¯1é±éæªæºïŒã®ç¯å²å
ã§ãããåèšèèã®ããŒã«ãŒã»ã¬ãã«ã¯ãèæ¯æ§ã«é¢é£ããªãæ£åžžã¬ãã«ã«æ»ããäŸãã°ããã(å¹³åçãªæ人ç·æ§)ã«ãããŠãALTã®æ£åžžãªé-æ¯æ§ã¬ãã«ã¯1ãªããã«åœãã7ãã55åäœ(U/L)ã§ããïŒASTã®æ£åžžãªé-æ¯æ§ã¬ãã«ã¯8ãã48U/Lã§ãããããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãæ£è
ã®è¡äžASTãALTãåã¯LDHã¬ãã«ã®ãã¡ã®å°ãªããšã1ã€ã¯ãåèšæ£è
ã«ã第1ã®çšéã®ADCãæäžããããšãšåèšç¬¬1ã®çšéãæäžãã14æ¥åŸãšã®éã«ãæ¯æ§ã¬ãã«ã«éããªããäŸãã°ãåèšæ£è
ã«ç¬¬1ã®çšéãæäžããç¶ããŠãåèšç¬¬1ã®çšéãæäžããŠããäŸãã°5ã10ãåã¯14æ¥ä»¥å
ã«ã第2ã®çšéã第3ã®çšéã第4ã®çšéãåã¯ãããã倧ããæ°ã®çšéãæäžããããšããããããããåèšæ£è
ã®è¡äžASTãALTãåã¯LDHã¬ãã«ã®ãã¡ã®å°ãªããšã1ã€ã¯ãåèšæ£è
ã«ã第1ã®çšéã®ADCãæäžããããšãšåèšç¬¬1ã®çšéãæäžãã14æ¥åŸãšã®éã«ãæ¯æ§ã¬ãã«ã«éããªãã
ããç¹å®ã®å®æœåœ¢æ
ã§ã¯ãåèšæ£è
ã®è¡äžASTãALTãåã¯LDHã¬ãã«ã®ãã¡ã®å°ãªããšã1ã€ã¯ãæ£åžžã¬ãã«ãè¶
ããŠäžæããªããæ£åžžã¬ãã«ã1.5åãè¶
ããŠäžæããªããæ£åžžã¬ãã«ã3åãè¶
ããŠäžæããªããæ£åžžã¬ãã«ã5åãè¶
ããŠäžæããªããåã¯æ£åžžã¬ãã«ã10åãè¶
ããŠäžæããªãã
æ¬åºé¡ã«èšèŒãããå Žåãé è¡å¹¹çŽ°è移æ€çæ³ãã1皮以äžã®è¡æ¶²çŽ°èåãççãããåã¯åççãããããã«ãæ²»çãå¿
èŠãšãã察象ã«åŠæ¹ããããšããããé è¡å¹¹çŽ°èã¯ãäžè¬ã«å€èœæ§ã瀺ããåŸã£ãŠãéå®ããããã®ã§ã¯ãªãããé¡ç²çïŒäŸãã°ãå骚é«çã奜äžçïŒå¥œé
žçã奜塩åºç)ãèµ€è¡ç(äŸãã°ã網ç¶èµ€è¡çãèµ€è¡ç)ãè¡å°æ¿(äŸãã°ãå·šæ žèœçãè¡å°æ¿(platelet)ç£çå·šæ žçãè¡å°æ¿(platelets))ãåç(äŸãã°ãåçããã¯ããã¡ãŒãž)ãæš¹ç¶çŽ°èããã¯ãã°ãªã¢ãç ŽéªšçŽ°èãåã³ãªã³ãç(äŸãã°ãNK现èãB现èåã³T现è)çãå«ããè€æ°ã®æ§ã
ãªè¡æ¶²ç³»åã«ååããããšãã§ãããé è¡å¹¹çŽ°èã¯ãæŽã«èªå·±è€è£œèœãæããåŸã£ãŠãæ¯çŽ°èãšåçã®æœåšèœåãæããåšçŽ°èãçããããããšãã§ãããŸãã移æ€ã¬ã·ããšã³ãã«åå°å
¥ãããé è¡å¹¹çŽ°èãããã«ããŒãã³ã°ããçç£çã§æç¶çãªé è¡ãå確ç«ããäœçšèœããç¹åŸŽãšããã
åŸã£ãŠãin vivoã§æ¬ é¥ã®ããåã¯æ¬ æãã现èéå£ãåæ§æããããã«ãé è¡ç³»åã®1皮以äžã®çŽ°èåã«æ¬ é¥ã®ããåã¯æ¬ æããæ£è
ã«ãé è¡å¹¹çŽ°èãæäžããããšããããããã«ãã£ãŠãå
å æ§ã®è¡æ¶²çŽ°èéå£ã«ãããæ¬ é¥åã¯æžå°ã«é¢é£ããç
æ
ãæ²»çããããšãã§ãããåŸã£ãŠãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ããé-æªæ§ç°åžžãã¢ã°ããã³ç(äŸãã°ãéç¶èµ€è¡ç貧è¡ããµã©ã»ãã¢ããã¡ã³ã³ããŒè²§è¡ãåçäžè¯æ§è²§è¡ãåã³ãŠã£ã¹ã³ããâã¢ã«ããªããçå矀ãããªã矀ããéžæãããç°åžžãã¢ã°ããã³ç)ãæ²»çããããã«ã䜿çšããããšããããæŽã«ãåã¯ãã®ä»£ãããšããŠãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ããå
倩æ§å
ç«äžå
šçãªã©ã®å
ç«äžå
šãæ²»çããããã«äœ¿çšããããšããããæŽã«ãåã¯ãã®ä»£ãããšããŠãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ããåŸå€©æ§å
ç«äžå
šç(äŸãã°ãHIVåã³AIDSãããªã矀ããéžæãããåŸå€©æ§å
ç«äžå
šç)ãæ²»çããããã«äœ¿çšããããšããããæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ãã代è¬æ§é害(äŸãã°ãã°ãªã³ãŒã²ã³èç©çãã ã³å€ç³çããŽãŒã·ã§ç
ãããŒã©ãŒç
ãã¹ãã£ã³ãŽè質çãåã³ç°ææ§çœè³ªãžã¹ãããã£ãŒãããéžæããã代è¬æ§é害)ãæ²»çããããã«äœ¿çšããããšãããã
æŽã«ãåã¯ãã®ä»£ãããšããŠãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãæªæ§è
«çåã¯å¢æ®æ§é害ãäŸãã°è¡æ¶²ããã骚é«å¢æ®æ§çŸæ£ãªã©ããæ²»çããããšãã§ãããããæ²»çã®å Žåãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã¯ãé è¡å¹¹çŽ°è移æ€çæ³ã®åã«å
å æ§ã®é è¡å¹¹çŽ°èã®éå£ãæžå°ãããããã«æ£è
ã«æäžãããŠãããããã®å Žåã移æ€ãã现èã¯ãå
å æ§ã®çŽ°èãæžå°ãããå·¥çšã«ãã£ãŠäœãåºããããããã«ããŒãã³ã°ããçç£çãªé è¡ã確ç«ããããšãã§ãããããã«ãã£ãŠãå
šèº«æ§ã®ååŠçæ³ã®éã®ãããªãã现èãæ ¹çµ¶ãããéã«æžå°ãã现èã®éå£ããä»åºŠã¯åæ§æããããšãã§ãããæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ãçšããŠæ²»çããããšãã§ããäŸç€ºçãªè¡æ¶²ãããšããŠã¯ãéå®ããããã®ã§ã¯ãªãããæ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«ãåã³é-ããžãã³ã»ãªã³ãè
«(non-Hodgkinâs lymphoma)ã䞊ã³ã«ç¥çµèœçŽ°èè
«ãå«ãä»ã®ããçç¶ããæããããã
æ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã§æ²»çããããšãã§ããæŽãªãçŸæ£ãšããŠã¯ã¢ããã·ã³ã»ãã¢ãããŒãŒæ¬ æçåã³é床è€åå
ç«äžå
šçãé«å
ç«ã°ãããªã³Mçå矀ããã§ãã£ã¢ãã¯âæ±ç
ãéºäŒæ§ãªã³ãçµç¹ççã倧çç³éªšç
ã骚圢æäžå
šçã貯èµçŸæ£ããµã©ã»ãã¢ã»ã¡ãžã£ãŒãå
šèº«æ§ç¡¬åçãå
šèº«æ§ãšãªããããŒãã¹(systemic lupus erythematosus)ãå€çºæ§ç¡¬åçã䞊ã³ã«è¥å¹Žæ§é¢ç¯ãªãŠãããæãããããããããã«éå®ããããã®ã§ã¯ãªãã
æ¬åºé¡ã«èšèŒãããæäœããã®æå-çµåãã©ã°ã¡ã³ãããªã¬ã³ããåã³ã³ã³ãžã¥ã²ãŒãã䜿çšããŠãåºåœ¢èåšç§»æ€ãã¬ã©ã³ã¹ãèªå°ããããšããããäŸãã°ãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãã¿ãŒã²ããçµç¹ãã现èã®éå£ãæžå°ããããåã¯æ¬ æãããããšããã(äŸãã°ã骚é«å¹¹çŽ°èãããããé è¡å¹¹çŽ°èãæžå°ããã)ãåèšã¿ãŒã²ããçµç¹ãã现èããã®ããã«æžå°ãããåŸãèåšãããŒããã®å¹¹çŽ°èåã¯åé§çŽ°èã®éå£(äŸãã°ãèåšãããŒããã®é è¡å¹¹çŽ°è)ã移æ€ã¬ã·ããšã³ãã«æäžããããšãããããããŠãã®ãããªå¹¹çŽ°èåã¯åé§çŽ°èãççããåŸã§ã¯ãäžæçãªåã¯å®å®ãªæ··åãã¡ã©ãšãªããããã«ãããæŽãªãå
ç«æå¶å€ãå¿
èŠãšããããšãªããé·æã®ç§»æ€èåšãã¬ã©ã³ã¹ãå¯èœã«ãªããäŸãã°ãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãåºåœ¢èåšç§»æ€ã¬ã·ããšã³ãã«ãããŠç§»æ€ãã¬ã©ã³ã¹ãèªå°ããããšããã(äŸãã°ããšããããè
è移æ€ãèºç§»æ€ãèè移æ€ãåã³å¿è移æ€)ãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã¯ãäŸãã°ãäžæçãªåã¯å®å®ãªãããŒã®ççãäœå²åã§ã移æ€ãããèåšã®é·æãã¬ã©ã³ã¹ãå
åã«èªå°ãããããåºåœ¢èåšç§»æ€ãã¬ã©ã³ã¹ãèªå°ããããšã«é¢é£ããŠäœ¿çšããã®ã«å
åã«é©ããŠããã
æŽã«ãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãCD45+ã§ãã现èãç¹åŸŽãšããããçã®ãããçŽæ¥çã«æ²»çããããšããããäŸãã°ãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãç¹ã«ãCD45+çœè¡ç
现èã瀺ãæ£è
ã«ãããŠãçœè¡ç
ãæ²»çããããšããããCD45+ããæ§çŽ°è(äŸãã°ãçœè¡ç
æ§çŽ°è)ãæžå°ãããããšã«ãã£ãŠãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãçš®ã
ã®ãããçŽæ¥çã«æ²»çããããšãããããã®æ§åŒã§æ²»çããããšãããäŸç€ºçãªãããšããŠã¯ãæ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«ãåã³é-ããžãã³ã»ãªã³ãè
«(non-Hodgkinâs lymphoma)ã®ãããªè¡æ¶²ãããæããããã
æŽã«ãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãèªå·±å
ç«é害ãæ²»çããããšããããäŸãã°ãæäœããã®æå-çµåãã©ã°ã¡ã³ããåã¯ãªã¬ã³ãããCD45+å
ç«çŽ°èãå·å®³ãããããã«ãèªå·±å
ç«é害ã«çœ¹æ£ããŠããããæ£è
ã®ãããªå¯Ÿè±¡ã«æäžããããšããããåèšCD45+å
ç«çŽ°èã¯ãèªå·±æåã«ç¹ç°çã«çµåããT-现èã¬ã»ãã¿ãŒãçºçŸãããåã³èªå·±æåã«å¯ŸããŠå
ç«åå¿ãéå§ãããT-现èã®ãããªèªå·±åå¿æ§ãªã³ãçã§ããããšããããèªå·±åå¿æ§CD45+现èãæžå°ãããããšã«ãã£ãŠãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠã以äžã«èšèŒããããããªèªå·±å
ç«æ§ã®ç
æ
ãæ²»çããããšããããæŽã«ãåã¯ãã®ä»£ãããšããŠãæ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ã䜿çšããŠãé è¡å¹¹çŽ°è移æ€çæ³ã®åã«ãå
å æ§ã®é è¡å¹¹çŽ°èã®éå£ãæžå°ãããããšã«ãã£ãŠãèªå·±å
ç«çŸæ£ãæ²»çããããšãããããã®å Žåã移æ€ãã现èã¯ãå
å æ§ã®çŽ°èãæžå°ãããã¹ãããã«ãã£ãŠäœãåºããããããã«ããŒãã³ã°ããçç£çãªé è¡ã確ç«ããããšããããããã«ãããèªå·±å
ç«çŽ°èãæ ¹çµ¶ãããéã«æžå°ãã现èã®éå£ããä»åºŠã¯åæ§æãããããšãã§ããã
æ¬åºé¡ã«èšèŒãããçµæç©åã³æ¹æ³ãçšããŠæ²»çããããšãã§ããèªå·±å
ç«çŸæ£ãšããŠã¯ãéå®ããããã®ã§ã¯ãªããã也ç¬ã也ç¬æ§é¢ç¯çã1åç³å°¿ç
(1åç³å°¿ç
)ãé¢ç¯ãªãŠãã(RA)ãããå
šèº«æ§ãšãªããããŒãã¹(SLE)ãå€çºæ§ç¡¬åç(MS)ãççæ§è
žçŸæ£(IBD)ããªã³ãçæ§å€§è
žçãæ¥æ§æ£åšæ§è³èé«ç(ADEM)ãã¢ãžãœã³ç
ãæ±çºæ§è±æ¯çã匷çŽæ§èæ€çãæãªã³è質æäœçå矀(APS)ãåçäžè¯æ§è²§è¡ãèªå·±å
ç«æ§æº¶è¡æ§è²§è¡ãèªå·±å
ç«æ§èçãèªå·±å
ç«æ§å
è³çŸæ£(AIED)ãèªå·±å
ç«æ§ãªã³ãå¢æ®çå矀(ALPS)ãèªå·±å
ç«æ§åµå·£çããããŒç
ãããŒãã§ããç
ãæ°Žç±æ§é¡å€©ç±ç¡ãå¿ççãã·ã£ãŒã¬ã¹ç
ãæ
¢æ§ç²åŽå
ç«äžå
šçå矀(CFIDS)ãæ
¢æ§ççæ§è±é«æ§å€çºãã¥ãŒããããŒãã¯ããŒã³ç
ãç¢çæ§é¡å€©ç±ç¡ãã»ãªã¢ãã¯ã»ã¹ãã«ãŒç±ç¹ç¶ç®èçãå¯å·åéçŽ çãCRESTçå矀ãããŽã¹ç
ãåæ¿ç¶ãšãªããããŒãã¹ãèªåŸç¥çµé害ãåå®®å
èçãæ¬æ
æ§æ··ååã¯ãªãªã°ãããªã³è¡çãç·ç¶çççïŒç·ç¶ççãã°ãããã¹ãã£ãŒçå矀ãã°ã¬ãŒãã¹ç
ãã®ã©ã³âãã¬ãŒçå矀(GBS)ãæ©æ¬ç²ç¶è
ºçãåè¿æ§æ±è
ºçãç¹çºæ§åã³ïŒåã¯æ¥æ§è¡å°æ¿æžå°æ§çŽ«æç
ãç¹çºæ§èºç·ç¶çãIgAãã¥ãŒããããŒãé質æ§èè±çãè¥å¹Žæ§é¢ç¯çãå·åŽç
ãæå¹³èç¬ãã©ã€ã ç
ãã¡ããšãŒã«ç
ãæ··åæ§çµåçµç¹ç
(MCTD)ãéççç¡åçããã¥ãŒãããªããã¢ããªããœã¯ããŒãã¹ã»ããªã¯ããŒãã¹çå矀(OMS)ãèŠç¥çµçããªã«ãç²ç¶è
ºçïŒOrd's thyroiditisïŒãå°åžžæ§å€©ç±ç¡ãæªæ§è²§è¡ãå€çºè»éªšçãå€çºæ§ççåã³ç®èççãåçºæ§èæ±æ§è硬å€ãçµç¯æ§å€çºåèçãå€å
åæ³è
ºçå矀ããªãŠããæ§å€çºçççãåçºæ§ç¡ã¬ã³ãã°ãããªã³è¡ç(primary agammaglobulinemia)ãã¬ã€ããŒçŸè±¡ãã©ã€ã¿ãŒçå矀ããªãŠããç±ããµã«ã³ã€ããŒã·ã¹ã匷ç®çãã·ã§ãŒã°ã¬ã³çå矀ãã¹ãã£ããã»ããŒãœã³çå矀ãé«å®åèçãåŽé åèç(巚现èæ§åèçãšããŠãç¥ããã)ã朰çæ§å€§è
žçãè åç·ç¶æ§å€§è
žçãã¶ã©ãèçãè¡ç®¡çãçœæãå€é°éšçïŒå€é°éšååºçïŒãåã³ãŽã§ãŒã²ããŒèèœè
«çããæããããã
å®æœäŸïŒïŒæ-CD45-ADC (104-PBD)ã¯ãin vitroã§ãT现èãå·å®³ãã
æ-CD45-ADCïŒ104-PBDïŒããin vitro T现èå·å®³ã¢ãã»ã€ã§ãT现èå·å®³æŽ»æ§ã«ã€ããŠãè©äŸ¡ããã104-PBDã¯ãã¢ãã¯ããŒãã«æäœ104ã®å¯å€é åãå«ã¿ãCD45.2ã¢ã€ãœãã©ãŒã ã«çµåããåžè²©ã®æ-CD45æäœã§ãã(BioLegend, San Diego, CA)ãåã³mAb Ly-5.2ãšããŠãç¥ãããŠãããmAb 104ã®å¯å€é åããã·ã¹ãã€ã³æ®åºãä»ããŠããã·ãªã³ã«ã³ã³ãžã¥ã²ãŒãããããã«ãS239Cåã³N297A ã®Fc眮æãå«ãããIgGå®åžžé åã«ãçµåããããPBMCãçš®ã ã®æ¡ä»¶äžã§å¹é€ããããŠã¹T现èã®çååã³å¢æ®ãä¿é²ãããã1ãŠã§ã«åœãã25,000 åã®T现èãæçš®ãããã®ãŠã§ã«ã«ãADCãæ§ã ãªæ¿åºŠã§æ·»å ãããã®åŸã37âåã³5% CO2ã®ã€ã³ãã¥ããŒã¿ãŒã«å ¥ããã3æ¥éã®å¹é€ã®åŸãåãµã³ãã«ãããããŒã»ãµã€ãã¡ããªãŒã§è§£æããããããŒã»ãµã€ãã¡ããªãŒè§£æã«ãã£ãŠãåãŠã§ã«ããååãããçããCD3+ T现èã®æ°ãæ°ããããšã«ãã£ãŠãT现èã®æ°(å³ïŒïŒ¡)ã枬å®ãããKi-67+ T现èã®å²åããKi-67ãçºçŸããçããCD3+ T现èã®æ°ãããã®ãµã³ãã«å ã®çããCD3+ T现èã®ç·æ°ã§å²ãããšã«ãã£ãŠæž¬å®ãããPDBã«ã³ã³ãžã¥ã²ãŒãããé-ç¹ç°çãªããIgG(ãIso PBDã)ã¯ããã¬ãã£ãã»ã³ã³ãããŒã«ãšããŠã®åœ¹å²ãšããã
æ-CD45-ADCïŒ104-PBDïŒããin vitro T现èå·å®³ã¢ãã»ã€ã§ãT现èå·å®³æŽ»æ§ã«ã€ããŠãè©äŸ¡ããã104-PBDã¯ãã¢ãã¯ããŒãã«æäœ104ã®å¯å€é åãå«ã¿ãCD45.2ã¢ã€ãœãã©ãŒã ã«çµåããåžè²©ã®æ-CD45æäœã§ãã(BioLegend, San Diego, CA)ãåã³mAb Ly-5.2ãšããŠãç¥ãããŠãããmAb 104ã®å¯å€é åããã·ã¹ãã€ã³æ®åºãä»ããŠããã·ãªã³ã«ã³ã³ãžã¥ã²ãŒãããããã«ãS239Cåã³N297A ã®Fc眮æãå«ãããIgGå®åžžé åã«ãçµåããããPBMCãçš®ã ã®æ¡ä»¶äžã§å¹é€ããããŠã¹T现èã®çååã³å¢æ®ãä¿é²ãããã1ãŠã§ã«åœãã25,000 åã®T现èãæçš®ãããã®ãŠã§ã«ã«ãADCãæ§ã ãªæ¿åºŠã§æ·»å ãããã®åŸã37âåã³5% CO2ã®ã€ã³ãã¥ããŒã¿ãŒã«å ¥ããã3æ¥éã®å¹é€ã®åŸãåãµã³ãã«ãããããŒã»ãµã€ãã¡ããªãŒã§è§£æããããããŒã»ãµã€ãã¡ããªãŒè§£æã«ãã£ãŠãåãŠã§ã«ããååãããçããCD3+ T现èã®æ°ãæ°ããããšã«ãã£ãŠãT现èã®æ°(å³ïŒïŒ¡)ã枬å®ãããKi-67+ T现èã®å²åããKi-67ãçºçŸããçããCD3+ T现èã®æ°ãããã®ãµã³ãã«å ã®çããCD3+ T现èã®ç·æ°ã§å²ãããšã«ãã£ãŠæž¬å®ãããPDBã«ã³ã³ãžã¥ã²ãŒãããé-ç¹ç°çãªããIgG(ãIso PBDã)ã¯ããã¬ãã£ãã»ã³ã³ãããŒã«ãšããŠã®åœ¹å²ãšããã
Ki-67+ T现èã¯ã104-PBDã«ããåŠçåŸãin vitroã§èç©ããªãã£ããå³ïŒïŒ¡ã«ç€ºãããã«ãin vitroã§ã104-PBDã®çšéã®å¢å ãšãšãã«ãT现èæ»ã芳å¯ããããæŽã«ãin vitroã§ã104-PBDã®çšéã®å¢å ãšãšãã«ãåè£çŽ°èã®åºçŸãæžå°ãã(å³ïŒïŒ¢)ã
å®æœäŸïŒïŒåçš®åå¿æ§T现è掻æ§åã®ããŠã¹ã»ã¢ãã«ã«ããããæ-CD45-ADC (104-PBD)ã®in vivoã§ã®æå¹æ§
æ-CD45-ADCïŒ104-PBDïŒã«ããåŠçœ®ããåçš®åå¿æ§ã®ããŠã¹ã»ã¢ãã«ã«ãããŠãin vivoã§è©äŸ¡ãã(ç 究ãã¶ã€ã³ã«ã€ããŠã¯è¡šïŒãåç §ã®ããš)ãèŠçŽãããšã650 cGyã®å šèº«ç §å°æ³(Total Body Irradiation (TBI))ã«ãã£ãŠã移æ€åã³ã³ãã£ã·ã§ãã³ã°ãè¡ã£ã24æéåŸã®Balb/c (CD45.2)宿䞻(ãã€ããŒHAãã¹ããã)ã«ãå šB10.D2èŸè现èãç§»å ¥ããã7æ¥åŸã1 mg/kgè¥ããã¯3 mg/kgã®æ-CD45-ADC (104-PBD; n=5å¹ã®ããŠã¹ïŒåŠçœ®çŸ€ïŒæ¥çš®)ãåã¯3 mg/kgã®ãã¬ãã£ã(ã¢ã€ãœã¿ã€ã)ã³ã³ãããŒã«(ãIso-PBDã)ããæäžãããããŠã¹ããæ«æ¢¢è¡åã³èŸèãæ¡åããADCæäž5æ¥åŸã«ãããŒã»ãµã€ãã¡ããªãŒã«ããè©äŸ¡ããã
æ-CD45-ADCïŒ104-PBDïŒã«ããåŠçœ®ããåçš®åå¿æ§ã®ããŠã¹ã»ã¢ãã«ã«ãããŠãin vivoã§è©äŸ¡ãã(ç 究ãã¶ã€ã³ã«ã€ããŠã¯è¡šïŒãåç §ã®ããš)ãèŠçŽãããšã650 cGyã®å šèº«ç §å°æ³(Total Body Irradiation (TBI))ã«ãã£ãŠã移æ€åã³ã³ãã£ã·ã§ãã³ã°ãè¡ã£ã24æéåŸã®Balb/c (CD45.2)宿䞻(ãã€ããŒHAãã¹ããã)ã«ãå šB10.D2èŸè现èãç§»å ¥ããã7æ¥åŸã1 mg/kgè¥ããã¯3 mg/kgã®æ-CD45-ADC (104-PBD; n=5å¹ã®ããŠã¹ïŒåŠçœ®çŸ€ïŒæ¥çš®)ãåã¯3 mg/kgã®ãã¬ãã£ã(ã¢ã€ãœã¿ã€ã)ã³ã³ãããŒã«(ãIso-PBDã)ããæäžãããããŠã¹ããæ«æ¢¢è¡åã³èŸèãæ¡åããADCæäž5æ¥åŸã«ãããŒã»ãµã€ãã¡ããªãŒã«ããè©äŸ¡ããã
å³ïŒïŒ¡åã³ïŒïŒ¢ã«ç€ºãããã«ãã¢ã€ãœã¿ã€ã-PBDãšæ¯èŒããŠãæ-CD45-ADC (å³ã¡ã104-PBD)ãæäžãããšãåçš®åå¿æ§T现è掻æ§åã®ããŠã¹ã»ã¢ãã«ã«ãããããããŒT现èã®æ°ãå®è³ªçã«æžå°ãããæŽã«ãåè£çŽ°èã®å²åã¯ãæ-CD45-ADC (å³ã¡ã104-PBD)ã§ã®åŠçœ®åŸã«ãã¢ã€ãœã¿ã€ã PBDã§åŠçœ®ããå Žåãšæ¯èŒããŠãæžå°ããããããã®çµæã¯ãæ-CD45-ADC(å³ã¡ã104-PBD)ã«å¯Ÿããin vivoã§ã®æŽé²ã«ãã£ãŠã掻æ§åããïŒåè£ããŠããT现èãéžæçã«å·å®³ãããããšãã瀺ããããã«ãã£ãŠãin vivoåã³in vitroã§èŠ³å¯ãããããã«ã104-PBDã¯ãèªå·±åå¿æ§åã¯åçš®-æ絶T现èãå·å®³ããããšã«ãå¹æçã§ããããšãã確èªãããã
å®æœäŸïŒïŒããåNSGããŠã¹ã»ã¢ãã«ã«ããããæ-CD45-PBD ADCã®in vivoã§ã®æå¹æ§
PBD现èæ¯çŽ (ãã»ãªã³)ã«ã³ã³ãžã¥ã²ãŒããããããCD45ã«ç¹ç°çã«çµåããããšãã§ããæäœãå«ããæ-CD45æäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ããæ¬å®æœäŸã«ãããŠè©äŸ¡ãã(ãCD45-PBDã)ãåèšADCã®æ-CD45 æäœã¯ãFcé åå ã«ãã¢ããé žçœ®æL234A L235A D265Cåã³H435Aãå«ãã§ããã
PBD现èæ¯çŽ (ãã»ãªã³)ã«ã³ã³ãžã¥ã²ãŒããããããCD45ã«ç¹ç°çã«çµåããããšãã§ããæäœãå«ããæ-CD45æäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ããæ¬å®æœäŸã«ãããŠè©äŸ¡ãã(ãCD45-PBDã)ãåèšADCã®æ-CD45 æäœã¯ãFcé åå ã«ãã¢ããé žçœ®æL234A L235A D265Cåã³H435Aãå«ãã§ããã
ããåNSGããŠã¹ã«ãããŠãæ«æ¢¢è¡ãªã³ãçã骚é«(BM) HSCãåã¯æçããã·ã³ã°ã«ã»ããžãã£ã(single positive (SP))èžè
ºçŽ°èããæžå°ãããäœçšèœã«ã€ããŠãCD45-PBDãè©äŸ¡ãã(å³ïŒ)ãåªäœ(PBS)ãPBDã«ã³ã³ãžã¥ã²ãŒãããã¢ã€ãœã¿ã€ãã»ã³ã³ãããŒã«æäœ(ãIso-PBDã)ãåã¯CD45-PBDã®ããããã®ã瀺ããååçšéããhNSGããŠã¹ã«æäžããã0.3 mg/kgã1 mg/kgã3 mg/kgãåã¯6 mg/kg ADCã®ååçšéã§ãCD45-PBDãããŠã¹ã«æäžããã1 mg/kgã3 mg/kgåã¯6 mg/kg ADCã®ååçšéã§ãIso-PBDãããŠã¹ã«æäžããã
0æ¥ç®ã7æ¥ç®ãåã³14æ¥ç®ã«æ«æ¢¢è¡ãæ¡åããå
šããè¡æ¶²çŽ°èå«æé(hβ2M+)ã骚é«çŽ°èå«æé(CD33+)ãB现èå«æé(CD19+)ãåã³T现èå«æé(CD3+)ãè©äŸ¡ãããæ¬æ«æ¢¢è¡è©Šéšã«ããçµæãå³ïŒã«ç€ºãããããã®çµæã¯ãæ«æ¢¢è¡ã«ãããŠãCD45-PBDã®å¿å®¹çšéã§ããã现èã®çšéäŸåçãªæžå°ãéæãããããšã瀺ãã3 mg/kg以äžã®CD45-PBDçšéã¯ãå¿å®¹æ§ããªãã£ãã
骚é«ã®æžå°ãè©äŸ¡ããããã«ãåŠçœ®åŸ14æ¥ç®ã«ããŠã¹ãã骚é«ãµã³ãã«ãæ¡åããããåé§çŽ°è/HSCå«æéãè©äŸ¡ãããæ¬éªšé«è©Šéšã®çµæãå³ïŒã«ç€ºãããã现èã®å²å(ãããŒã»ã³ããŒãžã)åã¯å€§è
¿éªšåœããã®çŽ°èã®çµ¶å¯Ÿæ°(ãæ°ã)ãšããŠç€ºãããããã®çµæã¯ãCD45-PBDã«ãã£ãŠãCD45-PBDåŠçœ®åŸã®éªšé«ã«ãããŠãããåé§çŽ°èåã³HSCããã¿ãŒã²ããåããŠãçšéäŸåçã«åã³å€§ããæžå°ããããšã瀺ãããã¢ã€ãœã¿ã€ã-PBDã¯ãé«çšéã®3 mg/kgåã³6 mg/kgã§ã骚é«ã«ãããŠãææãªãã©ããããŒã ã®æ¯æ§ã瀺ããã
次ã«ãããã«ã»ããžãã£ã(double positive (DP))èžè
ºçŽ°èåã³æçããã·ã³ã°ã«ã»ããžãã£ã(single positive (SP))èžè
ºçŽ°èã®ãCD45-PBDã«ããæžå°ãè©äŸ¡ãããhNSGããŠã¹ãç¡äœçºåããã¢ã€ãœã¿ã€ã-PBDãCD45-PBDåã¯åªäœ(PBS)ã®çšéãå¢å ãããªããåŠçœ®ãããæ¬èžè
ºçŽ°èæžå°è©Šéšã®çµæãå³ïŒã«ç€ºããCD45-PBDã§åŠçœ®ããåç©ã«ãããŠãããCD45+现èåã³ããã»ããã«ã»ããžãã£ã(double positive (DP))èžè
ºçŽ°èã®çšéäŸåçãªæžå°ã芳å¯ããããCD45-PBDã®å¿å®¹çšéã§ã¯ãæçããCD4åã³CD8 SPèžè
ºçŽ°èã«ã¿ãŒã²ããåããŠå®å
šã«æžå°ããããšã¯èŠ³å¯ãããªãã£ããé«çšéã®ã¢ã€ãœã¿ã€ã-PBDã§ããã«ã»ããžãã£ã(double positive (DP))èžè
ºçŽ°èã®æžå°ã芳å¯ãããããšã¯ãPBDã«é¢ããæ¢ç¥ã®ãã©ããããŒã ã®æ¯æ§ãšäžèŽããã
å®æœäŸïŒïŒããåNSGããŠã¹ã»ã¢ãã«ã«ããããæ-CD45-IGN ADCã®in vivo ã§ã®æå¹æ§
IGN现èæ¯çŽ (DGN549)ã«ã³ã³ãžã¥ã²ãŒããããããCD45ã«ç¹ç°çã«çµåããããšãã§ããæäœãå«ããæ-CD45æäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ããæ¬å®æœäŸã§è©äŸ¡ãã(ãCD45-IGNã)ãåèšADCã®æ-CD45æäœã¯ãFcé åå ã«ãã¢ããé žçœ®æL234A L235A D265Cåã³H435Aãå«ãã§ããã
IGN现èæ¯çŽ (DGN549)ã«ã³ã³ãžã¥ã²ãŒããããããCD45ã«ç¹ç°çã«çµåããããšãã§ããæäœãå«ããæ-CD45æäœè¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ããæ¬å®æœäŸã§è©äŸ¡ãã(ãCD45-IGNã)ãåèšADCã®æ-CD45æäœã¯ãFcé åå ã«ãã¢ããé žçœ®æL234A L235A D265Cåã³H435Aãå«ãã§ããã
åªäœ(PBS)ãIGNã«ã³ã³ãžã¥ã²ãŒãããã¢ã€ãœã¿ã€ãã»ã³ã³ãããŒã«(ãIso-IGNã)ãåã¯CD45-IGNã®ããããã®ãååçšéããhNSGããŠã¹ã«æäžããã0.3 mg/kgã1 mg/kgã3 mg/kgãåã¯6 mg/kg ADCã®ååçšéã§ãCD45-IGNãããŠã¹ã«æäžããã1 mg/kgã3 mg/kgåã¯6 mg/kg ADCã®ååçšéã§ãIso-IGNãããŠã¹ã«æäžããã
0æ¥ç®ã7æ¥ç®ãåã³14æ¥ç®ã«æ«æ¢¢è¡ãæ¡åããå
šããè¡æ¶²çŽ°èå«æé(hβ2M+)ã骚é«çŽ°èå«æé(CD33+)ãB现èå«æé(CD19+)ãåã³T现èå«æé(CD3+)ãè©äŸ¡ãããæ¬æ«æ¢¢è¡è©Šéšã«ããçµæãå³ïŒã«ç€ºãããããã®çµæã¯ãæ«æ¢¢è¡ã«ãããŠãCD45-IGNã®ååçšéã®æäžåŸã«ããã现èã®çšéäŸåçãªæžå°ãéæãããããšã瀺ããCD45-IGNã¯ãè©Šéšããå
šãŠã®çšéã§ãè¯å¥œãªå¿å®¹æ§ã瀺ããã
æäžåŸ14æ¥ç®ã«ããŠã¹ãã骚é«ãµã³ãã«ãæ¡åããããšã«ãã£ãŠã骚é«ã®æžå°ãè©äŸ¡ãããããåé§çŽ°èïŒHSCå«æéã«ã€ããŠããµã³ãã«ãè©äŸ¡ãããæ¬éªšé«è©Šéšã®çµæãå³ïŒã«ç€ºãããã现èã®å²å(ãããŒã»ã³ããŒãžã)åã¯å€§è
¿éªšåœããã®çŽ°èã®çµ¶å¯Ÿæ°(ãæ°ã)ãšããŠç€ºãããããã®çµæã¯ãCD45-IGNã«ãã£ãŠãCD45-IGNåŠçœ®åŸã®éªšé«ã«ãããŠãããåé§çŽ°èåã³HSCããã¿ãŒã²ããåããŠãçšéäŸåçã«åã³å€§ããæžå°ããããšã瀺ãããã¢ã€ãœã¿ã€ã-IGNã¯ãäœãã®è©Šéšããçšéã§ããææãªåœ±é¿ã瀺ããªãã£ãã
ããã«ã»ããžãã£ã(double positive (DP))èžè
ºçŽ°èåã³æçããã·ã³ã°ã«ã»ããžãã£ã(single positive (SP))èžè
ºçŽ°èã®ãCD45-IGNã«ããæžå°ãè©äŸ¡ãããhNSGããŠã¹ãç¡äœçºåããã¢ã€ãœã¿ã€ã-IGNãCD45-IGNåã¯åªäœã³ã³ãããŒã« (PBS)ã®çšéãå¢å ãããªããåŠçœ®ãããæ¬èžè
ºçŽ°èæžå°è©Šéšã®çµæãå³ïŒã«ç€ºããCD45-IGNã§åŠçœ®ããåç©ã«ãããŠãããCD45+现èåã³ããã»ããã«ã»ããžãã£ã(double positive (DP))èžè
ºçŽ°èã®çšéäŸåçãªæžå°ã芳å¯ããããå ããŠãCD45-IGNã«ããã¿ãŒã²ãã£ã³ã°ã¯ãããããããçšéã§ã®ã¢ã€ãœã¿ã€ã-IGNãšæ¯èŒããŠãCD4åã³CD8 SPèžè
ºçŽ°èããã倧ããæžå°ãããããã®ããšã¯ãCD45-IGN ADCãããèžè
ºçŽ°èã確å®ã«ãåã³ã¿ãŒã²ããåããŠæžå°ãããããšãå®èšŒããã
ãã®ä»ã®å®æœåœ¢æ
æ¬åºé¡ã«ãããŠèšåãããå šãŠã®åè¡ç©ãç¹èš±ãåã³ç¹èš±åºé¡ã¯ãããããåç¬ç«ããåè¡ç©åã¯ç¹èš±åºé¡ãå ·äœçãã€åå¥ã«ç€ºãããåç §ã«ããåã蟌ãŸãããã®ããã«ãåãçšåºŠãŸã§ãæ¬åºé¡ã«åç §ã«ããåã蟌ãŸããã
æ¬åºé¡ã«ãããŠèšåãããå šãŠã®åè¡ç©ãç¹èš±ãåã³ç¹èš±åºé¡ã¯ãããããåç¬ç«ããåè¡ç©åã¯ç¹èš±åºé¡ãå ·äœçãã€åå¥ã«ç€ºãããåç §ã«ããåã蟌ãŸãããã®ããã«ãåãçšåºŠãŸã§ãæ¬åºé¡ã«åç §ã«ããåã蟌ãŸããã
æ¬çºæãããã®ç¹å®ã®å®æœåœ¢æ
ã«é¢é£ããŠèª¬æããŠããããæŽãªãæ¹å€ãããããšãå¯èœã§ããããšãã䞊ã³ã«ãæ¬åºé¡ã¯ãäžè¬ã«ãæ¬çºæã®åçã«åŸãæ¬çºæã®ä»»æã®æ¹å€ã䜿çšãåã¯é©å¿ãã䞊ã³ã«ãæ¬çºæãé¢ä¿ããæè¡å
ã®æ¢ç¥ã®åã¯æ
£ç¿çãªå®åå
ã«å
¥ãæ¬çºæããã®éžè±ããåã³æ¬åºé¡ã«èšèŒãããç¹èš±è«æ±ã®ç¯å²ã«åŸãæ¬è³ªçãªç¹åŸŽã«é©çšããåŸãæ¬çºæããã®éžè±ããå«ãæ¬çºæã®ä»»æã®æ¹å€ã䜿çšãåã¯é©å¿ããå
å«ããããšãæå³ãããŠããããšããç解ãããã§ãããã
ä»ã®å®æœåœ¢æ
ã¯ãæ¬é¡ã®ç¹èš±è«æ±ã®ç¯å²ã®ç¯å²å
ã§ããã
Claims (27)
- é è¡å¹¹çŽ°è(HSC)移æ€ãå¿ èŠãšããããæ£è ã«ãããŠãCD45+现èã®éå£ãæžå°ãããããã®å»è¬çµæç©ã
ããã§ãåèšå»è¬çµæç©ã¯ãCD45+现èã®éå£ãæžå°ããããã«ãæå¹éã®æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãå«ãã
ããã§ãåèšADCã¯ããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããæ-CD45æäœåã¯ãã®æåçµåéšåãå«ããåã³ã
ããã§ãåèšçŽ°èæ¯çŽ ã¯ããããã³ãŸãžã¢ãŒãã³(PBD)ãåã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³ãå«ãã - é è¡å¹¹çŽ°è(HSC)移æ€ãåããããã«ãããæ£è ãã³ã³ãã£ã·ã§ãã³ã°ããããã®å»è¬çµæç©ã
ããã§ãåèšå»è¬çµæç©ã¯ãæå¹éã®æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒã(ADC)ãå«ãã
ããã§ãåèšADCã¯ããªã³ã«ãŒãä»ããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããæ-CD45æäœåã¯ãã®æåçµåéšåãå«ããåã³ã
ããã§ãåèšçŽ°èæ¯çŽ ã¯ããããã³ãŸãžã¢ãŒãã³(PBD) ãåã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³ãå«ã - è«æ±é ïŒåã¯ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšçŽ°èæ¯çŽ ã¯ãPBDäºéäœã§ããã
- è«æ±é ïŒããïŒã®äœããäžé ã«èšèŒã®å»è¬çµæç©ãããã§ãåèšãªã³ã«ãŒã¯ã1皮以äžã®ããããããªãªãŽç³ã-(CH2)p-, -(CH2CH2O)q-, -(C=O)(CH2)r-, -(C=O)(CH2CH2O)t-, -(NHCH2CH2)u-, -PAB, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, å㯠Ala-PABãå«ããããã§ãpãqãrãtãåã³uã®åã ã¯ã1ãã12ã®æŽæ°ã§ãããåå Žåæ¯ã«ãç¬ç«ããŠéžæãããã
- è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãR1ã¯ãCH3ã§ããã
- è«æ±é ïŒããïŒã®äœããäžé ã«èšèŒã®å»è¬çµæç©ãããã§ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããŠããã·ãªã³ã§ãããåŒ(IV)ã®æ§é ãæããïŒ
ã - è«æ±é ïŒããïŒã®äœããäžé ã«èšèŒã®å»è¬çµæç©ãããã§ãåèšADCã¯ãåŒ(V)ã®æ§é ãæããïŒ
ããã§ãAbã¯ãæ-CD45æäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã§ãããåã³Sã¯ãåèšæäœåã¯ãã®æåçµåãã©ã°ã¡ã³ãã®ãäžã«ååšããåã¯äžã«å°å ¥ãããç¡«é»ååã§ããã - è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšçŽ°èæ¯çŽ ã¯ãã€ã³ããªããã³ãŸãžã¢ãŒãã³äºéäœåã¯ã€ã³ããªããã³ãŸãžã¢ãŒãã³åœäºéäœã§ããã
- è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšçŽ°èæ¯çŽ -ãªã³ã«ãŒã»ã³ã³ãžã¥ã²ãŒãã¯ãåèšæäœåã¯ãã®æåçµåéšåã«ã³ã³ãžã¥ã²ãŒãããåã«ãåå¿æ§çœ®æåºZ'ãå«ã¿ãCy-L-Z'ãšããŠäžç·ã«ãªã£ãŠããŠãåŒ(VII)ã®æ§é ãæããïŒ
ã - è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšæäœã¯ããã¡ã©æäœãããåæäœãè¥ããã¯ããæäœã§ããïŒ
ããã§ãåèšæäœè¥ããã¯ãã®æå-çµåéšåã¯ãã¢ãã¯ããŒãã«æäœè¥ããã¯ãã®æå-çµåéšåãããªã¯ããŒãã«æäœè¥ããã¯ãã®æå-çµåéšåããã€ã¹ãã·ãã£ãã¯æäœè¥ããã¯ãã®æå-çµåéšåãäºéå¯å€å ç«ã°ãããªã³ã»ãã¡ã€ã³(dual-variable immunoglobulin domain)ãåéFvåå(scFv)ããã€ã¢ããã£ãããªã¢ããã£ãããããã£ãæäœ-æ§ã¿ã³ãã¯è³ªã¹ãã£ããã©ã«ããFvãã©ã°ã¡ã³ããFabãã©ã°ã¡ã³ããF(ab')2ååãåã³ã¿ã³ãã di-scFvããããªã矀ããéžæãããïŒäžŠã³ã«ïŒåã¯ã
ããã§ãåèšæäœã¯ãIgGãIgAãIgMãIgDåã³IgEããããªã矀ããéžæãããã¢ã€ãœã¿ã€ããæããã - è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšæäœåã¯ãã®æåçµåéšåã¯ãFcãã¡ã€ã³ãå«ããåã³CD45+现èã«ãã£ãŠå éšã«åã蟌ãŸããã
- è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšæäœåã¯ãã®æåçµåéšåã¯ãFcãã¡ã€ã³ãå«ããåã³ããã§ãåèšæäœåã¯ãã®æåçµåéšåã¯ãFcãã¡ã€ã³å ã®ã·ã¹ãã€ã³æ®åºãçµç±ããŠã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããã
- è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšã·ã¹ãã€ã³æ®åºããFcãã¡ã€ã³å ã®ã¢ããé žçœ®æã«ãã£ãŠå°å ¥ããã
- è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšã¢ããé žçœ®æã¯ãD265C (EUçªå·ä»ã)ãV205C (EUçªå·ä»ã)ãåã¯S239C (EUçªå·ä»ã)ã§ããã
- è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšæ£è ã¯ãé è¡å¹¹çŽ°èãå«ã移æ€çãåããåã«ãåèšå»è¬çµæç©ã®æäžãåããã
- è«æ±é 1ã«èšèŒã®å»è¬çµæç©ãããã§ãåèšæ£è ã¯ãè¡æ¶²çŸæ£ã代è¬é害ããããèªå·±å ç«çŸæ£ã幹现èé害ãåã¯é床è€åå ç«äžå šç(SCID)ããæããã
- è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšæ£è ã¯ãè¡æ¶²ãããæããã
- è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšè¡æ¶²ããã¯ãçœè¡ç è¥ããã¯ãªã³ãè «ã§ãããåã¯åèšèªå·±å ç«çŸæ£ã¯ãå€çºæ§ç¡¬åçè¥ããã¯åŒ·ç®çã§ããã
- è«æ±é ïŒã«èšèŒã®å»è¬çµæç©ãããã§ãå å æ§ã®CD45+ HSCã®éå£ã¯ãåèšå»è¬çµæç©ãæäžããåŸã«ãåèšããæ£è ã«ãããŠãæžå°ããã
- è«æ±é ïŒããïŒïŒã®äœããäžé ã«èšèŒã®å»è¬çµæç©ãããã§ãåèšæ£è ã¯ãæŽã«ãé è¡å¹¹çŽ°è移æ€çã®æäžãåããã
- è«æ±é ïŒïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšADCãåèšæ£è ã®è¡æ¶²ããå®è³ªçã«ã¯ãªã¢ã©ã³ã¹ãããåŸã«ãåèšç§»æ€çãåèšããæ£è ã«æäžããã
- è«æ±é ïŒïŒåã¯ïŒïŒã«èšèŒã®å»è¬çµæç©ãããã§ãåèšé è¡å¹¹çŽ°è移æ€çã¯ãåçš®ç°ç³»çŽ°èãå«ãã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962838280P | 2019-04-24 | 2019-04-24 | |
US62/838,280 | 2019-04-24 | ||
PCT/US2020/029929 WO2020219959A1 (en) | 2019-04-24 | 2020-04-24 | Anti-cd45 antibody drug conjugates and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022530089A JP2022530089A (ja) | 2022-06-27 |
JPWO2020219959A5 true JPWO2020219959A5 (ja) | 2023-05-08 |
Family
ID=72940686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021563185A Pending JP2022530089A (ja) | 2019-04-24 | 2020-04-24 | æïœïœïŒïŒæäœè¬ç©çµåäœãšãã®å©çšæ³ |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220175951A1 (ja) |
EP (1) | EP3958910A4 (ja) |
JP (1) | JP2022530089A (ja) |
WO (1) | WO2020219959A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6190534B2 (ja) | 2013-08-22 | 2017-08-30 | ãœããŒæ ªåŒäŒç€Ÿ | 氎溶æ§èå ææåã¯æè²ææåã³ãã®äœ¿çšæ¹æ³ |
US11685835B2 (en) | 2016-05-11 | 2023-06-27 | Sony Corporation | Ultra bright dimeric or polymeric dyes |
KR20200083605A (ko) | 2017-11-16 | 2020-07-08 | ìë 죌ìíì¬ | íë¡ê·žëšê°ë¥í ì€í©ì²Žì± ìœë¬Œ |
US11874280B2 (en) | 2018-03-19 | 2024-01-16 | Sony Group Corporation | Use of divalent metals for enhancement of fluorescent signals |
EP3861074A2 (en) | 2019-09-26 | 2021-08-11 | Sony Group Corporation | Polymeric tandem dyes with linker groups |
WO2023052970A1 (en) * | 2021-09-30 | 2023-04-06 | Sony Group Corporation | Pyrrolobenzodiazepine conjugates for cancer treatment |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3093293A1 (en) * | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Anti dll3 antibodies and methods of use thereof |
CA2982115A1 (en) * | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
CA3016901C (en) * | 2016-03-07 | 2023-06-13 | Actinium Pharmaceuticals, Inc. | Stabilized radiolabeled anti-cd45 immunoglobulin compositions |
AU2017204139B2 (en) * | 2016-06-17 | 2018-08-09 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
WO2020092654A1 (en) * | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Anti-cd45 antibodies and conjugates thereof |
-
2020
- 2020-04-24 WO PCT/US2020/029929 patent/WO2020219959A1/en unknown
- 2020-04-24 JP JP2021563185A patent/JP2022530089A/ja active Pending
- 2020-04-24 EP EP20795599.8A patent/EP3958910A4/en active Pending
-
2021
- 2021-10-22 US US17/508,641 patent/US20220175951A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220175951A1 (en) | Anti-CD45 Antibody Drug Conjugates and Uses Thereof | |
US20200255523A1 (en) | Fc silenced antibody drug conjugates (adcs) and uses thereof | |
KR20200069364A (ko) | Cd117+ ìží¬ì ê³ ê°ì ìí ì¡°ì±ë¬Œ ë° ë°©ë² | |
US20200407440A1 (en) | Amatoxin antibody-drug conjugates and uses thereof | |
US20220175944A1 (en) | Anti-cd117 antibody-drug conjugates and uses thereof | |
KR20210086683A (ko) | ëì¢ ìŽí ì¡°í ì€êž° ìží¬ ìŽì ë°©ë² | |
CN113302203A (zh) | æcd45æäœåå ¶çŒåç© | |
US20240075157A1 (en) | Fc silenced antibody drug conjugates (adcs) and uses thereof | |
US20220177577A1 (en) | Anti-cd117 antibody drug conjugates and uses thereof | |
KR20220091567A (ko) | í-cd45 í첎 ë° ìŽì 컚쥬ê²ìŽíž | |
US20220226493A1 (en) | Anthracycline antibody-drug conjugates and uses thereof | |
JPWO2020219959A5 (ja) | ||
JPWO2020219775A5 (ja) | ||
CN111867621A (zh) | çšäºèå°œcd134+ç»èçç»åç©åæ¹æ³ | |
JPWO2020219778A5 (ja) | ||
KR20220016922A (ko) | ìê°ë©Žì ì§íì ì¹ë£íêž° ìí ë°©ë² ë° ì¡°ì±ë¬Œ | |
JPWO2020219774A5 (ja) | ||
KR20220154676A (ko) | ëì¢ ìŽìì ìí ì¡°ì±ë¬Œ ë° ë°©ë² | |
WO2024064771A1 (en) | Anti-cd45-ign antibody drug conjugates and uses thereof | |
CN112154152A (zh) | æcd252æäœãçŒåç©å䜿çšæ¹æ³ |